BUDAPEST HUNGARY 28th International Epilepsy Congress

Final Programme 

BUDAPEST 

HUNGARY 

28 th International Epilepsy Congress 

28 th June – 2 nd July 2009 

www.epilepsybudapest2009.org

I S L A N D O F R H O D E S - G R E E C E


www.epilepsybudapest2009.org 

CONTENTS 

. Welcome Message and Committees 2 

2. ILAE Centenary 5 

3. General Congress Information 9 

4. Congress Centre Floor Plan 5 

5. Scientific Programme Information 6 

6. Full Week Timetable 20 

7. Scientific Programme 

Sunday 28 th June 22 

Monday 29 th June 26 

Tuesday 30 th June 36 

Wednesday 1 st July 46 

Thursday 2 nd July 54 

8. Platform Sessions 

Monday 29 th June 60 

Tuesday 30 th June 64 

Wednesday 1 st July 68 

Thursday 2 nd July 72 

9. Poster Presentations 

Monday 29 th June - Wednesday 1 st July 74 

0. Platform Session Abstracts 06 

. Speaker List 34 

2. List of Exhibitors and Exhibition Plan 50

WELCOME MESSAGES AND COMMITTEES 

2 


A MESSAGE FROM THE CHAIRS OF THE 28 TH INTERNATIONAL 

EPILEPSY CONGRESS 

Dear Friends and Colleagues, 

It is with great pleasure that we welcome the delegates of the 28 th International 

Epilepsy Congress to the beautiful city of Budapest in the heart of Europe. 

We are proud to present an interesting and varied scientific programme for your 

benefit with leading epileptologists and opinion leaders from around the world 

participating in the congress. Over the course of five days, you will be invited to 

experience a comprehensive and substantive programme offering a wide range 

of sessions covering the latest topics in epilepsy appealing to physicians and 

investigators, without neglecting social issues and the overall global care of people 

living with epilepsy. 

The centenary of ILAE will also be celebrated at the 28 th International Epilepsy 

Congress. Many special events have been added to the congress programme which 

we hope you will enjoy. A unique exhibition will give you the opportunity to observe 

the progress of ILAE in its first 100 years. 

Although there are plenty of sessions and activities to keep you occupied during 

the congress, we do hope that you find some time to explore the magical city of 

Budapest, the Pearl of the Danube. A wander down the river is fascinating as you 

take in the splendour of the many fine buildings, statues, parks and spas.You are all 

welcome to join us on Wednesday night at the Hungarian National Gallery for an 

exclusive gala evening where you will have the opportunity to view the exquisite 

collection of the country’s fine arts. 

Budapest has a thousand faces and we are confident that during your stay all of you 

will discover at least some of them. 

With warm regards, 

JÓZSEF JANSZKY 

Co-chair 

International Organising Committee 

PÉTER HALÁSZ 

Co-chair 

Scientific Advisory Committee 

PETER WOLF 

Co-chair 

International Organising Committee 

SUSANNE LUND 

Co-chair 

Scientific Advisory Committee 



SUSANNE LUND 

President 

International Bureau for Epilepsy 


A MESSAGE FROM THE PRESIDENTS OF IBE AND ILAE 

Dear Friends, 

On behalf of both the International Bureau for Epilepsy (IBE) and the International 

League Against Epilepsy (ILAE), it gives us pleasure and pride to welcome you all to 

the 28 th International Epilepsy Congress in Budapest. 

As always, the International Epilepsy Congress brings together people from around 

the world to share their experiences of epilepsy as part of the congress programme 

as well as networking with colleagues from near and far. In addition, this congress 

marks the centenary of ILAE which was founded in Budapest in 1909.Therefore in 

order to celebrate this historic milestone for ILAE, there will be various centenary 

events to complement the scientific and social arrangements in place for the 

congress such as a film festival and competition, an historical exhibit and a special 

lecture on literary writers on epilepsy. 

Budapest is a fitting backdrop for the congress. Not only is it rich with culture and 

history, it is also one of the world’s most beautiful cities and is listed on UNESCO’s 

World Heritage sites. Perhaps the most famous symbol of Budapest is the Chain 

Bridge which links Buda on one side of the river Danube with Pest on the other and 

also joins East with West and traditionalism with modernism.The ILAE and IBE are 

both associations full of bridges: between cultures, between traditions and common 

principles, between research and care that ultimately strive to work together to link 

the chapters and associations around the world. 

We look forward to meeting you over the coming days and trust that you will have a 

productive and enjoyable experience at the 28 th International Epilepsy Congress and 

in this most attractive city of Budapest. 

With our very best wishes, 

PETER WOLF 

President 

International League Against Epilepsy 

www.epilepsybudapest2009.org 3


INTERNATIONAL ORGANISING COMMITTEE 

JÓZSEF JANSZKY 

(HUNGARY) 

Co-chair 

4 

SHIH HUI LIM 

(SINGAPORE() 

PETER WOLF 

(DENMARK) 

Co-chair 

SUSANNE LUND 

(SWEDEN) 

SCIENTIFIC ADVISORY COMMITTEE 

PÉTER HALÁSZ 

(HUNGARY) 

Co-chair 

EDWARD DUDEK 

(USA) 

LILIA NÚÑEZ OROZCO 

(MEXICO) 

SUSANNE LUND 

(SWEDEN) 

Co-chair 

ANDRAS FOGARASI 

(HUNGARY() 

TERENCE O’BRIEN 

(AUSTRALIA) 


ATHANASIOS COVANIS 

((GREECE) 

SIMON SHORVON 

(UK) 

SUAD AL YAMANI 

(SAUDI ARABIA) 

SHICHUO LI 

(CHINA) 

FRIEDRICH WOERMANN 

(GERMANY) 

ANDRAS FOGARASI 

(HUNGARY() 



Centenary Committee 

SIMON SHORVON, UK (Chair) 

HOWARD GOODKIN, USA 

PÉTER HALÁSZ, HUNGARY 

JUDIT JERNEY, HUNGARY 

GISELLE WEISS, SWITZERLAND 

ILAE CENTENARY 

Activities 

2009 is a very special year for the 

International League Against Epilepsy 

(ILAE). It is celebrating its first 100 

years, having been founded on August 

30 th 1909 at a meeting in Budapest, 

held during the International Medical 

Congress of that year.To reach this 

landmark is a remarkable achievement 

for any voluntary organisation, and 

in fact the League is the oldest such 

international subspecialist organisation 

in the field of neurology, and one of 

the oldest in medicine.To mark its 

centenary, the ILAE has organised a 

number of centenary events at the 

congress, and we do hope that all 

participants will enjoy what is on show. 



ILAE Centenary exhibition and historical 

timeline – ILAE and Epilepsy 909-2009 

The exhibition consists of 65 posters to 

celebrate the 100 years of ILAE and the 

progress in epilepsy.The posters are 

based on the ILAE Centenary History 

Book.The exhibition starts in 1909 in 

the Hotel Bristol and finishes with an 

allegorical arch symbolizing the next 

100 years. A historial timeline is also on 

show to give context to the audience. 

Display of historical books – 909-2009 

A display of approximately 30 books of 

importance to the cultural history of 

epilepsy, and published between 1909- 

2009, will be on show at the exhibition, 

and linked to the special session 

‘Epilepsy and literature’.The display 

will be of the original editions, in their 

original languages, and demonstrates 

the importance of epilepsy in the 

development of the novel during the 

twentieth century. 

The Centenary of the ILAE Journal 

– Epilepsia 

2009 is also the centenary of the journal 

Epilepsia.The first edition was published 

in March 1909 and Epilepsia was then 

formally adopted as ‘the official organ’ 

of the ILAE in September 1909 and from 

henceforward ILAE have owned and 

run the journal. Over the years, it has 

published many important papers in the 

field of epilepsy and the journal 

has been a crowning achievement of 

the league. 

Wiley Blackwell, the current publishers 

of Epilepsia, will have a stand at the 

congress to which all participants are 

invited. Amongst the items on show 

at the stand will be the historical 

supplement, which was published with 

the Epilepsia centenary issue in March 

2009.This supplement contains 10 

chapters covering aspects of the history 

of epilepsy during the 100 years. 

On Monday 29 th June (10.30 - 12.30), 

there is a special session at the 

conference devoted to four landmark 

papers in the journal and the impact 

these had on the subsequent course 

of epilepsy (100 years of Epilepsia - 

landmark papers and their influence). 

6 


ILAE Centenary Film Festival 

It is fitting that the ILAE should celebrate 

their centenary with a film festival. 

Epilepsy has featured in films for almost 

100 years and continues to be a strong 

plot device for modern film makers. 

Whilst many of these films are not award 

winners, they often vividly convey the 

social and medical mores of the era in 

which they were made. Four films have 

been selected for screening as part 

of the ILAE centenary celebrations to 

showcase the history and development 

of the representation of epilepsy on 

the silver screen from the 1920’s to the 

21 st century.The four films are: To What 

Red Hell, Dr. Kildare’s Crisis, A Matter 

of Life and Death and Control. The 

showing of each film will be preceded 

by a brief introduction and followed by 

a short debate about the way epilepsy 

is depicted. 

Against the backdrop of this historical 

overview, the ILAE has also held a 

Centenary Film Competition, as 

part of its centenary celebrations, in 

order to encourage fresh perspectives 

on epilepsy and seizures in film.The 

competition was for the best film, in 

the opinion of the judges, made since 

January 2000 which was inspired by 

or related to epilepsy or seizures.The 

competition was not for educational 

or clinical films, but rather for creative 

or artistic works which used epilepsy 

as a theme directly or tangentially.The 

judging criterion was creative merit. 

The competition attracted entries from 

Europe, Asia, North and South America, 

Africa and the Middle East, representing 

many different film genres.These films 

were judged by a distinguished panel 

and at the congress, the award will be 

presented to the overall winner of this 

competition, who is Gus Cummins for 

his short film Ictal. The world premier 

screening of this short film will be held 

during the congress. 

There were also winners for the best fulllength 

feature film of the competition, 

Year of the Wolf, and the best 

documentary, Rachel: A Perfect Life. 

Both of these films will also be shown 

along with some of the runners-up, as 

part of the festival. 



The schedule for the ILAE Centenary Film Festival is as follows: 

Sunday 28 th June 


14:45 – 16:15 Welcome and Introduction to the Festival: Sallie Baxendale 

Early Cinematic Representations of Epilepsy 

Screening: To What Red Hell (1929) 

16:15 – 16:45 Debate 

Monday 29 th June 

10:00 – 12:15 ILAE Centenary Award for Film: Shorts Screening 

Stigma (2008) – runner up of the ILAE Centenary 

Film Competition 

A Better Waiting Room (2009) – runner up of the 

ILAE Centenary Film Competition 

Shaken (2009) – runner up of the ILAE Centenary 


14:00 - 14:10 Epilepsy under wraps Sallie Baxendale 

14:10 - 15:45 Screening: A Matter of Life & Death (1946) 

15:45 - 16:15 Debate 



Tuesday 30 th June 

10:30 – 12:00 Epilepsy and literature 

Wolf, P (Denmark) Chair 

8 

Epilepsy reflected in works of writers with epilepsy 

Wolf, P (Denmark) 

Literary descriptions of seizures 

Rajna, P (Hungary) 

Margiad Evans, centenary of an artist with epilepsy 

Pratt, J (UK) 


This session ’Epilepsy and literature’ connects an art film that was submitted to the 

cinema competition with an analysis of epilepsy and seizures in literature as it is 

described by writers with and without epilepsy. It specifically highlights the 

centenary of a writer and artist who was born in 1909, the foundation year of the ILAE. 

14:00 - 14:20 1930’s:The Eugenics Movement Simon Shorvon 

14:20 - 15:45 Screening: Dr Kildare’s Crisis (1940) 

15:45 – 16:20 Debate 

18:00 – 20:00 ILAE Centenary Award for Film 

Screening: Ictal (2009) – Overall Winner of 

the ILAE Centenary Film Competition 

Screening: Year of the Wolf (2007) – Winner of 

the best full length film in the ILAE Centenary 


Wednesday st July 

10:00 – 12:00 ILAE Centenary Award for Film 

Screening: Rachel: A Perfect Life (2008) 

– Winner of the best documentary film 

in the ILAE Centenary Film Competition 

14:00 – 14:10 Full Circle: Closing Comments Sallie Baxendale 

14:15 – 16:20 Screening: Control (2007) 

16:20 – 16:50 Debate 



Registration 

The Registration Area is located in 

the Registration Building near Gate 3 

of Hungexpo, beside Pavilion F 

(Exhibition Area). 

Congress Bags should be collected onsite 

in this area upon exchange of 

a voucher. 

Please note that name badges must be 

worn at all times. 

Speakers Room 

The Speakers Room is located behind 

Hall 1, at the end of Pavilion G . 

Please note that all speakers should 

submit their finalized PowerPoint 

presentations at the main desk in the 

Speakers Room no less than 3 hours in 

advance of their session. Speakers at 

early morning sessions are required to 

submit their material no later than 

17:00 on the evening before their 

session is scheduled. 

Posters 

Presenters should bring their 

acceptance letter and registration 

badge in order to gain access to the 

Poster Area, which will be located in 

Pavilion G. 

GENERAL CONGRESS INFORMATION 

Timetable: 

Mounting Time: Monday 29 th June 

from 08:00 to 09:00 

Viewing Time: Monday 29 th June to 

Wednesday 1 st July 

Dismantling Time: Wednesday 1 st July 

from 17:00 to 18:00 

The Scientific Advisory Committee 

would like to give the opportunity 

to poster presenters to meet with 

delegates who may have questions and 

would like to know more about the 

work presented. In order to facilitate this 

process, you may wish to be present at 

your poster during lunch between 12:00 

and 13:00. 

Exhibition 

The Exhibition Area is situated in 

Pavilion F, adjacent to the session 

rooms and Poster Area. Exhibition 

opening times are listed on the Facilities 

Timetable Overview. Exhibitor badges 

(pre-registered exhibitors only) will be 

available for collection at the exhibition 

desk situated in the Registration Area. 

Lunches and Coffee Breaks 

Lunch and coffee breaks will be served 

in the Exhibition Area. 



Facilities Timetable Overview 

0 


Sunday Monday Tuesday Wednesday Thursday 

Registration 08:00 - 19:00 07:00 - 18:00 07:00 - 18:00 07:00 - 17:30 07:00 - 13:30 

Speakers Room 08:00 - 19:00 07:00 - 18:00 07:00 - 18:00 07:00 - 17:30 07:00 - 12:00 

Posters - 09:00 - 18:00 09:00 - 18:00 09:00 - 18:00 - 

Exhibition - 09:00 - 17:00 09:00 - 17:00 09:00 - 17:00 09:00 - 12:00 

Coffee Breaks - 10:00 - 10:30 10:00 - 10:30 10:00 - 10:30 10:00 - 10:30 

- 15:30 - 16:00 15:30 - 16:00 15:30 - 16:00 - 

Lunch - 12:00 - 13:00 12:00 - 13:00 12:00 - 13.00 - 

Language 

The official language of the Congress 

is English; please note that translation 

facilities will not be provided. 

Replacement Badges 

Please note that replacement badges 

will be charged at a fee of Euro 50. 

Delegates should ensure that badges 

are kept at all times. 

Certificates of Attendance 

Certificates of attendance will be 

available for all delegates upon request 

at the registration desk. 

Congress Secretariat 

Members of the Congress Secretariat 

may be contacted at anytime at the 

Registration Area. For queries arising 

after the congress, please contact: 

28th International Epilepsy Congress 

ILAE / IBE Congress Secretariat 

7 Priory Hall 

Stillorgan 

Dublin 18 

Ireland 

Tel +353 1 2056720 

Fax +353 1 2056156 

Email info@epilepsycongress.org 

Congress Centre 

HUNGEXPO Budapest Fair Centre, 

H-1101 Budapest Albertirsai út 10, 

Budapest, Hungary 

www.hungexpo.hu 



Transport Information 

Transport to the Congress Centre (Hungexpo) 



Taxis 

Taxis are widely available all over Budapest and will take you anywhere around the 

city. It is advisable to set the price prior to the journey.Taxis may be booked at the 

Főtaxi desk in the registration area. 

Metro and Buses 

In order to reach the congress centre (Hungexpo), take the M2 (red) underground line 

to Örs vezér tere station which is the last stop.Turn right on leaving the station and 

walk approximately 100 metres to the bus stop for bus no. 100; this will take you to 

the entrance for the 28th International Epilepsy Congress (Gate 3 of Hungexpo). 

To return to the Örs vezér tere station, take the shuttle bus from Gate 3. 

Discounted travel cards can be purchased at any metro station and also the City/Tour 

Information desk in the registration area: 3-day (3,500 HUF) or 7-day (4,000 HUF). 

Transport maps as well as timetables for the bus number 100 and the metro line M2 

are available to pick up at the registration area. 

For any further information or assistance during the congress, please ask at the City/ 

Tour Information desk in the registration area.


On-site Information 

Liability and Insurance 

The congress organisers will not 

accept liability for personal injury or 

loss/damage to property/belongings of 

participants or accompanying persons, 

either before, during or following the 

congress, tours or their stay in Budapest. 

It is therefore recommended that 

participants arrange their own personal 

health, accident and travel insurance. 

IBE General Assembly 

The IBE General Assembly will take place 

on Wednesday 1 st July, 13:00 - 17:00, 

in Hall 7. 

ILAE General Assembly 

The ILAE General Assembly will take 

place on Wednesday 1 st July, 

17:00 - 18:30, in Room 25. 

IBE Members Poster Display 

Following successful displays in Paris 

and Singapore, IBE is organising another 

display of posters in Budapest to 

highlight the activities and achievement 

of its members.This initiative has been 

very popular with IBE members and 

congress delegates. IBE is expecting 

almost 50 members to take part in this 

initiative in Budapest. 

2 


Smoking Policy Smoking is only permitted outside of the pavillions. 

Cloakroom Cloakroom facilities are available near the entrance to pavillions G 

(coats & luggage) by Hall 1. It is open daily from the beginning of the first session 

until the end of the last session. A small charge is applicable. 

Wheelchair Accessibility All parts of Hungexpo are wheelchair accessible. 

Message Board The Message Board is situated in the Registration Area. 

Delegates are advised to check it regularly. 

Speakers Room The Speakers Room is located in Pavilion G, beside Hall 1 

Internet Centre The Internet Centre is located in the Exhibition Area. 

ATM / Bank A bank and ATM machine are located behind Building 25. 

The bank opening hours are 09:00 – 17:00. 

The IBE Members Poster Display 

promotes the international exchange 

of information and ideas about how 

IBE members operate, the issues they 

address and the services they provide. 

This initiative allows the international 

epilepsy community to learn from each 

other, build their resource capacity and 

be more effective. 

The IBE Members Poster Display 

will be on permanent display during 

the congress. 



MAIN SPONSORS 

The congress would like to thank the 

following companies for their support: 

SOCIAL EVENTS 

Opening Ceremony and 

Welcome Reception 

The Opening Ceremony will take place 

on Sunday 28th June at 19:00 in Hall 

1 in Hungexpo.The Ceremony will 

open with welcome addresses from 

representatives of IBE and ILAE as well 

as the congress’ committees.This will 

be followed by the Awards Ceremony, 

which this year will consist of the 

Ambassador for Epilepsy Award, the 

Award for Social Accomplishment, the 

Michael Prize, the Morris-Coole Prize 

and the Lifetime Achievement Award. 

Further details on these awards can 

be found on pages 17 -19 and in the 

Awards Booklet which will be available 

at the Opening Ceremony. 

All delegates are welcome to join a 

Welcome Reception which will be held 

after the Opening Ceremony in the 

lobby outside Hall 1. 


Gala Dinner 

A Gala Dinner will be held in the 

Hungarian National Gallery in Buda 

Castle overlooking the river Danube 

on the evening of Wednesday 1 st July. 

Please note that this is a ticketed event 

and that advance booking is required. 

Entry to the collection of Late Gothic 

Winged Altarpieces is included with the 

gala dinner. For further details on this 

unique event including transportation 

details, please go to the Social Events 

Desk in the Registration Area. 

Tours 

Budapest and the beautiful countryside 

of Hungary present a wealth of culture 

and history that will appeal to all 

delegates and accompanying persons 

attending the 28 th IEC. A wide range of 

full and half-day excursions are available 

daily throughout the congress and can 

be booked with Asszisztencia at the 

Tours Desk in the Registration Area. 



BUDAPEST PRACTICAL 

INFORMATION 

Business Hours 

Generally, shops are open Monday 

to Friday from 10:00 to 18:00 and on 

Saturdays from 10:00 to 13:00. Some 

supermarkets also open on Sunday. In 

the city centre there are several 24-hour 

shops that sell basic products. 

Currency 

The unit of currency is Hungarian Forint 

(HUF). In Hungary the abbreviation 

of Forint is Ft. Coins: 1, 2, 5, 10, 20, 50, 

100 HUF. Bank notes: 200, 500, 1,000, 

2,000, 5,000, 10,000, 20,000 HUF. As 

of May 2009, one Euro was worth 290 

Hungarian Forints; one US$ was worth 

212 Hungarian Forints. A bank and cash 

machine are located onsite at Hungexpo 

behind Building 25 (opening hours: 

from 09:00 to 17:00). 

4 


Credit Cards 

All of the most popular credit, debit and 

charge cards (AMEX, Diners Club, Cirrus, 

EnRoute, Euro/Mastercard, JCB and 

VISA) can be used in banks and in ATM’s 

to withdraw money, and also in hotels, 

restaurants and shops for purchases 

(signs are displayed at the entrance 

of the shops and restaurants showing 

which cards are acceptable). 

Electricity 

The voltage in Hungary is 230 volts 

and plugs are the two-pin continental 

European type. 

Communications 

Reliable internet access is readily 

available in hotels and internet centres 

located throughout Budapest. 

Time Difference 

Budapest is in the Central European 

Time Zone (Greenwich Mean Time 

+ 1 hour / U.S. Eastern Standard Time 

+ 6 hours). 



REGISTRATION AREA 

SESSION ROOMS 

POSTER AREA 

SPEAKERS ROOM 

BUSINESS MEETING ROOMS 

EXHIBITION AREA 

INTERNET CENTRE 

LUNCH & COFFEE BREAKS 

CAFÉ 

Congress Entrance 

(HUNGEXPO Gate 3) 

Bus drop off point 

CONGRESS CENTRE FLOOR PLAN 

Room 25 

Room 107 

Room 109 

Room 110 

Room 113 

Room 114 

Room 117 

Room 119 

Press Room 

Speakers 

Room 

HALL 

5 

HALL 

6 

HALL 

1 

PAVILION G 

Internet 

Centre 

HALL 

2 

POSTER 

AREA 

PAVILION F 

EXHIBITION 

AREA 

Main 

Entrance 

Bank 

ATM 

Building 25 

PASSAGE 

www.epilepsybudapest2009.org 5 

HALL 

7 

HALL 

3 

HALL 

4 

Gallery 

Room 

REGISTRATION

GENERAL SCIENTIFIC INFORMATION 

PRESIDENTIAL SYMPOSIUM 

Presidential Symposium 

909 - 2009: a century of achievements 

Lund, S (Sweden) & Wolf, P (Denmark) Chair 

History medical and social 

Reynolds, EH (UK) 

Stigma: has perception of epilepsy changed at all? 

Acevedo, C (Chile) 

The role of genetic discoveries 

Avanzini, G (Italy) 

Paths to seizure freedom: the achievements in 

epilepsy treatment 

Andermann, F (Canada) 

Political influence and impact - has epilepsy legislation 

been successful? 

Lee, P (UK) 

The future hopes and aspirations perspective: 

where are we going? 


6 


Many developments and many changes have occurred about epilepsy in the 100 

years of the ILAE’s existence, and the League has contributed to many of them. 

Numerous examples can be found in the programme of our Centenary Congress. In 

this symposium we wish to highlight and review some of the developments which 

we consider particularly important, both in the medical and the social field. At the 

end we will try to make some guesses into where epileptology will move in the 

coming years. 



The Highlights Session 

The Highlights Session will be held 

on Thursday 2 nd July between 

12:00 and 13:30. 

Delegates will be offered a unique 

opportunity to attend a concluding 

session with the participation of all 

chairs of the seven main topics 

debated during the 28 th International 

Epilepsy Congress. 

Organised by the co-chairs of the 

Scientific Advisory Committee, 

this special session will include a 

commented selection of original data 

presented during the Congress. 

EUREPA / VIREPA Sessions 

EUREPA teaching sessions will be held 

between 07:30 and 09:00 on Monday, 

Tuesday, Wednesday and Thursday.There 

will be four sessions entitled ‘Comorbidity 

in epilepsy’,‘Epilepsy in infants and 

children’,‘Differential diagnosis of 

epileptic and non-epileptic events’ and 

‘Surgical treatment of epilepsy’.These will 

be case-oriented learning sessions, free 

of charge and available to all registered 

congress participants. 


In addition, Introductory Sessions to 

the VIREPA (Virtual Epilepsy Academy) 

programme will take place every day 

from 07:30 to 09:00. At the end of these 

sessions, a short description of the 

course format will be given. Further 

information on these VIREPA courses 

is available at the EUREPA / Epilepsy 

Academy booth in the Exhibition Hall. 

Scientific Exhibit 

UCB Pharma will hold a Scientific Exhibit 

on Tuesday 30 th June from 09:00 to 

17:00 in Room 25 in Building 25. 

AWARDS 

Bursary for Young Investigator Awardees 

Bursary for Young Investigator 

In order to further encourage Young 

Investigators to participate in the 

28 th International Epilepsy Congress, 

a number of Bursaries for Young 

Investigators have been awarded to 

assist with registration, travel and 

accommodation expenses. 

First Name Last Name Country 

Keryma Acevedo Chile 

Satish Bajaj Nepal 

Daniela Brazzo UK 

Rebecca Bromley UK 

Benedetta Frassine Italy 

Aslihan Gunel Turkey 

Silvia Regina Bica Kohek Brazil 

Pushpalatha Sudhakar Lakkunta India 

Eliângela Lima Brazil 

Tuan Nguyen Anh Vietnam 

Litsa Nikitidou Sweden 

Natela Okujava Georgia 

Fabricio Pereira Brazil 

Nehama Prus USA 

Ashalatha Radhakrishnan India 

Kiarash Riazi Canada 

Garima Shukla India 

Andreas Toft Sorensen Sweden 

Jan Tønnesen Sweden 



The Michael Prize 

Presented bi-annually, this prize was 

originally set up to stimulate epilepsy 

research among young scientists 

in Germany. 

It has now developed into an 

international award for the best 

scientific and clinical research, 

promoting further development 

in epileptology. 

The recipients of the Michael Prize 

2009 are: 

Hrissanthi Ikonomidou (USA) 

Ivan Soltesz (USA) 

The presentation of this award will take 

place during the Opening Ceremony 

on Sunday evening.The winning 

researchers will also present their 

papers during the Prize Symposium to 

be held on Monday 29 th June between 

16:00 and 17:30 in Hall 5. 

The Morris-Coole Prize 

The Morris-Coole prize awarded by 

ILAE is the initiative of Mr. and Mrs. 

Christopher Morris-Coole, from London, 

who have endowed the prize. 

The annual prize of €10,000 is awarded 

to the first author of the paper 

published in Epilepsia during the 

preceding year which has, in the judges’ 

opinion, made the most significant 

advance in knowledge in the field 

of epilepsy. 

The prize has been awarded to 

Dr. Julia Jacobs for her abstract entitled: 

‘Interictal high-frequency oscillations 

(80-500 Hz) are an indicator of seizure 

onset areas independent of spikes in the 

human epileptic brain.’ 

(Epilepsia. 2008 49:1893-907). 

Her findings will be presented during 

the Prize Symposium on Monday 29 th 

June from 16:00 - 17:30 in Hall 5. 

8 


Lifetime Achievement Award 

The Lifetime Achievement Award 

in Epilepsy is given jointly by the 

International Bureau for Epilepsy (IBE) 

and the International League against 

Epilepsy (ILAE).The Award is given to 

an individual to recognise and honour 

his or her exceptional and outstanding 

personal contribution over a long 

period of time to activities that advance 

the cause of epilepsy. 

The Award reflects international 

peer recognition. It consists of two 

commemorative and inscribed silver 

candlesticks, a financial prize of 

US$5,000, a scroll and the name of 

each recipient is added to the Lifetime 

Achievement Award winners’ Hall of 

Fame maintained by IBE and ILAE. 

This Award is the highest honour of IBE 

and ILAE. 

The recipients of the Lifetime 

Achievement Award are: 

Jean Aicardi (France) 

Hanneke De Boer (The Netherlands) 

Social Accomplishment Award 

The Social Accomplishment Award 

in Epilepsy is given jointly by the 

International Bureau for Epilepsy (IBE) 

and the International League against 

Epilepsy (ILAE) every two years. It is 

given to an individual to recognise his or 

her outstanding personal contribution 

to activities that have resulted in a 

significant advance in the social wellbeing 

and / or quality of life of people 

with epilepsy. 

The Award reflects international peer 

recognition. It consists of an engraved 

glass trophy, a financial prize of 

US$5,000, a certificate and the name of 

each recipient is added to the Award 

winners’ Hall of Fame maintained by IBE 

and ILAE. 

The recipient of the Social 

Accomplishment Award is: 

Michael Hills (New Zealand) 



Ambassador Awards 

The Ambassador for Epilepsy Award is 

given jointly by the International Bureau 

for Epilepsy (IBE) and the International 

League against Epilepsy (ILAE) and not 

more than 12 Awards will be given at 

any one time. 

The Award recognises outstanding 

personal contributions to activities 

that advance the cause of epilepsy. 

The Award reflects international peer 

recognition and it is given for the 

lifetime of the recipient. 

The following recipients will be 

presented with an Ambassador’s pin 

during the Opening Ceremony of the 

28 th International Epilepsy Congress. 

This brings to 277 the total number of 

Ambassadors for Epilepsy created since 

the award was first introduced at the 

suggestion of IBE in 1968. 

The recipients for Ambassador for 

Epilepsy Award are: 

Ettore Beghi (Italy) 

Anne T. Berg (USA) 

Warren Blume (Canada) 

Norman Delanty (Ireland) 

Jacqueline A. French (USA) 

Shung-Lon Lai (Taiwan) 

Shichuo Li (China) 

Cigdem Ozkara (Turkey) 

Lilia Núñez-Orozco (Mexico) 

Ernest Somerville (Australia) 

Carol D’Souza (India) 

William H. Theodore (USA) 

Volunteer Award 

The International Bureau for Epilepsy 

(IBE) is aware of the tremendous efforts 

of volunteers working with IBE member 

associations at local and national level 

to improve conditions for all those 

affected by epilepsy.To recognize the 

spirit of these steadfast volunteers, the 

International Executive Committee has 

launched the IBE Volunteer Award. 


The purpose of the Award is to highlight 

the dedication and selflessness of those 

who work without financial reward to 

improve the quality of life for people 

with epilepsy.The award is presented 

every two years to an individual who 

has carried out outstanding activities, 

on a voluntary basis, which have made a 

difference at national level. 

The Volunteer Award will be presented 

during the IBE General Assembly on 

Wednesday 1 st July.The name of the 

recipient will not be announced until 

the event. 

CME ACCREDITATION 

The 28 th International Epilepsy 

Congress is accredited by the European 

Accreditation Council for Continuing 

Medical Education (EACCME) to provide 

CME activity for medical specialists. 

The EACCME is an institution of the 

European Union of Medical Specialists 

(UEMS). Please view www.uems.net for 

further details. 

The 28 th International Epilepsy 

Congress is designated for a maximum 

of 2 hours of European external 

CME credits. 

Each medical specialist should claim 

only those hours of credit that 

he/she actually spent in the 

educational activity. 

EACCME credits are recognized by the 

American Medical Association towards 

the Physician’s Recognition Award (PRA). 

To convert EACCME credit to AMA PRA 

category 1 credit, contact the AMA. 

Please view http://www.ama-assn.org 

for further details. 

The statement of accreditation will 

be incorporated into the attendance 

certificates issued to fully registered 

delegates during the congress. Please 

contact the Congress Secretariat in the 

Registration Area if you require further 

information on the issuance of 

CME Accreditation. 


07:30 - 07:45 

07:45 - 08:00 

08:00 - 08:15 

08:15 - 08:30 

08:30 - 08:45 

08:45 - 09:00 

09:00 - 09:15 

09:15 - 09:30 

09:30 - 09:45 

09:45 - 10:00 

10:00 - 10:15 

10:15 - 10:30 

10:30 - 10:45 

10:45 - 11:00 

11:00 - 11:15 

11:15 - 11:30 

11:30 - 11:45 

11:45 - 12:00 

12:00 - 12:15 

12:15 - 12:30 

12:30 - 12:45 

12:45 - 13:00 

13:00 - 13:15 

13:15 - 13:30 

13:30 - 13:45 

13:45 - 14:00 

14:00 - 14:15 

14:15 - 14:30 

14:30 - 14:45 

14:45 - 15:00 

15:00 - 15:15 

15:15 - 15:30 

15:30 - 15:45 

15:45 - 16:00 

16:00 - 16:15 

16:15 - 16:30 

16:30 - 16:45 

16:45 - 17:00 

17:00 - 17:15 

17:15 - 17:30 

17:30 - 17:45 

17:45 - 18:00 

18:00 - 18:15 

18:15 - 18:30 

18:30 - 18:45 

18:45 - 19:00 

19:00 - 19:15 

19:15 - 19:30 

19:30 - 19:45 

19:45 - 20:00 

20:00 - 20:15 

20:15 - 20:30 

20:30 - 20:45 

20:45 - 21:00 

SCIENTIFIC PROGRAMME 

FULL WEEK TIMETABLE 

20 

Sunday 

28 th June 

Special Interest Group 

10:30 - 12:30 

Ring 

Chromosome 

20 Symposium 

14:00 - 16:00 

Centenary 

Film Festival 

14:45 - 16:45 

Presidential Symposium 

17:00 - 18:30 

Opening Ceremony 

19:00 - 20:00 

Welcome Reception 

20:00 - 21:00 

Set up 

Posters 

Monday 

29 th June 

Morning Seminars 

07:30 - 09:00 

Autonomic functions and biorythmicity 

09:00 – 10:00 

Autonomic 

functions 

10:30 - 12:00 

Centenary Film 

Festival 


Tuesday 

30 th June 


07:30 - 09:00 

Coffee Break Coffee Break 

Cof 

Parallel 

Sessions 

10:30 - 

12:00 

Lunch 

- Posters - 

Platform 

Sessions 

10:30 - 

12:00 

UCB Pharma Satellite Symposium 

13:00 - 14:30 

Should we treat the family? 

14:30 - 15:30 

Should we 

treat the 

family? 

16:00 - 17:30 


Festival 

Posters 

Beyond the 

medical 

model 

10:30 - 12:00 

Beyond the medical model 

09:00 - 10:00 

Parallel 

Sessions 

10:30 - 12:00 

Lunch 

- Posters - 

Platform 

Sessions 

10:30 - 

12:00 

Eisai Europe Ltd. Satellite Symposium 

13:00 - 14:30 

Brain development, plasticity and 

epilepsy 

14:30 - 15:30 

Epilepsy in 

Literature 


Festival 


Posters 

Dismantle 

W 

Mo 

0 

The need 

The need for 

comprehensive 

care 

10:30 - 12:00 

GlaxoSmithKlin 

13: 

Models to 

epile 

14: 

Coffee Break Coffee Break Cof 

Parallel 

Sessions 

16:00 - 

17:30 

Platform 

Sessions 

16:00 - 

17:30 

Merritt - Putnam Symposium 

18:00 - 19:30 

Brain 

development, 

plasticity and 

epilepsy 

16:00 - 17:30 

Session topics 

Main Session Post Main Session 

Parallel 

Sessions 

16:00 - 17:30 

Platform 

Sessions 

16:00 - 17:30 


Festival 

Identifying and 

screening new 

AEDs 

16:00 - 17:30 

G

day 

June 

Seminars 

- 09:00 

medical model 

0 - 10:00 

ee Break 

Platform 

llel 

Sessions 

ons 

10:30 - 

12:00 

12:00 

unch 

osters - 

tellite Symposium 

14:30 

t, plasticity and 

sy 

15:30 


FULL WEEK TIMETABLE 


Literature 


Festival 

Posters 

Dismantle 

Wednesday 

1 st July 


07:30 - 09:00 

The need for comprehensive care 

09:00 - 10:00 

The need for 

comprehensive 

care 

10:30 - 12:00 

Coffee Break 

Parallel 

Sessions 

10:30 - 

12:00 

Lunch 

- Posters - 

Platform 

Sessions 

10:30 - 

12:00 

GlaxoSmithKline Satellite Symposium 

13:00 - 14:30 

Models to study acquired 

epileptogenesis 

14:30 - 15:30 

reak Coffee Break 

llel 

ons 

17:30 

Platform 

Sessions 

16:00 - 17:30 


Festival 


screening new 

AEDs 

16:00 - 17:30 

Parallel 

Sessions 

16:00 - 

17:30 

Gala Evening 

20:00 - late 

Platform 

Sessions 

16:00 - 

17:30 


Festival 

Centenary Film Festival 


Neuroimaging 

and nosology 

10:30 - 12:00 

Thursday 

2 nd July 


07:30 - 09:00 

Neuroimaging and nosology 

09:00 - 10:00 

Coffee Break 

Parallel 

Sessions 

10:30 - 12:00 


12:00 - 13:30 

Platform 

Sessions 

10:30 - 

12:00 

07:30 - 07:45 

07:45 - 08:00 

08:00 - 08:15 

08:15 - 08:30 

08:30 - 08:45 

08:45 - 09:00 

09:00 - 09:15 

09:15 - 09:30 

09:30 - 09:45 

09:45 - 10:00 

10:00 - 10:15 

10:15 - 10:30 

10:30 - 10:45 

10:45 - 11:00 

11:00 - 11:15 

11:15 - 11:30 

11:30 - 11:45 

11:45 - 12:00 

12:00 - 12:15 

12:15 - 12:30 

12:30 - 12:45 

12:45 - 13:00 

13:00 - 13:15 

13:15 - 13:30 

13:30 - 13:45 

13:45 - 14:00 

14:00 - 14:15 

14:15 - 14:30 

14:30 - 14:45 

14:45 - 15:00 

15:00 - 15:15 

15:15 - 15:30 

15:30 - 15:45 

15:45 - 16:00 

16:00 - 16:15 

16:15 - 16:30 

16:30 - 16:45 

16:45 - 17:00 

17:00 - 17:15 

17:15 - 17:30 

17:30 - 17:45 

17:45 - 18:00 

18:00 - 18:15 

18:15 - 18:30 

18:30 - 18:45 

18:45 - 19:00 

19:00 - 19:15 

19:15 - 19:30 

19:30 - 19:45 

19:45 - 20:00 

20:00 - 20:15 

20:15 - 20:30 

20:30 - 20:45 

20:45 - 21:00 


SUNDAY 28 TH JUNE 2009 



22 

Hall 1 Hall 6 


07:30 - 07:45 07:30 - 07:45 

07:45 - 08:00 07:45 - 08:00 

08:00 - 08:15 08:00 - 08:15 

08:15 - 08:30 08:15 - 08:30 

08:30 - 08:45 08:30 - 08:45 

08:45 - 09:00 08:45 - 09:00 

09:00 - 09:15 09:00 - 09:15 

09:15 - 09:30 09:15 - 09:30 

09:30 - 09:45 09:30 - 09:45 

09:45 - 10:00 09:45 - 10:00 

10:00 - 10:15 10:00 - 10:15 

10:15 - 10:30 10:15 - 10:30 

10:30 - 10:45 10:30 - 10:45 

10:45 - 11:00 10:45 - 11:00 

11:00 - 11:15 11:00 - 11:15 

11:15 - 11:30 Special Interest Group: 11:15 - 11:30 

11:30 - 11:45 sleep and epilepsy 11:30 - 11:45 

11:45 - 12:00 11:45 - 12:00 

12:00 - 12:15 12:00 - 12:15 

12:15 - 12:30 12:15 - 12:30 

12:30 - 12:45 12:30 - 12:45 

12:45 - 13:00 12:45 - 13:00 

13:00 - 13:15 13:00 - 13:15 

13:15 - 13:30 13:15 - 13:30 

13:30 - 13:45 13:30 - 13:45 

13:45 - 14:00 13:45 - 14:00 

14:00 - 14:15 14:00 - 14:15 

14:15 - 14:30 14:15 - 14:30 

14:30 - 14:45 14:30 - 14:45 

14:45 - 15:00 Ring Chromosome 20 14:45 - 15:00 

15:00 - 15:15 Symposium 15:00 - 15:15 

15:15 - 15:30 15:15 - 15:30 

15:30 - 15:45 Centenary Film 

15:30 - 15:45 

15:45 - 16:00 Festival 

15:45 - 16:00 

16:00 - 16:15 16:00 - 16:15 

16:15 - 16:30 16:15 - 16:30 

16:30 - 16:45 16:30 - 16:45 

16:45 - 17:00 16:45 - 17:00 

17:00 - 17:15 17:00 - 17:15 

17:15 - 17:30 17:15 - 17:30 

17:30 - 17:45 Presidential 

17:30 - 17:45 

17:45 - 18:00 Symposium 

17:45 - 18:00 

18:00 - 18:15 18:00 - 18:15 

18:15 - 18:30 18:15 - 18:30 

18:30 - 18:45 18:30 - 18:45 

18:45 - 19:00 18:45 - 19:00 

19:00 - 19:15 19:00 - 19:15 

19:15 - 19:30 

19:30 - 19:45 Opening Ceremony 

19:15 - 19:30 

19:30 - 19:45 

19:45 - 20:00 19:45 - 20:00 

20:00 - 20:15 20:00 - 20:15 

20:15 - 20:30 

20:30 - 20:45 Welcome Reception 

20:15 - 20:30 

20:30 - 20:45 

20:45 - 21:00 20:45 - 21:00 





0:30 - 2:30 Special Interest Group Hall 6 

The influence of therapy on the interaction 

epilepsy and sleep 

Influence of drugs acting on the GABA-A receptor 

complex on generalized paroxysmal fast activity: 

improvement or worsening? 

Kelemen, A (Hungary) & Halasz, P (Hungary) 

Circadian rhythms in epilepsy and the influence 

of AEDs 

Hofstra, W (The Netherlands) & De Weerd, A (The Netherlands) 

Case discussions 

Van Emde Boas, W (The Netherlands), Nobili, L (Italy), 

De Weerd, A (The Netherlands) 

4:00 - 6:00 Satellite Symposium Hall 6 

The Ring Chromosome 20 Foundation symposium 

Berkovic, S (Australia) Chair 

Ring Chromosome 20 epilepsy syndrome: is there a 

distinct phenotype? 

Hosain, SA (USA) 

Molecular analysis of Ring Chromosome 20 reveals 

two distinct subgroups 

Spinner, NB (USA) 

Dopamine metabolism in patients with epilepsy 

associated with Ring 20 mosaicism: physiological 

and possible therapeutic consequences 

Biraben, A (France) 


SUNDAY 28 TH JUNE 2009




24 


4:45 - 6:45 Film Screening Hall 

Welcome and introduction to the festival: 

early cinematic representations of epilepsy 

Baxendale, S (UK) Chair 

Screening: To What Red Hell ( 929) 

Debate 

7:00 - 8:30 Presidential Symposium Hall 

909 - 2009: a century of achievements 

Lund, S (Sweden) & Wolf, P (Denmark) Chairs 

History medical and social 

Reynolds, EH (UK) 

Stigma: has perception of epilepsy changed at all? 

Acevedo, C (Chile) 

The role of genetic discoveries 

Avanzini, G (Italy) 

Paths to seizure freedom: the achievements in 

epilepsy treatment 

Andermann, F (Canada) 

Political influence and impact: has epilepsy 

legislation been successful? 

Lee, P (UK) 

The future hopes and aspirations perspective: 

where are we going? 





MONDAY 29 TH JUNE 2009 



07:30 - 07:45 

07:45 - 08:00 

08:00 - 08:15 

08:15 - 08:30 

08:30 - 08:45 

08:45 - 09:00 

09:00 - 09:15 

09:15 - 09:30 

09:30 - 09:45 

09:45 - 10:00 

10:00 - 10:15 

10:15 - 10:30 

10:30 - 10:45 

10:45 - 11:00 

11:00 - 11:15 

11:15 - 11:30 

11:30 - 11:45 

11:45 - 12:00 

12:00 - 12:15 

12:15 - 12:30 

12:30 - 12:45 

12:45 - 13:00 

13:00 - 13:15 

13:15 - 13:30 

13:30 - 13:45 

13:45 - 14:00 

14:00 - 14:15 

14:15 - 14:30 

14:30 - 14:45 

14:45 - 15:00 

15:00 - 15:15 

15:15 - 15:30 

15:30 - 15:45 

15:45 - 16:00 

16:00 - 16:15 

16:15 - 16:30 

16:30 - 16:45 

16:45 - 17:00 

17:00 - 17:15 

17:15 - 17:30 

17:30 - 17:45 

17:45 - 18:00 

18:00 - 18:15 

26 

Poster 

Area 

Posters set 

up 

Posters 

Authors of 

Posters present 

12:00 - 13:00 

Posters 


Hall 1 Hall 2 Hall 3 Hall 4 

Autonomic functions 

and biorythmicity 

Autonomic functions 

and biorythmicity 

UCB Pharma Satellite 

Symposium 

Should we treat the 

family? 

Should we treat the 

family? 

The variability of 

absence seizures and 

syndromes across 

ages 

Coffee Break 10:00 - 10:30 

Platform: 

Clinical epileptology 

Lunch 12:00 - 13:00 


Platform: 

Drug therapy 

Catastrophic 

epilepsies caused by 

cortical dysplasia in 

early childhood 

100 years of Epilepsia: 

landmark papers and 

their influence 

Imaging depression in 

epilepsy 

18:15 - 18:30 So 

18:30 - 18:45 Merritt-Putnam 

Dru 

18:45 - 19:00 Symposium 

Su 

19:00 - 19:15 Dia 

19:15 - 19:30 Sp 


Mechanism 

interictal spike 

Brain develo 

plasticity and e 

in childre 

Mechanism 

aberrant g 

expression re 

in epileptoge 

Ge



all 3 Hall 4 Hall 5 Hall 6 

astrophic 

es caused by 

dysplasia in 

childhood 

s of Epilepsia: 

k papers and 

influence 

depression in 

ilepsy 

Mechanisms of 

interictal spike genesis 

Brain development, 

plasticity and epilepsy 

in children 

Mechanisms of 

aberrant gene 

expression regulation 

in epileptogenesis 

Clinical pharmacology 

and pharmacotherapy 


Infections and 

inflammation 

Lunch 12:00 - 13:00 


The Prize Symposium 


07:30 - 07:45 

07:45 - 08:00 

08:00 - 08:15 

08:15 - 08:30 

08:30 - 08:45 

08:45 - 09:00 

09:00 - 09:15 

09:15 - 09:30 

09:30 - 09:45 

09:45 - 10:00 

10:00 - 10:15 

10:15 - 10:30 

10:30 - 10:45 

10:45 - 11:00 

11:00 - 11:15 

11:15 - 11:30 

11:30 - 11:45 

11:45 - 12:00 

12:00 - 12:15 

12:15 - 12:30 

12:30 - 12:45 

12:45 - 13:00 

13:00 - 13:15 

13:15 - 13:30 

13:30 - 13:45 

13:45 - 14:00 

14:00 - 14:15 

14:15 - 14:30 

14:30 - 14:45 

14:45 - 15:00 

15:00 - 15:15 

15:15 - 15:30 

15:30 - 15:45 

15:45 - 16:00 

16:00 - 16:15 

16:15 - 16:30 

16:30 - 16:45 

16:45 - 17:00 

17:00 - 17:15 

17:15 - 17:30 


17:30 - 17:45 

17:45 - 18:00 

18:00 - 18:15 

Social issues Neuropsychology 18:15 - 18:30 

Drug therapy Paediatric epileptology 18:30 - 18:45 

Surgery Satellite Symposium 18:45 - 19:00 

Diagnostics Neuroimaging 19:00 - 19:15 

Special session Clinical epileptology 19:15 - 19:30 

Genetics Basic science 

Comorbidity in epilepsy 

Platform: 

Neuroprotection and 

therapy 

Platform: 

Pathophysiology 

Hall 7 


Festival 


Festival 


MONDAY 29 TH JUNE 2009




28 


07:30 - 09:00 Teaching Session Hall 2 

The variability of absence seizures and 

syndromes across ages 

Covanis, A (Greece) Chair 

Absence seizures and syndromes in infancy 

and childhood 

Covanis, A (Greece) 

Absence seizures and syndromes in adolescence 

and adulthood 

Trinka, E (Austria) 

Focal seizures and EEG abnormalities in children 

and adults with absence seizures syndromes 

Koutroumanidis, M (UK) 


Catastrophic epilepsies caused by cortical 

dysplasia in early childhood 

Komarek, V (Czech Republic) Chair 

Electroclinical syndromes associated with cortical 

dysplasia in early childhood 

Krsek, P (Czech Republic) 

Neuroimaging in early catastrophic epilepsies 

Woermann, F (Germany) 

Long-term surgical outcome of children operated 

on because of cortical dysplasia in early childhood 

Cross, H (UK) 





07:30 - 09:00 Workshop Hall 4 

Mechanisms of interictal spike genesis 

Halász, P (Hungary) Chair 

Cellular and circuit mechanisms of interictal spiking 

De Curtis, M (Italy) 

EEG spikes and fast ripples as indicators of regional 

and local pathology 

Bragin, A (USA) 

Laminar analysis of cortical origin interictal spikes 

Ulbert, I (Hungary) 

Laminar origin of interictal spike associated high 

frequency oscillations in the human hippocampus 

Fabo, D (Hungary) 

Induction of epileptiform discharges by 

electrical stimulation 

Valentin, A (UK) 

07:30 - 09:00 VIREPA Introduction Session Hall 5 

Clinical pharmacology and pharmacotherapy 

(co-organised with the ILAE Commission on 

Therapeutic Strategies) 

The choice of the first AED 

French, J (USA) 

Therapeutic drug monitoring in the management 

of epilepsy 

Perucca, E (Italy) 

07:30 - 09:00 EUREPA Teaching Session Hall 6 

Comorbidity in epilepsy 

Guekht, A (Russia) Chair 

Psychiatric comorbidity: diagnosis and treatment 

Schmitz, B (Germany) 

Elderly 

Guekht, A (Russia) 

Pharmacokinetic problems in somatic comorbidities 

Johannessen, S (Norway) & 

Johannessen-Landmark, C. (Norway) 






30 


09:00 - 0:00 Main Session Hall 


Fogarasi, A (Hungary) Chair 

Circadian rhythms, seizures and epilepsy 

Quigg, M (USA) 

Ultradian cyclicity and beyond: NREM sleep 

microcycles and epilepsy 

Halász, P (Hungary) 

0:00 - 2: 5 Film Screening Hall 7 

ILAE Centenary Award for Film: Shorts Screening 

Stigma (2008) 

Runner up of the ILAE Centenary Film Competition 

A Better Waiting Room (2009) 


Shaken (2009) 


0:30 - 2:00 Post Main Session Hall 


Fogarasi, A (Hungary) Chair 

Autonomic symptoms in adults with epilepsy 

Janszky, J (Hungary) 

Autonomic symptoms in childhood epilepsies 

Fejerman, N (Argentina) 

Interictal and ictal electrocardiographic changes 

Baumgartner, C (Austria) 

Peri-ictal cardiac and respiratory abnormalities: 

do they increase the risk of SUDEP? 

Tomson, T (Sweden) 





0:30 - 2:00 Platform Session Hall 2 


Ryvlin, P (France) & Juhos, V (Hungary) Chairs 

0:30 - 2:00 Parallel Session Hall 3 

00 years of Epilepsia: landmark papers and their influence 

Shorvon, S (UK) Chair 

Neuropsychiatry of epilepsy 

Hermann, B (USA) 

Epidemiology of epilepsy 

Beghi, E (Italy) 

Investigation of epilepsy 

Sperling, MR (USA) 

Treatment of epilepsy 

Cook, M (Australia) 


Brain development, plasticity and epilepsy 

in children 

Mathern, GW (USA) Chair 

Abnormal human brain development: molecular 

mechanisms and neuroimaging 

Guerrini, R (Italy) 

Strategies and pre-surgical evaluation of children 

with refractory epilepsy 

Harvey, S (Australia) 

International practice of paediatric epilepsy surgery 

Mathern, GW (USA) 

Developmental plasticity and early surgery: 

evidence based data 

Cross, H (UK) 






32 



Infections and inflammation 

Al Yamani, S (Saudi Arabia) Chair 

Addressing neurocysticercosis in epilepsy 

Garcia, HH (Peru) 

HIV and epilepsy 

Birbeck, G (USA) 

Tuberculosis and epilepsy 

Singh, G (India) 


Neuroprotection and therapy 

Pitkanen, A (Finland) & Freund, T (Hungary) Chairs 

3:00 - 4:30 Satellite Symposium Hall 

Satellite Symposium UCB Pharma: Management 

of inadequately controlled epilepsy: evaluating 

the evidence 

Berkovic, SF (Australia) Chair 

Expectations vs reality: pharmacology of 

antiepileptic drugs 

Patsalos, P (UK) 

Inadequately controlled epilepsy: evidence-based 

decision-making in clinical practice 

Sander, L (UK) 

Treatment options for inadequately controlled 

epilepsy: what next? 

Steinhoff, B (Germany) 

4:00 - 6: 5 Film Screening Hall 7 

Epilepsy under wraps 


Screening: A Matter of Life & Dead ( 946) 

Debate 







Núñez Orozco, L (Mexico) Chair 

Family and epilepsy: an overview 

Núñez Orozco, L (Mexico) 

Overprotection vs rejection 

Kanner, AM (USA) 

Burden of the caregiver 

Yacubian, EM (Brazil) 



Núñez Orozco, L (Mexico) Chair 

Founding a new family 

Lai, S-L (Taiwan) 

Family therapy in epilepsy 

Bekes, J (Hungary) 

Role of society in supporting people with epilepsy 

and their family 

Campos, M (Chile) 


Drug therapy 

Bialer, M (Israel) & Rajna, P (Hungary) Chairs 






34 



Imaging depression in epilepsy 

Theodore, W (USA) Chair 

Structural and functional imaging of depression 

in epilepsy 

Gilliam, F (USA) 

5HT1A receptor imaging of depression in epilepsy 

Ryvlin, P (France) 

Serotonin transport in epilepsy: genetics 

and depression 

Theodore, W (USA) 


Mechanisms of aberrant gene expression 

regulation in epileptogenesis 

Becker, AJ (Germany) Chair 

Genetic and epigenic control of modulators of 

cellular excitability 

O’Brien, T (Australia) 

Altered histone acetylation at glutamate 

receptor 2 and brain-derived neurotrophic factor 

genes by status epilepticus 

Dingledine, R (USA) 

Impaired astrocytic gene expression patterns 

due to aberrant TGF-beta receptor signaling in 

neocortical epileptogenesis 

Friedman, A (Israel) 

Acquired channelopathy in epileptogenesis 

mediated by transcriptional Cav3.2 upregulation 

Becker, AJ (Germany) 





6:00 - 7:30 The Prize Symposium Hall 5 

Moshé, SL (USA) Chair 

The Michael Prize: 

Antiepileptic drugs and the developing brain 

Ikonomidou, H (USA) 

Epileptogenesis in carbon and silicon brain 

Soltesz, I (USA) 

The Morris-Coole Prize: 

Interictal high-frequency oscillations (80-500 Hz) 

are an indicator of seizure onset areas independent 

of spikes in the human epileptic brain 

Jacobs, J (Canada) 



Ravizza, T (Italy) & Seress, L (Hungary) Chairs 


Merritt-Putnam Symposium: 

early status epilepticus: from basic science to 

clinical implications 


Acute molecular and functional charges in 

neurotransmission during early status epilepticus 

Kapur, J (USA) 

Is the brain damaged by acute seizures or early 

status epilepticus? 

Sutula, T (USA) 

The emergency treatment of acute seizures and 

early status epilepticus 

Kälviäinen, R (Finland) 



TUESDAY 30 TH JUNE 2009 



07:30 - 07:45 

07:45 - 08:00 

08:00 - 08:15 

08:15 - 08:30 

08:30 - 08:45 

08:45 - 09:00 

09:00 - 09:15 

09:15 - 09:30 

09:30 - 09:45 

09:45 - 10:00 

10:00 - 10:15 

10:15 - 10:30 

10:30 - 10:45 

10:45 - 11:00 

11:00 - 11:15 

11:15 - 11:30 

11:30 - 11:45 

11:45 - 12:00 

12:00 - 12:15 

12:15 - 12:30 

12:30 - 12:45 

12:45 - 13:00 

13:00 - 13:15 

13:15 - 13:30 

13:30 - 13:45 

13:45 - 14:00 

14:00 - 14:15 

14:15 - 14:30 

14:30 - 14:45 

14:45 - 15:00 

15:00 - 15:15 

15:15 - 15:30 

15:30 - 15:45 

15:45 - 16:00 

16:00 - 16:15 

16:15 - 16:30 

16:30 - 16:45 

16:45 - 17:00 

17:00 - 17:15 

17:15 - 17:30 

17:30 - 17:45 

17:45 - 18:00 

18:00 - 18:15 

18:15 - 18:30 

18:30 - 18:45 

18:45 - 19:00 

19:00 - 19:15 

36 


19:15 - 19:30 Socia 

19:30 - 19:45 Drug 

19:45 - 20:00 Surge 

20:00 - 20:15 Diagn 

20:15 - 20:30 Speci 

20:30 - 20:45 Gene 

20:45 - 21:00 

Poster 

Area 

Posters 

Authors of 

Posters 

present 

12:00 - 13:00 

Posters 


Beyond the medical 

model 

Beyond the medical 

model 

Eisai Europe Ltd. 

Satellite Symposium 






Pearls and pitfalls of 

seizure assessment: 

a video session 

Lunch 12:00 - 13:00 


Novel antiepileptic 

drugs: what the 

guidelines do not tell 

you 

Epilepsy in infants and 

children 

Reclassifying the 

epilepsies? 

Imaging language 

systems 


Genetics of e 

Non - conve 

mechanism 

epileps 

Platform 

Candidates fo 

therapie

all 3 

n infants and 

ildren 

sifying the 

psies? 

language 

stems 





Genetics of epilepsy 

Non - conventional 

mechanisms in 

epilepsy 

Platform: 

Candidates for future 

therapies 

Learning disability and 

neuropsychiatry 


Platform 

Advances in clinical 

neurophysiology 

Lunch 12:00 - 13:00 

07:30 - 07:45 

07:45 - 08:00 

08:00 - 08:15 

08:15 - 08:30 

08:30 - 08:45 

08:45 - 09:00 

09:00 - 09:15 

09:15 - 09:30 

09:30 - 09:45 

09:45 - 10:00 

10:00 - 10:15 

10:15 - 10:30 

10:30 - 10:45 

10:45 - 11:00 

11:00 - 11:15 

11:15 - 11:30 

11:30 - 11:45 

11:45 - 12:00 

12:00 - 12:15 

12:15 - 12:30 

12:30 - 12:45 

12:45 - 13:00 

13:00 - 13:15 

13:15 - 13:30 

13:30 - 13:45 

13:45 - 14:00 

2009 

14:00 - 14:15 

14:15 - 14:30 

JUNE 

14:30 - 14:45 

14:45 - 15:00 

30TH 15:00 - 15:15 

15:15 - 15:30 

15:30 - 15:45 


15:45 - 16:00 

TUESDAY 

Platform: 

Surgical outcomes 

Seizure related 

affective symptoms 

Platform: 

Epilepsy outcomes 

Empowering youth to 

create attitude change 


literature 

Symposium 


Festival 


Winner 

16:00 - 16:15 

16:15 - 16:30 

16:30 - 16:45 

16:45 - 17:00 

17:00 - 17:15 

17:15 - 17:30 

17:30 - 17:45 

17:45 - 18:00 

18:00 - 18:15 

18:15 - 18:30 

18:30 - 18:45 

18:45 - 19:00 


19:00 - 19:15 






Genetics Basic science 20:30 - 20:45 

20:45 - 21:00 





38 



Epilepsy in infants and children 

Plouin, P (France) Chair 

Plouin, P (France) 

Cross, H (UK) 

Covanis, A (Greece) 


Genetics of epilepsy 

(co-organised with the ILAE Commission on Genetics) 

Basics of molecular and clinical genetics: what can 

be wrong with our genes when we develop epilepsy? 

Zara, F (Italy) 

Mechanisms of mutations leading to epilepsy: 

how can a mutation cause epilepsy? 

Lerche, H (Germany) 


Learning disability and neuropsychiatry 

Kerr, M (UK) & Besag, F (UK) Chairs 

The behavioural manifestations of epilepsy in 

children and adolescents 

Besag, F (UK) 

The interface between epilepsy and learning disability 

Kerr, M (UK) 


Seizure related affective symptoms 

Epilepsy and depression: the nature of the problem 

Schmitz, B (Germany) 

Peri-ictal mood changes in epilepsy 

Mula, M (Italy) 

Paraepileptic mechanisms in psychiatric disorders 

Tebartz Van Elst, L (Germany) 







Li, S (China) Chair 

Epilepsy and legislation 

De Boer, H (The Netherlands) 

Progress with the (WHO) Global Campaign 

Against Epilepsy 

Dua, T (Switzerland) 

The ‘green book’ for epilepsy control strategies 

Li, S (China) 



Li, S (China) Chair 

The experience of the Epilepsy Foundation 

of America 

Hargis, E (USA) 

Self-help organisations and activities for people 

with epilepsy 

Wu, J (China) 

Stigma and social issues for people with epilepsy 

Aziz, H (Pakistan) 


Pearls and pitfalls of seizure assessment: a video session 

Janszky, J (Hungary) Chair 

Assessment of lateralizing signs in infants and young children 

Fogarasi, A (Hungary) 

False-lateralizing or localised seizures 

Baumgartner, C (Austria) 

Differentiating psychogenic non-epileptic seizures 

Halász, P (Hungary) 


TUESDAY 30 TH JUNE 2009




40 



Reclassifying the epilepsies? 

Berg, A (USA) Chair 

New approaches to organising our knowledge 

about the traditional syndromes of epilepsy 

Berg, A (USA) 

Generalized and focal seizures and syndromes: 

time for a new paradigm 

Berkovic, SF (Australia) 

What is a syndrome? Interrogating patient 

phenotypes to identify diagnostic entities 

Glauser, T (USA) 

Paradigms for validating and modifying 

phenotypes: the use of genetics and imaging 

Scheffer, I (Australia) 


Non-conventional mechanisms in epilepsy 

Vezzani, A (Italy) Chair 

TGF-beta signaling in epilepsy 

Friedman, A (Israel) 

Mechanism suppressing glycogen synthesis in neurons 

and its demise in progressive myoclonous epilepsy 

Guinovart, JJ (Spain) 

Growth factors, neuronal excitability and seizures 

Scharfman, HE (USA) 

Cytokines and glutamate receptors: novel pathophysiological 

communication pathways 

Ravizza, T (Italy) 






Advances in clinical neurophysiology 

Avanzini, G (Italy) & Baulac, M (France) Chairs 



Engel, J (USA) & Rasonyi, G (Hungary) Chairs 

0:30 - 2:00 Special Session Hall 7 

Epilepsy and literature 

Wolf, P (Denmark) Chair 

Epilepsy reflected in works of writers with epilepsy 


Literary descriptions of seizures 

Rajna, P (Hungary) 

Margiad Evans, centenary of an artist with epilepsy 

Pratt, J (Scotland) 


Satellite Symposium Eisai Europe Ltd.: 

the times they are a-changing 

Arzimanoglou, A (France) Chair 

Learning from the past: learning from history 

Glauser, T (USA) 

The evolution of our understanding 

Ben-Menachem, E (Sweden) 

Challenging the present to shape the future 

Cramer, J (USA) 






42 


4:00 - 6:20 Film Screening Hall 7 

1930’s:The Eugenics Movement 


Screening: Dr Kildare’s Crisis ( 940) 

Debate 



O’Brien, T (Australia) Chair 

How does the brain become epileptic? 

Baram, TZ (USA) 

What does epilepsy do to the brain? 

Pitkanen, A (Finland) 



O’Brien, T (Australia) Chair 

Clinical genetics: relationship between 

developmental age and presentation of different 

epilepsy syndromes? 

Scheffer, I (Australia) 

Inflammation and epileptogenesis in developing 

brain: mechanistic insights 

Vezzani, A (Italy) 

Effects of treatment: can anti-epileptic drugs have 

adverse effects on the developing brain? 


Effects of treatment: can epilepsy be prevented? 

Blumenfeld, H (USA) 






Novel antiepileptic drugs: what the guidelines 

do not tell you 

Cook, M (Australia) Chair 

What doses of the novel antiepileptic drugs should 

be used in routine practice - and how and why 

doses differ from those used in clinical trials? 

Tomson, T (Sweden) 

Clinical criteria on which to base a choice of novel 

antiepileptic drug in antiepileptic drug in patients 

with chronic epilepsy 

Cook, M (Australia) 

What are the chances of the new antiepileptic drugs 

controlling seizures in chronic epilepsy? 

Shorvon, S (UK) 

Novel side-effects of the novel antiepileptic drugs 

and their mechanisms 

Perucca, E (Italy) 


Imaging language systems 

Gaillard, WD (USA) Chair 

General introduction 

Gaillard, WD (USA) 

FMRI of language systems: a critical appraisal 

Loring, DW (USA) 

MEG of language systems: a critical appraisal 

Hirata, M (Japan) 

DTI tractography and language dominance 

Catani, M (UK) 






44 



Candidates for future therapies 

French, J (USA) & Szente, M (Hungary) Chairs 



Wiebe, S (Canada) & Janszky, J (Hungary) Chairs 


Empowering youth to create attitude change 

Secco, M (Canada) Chair 

Epilepsy attitudes and knowledge of youth 

Secco, M (Canada) & Martiniuk, A (Australia) 

Take charge of the facts: a school based youth 

outreach program 

Hargis, E (USA) & Carr, D (USA) 

Development of a curriculum unit to teach senior 

science students about epilepsy 

Burneo, J (Canada) 

How to increase youth participation in your community 

Mia Bohn, N (Norway) 


Centenary Award for Film 

Screening: Ictal (2009) 

Overall Winner of the ILAE Centenary Film Competition 

Screening: Year of the Wolf (2007) 

Winner of the best full length film in the 



WEDNESDAY ST JULY 2009 



07:30 - 07:45 

07:45 - 08:00 

08:00 - 08:15 

08:15 - 08:30 

08:30 - 08:45 

08:45 - 09:00 

09:00 - 09:15 

09:15 - 09:30 

09:30 - 09:45 

09:45 - 10:00 

10:00 - 10:15 

10:15 - 10:30 

10:30 - 10:45 

10:45 - 11:00 

11:00 - 11:15 

11:15 - 11:30 

11:30 - 11:45 

11:45 - 12:00 

12:00 - 12:15 

12:15 - 12:30 

12:30 - 12:45 

12:45 - 13:00 

13:00 - 13:15 

13:15 - 13:30 

13:30 - 13:45 

13:45 - 14:00 

14:00 - 14:15 

14:15 - 14:30 

14:30 - 14:45 

14:45 - 15:00 

15:00 - 15:15 

15:15 - 15:30 

15:30 - 15:45 

15:45 - 16:00 

16:00 - 16:15 

16:15 - 16:30 

16:30 - 16:45 

16:45 - 17:00 

17:00 - 17:15 

17:15 - 17:30 

17:30 - 17:45 

17:45 - 18:00 

18:00 - 18:15 

46 


18:15 - 18:30 Soc 

18:30 - 18:45 Dru 

18:45 - 19:00 Sur 

19:00 - 19:15 Dia 

19:15 - 19:30 Spe 

19:30 - 19:45 Gen 

19:45 - 20:00 

20:00 - 20:15 

20:15 - 20:30 

Poster 

Area 

Posters 

Authors of 

Posters present 

12:00 - 13:00 

Posters 

Posters 

Dismantle 


The need for 

comprehensive care 

around the world 

The need for 

comprehensive care 

around the world 

GlaxoSmithKline 

Satellite Symposium 

Models to study 

acquired 



screening new 

antiepileptic drugs: 

future strategies 


Neonatal seizures: 

from the clinic to the 

bench and back 

Lunch 12:00 - 13:00 


Platform: 

Paediatrics: clinical 

epileptology 

Gala Evening 

Epileptic reorganization 

of the temporal lobe 

Platform: 

Neuroimaging 

Disparities in epilepsy 

care, the role of the 

Global Campaign 


Neuro-psych 

behaviou 

syndrom 

Platform 

Genotype 

phenotyp 

Genetic test 

epilepsie




all 3 Hall 4 Hall 5 Hall 6 Hall 7 

eorganization 

mporal lobe 

tform: 

oimaging 

s in epilepsy 

e role of the 

Campaign 

Neuro-psycho-biobehavioural 

syndromes 

Platform: 

Genotype and 

phenotype 

Genetic testing in 

epilepsies 

Differential diagnosis 

of epileptic and 

non-epileptic events 


Variability in epilepsy 

outcome measures 

Lunch 12:00 - 13:00 


Platform: 

Neuropsychology 

Affective disorders in 

epilepsy: exploring the 

nexus 


Festival 

07:30 - 07:45 

07:45 - 08:00 

08:00 - 08:15 

08:15 - 08:30 

08:30 - 08:45 

08:45 - 09:00 

09:00 - 09:15 

09:15 - 09:30 

09:30 - 09:45 

09:45 - 10:00 

10:00 - 10:15 

10:15 - 10:30 

10:30 - 10:45 

10:45 - 11:00 

11:00 - 11:15 

11:15 - 11:30 

11:30 - 11:45 

11:45 - 12:00 

12:00 - 12:15 

12:15 - 12:30 

12:30 - 12:45 

12:45 - 13:00 

13:00 - 13:15 

13:15 - 13:30 

13:30 - 13:45 

13:45 - 14:00 

14:00 - 14:15 

14:15 - 14:30 

14:30 - 14:45 

14:45 - 15:00 

15:00 - 15:15 

15:15 - 15:30 

15:30 - 15:45 

15:45 - 16:00 

16:00 - 16:15 

16:15 - 16:30 

16:30 - 16:45 

16:45 - 17:00 

17:00 - 17:15 

17:15 - 17:30 

17:30 - 17:45 


17:45 - 18:00 

18:00 - 18:15 







Gala Evening 

Neuroimaging 

(co-organised with the 

ILAE Commission on 

Diagnostic Methods) 

19:45 - 20:00 

20:00 - 20:15 

20:15 - 20:30 


Centenary Film Festival 

WEDNESDAY ST JULY 2009




48 



Epileptic reorganization of the temporal lobe 

Heinemann, U (Germany) & Magloczky, Z (Hungary) Chairs 

Epileptogenesis as a result of disturbed 

homeostatic plasticity 

Heinemann, U (Germany) 

Morphological and neurochemical reorganization 

of the subiculum in the kainic acit model of TLE 

Sperk, G (Austria) 

Reorganization of GABAergic circuits during 

epileptogenesis in animal models 

Bernard, C (France) 

Reorganization of GABAergic circuit in the human 

epileptic hippocampus 

Magloczky, Z (Hungary) 


Neuro-psycho-bio-behavioural syndromes 

Tebartz Van Elst, L (Germany) Chair 

Imaging at the interface between epilepsy and 

behaviour, does structural pathology have specific 

neurobehavioural correlates? 

Tebartz Van Elst, L (Germany) 

Is the psychoses of epilepsy a distinct neurobiological 

entity? A critical review of the available evidence 

Kanemoto, K (Japan) 

The neuro-psycho-bio behavioural syndrome of 

mesial temporal lobe epilepsy 

Krishnamoorthy, ES (India) 


Differential diagnosis of epileptic and 

non-epileptic events 

Van Emde Boas, W (The Netherlands) Chair 

Van Emde Boas, W (The Netherlands) 

Ozkara, C (Turkey) 

Kelemen, A (Hungary) 






Neuroimaging 

(co-organised with the ILAE Commission on 

Diagnostic Methods) 

Why, when and how to perform SPECT and PET in 

a child with focal epilepsy 

Chiron, C (France) 

Structural and functional MRI in epilepsy 

Gaillard, WD (USA) 


The need for comprehensive care around the world 


Defining the gold standard of comprehensive care 

Gumnit, RJ (USA) 

Measures to standardize epilepsy care across the world 

Khan, S (Saudi Arabia) 



Screening: Rachel: A Perfect Life (2008) 

Winner of the best documentary film in the 



The need for comprehensive care around the world 


The Japanese experience 

Inoue, Y (Japan) 

The European approach 

Pfaefflin, M (Germany) 

Comprehensive care in developing countries 

Damtie Gablie, Z (Ethiopia) 






50 



Neonatal seizures: from the clinic to the bench and back 

Baram, TZ (USA) Chair 

Neonatal seizures: the EEG as a diagnostic tool 


What does in vitro and in vivo recording from 

neonatal human brain teach us? 

Khazipov, R (France) 

Back to the clinic: translational therapy 

Staley, KJ (USA) 


Neuroimaging 

Cook, M (Australia) & Barsi, P (Hungary) Chairs 


Genotype and phenotype 

Berkovic, SF (Australia) & Kelemen, A (Hungary) Chairs 


Variability in epilepsy outcome measures 

Kasteleijn-Nolst Trenité, D (Italy) Chair 

Reproducibility of photoparoxysmal EEG responses 

Kasteleijn-Nolst Trenité, D (Italy) 

Variation in outcomes from randomised monotherapy 

comparisons in newly diagnosed epilepsy 

Brodie, MJ (UK) 

Subjective versus objective reporting of epileptic seizures 

Steinhoff, B (Germany) 

Lack of replication in human genetic studies 

Greenberg, DA (USA) 






Affective disorders in epilepsy: exploring the nexus 

De Toffol, B (France) & Krishnamoorthy, ES (India) Chairs 

Are available screening instruments appropriate to 

identify depression in patients with epilepsy? 

Krishnamoorthy, ES (India) 

Do mood stabilizing AEDs protect patients from 

experiencing mood disorders? 

Mula, M (Italy) 

Can we improve the quality of life of the person 

with epilepsy through better interventions for 

affective disorder? 

Kanner, AM (USA) 


Refractory epilepsy - burden and management 

Brodie, MJ (UK) Chair 

Refractory epilepsy: burden of management 

Gil Nagel, A (Spain) 

Mechanistic approaches to the treatment of 

refractory epilepsy 

Lerche, H (Germany) 

Refractory epilepsy and realistic goals: can control 

be achieved? 

Ryvlin, P (France) 



Full Circle: Closing Comments 


Screening: Control (2007) � 

Debate 






52 



Models to study acquired epileptogenesis: 

prevention, suppression or cure? 

Dudek, FE (USA) Chair 

Development and analysis of clinically relevant 

models to study the chronic nature of epilepsy 

Dudek, FE (USA) 

How do we use models to study the prevention or 

cure of acquired epilepsy? 

Holmes, GL (USA) 


Identifying and screening new antiepileptic drugs: 

future strategies 

Dudek, FE (USA) Chair 

What is wrong with the current process for 

AED discovery? 

White, HS (USA) 

Which animal models of chronic epilepsy are 

potentially available, and what are their advantages 

and disadvantages? 

Nehlig, A (France) 

What are the possible experimental designs and 

methods of AED administration? 

Loescher, W (Germany) 


Paediatrics: clinical epileptology 

Arzimanoglou, A (France) & Fogarasi, A (Hungary) Chairs 






Disparities in epilepsy care, the role of the 

Global Campaign 

Avanzini, G (Italy) & Lee, P (UK) Chairs 

Magnitude and causes of disparities in 

developing countries 

Begley, C (USA) 

An integrated approach to improve care and 

livelihood: the ILAE basic needs partnership 

Underhill, C (UK) 

Preventable epilepsies: the model of cysticercosis 

Tulio Medina, M (Honduras) 

Assessment of quality aspects of epilepsy care 

Wiebe, S (Canada) 


Genetic testing in epilepsies 

Scheffer, I (Australia) Chair 

Introduction to genetic testing: types of tests and the 

need for guidance 

Ottman, R (USA) 

How to decide whether to test and how to carry out 

a test 

Lopes-Cendes, I (Brazil) 

Ethical, legal and social issues in different countries 

Jain, S (India) 



Borbély, C (Hungary) Chair 



THURSDAY 2 ND JULY 2009 



07:30 - 07:45 

07:45 - 08:00 

08:00 - 08:15 

08:15 - 08:30 

08:30 - 08:45 

08:45 - 09:00 

09:00 - 09:15 

09:15 - 09:30 

09:30 - 09:45 

09:45 - 10:00 

10:00 - 10:15 

10:15 - 10:30 

10:30 - 10:45 

10:45 - 11:00 

11:00 - 11:15 

11:15 - 11:30 

11:30 - 11:45 

11:45 - 12:00 

12:00 - 12:15 

12:15 - 12:30 

12:30 - 12:45 

12:45 - 13:00 

13:00 - 13:15 

13:15 - 13:30 

13:30 - 13:45 

13:45 - 14:00 

14:00 - 14:15 

54 


14:15 - 14:30 Socia 

14:30 - 14:45 Drug 

14:45 - 15:00 Surg 

15:00 - 15:15 Diagn 

15:15 - 15:30 Spec 

15:30 - 15:45 Gene 

15:45 - 16:00 

19:30 - 20:00 

Hall 2 Hall 3 Hall 4 Hall 

Neuroimaging and 

nosology: generalized 

vs.focal epilepsy 

Neuroimaging of 

malformations of cortical 

development 



High frequency 

oscillations, what is 

normal and what is not 

Surgical treatment of 

epilepsy 

Platform: 

Paediatrics: brain 

development and 

plasticity 


New targ 

disease mo 

and epi 

preven 

What is m 

refractory e



ll 4 Hall 5 Hall 6 Hall 7 

eatment of 

epsy 

form: 

cs: brain 

ent and 

ticity 

New targets for 

disease modification 

and epilepsy 

prevention 

What is medically 

refractory epilepsy? 

Neonatal seizures: 

WHO/ILAE 

guidelines 


Platform: 

Impact of epilepsy 

worldwide 


EEG in the 

diagnosis and 

treatment of 

epilepsy 

Transcranial 

magnetic brain 

stimulation as a 

surrogate marker 

07:30 - 07:45 

07:45 - 08:00 

08:00 - 08:15 

08:15 - 08:30 

08:30 - 08:45 

08:45 - 09:00 

09:00 - 09:15 

09:15 - 09:30 

09:30 - 09:45 

09:45 - 10:00 

10:00 - 10:15 

10:15 - 10:30 

10:30 - 10:45 

10:45 - 11:00 

11:00 - 11:15 

11:15 - 11:30 

11:30 - 11:45 

11:45 - 12:00 

12:00 - 12:15 

12:15 - 12:30 

12:30 - 12:45 

12:45 - 13:00 

13:00 - 13:15 

13:15 - 13:30 


13:30 - 13:45 

13:45 - 14:00 

14:00 - 14:15 







15:45 - 16:00 

19:30 - 20:00 


THURSDAY 2 ND JULY 2009




56 



Surgical treatment of epilepsy 

Ozkara, C (Turkey) Chair 

Kahane, P (France) 

Najm, I (USA) 

Velis, D (The Netherlands) 


New targets for disease modification and 

epilepsy prevention 

Potschka, H (Germany) Chair 

Identification of potential new antiepileptogenic 

targets by microarray analysis 

Gorter, J (The Netherlands) 

Adenosine kinase hypothesis of epileptogenesis 

Boison, D (USA) 

Targeting neurogenesis as a disease-modifying or 

antiepileptic strategy? 

Potschka, H (Germany) 

Potential of erythropoetin for disease-modification 

or antiepileptogenesis 

Bezin, L (France) 


Neonatal seizures: WHO/ILAE guidelines 

Mizrahi, EM (USA) & Jovic, N (Serbia)) Chairs 

WHO and ILAE methodology and strategies to 

establish evidenced based guidelines for global use 

Elia, M (Italy) 

Application of guidelines in Africa 

Kakooza, A (Uganda) 

Application of guidelines in India 

Vinayan, KP (India) 

Application of guidelines in Brazil 

Nunes, ML (Brazil) 

Application of guidelines in Japan 

Yamamoto, H (Japan) 






EEG in the diagnosis and treatment of epilepsy 

Use and the abuse of the EEG in the diagnosis of epilepsy 

Van Emde Boas, W (The Netherlands) 

EEG in paediatric epilepsy: special aspects 


09:00 - 0:00 Main Session Hall 2 

Neuroimaging and nosology: generalised vs. 

focal epilepsy 

Woermann, F (Germany) Chair 

Is juvenile myoclonic epilepsy a disorder within a 

system otherwise subserving attention 

Koepp, MJ (UK) 

Temporal lobe epilepsy: a system disorder beyond 

hippocampal sclerosis? 

Kahane, P (France) 

0:30 - 2:00 Post Main Session Hall 2 

The ‘tip-of-the-iceberg’ controversy: neuroimaging 

of malformations of cortical development 

Woermann, F (Germany) Chair 

Neuroimaging localization of focal epileptogenic 

pathology in ‘generalized’ epilepsies 

Juhasz, C (USA) 

Widespread changes in advanced structural and 

functional neuroimaging of circumscript MCD 

in adults 


Pathologic and physiologic function in malformations 

of cortical development 

Jackson, G (Australia) 

Neuroimaging and genetics in malformations of 

cortical development 

Bernasconi, A (Canada) 






58 



High frequency oscillations, what is normal and 

what is not 

Engel, J (USA) Chair 

General introduction 

Engel, J (USA) 

Normal high frequency oscillations 

Buzsaki, G (USA) 

Pathological high frequency oscillations 

Bragin, A (USA) 

Basic mechanisms, one view 

De La Prida, LM (Spain) 

Basic mechanisms, another view 

Le Van Quyen, M (France) 


Paediatrics: brain development and plasticity 

Jerney, J (Hungary) Chair 


What is medically refractory epilepsy? 

Brodie, MJ (UK) & Kwan, P (Hong Kong) Chairs 

The ILAE consensus definition of medically 


Berg, A (USA) 

Implications of the consensus definition of refractory 

epilepsy for epilepsy surgery and psychosocial measures 

Wiebe, S (Canada) 

Impact and application of the consensus definition 

of refractory epilepsy for drug therapy and drug trials 

French, J (USA) 






Impact of epilepsy worldwide 

Bekes, J (Hungary) Chair 


Transcranial magnetic brain stimulation as a 

surrogate marker 

Kimiskidis, V (Greece) Chair 

Basic principals of TMS and safety issues in patients 

with epilepsy 

Mills, KR (UK) 

Pharmaco - TMS studies: exploring in-vivo the cortical 

effects of antiepileptic drugs 

Ziemann, U (Germany) 

TMS in epilepsy: insight into pathophysiological 

mechanisms and emerging clinical applications 

Kimiskidis, V (Greece) 

2:00 - 3:30 Special Session Hall 2 


Lund, S (Sweden) & Halász, P (Hungary) Chairs 

Al Yamani, S (Saudi Arabia) 

Dudek, FE (USA) 

Fogarasi, A (Hungary) 

Li, S (China) 

Núñez Orozco, L (Mexico) 





PLATFORM SESSIONS 


60 


0:30 – 2:00 Platform Session Hall 2 

Refer to Page 06 


Chairs: Ryvlin P (France) & Juhos V (Hungary) 

00 The serbian version of the quality-of-life in 

epilepsy inventory (QUOLIE-3 ): translation and 

psychometric evaluation 

Milovanovic M, Martinovic Z, Djokic R, Jovanovic M, 

Buder N, Simonovic P (Serbia and Montenegro) 

002 Patterns of psychiatric illness in juvenile 

myoclonic epilepsy 

Gaddamanugu P, Jayalakshmi S, Anand B (India) 

003 A study on alterations of cognitive function and 

relative factors in epilepsy patients 

Hong Z, Yu P, Xu Y, Zhao D, Wu X, Zhu G (China) 

004 SUDEP recorded by a responsive neurostimulator: 

one mechanism for sudden death in intractable 

epilepsy clarified 

Van Ness P, Whitworth L A (USA) 

005 Startle disease V’s propriospinal myoclonia on 

idiopathic generalized epilepsy (IGE) 

Pepe F, Famà F, Morrone E, Ferrari A, Grancelli T, Morrone C, 

Spizzica F, Ferrillo F, Striano P (Italy) 

006 Application of brief electrical pulses in the primary 

motor and supplementary motor cortex for the 

termination of afterdischarges 

Jobst B, Darcey T, Bujarski K, Thadani V, Roberts D (USA) 





0:30 - 2:00 Platform Session 2 Hall 6 



Chairs: Pitkanen A (Finland) & Freund T F (Hungary) 

007 Melatonin administration after the status 

epilepticus induced by pilocarpine experimental 

model: could be a possible way to prevent or 

attenuate the post lesion epilepsy? 

Lima E, Cavalheiro E A, da Graça Naffah-Mazzacoratti M, 

Amado D (Brazil) 

008 Synaptic integration of grafted neural stem cells for 

replacement and ex vivo gene therapy in epilepsy 

Sorensen A T, Rogelius N, Lundberg C, Kokaia M (Sweden) 

009 Protective effects of environmental enrichment 

in Marlau on the development of spontaneous 

seizures and cognition in rats subjected to status 

epilepticus at weaning 

Fares R P, Bonnet C, Sanchez P E , Le Cavorsin M, Belmeguenai A, 

Morales A, Bodennec J, Ryvlin P, Bezin L (France) 

0 0 Restraint stress accelerates amygdala kindling 

epileptogenesis in rats 

Salzberg M, Lee H E, Kumar G, Morris M, Rees S, O’Brien T, 

Jones N (Australia) 

0 Progressive functional and structural brain changes 

on serial manganese-enhanced MRI acquisition 

following traumatic brain injury in the rat 

Bouilleret V, Cardamone L, Liu Y, Koe A, Myers D, 

O’Brien T (Australia, France) 

0 2 Transvascular delivery of siRNAs into the rat brain in 

an animal model of temporal lobe epilepsy 

Pascoal V, Marchesini R B, Pereira T C, Gilioli R, Cavalheiro E A, 

Lopes-Cendes I (Brazil) 




62 




Drug therapy 

Chairs: Bialer M (Israel) & Rajna P (Hungary) 

0 3 Improvement in health related quality of life in 

epilepsy after withdrawal of carbamazepine in 

seizure-free patients 

Lossius M I, Hessen E, Gjerstad L (Norway) 

0 4 A meta-analytic comparison of topiramate-related 

adverse drug reactions in epilepsy and migraine 

Carpay J, Luykx J, Mason M, Ferrari M (The Netherlands) 

0 5 Protective effects of brivaracetam in phenytoin-resistant 

amygdala-kindled mice: a comparison with levetiracetam 

Kaminski R, Matagne A, Klitgaard H (Belgium) 

0 6 Clinical research in epilepsy is dominated by the 

pharmaceutical industry 

Morrow J, Bergin P (UK, New Zealand) 

0 7 Patterns of drug utilization in patients with 

refractory epilepsy at tertiary referral centres in Italy. 

The SOPHIE Study 

Malerba A, Canevini M P, Ciampa C, Franco V, Frassine B, 

Galimberti C A, Gambardella A, La Neve A, Pellacani S, 

Rosati E, Tinuper P, Perucca E (Italy) 

0 8 Neuroprotective effect of Lamotrigine on 

hypoxic-ischemic injury in neonatal rat brain 

Eun B L, Shin H K, Eun S, Chung H J (Korea) 








Chairs: Ravizza T (Italy) & Seress, L (Hungary) 

0 9 Pyramidal cells and interneurons interactions 

in the initiation of ictal discharges in human 

epileptic tissue in vitro 

Huberfeld G, Menendez de la Prida L, Clemenceau S, 

Pallud J, Cohen I, Le Van Quyen M, Baulac M, 

Miles R (France, Spain) 

020 Differential presence of HHV-6 DNA in 

hippocampi of temporal lobe epilepsy patients 

with distinct etiology 

Niehusmann P, Drexler J F, Bien C G, Grote A, Schoch S, 

Becker A J (Germany) 

02 Olfactory function in patients after temporal lobe 

resection compared to normosmic controls 

Hopp P, Henkel S, Gerber J, Reuner U, Hallmeyer-Elgner S, 

Lutz M, Mayer T, Schackert G, Hummel T (Germany) 

022 The cortical focus theory of absence epilepsy: 

the role of the thalamus 

Van Luijtelaar G, Sitnikova E, Meeren H (The Netherlands, Russia) 

023 Electrically evoked potentials and evoked ripples 

in the human hippocampal formation 

Fabo D, Zsofia M, Toth E, Eross L, Solyom A, Czirjak S, 

Rasonyi G, Halasz P, Freund T, Karmos G, Ulbert I (Hungary) 

024 Human KvLQT mutations in mice link the dual 

phenotype of cardiac arrhythmias and epilepsy 

with sudden unexplained death in epilepsy 

Goldman A, Glasscock E, Yoo J, Chen T, Klassen T, Noebels J (USA) 




64 





Chairs: Avanzini G (Italy) & Baulac M (France) 

025 Characterising the role of brainstem physiology 

as a cause of asystole in seizures 

Pini G, Julu P, Hansen S, Bigoni S, Smeets E, 

Witt Engerström I, Russell A, Delamont R, 

Apartopoulos F, Curfs L (Italy, UK) 

026 Brainstem autonomic influence on cortical 

epileptiform activity: evidence of music-induced 

vagal suppression of seizure pattern 

Witt Engerström I, Julu P, Hansen S, Delamont R, 

Bergström-Isacsson M, Smeets E, Apartopoulos F, Pini G, 

Bigoni S, Curfs L (Sweden, UK, The Netherlands, Italy) 

027 In-phase synchronized gamma oscillations precede 

spike-and-wave complexes in human absence seizures 

Kohsaka S, Kohsaka M, Shiraishi H, Saitoh S (Japan) 

028 Anatomo-functional organization of the insular 

cortex in epileptique humans: study by intracerebrale 

electrical stimulations 

Afif A, Minotti L, Kahane P, Hoffmann D (France) 

029 Apneas associated with temporal lobe seizures are 

dependent on contralateral spread of the seizure: 

results from intracranial EEG recordings 

Seyal M, Bateman L (USA) 

030 Tonic and absence seizures have different networks 

in Lennox-Gastaut syndrome on EEG-fMRI 

Pillay N, Flanagan D, Abbott D, Archer J, 

Jackson G (Canada, Australia) 








Chairs: Engel J (USA) & Rasonyi G (Hungary) 

03 2 -24 year follow-up mortality rates from the 

National General Practice Study of Epilepsy (NGPSE) 

Neligan A, Bell G, Goodridge D M, Shorvon S D, 

Sander J W (UK) 

032 The incidence rate of epilepsy in a rural district 

of Vietnam: a population-based study from the 

EPIBAVI project 

Nguyen Ahn Tuan T, Le Quang C, Allebeck P, 

Nguyen Thi Kim C, Persson H, Tomson T (Vietnam, Sweden) 

033 Survival in epilepsy patients: an year follow 

up study 

Kharazmi E, Fallah M, Peltola J (Finland) 

034 Summary of the U.S. National Institute of Neurological 

Disorders and Stroke (NINDS) Workshop on SUDEP 

So E, Hirsch L, Donner E, Noebels J, Jacobs M, Buchhalter J (USA) 

035 Epilepsy care and information and communication 

technology (ICT) in Irish general practice: results of 

a national survey 

Varley J, Fitzsimmons M, Delanty N, Collins C, Boland M, 

Normand C (Ireland) 

036 Interictal electrocardiographic (ECG) abnormalities 

and cardiac morbidity in an adult population with 

difficult to control epilepsy and learning disabilities 

Petkar S, Masih I, Mitchell P, Clifford A, Homa S, Forrester C, 

Thomas H, Madden P, Hammonds G, Cooper P, Fitzpatrick A (UK) 




66 





Chairs: French J (USA) & Szente M (Hungary) 

037 Effects of 532 or 808 nm low-power laser irradiation 

on the paroxysmal discharge threshold in the rabbit 

hippocampus CA 

Kogure S, Saito N, Kozuka K, Tsuchiya K, Kakuno M (Japan) 

038 Combination gene therapy for epilepsy: NPY-Y2 

receptor transfection strategy in animal models 

Kokaia M (Sweden) 

039 Suppressed epileptiform activity by optogenetic 

cell control in vitro 

Tønnesen J, Toft Sørensen A, Deisseroth K, Lundberg C, 

Kokaia M (Sweden, USA) 

040 Effectiveness and tolerability of rufinamide in 

children and adults with refractory epilepsy: 

first experience as orphan drug 

Kluger G, Kurleman G, Haberlandt E, Ernst J P, Runge U, 

Schneider F, Makowski C, Boor R, Bast T (Germany, Austria) 

04 Vascular endothelial growth factor suppresses 

epileptic activity in mice 

Nikitidou L, Kanter-Schlifke I, Kokaia M (Sweden) 

042 Short-term and long-term effects of Brivaracetam 

in an animal model of status 

Wasterlain C G, Suchomelova L, Matagne A, Klitgaard H, 

Niquet J, Baldwin R (USA, Belgium) 








Chairs: Wiebe S (Canada) & Janszky J (Hungary) 

043 Anterior temporal lobe resection without 

hippocampectomy due to epileptogenic lesion 

in amygdala 

Gyimesi C, Pannek H, Woermann F, Schulz R, Hoppe M, 

Elsharkawy A, Tomka-Hoffmeister M, Horstmann S, 

Aengenendt J, Janszky J, Ebner A (Hungary, Germany) 

044 Predicting outcome following epilepsy surgery 

Baxendale S, Heaney D, Duncan J, McEvoy A (UK) 

045 Complete withdrawal of antiepileptic drug 

treatment after paediatric epilepsy surgery 

Gröppel G, Dressler A, Freilinger M, Mayer H, Pahs G, 

Plattner B, Porsche B, Reiter E, Urak L, Hainfellner J, 

Prayer D, Czech T, Feucht M (Austria) 

046 High frequency oscillations as markers of 

epileptogenicity - correlation with the 

postsurgical outcome 

Jacobs J, Zijlmans M, Zelmann R, Chatillon C E, Hall J, 

Olivier A, Dubeau F, Gotman J (Canada) 

047 AED outcomes after resective epilepsy surgery: 

a systematic review 

Tellez-Zenteno J, Hamiwka L, Jette N (Canada) 

048 Seizure outcome after resective epilepsy surgery: 


Burneo J, Tellez-Zenteno J, Jette N (Canada) 




68 




Neuroimaging 

Chairs: Cook M (Australia) & Barsi P (Hungary) 

049 Prediction of postoperative verbal and non-verbal 

memory decline using preoperative memory fMRI 

Duncan J, Bonelli S, Powell R, Yogarajah M, Samson R, 

Focke N, Thompson P, Symms M, Koepp M (UK) 

050 EEG-Triggered fMRI and EEG source analyses to 

evaluate anatomical and functional networks in 

Landau Kleffner Syndrome 

Brazzo D, Pisano T, Bill P, Thaj J, Seri S (UK) 

05 Functional connectivity changes in frontal-hippocampus 

circuity after withdrawal of topiramate in 

epilepsy patients 

Chen Q, Wu X, Zhou B, Lui S, Tang H H, Gong Q Y, Shang H, 

Yan B, Zhou D (China, UK) 

052 SPECT perfusion patterns in temporal lobe epilepsy 

- correlation with surgical outcome 

Lakkunta P, Sita Jayalakshmi S, Panigrahi M, 

Prabhakar Rao V V, Sundaram C, Kaul S (India) 

053 Presurgical evaluation using combined fMRI/EEG in 

temporal lobe epilepsy 

Hauf M, Schindler K, Jann K, Koenig T, Wiest R (Switzerland) 

054 Abnormal functional hippocampal inter-connectivity 

in patients with unilateral mesial TLE is worse in 

left-sided hippocampal seizure focus 

Pereira F, Alessio A, Rondina J, Pedro T, Sercheli M, Ozelo H, 

Bilevicius E, Zibetti M, Castellano G, Covolan R, Damasceno B, 

Cendes F (Brazil) 







Genotype and phentotype 

Chairs: Berkovic S F (Australia) & Kelemen A (Hungary) 

055 Clinical spectrum of Ohtahara syndrome caused 

by STXBP mutation 

Kato M, Saitsu H, Mizuguchi T, Osaka H, Tohyama J, 

Uruno K, Kumada S, Hamada K, Nishimura A, Hirai S, 

Kumada T, Fukuda A, Ogata K, Hayasaka K, 

Matsumoto N (Japan) 

056 A novel three base-pair, in-frame, LGI deletion 

leading to loss of function in a family with 

autosomal dominant lateral temporal epilepsy 

and migraine-like episodes 

Lesca G, de Bellescize J, Boutry N, Chabrol E, 

André-Obadia N, Arzimanoglou A, Leguern E, Baulac S, 

Calender A, Ryvlin P (France) 

057 Does a SCN A gene mutation confer earlier age 

of onset of febrile seizures in GEFS+? 

Sijben A, Sithinamsuwan P, Radhakrishnan A, Badawy R, 

Dibbens L, Mazarib A, Lev D, Lerman-Sagie T, Straussberg R, 

Berkovic S, Scheffer I (The Netherlands, Australia, Israel) 

058 Mesial temporal lobe epilepsy has differential gene 

expression pattern in familial and sporadic forms 

Maurer-Morelli C, Rocha C, Domingues R, Tedeschi H, 

De Oliveira E, Cendes F, Lopes-Cendes I (Brazil) 

059 STXBP mutation screening in a cohort of patients 

with early onset epileptic encephalopathies 

Weckhuysen S, Deprez L, Holmgren P, Verhaert K , An J, 

Lagae L, Van Paesschen W, Jordanova A, Ceulemans B, 

De Jonghe P (The Netherlands, Belgium) 

060 Partial epilepsy with auditory features: clinical 

and genetic features of 20 sporadic cases 

Bisulli F, Stipa C, Pittau F, Capanelli D, Licchetta L, Naldi I, 

Striano P, Striano S, Michelucci R, Nobile C, Tinuper P (Italy) 




70 





Chairs: Arzimanoglou A (France) & Fogarasi A (Hungary) 

06 Is prognosis of epilepsy predictable in malformations 

of cortical development? 

Jovic N (Serbia and Montenegro) 

062 Prevalence of epilepsy in children with emphasis 

on etiology: a population based study in a Brazilian 

area of high deprivation 

Pereira De Brito Sampaio L, Caboclo L O, Kuramoto K, 

Reche A, Yacubian E, Giraldes de Manreza M L (Brazil) 

063 MEG identification of epileptic focus in children 

with generalized EEG abnormalities but focal 

imaging abnormalities 

Shukla G, Gupta A, Jin K, Mosher J, Jones S, Burgess R (USA) 

064 Risk of subsequent non-febrile seizure in Korean 

children who experienced first provoked seizure 

with fever over 6 years of age: preliminary report 

H Kim S, J Seol I (Korea) 

065 Efficacy of a three day treatment protocol with oral 

Pyridoxine in children with West syndrome 

Haas-Lude K, Kratzer W, Krägeloh-Mann I, Wolff M (Germany) 

066 Head or heart: a diagnostic dilemma 

Agrawal S, Philip S (UK) 








Chair: Borbely C (Hungary) 

067 Evidence for idiosyncratic and dose-dependent 

effects of Topiramate on verbal fluency 

Witt J A, Elger C E, Helmstaedter C (Germany) 

068 Neuropsychological outcome in adults with 

intractable epilepsy after hemispherectomy 

Le N M, Busch R, Jehi L, Alexopoulos A, Kalman C, 

Loddenkemper T (USA) 

069 Executive functions of patients treated with stable 

dose of topiramate measured by Wisconsin Card 

Sorting Test 

Sokic D, Ristic A, Salak-Djokic B, Milosevic N, Trajkovic G, 

Bascarevic V, Vojvodic N, Jankovic S, Zovic L (Serbia) 

070 Language and executive functions in medial 


Borbély C (Hungary) 

07 Autobiographical memory in temporal lob 

epilepsy patients: impact of focus lateralization 

and localization 

Pauli E, Herfurt K, Schwarz M, Stefan H (Germany) 

072 Cognitive function of patients with 

Unverricht-Lundborg disease (EPM ) 

Äikiä M, Khyuppenen J, Lehesjoki A E , Kälviäinen R (Finland) 




72 





Chair: Jerney J (Hungary) 

073 How common is ictal hypoxemia in children with 

partial complex and generalized convulsive seizures? 

Wirrell E, Nickels K (USA) 

074 Influence of frequency and duration of neonatal 

seizures on neurodevelopmental outcome 

Tatishvili N, Kipiani T, Tatishvili S (Georgia) 

075 Childhood epilepsy!...And what about the 

child’s sleep? 

De Weerd A, Geerts Y (The Netherlands) 

076 Benign focal epilepsy in childhood: evidence for 

interference of interictal spikes with selective 

cognitive deficits 

Wolff M, Serra E, Pastoors C, Krägeloh-Mann I (Germany) 

077 Language lateralization in childhood-onset focal 

epilepsy: evidence from fMRI 

Pahs G, Rankin P, Cross J, Northam G, Vargha-Khadem F, 

Baldeweg T (UK) 

078 The consequences of childhood epilepsy in ADHD, 

cognitive and academic performance: a different 

transcultural view: the Latin American experience 

Barragán E, Guerreiro M, Duron R, Espinosa E, 

Hernández M (Mexico, Brazil, Colombia) 








Chair: Bekes J (Hungary) 

079 Designing research in epilepsy to ensure policy 

change: Sydney epilepsy incidence study to 

measure illness consequences (SEISMIC) 

Martiniuk A, Anderson C, Somervile E, Hackett M, 

Glozier N, Bleasel A, Lawson J, Jan S, Mohamed A, 

Hassan B (Australia) 

080 Cost of hospitalisations of 772 patients with 

epilepsy within a one-year (2006) observation. 

Preliminary report 

Majkowska-Zwoliñska B, Majkowski J (Poland) 

08 The experience of epilepsy in Australia 

Chapman D, Cole R, Cummins J, Elphinstone K, Pollard R, 

Roberts K, Sharp D, Whitehead H (Australia) 

082 Psychosocial impact of diagnose and treatment 

of epilepsy in young people 

Mesa T, Peralta M, Fuentes D , González L (Chile) 

083 Are social class and level of education important 

factors regarding different formulation of 

antiepileptic drugs? 

Santos C, Alexandre Jr. V, Martins H, Silva A, Mesquita S, 

Castro A, Faveret E, Lin K, Masuko A, Guilhoto L, 

Yacubian E (Brazil) 

084 Those with epilepsy are vulnerable to homicides, 

suicides and motor vehicle accidents 

Jette N, Kwon C S, Liu M, Quan H (Canada) 


POSTER PRESENTATIONS 

p085 Adult onset epilepsy: should remember 

the coexistence of obstructive sleep apnea 

Cinar N, Sahin S, Okluoglu T, Karsidag S (Turkey) 

p086 The prevalence and distribution of the 

idiopathic generalized epilepsies and their 

seizures in Tasmania, Australia 

D’Souza W, Roberts H, Stankovich J, O’Brien T, 

Cook M, Pearce N (Australia) 

p087 Effect of serum homocysteine and folate 

on the seizure severity in patients with 

idiopathic epilepsy 

Kim K, Ha S, Lee J (South Korea) 

p088 Memory performance in temporal lobe 

epilepsy patients associated with 

hippocampal sclerosis and focal 

cortical dysplasia 

Kuchukhidze G, Bonatti E, Larch J, Bodner T, 

Unterberger I, Koppelstaetter F, Delazer M, 

Trinka E (Austria) 

p089 A glance at our experience in the pre 

surgical evaluation of epileptic patients 

with invasive EEG recording 

Alsemari A, Baz S, Thubaiti I, Al Dossari M, 

Al Yamani S, Chedrawi A, 

Al Dhalaan H (Saudi Arabia) 

p090 Aetiology of dyslexia in children, the 

offspring of epileptic mothers - 

preliminary study 

Wisniewska B, Wendorff J (Poland) 

p09 Mortality in children with epilepsy, 996 

to 2008 

Devilat Barros M, Gomez V, Sepulveda J (Chile) 

p092 Expression of nestin, vimentine, and GFAP 

in the cortex and the hippocampus 

of patients with mesial temporal 

love epilepsy 

Villeda J, Alonso M, Osorio L, Rocha L, 

Orozco S (Mexico) 

p093 Malformation risks of antiepileptic drugs 

in pregnancy: updated experience from 

the UK and Ireland epilepsy and 

pregnancy register 

Hunt S, Morrow J, Irwin B, Delanty N, Liggan B, 

Russell A, Smithson W H, Robertson I, Parsons L, 

Waddell R, Morrison P, Craig J (UK) 

p094 Hypothalamic hamartoma associated with 

left vestibular schwannoma presenting 

with epilepsy-psychosis and gelastic 

seizures: a case report 

Al Hail H, Al Moslamani N, Alalamy O, 

Maryisa T Sokrab F, Osman Y, Akhtar N, 

Eleger C (Qatar) 

p095 The roles and functions of a national 

epilepsy association 

Hills M (New Zealand) 

p096 Types and distribution of epilepsy in 

adults with cerebral palsy: Iraqi experience 

Mezaal M (UAE) 

74 


p097 The relationship of epilepsy and 

intellectual disabilities (ID) in autism 

spectrum disorders (ASD) and attention 

- deficit / hyperactivity disorder (ADHD) 

Martsenkovsky I, Bikshaeva I, Martsenkovsky D, 

Shvejkina V (Ukraine) 

p098 Exploring the health-related quality of 

life of those who provide care to persons 

with epilepsy in Ireland 

Linehan C, Burke T, Noonan Walsh P, Kerr M, 

Glynn M, Hall L, Ryan D (Ireland) 

p099 Developing epilepsy surgery: middle 

income country in South East Asia 

Selladurai B, Ong L, Wong S, Tan H, 

Ali R (Malaysia) 

p 00 Prolonged transient response to 

pharmacotherapy is limited to epilepsy 

patients with mild cortical dysplasia 

Schulze-Bonhage A, Fauser S (Germany) 

p 0 Results of surgery for refractory epilepsy: 

highlights from a series of 270 patients 

submitted to surgery 

Cukiert C, Cukiert A, Burattini J, Mariani P, 

Agapito D, Forster C, Baise C, 

Argentoni-Baldochi M, Mello V (Brazil) 

p 02 Sildenafil may inhibit the anticonvulsant 

effect of diazepam via nitric oxide/ cyclic 

GMP pathway 

Rasouli A, Gholipour T, Riazi K, Jabbarzadeh A, 

Ghazi Nezami B, Sharifzadeh M, 

Dehpour A (Iran) 

p 03 Patient beliefs about epilepsy and brain 

surgery in a multi-cultural urban 

population in the USA 

Prus N, Nakhutina L, Grant A (USA) 

p 04 Estimation of the global burden of active 

epilepsy: a meta-analytic approach 

Ngugi A, Sander J, Newton C (Kenya) 

p 05 Risk factors for seizure recurrence after 

more than -year remission in newly 

diagnosed epilepsy 

Maryenko L, Maryenko K (Ukraine) 

p 06 Occupational medicine and ability to work 

in epileptic patients 

Gueguen B, Poncet M, De Claviere C, 

Pairon J (France) 

p 07 The history of the treatment of 

status epilepticus 

Neligan A, Shorvon S (UK) 

p 08 A tool for comprehensive care: a center 

for support in social life for people 

with epilepsy 

Gueguen B, Piel-Desruisseaux B, Odier F, 

Lepagnot C, Walz J, Foucat F (France) 



p 09 Familial and sporadic patients with 

refractory mesial temporal lobe epilepsy 

present distinct patterns of pre-operatory 

hippocampal volumetry and grey 

matter atrophy revealed by voxel 

based morphometry 

Yasuda C, Morita M, Pereira A, Alessio A, 

Costa A, Betting L, Salgado P, Cardoso T, Costa A, 

Abraão C, Tedeschi H, Oliveira E, Damasceno B, 

Guerreiro C, Guerreiro M, Cendes I, 

Cendes F (Brazil) 

p 0 Inflammatory process is associated with 

temporal lobe epilepsy and mesial 

temporal sclerosis (TLE-MTS) 

Vasconcellos Varella P, Ferreira Carvalho 

Santiago J, Targas Yacubian E, Silva Centeno R, 

Carrete Jr. H, Canzian M, 

Ferreira de Castro Neto E, 

Mieko Suemitsu Higa E, Amado D, 

Abrão Cavalheiro E, 

Naffah Mazzacoratti M (Brazil) 

p Clinical epileptology of juvenile neuronal 

ceroid lipofuscinosis 

Brodtkorb E, Strandheim J (Norway) 

p 2 Tuberous sclerosis and epilepsy 

Kruja J, Kapisyzi M, Mijo S, Kerri I, 

Daka O (Albania) 

p 3 State of consciousness and interictal 

epileptiform discharges predict seizure 

occurrence during routine EEG 

Gandelman-Marton R, Neufeld M (Israel) 

p 4 How important is invasive ictal recording 

in patients with itractable TLE and 

normal MRI? 

Chung J, Meador K, Eisenschenk S, Ghacibeh G, 

Townsend D, Roper S (USA) 

p 5 Cervical spinal MRI in a patient with vagus 

nerve stimulator (VNS) 

Roebling R, Huch K, Kassubek J, Lerche H, 

Weber Y (Germany) 

p 6 Unilateral thalamic lesion causes 

status epilepticus in two cases of patients 

who contracted viral encephalitis 

Park H, Jin S, Seo Y (Korea) 

p 7 Factors for the seizure relapse after 

withdrawal from antiepileptic drug 

monotherapy in cryptogenic 

partial epilepsy 

Hong-Ki S, Hwi-Cheol C, Tae-Cheon K, 

Dong-Jin S, Yeung-In K (South Korea) 

p 8 Lamotrigine retrial after previous rash 

Kim J, Chu M, Ma H (South Korea) 

p 9 Prolonged systemic hypotension after 

discontinuation of intravenous midazolam 

infusion in status epilepticus 

Kim O (South Korea) 


p 20 Use of the internet to facilitate 

investigator-driven trials in epilepsy 

Bergin P, Ip T, Sheehan R, Frith R, Sadleir L, 

McGrath N, Ranta A, Walker E (New Zealand) 

p 2 Initial monotherapy with carbamazepine, 

valproic acid, and topiramate: 

retrospective study 

Kim J, Oh G, Lee G, Lee S, Park H, Lee S, Yi S, 

Park S (South Korea) 

p 22 A comparison of midazolam and 

midazolam plus other antiepileptic 

drugs in management of refractory 


Oh S E, Jung H, Kim J, Park S, Yi S (South Korea) 

p 23 Refractory status epilepticus in 

limbic encephalitis 

Choi Y J, Lim T, Kim D, Sohn Y S, 

Huh K (South Korea) 

p 24 Orofacial injuries due to seizures in 

persons with epilepsy 

Costa A, Yasuda C, Morita M, Cendes F (Brazil) 

p 25 Simultaneous EEG and Functional MRI as 

compared to MEG localizations 

Eliashiv D, Stern J (USA) 

p 26 ‘Deja-Vu’: epileptic or not? 

Matsuo F (USA) 

p 27 Effect of antipsychotics in epilepsy 

patients with psychiatric symptoms 

Okazaki M, Ito M, Kato M, Adachi N, Tanaka S, 

Watanabe M, Watanabe Y, Onuma T (Japan) 

p 28 Treatment-seeking behavior of the people 

with epilepsy (PWE) in Taiwan: a hospitalbased 

study 

Yu H, Lai C, Yen D, Yiu C, Kwan S, Lin Y, 

Chen C (Taiwan) 

p 29 The responsibility to st AED 

monotherapy in newly diagnosed 

cryptogenic partial epilepsy: a 2 years 

observational study 

Kim S, Kim S, Tae Gyu H (South Korea) 

p 30 Clinical factors relating with responsibility 

to anti-epileptics in temporal lobe 

epilepsy with hippocampal sclerosis 

Kim S, Nho S, Park H (South Korea) 

p 3 Decreased presentation of seizures to 

ED in a large Australian population 

998-2007 

Beran R, Taneja S, Thomas P, Cappelen-Smith 

C, Griffith N, Hanna I, Hodgkinson S, McDougall 

A, Worthington J, Cordato D (Australia) 

p 32 Epidemiological profile of seizurepresentations 

for an Area Health Service 

2003-2007 (inclusive) 

Cordato D, Taneja S, Thomas P, 

Cappelen-Smith C, Griffith N, Hanna I, 

Hodgkinson S, McDougall A, Beran R (Australia) 



p 33 Sexual dysfunction in men with epilepsy 

Bozdemir H, Aslan K, Balal M, 

Seydaoðlu G (Turkey) 

p 34 First stroke and acute symptomatic 

seizures: a prospective cohort study. 

The epistroke group 

Beghi E, D’Alessandro R, Consoli D, Crespi V, 

Delaj L, Gandolfo C, Greco G, Manfredi M, 

Mattana F, Musolino R, Provinciali L, 

Santangelo M, Specchio L (Italy) 

p 35 Refractory epilepsy in tuberous sclerosis 

complex in adult 

Ristic S, Ristic D (Serbia and Montenegro) 

p 36 Epilepsy in the elderly 

Marquez F, Marquez J (Spain) 

p 37 Vagus nerve stimulation for drug resistant 

epilepsy in adults: a follow up study 

Aguilar-Amat M, Abenza M, Iváñez V (Spain) 

p 38 Clinical profile of new-onset unprovoked 

seizures in the elderly in south India: a 

territory hospital-based study 

Jagaralapudi M, Deshmukh D, Saxena A, 

Tripathi G (India) 

p 39 in 8 patients with syncope are 

misdiagnosed as epilepsy on long term 

cardiac rhythm monitoring by an 

implantable ECG loop recorder (ILR) 

Hamid T, Rose S, Clifford A, Homa S, Garratt C, 

Clarke B, Cooper P, Fitzpatrick A, Petkar S (UK) 

p 40 A European registry of anti epileptic 

drug use in patients with lennox-gastaut 

syndrome 

Seeruthun R, Yeates A, Ashworth S (UK) 

p 4 Post-operative seizure control and 

tolerability of antiepileptic drugs in 

glioma-related epilepsy 

Pauletto G, Belluzzo M, Budai R, Skrap M, Gigli G, 

Bergonzi P (Italy) 

p 42 The change of seizure frequency 

during pregnancy - retrospective study on 

50 pregnancies 

Szaba T, Anwar A, Ruzics C, Juhos V (Turkey) 

p 43 Adenylate kinase 2 in neuronal 

apoptosis process in hippocampus of 

human and experimental temporal 

lobe epilepsy 

Wang L, Wang X (China) 

p 44 Generic AEDs Switching - time for a 

new approach 

Glynn M (Ireland) 

p 45 Anti-inflammatory drug cocktail provides 

partial hippocampal neuroprotection in 

a model of status epilepticus in 

immature rats 

Sankar R, Kwon Y, Auvin S, Shin D, 

Mazarati A (USA) 

76 


p 46 The state of free radical oxidation in 

epileptic patients with comorbidity 

vascular disorder 

Dubenko A, Cherevatenko G, Vasilyeva O, 

Babkina Y, Bibik O (Ukraine) 

p 47 The study of protein level expression of 

phosphorylation myosin light chain and 

myosin light chain kinase in refractory 

temproal epilepsy 

Wang X, Li J (China) 

p 48 GABRG2 and SCN A analysis within the 

genetic basis of familial epilepsy in Wales 

Johnston J, Hammond C, Morris H, Smith P, 

Rees M (UK) 

p 49 A locus for familial cortical myoclonic 

tremor with epilepsy maps to 

chromosome 7p 5 

Xi Z, Wang X (China) 

p 50 Altered expression of Dynamin in 

temporal lobe tissue of patients with 


Xiao Z, Wang X (China) 

p 5 Epilepsy care in Ireland: an exploration of 

patient healthcare journeys and 

experiences: what are the implications 

for practice? 

Fitzsimons M, Delanty N, Varley J, 

Normand C (Ireland) 

p 52 Netrin-G2 in the brain tissue of patients 

with intractable epilepsy and rat models 

Pan Y, Wang X (China) 

p 53 “Migralepsy” revisited 

Pimentel J, Gouveia L, Bentes C (Portugal) 

p 54 Apnoea detector to prevent SUDEP 

Rodriguez-Villegas E, Aguilar-Pelaez E, Chen G, 

Duncan J (UK) 

p 55 Does hippocampus play any role in 

determining language lateralization? 

Rathore C, George A, Sarma P, 

Radhakrishnan K (India) 

p 56 The most frequent etiology of 

symptomatic epileptic attacks at the 

urgent neurological service during the 

perid of two years (2005, 2006) at the clinic 

of neurology of clinical hospital in Osijek 

Juric S, Butkovic-Soldo S (Croatia) 

p 57 Comparing beliefs about epilepsy and 

brain surgery between epilepsy patients 

and their relatives in a multi-cultural 

urban population 

Grant A, Nakhutina L, Prus N (USA) 

p 58 Epilepsy, anti-epileptic drugs and bone 

health: what about the guidelines? 

Beerhorst K, de Krom M, 

Aldenkamp B (The Netherlands) 



p 59 Adherence to treatment in patients with 

juvenile myoclonic epilepsy: correlation 

with quality of life measurements and 

adverse events of medication 

Martins H, Barreira Alonso N, 

Maria Ferreira F Guilhoto L, Guaranha Bittar M, 

Barreto Cabral F, Sales Ferreira Caboclo L, 

Targas Yacubian E (Brazil) 

p 60 Cardiovascular and metabolic risk factors 

for incident unprovoked seizures a casecontrol 

study 

Adelöw C, Andersson T, Ahlbom A, 

Tomson T (Sweden) 

p 6 Efficacy and tolerability of rufinamide in 

adults with Lennox-Gastaut syndrome or 

Lennox-Gastaut like conditions 

Lund C, Lossius M (Norway) 

p 62 Symptomatic epilepsies in adults - the 

most common etiology and response to 

antiepileptic drug therapy 

Vujisic S, Kolinovic M, Bozic K (Montenegro) 

p 63 Personality traits related to juvenile 

myoclonic epilepsy: MRI reveals prefrontal 

abnormalities through a voxel-based 

morphometry study 

Araujo Filho G, Jackowski A, Lin K, Guaranha M, 

Guilhoto L, Carrete H, Caboclo L, Bressan R, 


p 64 Extratemporal involvement in temporal 

lobe epilepsy with mesial temporal 

sclerosis – a VBM study 

Santana M, Silva H, Guimarães M, Bussoletti R, 

Caboclo L, Centeno R, Carrete Junior H, 

Jackowski A, Yacubian E (Brazil) 

p 65 Lack of electroclinical and metabolic 

differences between hippocampal 

sclerosis with and without 

microdysgenesis in temporal neocortex 

Kim J, Lee S, Im K, Kim J, Jung K, Khang S, 

Kang J (Korea) 

p 66 Surgical treatment for intractable epilepsy 

due to focal cortical dysplasia 

Zhang G, Yu T, Li Y (China) 

p 67 Epilepsy and weather: a significant 

correlation between the temperature 

and patients with epilepsy visit 

emergency services 

Liou H, Chen L, Chen C, Chen T (Taiwan) 

p 68 Network analysis of some 

epileptic mechanisms 

Ruzics C, Anwar A, Szabó T, Balogh A (Turkey) 

p 69 Surgical outcome in patients with 

dual pathology 

Saygi S, Bekircan C, Tezer F, Dericioglu N, 

Karli Oguz K, Akalan N (Turkey) 


p 70 Incidence of epilepsy and epileptic 

syndromes in 0- 5 year-olds 

Mª Eugenia Y, Teodoro D, Amalia A, 

Silvia S (Spain) 

p 7 Seizure freedom with additional 

anticonvulsants in patients who 

underwent resective epilepsy 

surgery and had seizure recurrence 

postoperatively 

Dericioglu N, Binol E, Tezer I, Ciger A, 

Akalan N, Saygi S (Turkey) 

p 72 P glycoprotein modulator verapamil 

treatment in carbamazepine: 

unresponsive patients with 


Sun M, Chen L, Liu Y, Lin J, Deckers C (China) 

p 73 Observational longitudinal study on late 

seizures in neurosurgical patients 

Bartolini E, Lenzi B, Vannozzi R, Iudice A, 

Baldini M, Parenti G, Murri L (Italy) 

p 74 Influence of the air pressure and 

temperature changes in four seasons 

on seizures frequency and brain 

bioelectrical activity 

Motta E, Kazibutowska Z, Lasek-Bal A, Goba A, 

Dêbski M, Strzaa-Orze M (Poland) 

p 75 Hypersomnia and epilepsy 

Klobuèníková K, Kollár B (Slovak Republic) 

p 76 Non ketotic hyperglycemic seizures: 

an EEG-FMRI coregistration study 

Del Felice A, Zanoni T, Avesani M, Formaggio E, 

Storti S, Fiaschi A, Moretto G, Manganotti P (Italy) 

p 77 First unprovoked seizure - different risk 

of recurrence. Evaluation of the possible 

risk factors 

Kollár B, Zuzana M, Katarína K, Zoltán G, 

Zuzana V (Slovak Republic) 

p 78 Neurocardiogenic (vasovagal) syncope 

- diagnosis associatd with mistakes 

Mike P, Kollár B, Urban U (Slovak Republic) 

p 79 Prevalence of active epilepsy and 

treatment gap of epilepsy in Tbilisi, 

Georgia 

Okujava N, Toidze O, Kasradze S, Lomidze G, 

Alkhidze M, de Boer H, Dua T, Sander L (Georgia) 

p 80 Neuropsychological profile and psychiatric 

comorbidity in patients with juvenile 

myoclonic epilepsy: a controlled study 

Somayajula S, Sattaluri S (India) 

p 8 Clinical characteristics of alcohol 

related seizures 

Lee J, Park K, Lee S, Park J (Korea) 

p 82 Levetiracetam (Epixx®) efficacy in 

treatment of refractory focal epilepsies 

Alkhidze M, Jishkariani T, Khajalia T, Japaridze G, 

Kvernadze D, Kasradze S (Georgia) 



p 83 Status psychosus epilepticus: a special 

type of non-convulsive status epilepticus 

Kitchener N (Egypt) 

p 84 Clinical consequences of generic 

substitution of topiramate 

Paradis P, Dominick L, Patrick L, Marie-Hélène L, 

Natalia M, Moore Y, Gaudig M, Duh M (Germany) 

p 85 The prevalence of anti-epileptic drug 

associated bone disorder in an adult 

epilepsy clinic population 

Liggan B, Tirupathi S, O’Connell P, Doherty C, 

Delanty N (Ireland) 

p 86 Impact of gender on outcome of epilepsy 

Gopinath M, Sarma S, Thomas S (India) 

p 87 Prolonged cortical silent period in patients 

with generalized or focal epilepsy 

Joo E, Park H, Lee J, Hong S (Korea) 

p 88 Brainstem autonomic influence on cortical 

epileptiform activity: evidence of a 

relationship to oxygenation 

Julu P, Hansen S, Smeets E, Witt Engerström I, 

Delamont R, Apartopoulos F, Pini G, Bigoni S, 

Curfs L (UK) 

p 89 Study for relationship between 

hyperthyroidism and seizure 

Kim S, Kim W (South Korea) 

p 90 A long-term follow-up study of 00 

patients with Nocturnal Frontal Lobe 

Epilepsy (NFLE) 

Licchetta L, Bisulli F, Di Vito L, Naldi I, Mostacci B, 

Pittau F, Provini F, Vignatelli L, Fares J, 

Montagna P, Tinuper P (Italy) 

p 9 Dopaminergic dysfunction shows a similar 

pattern in patients with ring chromosome 

20 epilepsy and temporal lobe epilepsy 

Chiesa V, Del Sole A, Lucignani G, Giordano I, 

La Briola F, Vignoli A, Elisei F, Gilardi L, 

Canevini M (Italy) 

p 92 The epilepsy genetic association database 

(epiGAD): analysis of 39 published 

epilepsy genetic association studies, 

997-2007 

Tan N, Berkovic S (Singapore) 

p 93 Orienting clinical features in the 

differential diagnosis of nocturnal seizures 

Silvestri R, Aricò I, Condurso R (Italy) 

p 94 Correlational study of sleep quality, 

excessive daytime sleepiness and quality 

of life in patients with epilepsy 

Tzeng R, Hsu C (Taiwan) 

p 95 Reconciling clinical theory and practise 

in an epilepsy-specific electronic 

patient record 

Breen P, McQuaid L, Grimson J, Delanty N, 

Dunne M, Dunleavy B, Normand C, Fitzsimons 

M (Ireland) 

78 


p 96 Latencies to the first typical generalized 

spike-wave discharge in idiopathic 

generalized epilepsies- an analysis by 

video-EEG monitoring 

Oehl B, Götz-Trabert K, Brandt A, Lehmann C, 

Schulze-Bonhage A (Germany) 

p 97 Emotional state predicts seizure 

occurrence in an electronic diary study 

Haut S, Hall C, Tennen H, Borkowski T, 

Lipton R (USA) 

p 98 Diagnosis is challenging when complaint 

is only vertigo and dizziness 

Akdal G, Ozer A, Onur E, Baklan B (Turkey) 

p 99 Brivaracetam in patients with unverrichtlundborg 

disease: results from two 

randomized, lacebo-controlled, 

double-blind studies 

Kalviaiinen R, Genton P, Andermann E, 

Magaudda A, Frucht S, Schlit A, Gerard D, Van 

Otterdijk E, von Rosenstiel P (Finland) 

p200 Sulcal areas in baboons (papio hamadryas 

spp) with generalized interictal epileptic 

discharges on scalp EEG 

Szabo C, Kochunov P, Knape K, McCoy K, 

Leland M, Lancaster J, Fox P, Williams J, 

Rogers J (USA) 

p20 Seizure control and quality of life in 

patients with brain tumour-related 

epilepsy treated with levetiracetam 

monotherapy 

Maschio M, Dinapoli L, Jandolo B, Fabi A, Pace A, 

Sperati F (Italy) 

p202 Does acute electrocorticography predicts 

seizure outcome following anterior 

temporal lobectomy? 

Rekalakunta C, Rathore C, Nayak D, Abraham M, 

Radhakrishnan A, Radhakrishnan K (India) 

p203 Idiopathic generalized epilepsy with 

generalized tonic clonic seizures: clinical 

features and prognosis 

Cortés Velarde M, Oliva Nacarino P, Temprano 

Fernández T, García Martínez A, 

Salas Puig J (Spain) 

p204 The forgotten generation 

Pierri M, Hamandi K (UK) 

p205 Epilepsy perception in relatives of 

epilepsy patients: a preliminary study 

Canbaz Kabay S, Ozisik Karaman H, Yilmaz Z, 

Bakar C, Erdinc O (Turkey) 

p206 The proposed mechanism of action 

of lacosamide, the newly available 

antiepileptic drug for partial-onset seizures 

Wolff C, Errington A, Stoehr T, Lees G (Germany) 

p207 Ictal affective symptoms in temporal 

lobe epilepsy 

Toth V, Fogarasi A, Karadi K, Schulz R, Ebner A, 

Janszky J (Turkey) 



p208 Effect of intraoperative thermal 

inactivation on outcome of anterior 

temporal lobectomy 

Tyrlikova I, Novak Z, Brazdil M, Kubikova R, 

Kuba R, Chrastina J, Megova S, 

Rektor I (Czech Republic) 

p209 Fatigue in epileptic patients: 

a prospective study 

Hamelin S, Kahane P, Vercueil L (France) 

p2 0 Tobacco habits in nocturnal frontal lobe 

epilepsy (NFLE) 

Naldi I, Bisulli F, Luca V, Laura L, Francesca P, 

Carlotta S, Barbara M, Federica P, Pasquale M, 

Paolo T (Italy) 

p2 SISCOM in patients with extratemporal 

focal epilepsy and normal MRI: correlation 

with intracranial EEG, histology and 

seizure outcome 

Kudr M, Kraek P, Marusia P, Trnka J, Michalova K, 

Åanda J, Kyna M, Zameank J, Jahodova A, 

Komarek V (Czech Republic) 

p2 2 Inverse relationship between 

extrasynaptic NMDAR function and 

seizure expression following chronic 

treatment with nonsubtype- and 

NR2B-selective NMDAR antagonists in 

hippocampal slice cultures 

Bausch S, He S (USA) 

p2 3 Cardiac autonomic modulation in patients 

with epilepsy 

Tighe M, Hennessy M, Binnie C, Delamont R (UK) 

p2 4 Clinical effectiveness of zonisamide in a 

sample of adult patients with epilepsy 

Murphy C, Blattner R, Cooper P (UK) 

p2 5 Effects of smoking on seizure control in 

treatment resistant adult epilepsy 

patients: a pilot study 

Lozsadi D (UK) 

p2 6 The Brandenburg Questionnaire for 

quality of life in epilepsy patients (BQLE) 

C a new, short and valid instrument 

Straub H, Hänsch S, Ballaschk K, 

Esser G (Germany) 

p2 7 Knowledge, attitudes and practices with 

respect to epilepsy among student nurses 

and laboratory assistants in the 

South-West region of Cameroon 

Njamnshi A, Tabah E, Yepnjio F, Kollo B, 

Angwafor S, Kuate C, Dema F, Fonsah J, 

Angwafo III F, Muna W (Cameroon) 

p2 8 Knowledge, attitudes and practices 

towards epilepsy in Badissa village, 

Cameroon 

Dema F, Njamnshi A, Angwafo III F, Jallon P, 

Muna W (Cameroon) 


p2 9 HSV infection in 27 patients with mesial 

temporal lobe epilepsy and the 

association with NF-kB 

Li J, Zhou D, Lei D, Peng F, Zeng Y (China) 

p220 Dinamic movements on the EEG 

frequency spectrum / 0.5- 20 Hz / of 

epileptic patients 

Balogh A, Szabó G, Pártos I (Turkey) 

p22 Lesion, semiology, network 

Balogh A, Czirják S, Barsi P (Turkey) 

p222 Temporal lobe and sinus node: 

a case series provides evidence for 

bidirectional effects 

O’Dwyer R, Alexopoulos A, Kaw R, Walid S, 

Hantus S, Burgess R (USA) 

p223 Prevalence, patterns, and risk factors for 

headache in Brazilian epileptic patients 

Bianchin M, Londero R, Dal-Pizzol A, Bragatti J, 

Torres C, Bohn-Assmann J (Brazil) 

p224 The dose response relationship of 

carisbamate as an adjunctive treatment 

for partial onset seizures based on 

pharmacokinetic/pharmacodynamic 

modeling of 3 randomized, 

placebo-controlled trials 

Faught E, Sperling M, De Ridder F, Schmitt J, 

Kimko H, Novak G (USA) 

p225 Carisbamate as adjunctive treatment of 

partial onset seizures in adults: results 

from an ongoing open-label extension 

of a double-blind randomized dose 

ranging study 

Rosenfeld W, Wiegand F, Schmitt J, 

Novak G (USA) 

p226 The association between prenatal stress 

and infantile spasms: a case control study 

Zou L, Shang N (China) 

p227 Infantile spasms: can topiramate be on top? 

Al-Baradie R (Saudi Arabia) 

p228 Seizure relapses after child-bearing 

and the seizure outcome; over 5 years 

follow up 

Hara M, Matsuura M, Watanabe M, Watanabe Y, 

Hara K (Japan) 

p229 Seizure clustering during VEEG monitoring 

in patients with intractable seizures, its 

localizing value and predictors 

Tripathi M, Singh P, Padma V, Bhatia R, Singh M, 

Prasad K (India) 

p230 Viability of hippocampal slices does 

not depend on the anesthetic used during 

the epilepsy surgery 

Antonio L, Martins C, Centeno R, Ueda E, 

Nascimento A, da Silva A, Yacubian E, 

Cavalheiro E (Brazil) 



p23 Comorbidity between sleep paralysis 

and epilepsy 

Galimberti C, Colnaghi S, Ossola M (Italy) 

p232 A patient with unilateral visual 

hallucination and headache: migraine 

or epilepsy? 

Hsiao C, Chen I (Taiwan) 

p233 Invasive recordings of patients with 

‘burned-out’ hippocampus 

Mareckova I, Vojtech Z, 

Prochazka T (Czech Republic) 

p234 Community control of epilepsy in 79 

counties in rural China 

Wang W, Wu J, Li S, de Boer H, Sander L (China) 

p235 Prediction of seizure control in non-ketotic 

hyperglycemic induced seizures 

Tiamkao S (Thailand) 

p236 Progressive myoclonus epilepsy 

and mental decline; A case report of 

Lafora’s disease 

Moghaddasi M, Mamarabadi M, Ebrahimi A, 

Fallah M (Iran) 

p237 Generalized convulsive status epilepticus 

treatment: agreement of a standard is 

not sufficient 

Valadas A, Bentes C, Ferro J (Portugal) 

p238 Epilepsy with nonconvulsive status 

epilepticus as predominant seizure type 

Ikeda H, Nakamura F, Hiyoshi T, Fujiwara T, 

Inoue Y (Japan) 

p239 Paroxysmal dystonia during exposure to 

topiramate for refractory focal epilepsy: 

two cases report 

Benna P, Montalenti E, Bert F, Colonna R (Italy) 

p240 Cortical-subcortical lesions near the 

temporal pole, the medial temporal and 

the insular cortex are associated with 

epileptic seizures in patients with MS 

Rizzi R, Zuccoli G, Motti L, Bondavalli M, 

Marcello N (Italy) 

p24 The effect of heatstroke treated with 

aggressively combined cooling on 

seizure activities, neurological 

presentations and sequelae 

Sithinamsuwan P, Chinvarun Y, Chusri W, 

Orrawanhanothai P, Chairangsaris P, 

Udommongkol C, Nidhinandana S, 

Wongmek W, Suphakasem S, 

Suwantamee J (Thailand) 

p242 Are there real unprovoked/unprecipitated 

seizures? 

Rajna P, Sólyom A, Mezõfi L, Vargyai É (Turkey) 

p243 Electrophysiological features of stroke’s 

patients submitted to autologous bone 

marrow stem cells transplant 

Alves-Leon S, Batistela V, André C, 

Coelho SR Pereira V, Mendez-Otero R (Brazil) 

80 


p244 Cysticercus inside of a hippocampus with 

Sclerosis Mesial: dual pathology or an 

indirect inflammatory response? 

Alves-Leon S, D’Andrea Meira I, 

Coelho SR Pereira V, Chimelli L, Gaspareto E, 

Paes Barreto Marcondes De Souza J (Brazil) 

p245 Temporal lobe epilepsy associated to 

mesial hippocampus Sclerosis: frequency 

of initial precipitant incidents and 

clinical outcome 

Alves-Leon S, D’Andrea-Meira I, 

Coelho SR Pereira V, Bento de Souza Cardoso M, 

Reis M, Gaspareto E, 

Paes Barreto Marcondes De Souza J (Brazil) 

p246 Dysembryoplastic neuroepithelial tumor: 

sistematic review of clinical spectrum, 

seizure outcome, neuroradiology, and 

surgery response 

Alves-Leon S, Mussi M, Thuler L (Brazil) 

p247 Adult absence epilepsy: an epilepsy 

syndrome with special clinical and 

EEG features 

Huicong K, Suiqiang Z, Qi H, Xiaoyan L, 

Feng X (China) 

p248 EEG pattern of symptomatic visual 

disorder in occipital lesion: visual aura 

with migraine headache or visual 

epileptic seizure? 

Dainese F, Mainardi F, Zanchin G, 

Paladin F (Italy) 

p249 Relapse rate in idiopathic generalized 

epilepsies during adulthood 

Kiteva-Trencevska G (Macedonia) 

p250 Epilepsy perception in epileptic pateints 

and their relatives and a control group 

Degirmenci Y, Oziþik Karaman H, 

Bakar C (Turkey) 

p25 Seizure outcome of 75 patients with 

Juvenile Myoclonic Epilepsy - a long-term 

observational study 

Larch J, Unterberger I, Dobesberger J, 

Embacher N, Walser G, Luef G, Bauer G, 

Trinka E (Austria) 

p252 Prevalence of etiological and clinical 

factors of an ischaemic stroke in the 

development of vascular epilepsy 

Santamarina E, Toledo M, Sueiras M, Rovira R, 

Álvarez-Sabín J, Salas X (Spain) 

p253 Teddy bear sign revisited 

Procházka T, Vojtech Z, Marecková I, 

Kalina M (Czech Republic) 

p254 Epilepsy management in rural health 

centers in Malang, Indonesia: a five 

year experience 

Agoes A (Indonesia) 



p255 Motor manifestatioins that occur during 

sleep: nocturnal frontal lobe epilepsy 

(NFLE) or parasomnias. Differential 

diagnosis with videopolysomnography 

Rondon J (Venezuela) 

p256 Epilepsy in Kazakhstan: population-based 

studies of epidemiology 

Aldungarova R, Arinova O, Nyamdordgiyn G, 

Arinova E (Kazakhstan) 

p257 Progressive symptomatic seizures or 

epilepsy in brain tumors: a matter of 

interictal epileptiform abnormalities 

Rosati A, Codella M, Antonini L, De Maria G, 

Todeschini A, Padovani A (Italy) 

p258 Video-EEG analysis of frequent clinical 

features in patients with psychogenic 

nonepileptic seizures 

Vojvodic N, Ljubica P, Sokic D, Ristic A, 

Jankovic S (Serbia) 

p259 Reliability of clock drawing test for 

lateralization of epileptogenic zone in 


Popovic L, Vojvodic N, Sokic D, Ristic A, 

Jankovic S (Serbia) 

p260 Temporal lobe epilepsy surgery result: 

Indonesia experiences 

Thohar Arifin M, Muttaqin Z, Andar E, Kurnia H, 

Kusnarto G (Indonesia) 

p26 Classification of unexplained episodes of 

unconsciousness can be improved easily 

and cost-effectively by showing a DVD 

including different types of epileptic 

seizures and non-epileptic seizure-like 

episodes to someone who has observed 

the event 

Kurth C, Steinhoff B (Germany) 

p262 Correlation of aetiology and prognosis of 

symptomatic epilepsy 

Ismajli-Marku M, Cvetkovska E, Taravari A, 

Cepreganova-Cangovska T, Kuzmanovski I, 

Nikodijevic D, Kuzmanovska G (Macedonia) 

p263 Reciprocal interrelationship between 

epilepsy and NREM sleep parasomnia: 

a report of two cases 

Dylgjeri S, Villani F, Freri E, Pincherle A, Didato G, 

Mastrangelo M, Nobili L (Italy) 

p264 Comorbitity of migraine and epilepsy 

Cepreganova Cangovska T, Cvetkovska E, 

Ismajli Marku M, Kuzmanovski I, Nikodijevic D, 

Arsovska A (Macedonia) 

p265 Malformation of cortical development: 

often an underdiagnosed and 

misdiagnosed entity 

Mehndiratta M, Mishra S (India) 

p266 Ictal bipedal behavior: clinical 

neuroanatomical considerations 

Gardella E, Francione S, Tassi L, Rubboli G, 

lo Russo G, Tassinari C, Canevini M (Italy) 


p267 Balance dysfunction in patients with 

epilepsy assessed by static posturography 

Blatt I, Yahalom G, Dvir Z, Neufeld M, 

Gandelman-Marton R (Israel) 

p268 Characteristics of patients attending 

the neurology emergency room with 

fainting spell 

Ozturk M, Baybas S, Kutlubay N, Elibirlik S, 

Dirican A, Demir N (Turkey) 

p269 Characteristics of patients with juvenile 

myoclonic epilepsy 

Ozturk M, Baybas S, Ataklý D, Dirican A, 

Elibirlik S, Arslan E, Sarý H, Arpacý B (Turkey) 

p270 Pharmacogenetic study of Topamaxinduced 

cognitive dysfunction 

Hung C, Liou H (China) 

p27 Ictal EEG onset patterns in temporal 

lobe epilepsy – correlation with 

surgical outcome 

Sattaluri S, Chaya S , Sailaja S, Panigrahi M, 

Sundaram C (India) 

p272 Steroid-responsive encephalopathy 

associated with elevated antithyroid 

antibodies (Hashimoto`s encephalopathy) 

Kraus R, Fischer P, Bayas A, 

Naumann M (Germany) 

p273 Non-convulsive status epilepticus in 

comatose adults: clinical, EEG and 

neuroimaging features, treatment and 

outcome of 8 consecutive patients. 

Fernandez-Torre J, Rebollo M, Gutierrez A, 

Lopez-Espadas F (Spain) 

p274 Early epileptic seizure detection using the 

k-nearest neighbor algorithm for fractal 

dimension estimation 

Siatouni A, Polychronaki G, Ktonas P, Gatzonis S, 

Asvestas P, Tsekou H, Sakas D, Nikita K (Greece) 

p275 Epilepsy in rett syndrome 

Pintaudi M, Vignoli A, Baglietto M, Hayek J, 

La Briola F, Parodi E, Aiello F, Giordano L, 

Veneselli E, Canevini M (Italy) 

p276 Ictal asystole: a Video EEG (VEEG) and 

Stereo EEG (SEEG) study 

Guellerin J, Hamelin S, Minotto L, 

Kahane P (France) 

p277 Epilepsy and family life in Lithuania 

Mameniskiene R, Budrys V, Balcytyte R, 

Guk J (Lithuania) 

p278 Fertility trends in women with epilepsy: 

observations from Kerala registry of 

epilepsy and pregnancy 

Cheravalloor Sukumaran S, Thomas S (India) 

p279 Epidemiological profile of epilepsy in a 

university hospital in Bogota, Colombia 

Quintero Cusguen P, 

Gonzalez Hernandez A (Colombia) 



p280 Do subclinical electrographic seizure 

patterns affect autonomic function as 

assessed by heart rate variability? 

Adjei P, Surges R, Kallis C, Scott C, Walker M, 

Shorvon S (UK) 

p28 Common mechanisms of auditory 

hallucinations – perfusion studies 

in epilepsy 

Hauf M, Wiest R, Schindler K, Federspiel A, 

Hubl D (Switzerland) 

p282 Epilepsy in the central region of 

Cameroon: clinical and 

electroencephalographic features 

Bonini F, Jinane F, Egeo G, Bruno F, Prischich F, 

De Rinaldis M, Di Bonaventura C, Casciato S, 

Petrucci S, Lapenta L, Giallonardo A, 

D’Erasmo A, Vanacore N (Italy) 

p283 Metabolism of eslicarbazepine acetate 

in humans 

Falcão A, Almeida L, Soares-da-Silva P (Portugal) 

p284 Seizures: a symptom of multiple sclerosis? 

Nobrega C, Capela C, Pinto Viana J, 

Almeida R (Portugal) 

p285 Atypical clinical presentations of 

pyridoxine dependent epilepsy and a 

novel mutation in the ALDH7A gene 

Yýlmaz S, Serdaroglu G, Tekgul H, Aykut A, 

Ozkýnay F, Gokben S (Turkey) 

p286 Time of occurrence of adverse events 

in relation to start of treatment 

with eslicarbazepine acetate as 

add-on treatment in patients with 

partial-onset seizures 

Gama H, Elger C, Halász P, Ben-Menachem E, 

Alain-Gabbai A, Lopes-Lima J, Gil-Nagel A, 

Nunes T, Moreira J, Mota F, Maia J, Almeida L, 

Soares-da-Silva P (Portugal) 

p287 The importance of laboratory examination 

in epilepsy outpatient database in 

eastern Turkey 

Fekete I, Fekete K, Puskas S, Csoto E, 

Horvath L (Turkey) 

p288 Long-term add-on treatment of partial 

epilepsy with eslicarbazepine acetate 

Elger C, Halasz P, Moreira J, Maia J, Nunes T, 

Almeida L, Soares-da-Silva P (Germany) 

p289 The effects of 0.5 Hz repetitive transcranial 

magnetic stimulation on EEG power 

spectrum in patients with focal epilepsy 

García-Gomar M, Santiago-Rodríguez E, 

Harmony T, Fernández-Bouzas A (México) 

p290 Bilateral thalamic glucose metabolism is 

increased in patients with epilepsy 

responding to vagal nerve stimulation 

Feichtinger M, Ropele S, Zaar K, Eder H, 

Urbanic Purkart T, Aigner R, Fazekas F (Austria) 

82 


p29 Initial results from population-based 

study of sudden unexpected death in 

epilepsy in the Republic of Ireland 

O’Rourke D, Delanty N, Farrell M, 

Hennessy M (Ireland) 

p292 Selective amygdalohippocampectomy: 

a study of indications and contraindications 

Boling W, Palade A, Brick J (USA) 

p293 Therapeutic choices in senile myoclonic 

epilepsy in Down’s disease 

De Simone R, Philippe G, Crespel A, Salas-Puig X, 

Genton P (Italy) 

p294 Experience with extended-release 

valproate combined with valproic acid 

therapy in epilepsy in common clinical 

practice in Slovakia 

Donath V, Lietava J, Fillova J, 

Luliak M (Slovak Republic) 

p295 MDS indication of epilepsy in elderly 

nursing home residents 

Eberly L, Birnbaum A, Li S, Leppik I (USA) 

p296 Topiramate and teratogenecity 

Abdool S, Shawabkeh A (UAE) 

p297 Circadian rhythm in patients with juvenile 

myoclonic epilepsy and their healthy 

unaffected siblings 

Wandschneider B, Schmitz B (Germany) 

p298 Two year seizure outcome of vagal-nerve 

stimulation for epilepsy in Budapest 

Muller K, Eross L, Entz L, Halasz P, Rasonyi G, 

Fabo D (Turkey) 

p299 Efficacy and safety of eslicarbazepine 

acetate as add-on treatment to 

carbamazepine in patients with 

partial-onset seizures 

Halasz P, Elger C, Ben-Menachem E, 

Alain-Gabbai A, Lopes-Lima J, Gil-Nagel A, 

Moreira J, Maia J, Nunes T, Almeida L, 

Soares-da-Silva P (Turkey) 

p300 Ictal spitting automatism in four epileptic 

patients with different etiologies 

Seferoglu M, Taskapilioglu O, Hakyemez B, 

Bora I (Turkey) 

p30 Vagus nerves stimulation in aicardi 

syndrome with status epilepticus 

Ardesch J, Griens A, 

Hageman G (The Netherlands) 

p302 Central type sleep apneas: an adverse 

effect of vagus nerve stimulation 

Ardesch J, van Lambalgen H, 

de Weerd A (The Netherlands) 

p303 Evaluation of low frequency stimulation in 

fully kindled rats 

Graciolli Cordeiro J, Kohn Cordeiro K, Aertsen A, 

Schulze-Bonhage A (Germany) 



p304 Literature and epilepsy 

Iniesta I (UK) 

p305 Knowledge, perceptions and practice 

towards epilepsy among tradiontal 

healers in the Batibo health district, 

Cameroon 

Angwafor S, Njamnshi A, Yepnjio F, Tabah E, 

Dema F, Fonsah J, Angwafo III F, 

Muna W (Cameroon) 

p306 Can we predict who will benefit from the 

ketogenic diet? 

Beniczky S, Miranda M, Alving J, Povlsen J, 

Wolf P (Denmark) 

p307 Effect of Ketocal on childhood intractable 

epilepsy in China 

Liao J, Li Y, Xiao Z (China) 

p308 Chemotherapy for refractory epilepsy 

Hilkman D, de Krom M, 

Twijnstra A (The Netherlands) 

p309 Seizure outcome in patients with 

radiosurgically treated cerebral 

arteriovenous malformations 

Yang S (Korea) 

p3 0 Therapeutic effect of health food items 

(honey, dates, figs, olives) on children 

with epilepsy 

Chaudhry H, Arshad, N, Shabbir A, Shaheen A, 

Mufti K (Pakistan) 

p3 Physical exercise in rats submitted to 

multiple status epilepticus in the early life 

period of life increases hippocampal 

parvalbumin expression 

Arida R, Gomes da Silva S, Doná F, Fernandes M, 

Scorza F, Cavalheiro E (Brazil) 

p3 2 Lateralized ictal upper and lower limb 

dystonia in patients with temporal 

lobe epilepsy 

Kuba R, Tyrlíková I, Brázdil M, 

Rektor I (Czech Republic) 

p3 3 Which pulse width should be used in 

patients with vagus nerve stimulation 

and epilepsy? 

Kostov H, Hellum K, Henning O, 

Larsson P (Norway) 

p3 4 Peri-ictal water drinking is a good 

localizing and lateralizing of non 

dominant temporal lobe epilepsy. Two 

case reports and review of the literature 

Chahidi A, Benkhadra A, Ouazzani R (Morocco) 

p3 5 Hyperactivity of hypothalamo-pituitaryadrenocortical 

axis in a rat model of 

temporal lobe epilepsy: a mechanism 

of co-morbidity between epilepsy 

and depression 

Mazarati A, Shin D, Bragin A, Tio D, Taylor A, 

Sankar R (USA) 


p3 6 Brain-derived neurotrophic factor 

expression augmented by betahydroxybutyrate 

treatment in 

pilocarpine seizure mouse model 

Kim D, Yum M, Ko T, Jeong S (Korea) 

p3 7 Role of GABAA receptor-modulating 

neurosteroids during the epileptogenesis 

in the parietal cortex of the epileptic 

mutant EL 

Murashima Y, Yoshii M (Japan) 

p3 8 Maternal behavior and their consequences 

on the offspring: a study in genetic 

epileptic rats 

Dobryakova Y, Dubynin V, 

Van Luijtelaar G (Russia) 

p3 9 Neuropeptide Y decreases synaptic 

transmission onto CCK-positive 

basket cells in the dentate gyrus of 

the hippocampus 

Ledri M, Sørensen A, Erdelyi F, Szabo G, 

Kokaia M (Sweden) 

p320 Activation of Toll-like/RAGE receptor 

signalling during seizures: a novel target 

of pharmacological intervention 

Maroso M, Balosso S, Ravizza T, Vanzulli I, 

Aronica E, Liu J, Bianchi M, Vezzani A (Italy) 

p32 Modulation of NR2B-containing N-methyl- 

D-aspartate (NMDA) receptors in a rat 

model of epilepsy 

Frasca A, Ravizza T, Noè F, Colciaghi F, Finardi A, 

Battaglia G, Vezzani A (Italy) 

p322 The effect of ketogenic diet on the 

neuronal damage in pilocarpine-induced 


Lee K, Hwang T, Woo Y (South Korea) 

p323 Long-term increasing co-localization of 

SCN8A and Ankyrin-G in rats with chronic 

epileptic seizures 

Chen Z, Chen S, Chen L, Zhou J, Dan Q, Yang L, 

Li X, Zhou L (China) 

p324 Comparison between single injection 

of Pentylentetrasole and separated 

injections for induction of epileptiform 

convulsions 

Moghimi A (Iran) 

p325 Experimental model of chronic 


Vastyanov R, Shandra A (Ukraine) 

p326 Lovastatin: a new approach to control 

neuroinflammatory response in epilepsy 

Furtado Gouveia T, Scorza F, Vieira da Silva M, 

de Aquino Bandeira T, Cunha R, Berzaghi 

Frangiotti M, Silva Jr J, Abrao Cavalheiro E, 

Naffah-Mazzacoratti M (Brazil) 



p327 Effect of neural precursor cells 

transplantation on mice models of anxiety 

and seizures 

Longo B, Ruiz L, Blanco M, dos Santos J, 

Valente M, Patti C, Frussa Filho R, Santiago M, 

Zipanzic I, Álvarez Dolado M, Mello L, 

Calcagnotto M E (Brazil) 

p328 Effects of epileptic seizures over the brain 

vascularization in chimeric mice 

Longo B, Garcia K, Romariz S, Soares M, 

Ribeiro dos Santos R, Mello L (Brazil) 

p329 Tonic GABAergic transmission is 

suppressed in PRIP- KO mice with 

epileptic phenotype 

Ueno S, Yamada J, Migita K, Yoshida S, Okada M, 

Zhu G, Kanematsu T, Hirata M, Kaneko S (Japan) 

p330 Electrical stimulation of the focal zone in 

absence epilepsy 

Zhang S, Luttjohann A, Pijper R, 

Luijtelaar G (China) 

p33 Pathophysiology of balloon cells in 


Kim J, Oh H, Lee M, Kim H (South Korea) 

p332 A revised Racine scale for PTZ 

induced seizures 

Lüttjohann A, Fabene P, 

van Luijtelaar G (The Netherlands) 

p333 Treatment with the COX-2 inhibitor 

parecoxib after status epilepticus: effect 

on epileptogenesis, behavioral alterations, 

and neuronal damage in rats 

Bankstahl M, Polascheck N, Brandt C, 

Löscher W (Germany) 

p334 Bumetanide, a selective inhibitor of 

the Na+-K+-2Cl- cotransporter NKCC , 

does not prevent epileptogenesis in the 

pilocarpine model of temporal lobe 

epilepsy in rats 

Brandt C, Nozadze M, Rattka M, Heuchert N, 

Löscher W (Germany) 

p335 Effect of (S)-3,4-dicarboxyphenylglycine 

on epileptogenesis and cognitive 

impairment following seizures induced in 

immature rats by homocysteic acid 

Folbergrová J, Otáhal J, Druga R, Tsenov G, 

Haugvicová R, Kubová H (Czech Republic) 

p336 Feasibility of seizure prediction from 

intracranial EEG recordings 

Henriksen J, Kjaer T, Thomsen C, Madsen R, 

Sørensen H (Denmark) 

p337 Degenerative neuronal changes revealed 

by Fluoro-Jade C staining in the mouse 

pilocarpine model 

Wang L, Liu Y, Huang Y, Deng Y (China) 

84 


p338 Anti-epileptogenic effect of orexin B in the 

kindling model of epilepsy in rats 

Morales A, Bouvard S, Le Cavorsin M, Bonnet C, 

Georges B, Moulin C, Kouchi H, Belmeguenai A, 

Ryvlin P, Bezin L (France) 

p339 Effects of AMN082 administration 

on cortical afterdischarges during rat 

brain development 

Szczurowska E, Mares P (Czech Republic) 

p340 Effects of early postnatal caffeine 

exposure on seizure susceptibility of rats 

are age-and model-dependent 

Tchekalarova J, Kubová H, 

Mareš P (Czech Republic) 

p34 Hyperthermia-induced seizure enhanced 

by the suppression of the adenosine A 

receptor as a possible cause of 

theophylline-associated seizure 

Fukuda M, Suzuki Y, Hino H, Kuzume K, 

Morimoto T, Ishii E (Japan) 

p342 Evidence of D-serine signaling involving 

in pathogenesis of Pilocarpine-induced 

epilepsia 

Liu Y, Wang L, Zhang Y, Huang Y, Deng Y, 

Zhao G (China) 

p343 Severe cognitive dysfunctions, but 

discrete neuronal lesions, in adult 

epileptic rats subjected to status 

epilepticus at weaning 

Bonnet C, Fares R, Sanchez P, Kouchi H, 

Bouvard S, Le Cavorsin M, Belmeguenai A, 

Bodennec J, Ry P (France) 

p344 Long-term expressional changes of 

P-glycoprotein in CA , CA3 and DG 

regions of hippocampus following 

lithium-pilocarpine induced status 

epilepticus (PISE) 

Chen S, Zhou L, Chen Z, Zhou J, Li X, Yang L, 

Chen L, Qian W (China) 

p345 Cortical layer formation of 

hemimegalencephaly: 

immunohistochemical consideration 

Saito T, Hanai S, Arai A, Nakagawa E, Sasaki M, 

Otsuki T, Goto Y, Itoh M (Japan) 

p346 Effects of topiramate on gene expression 

of protein kinase C 

Yoshida S, Okada M, Yoshida S, 

Kaneko S (Japan) 

p347 Fractal properties of epileptic field 

potentials recorded from the CA area 

of the hippocampus in the mouse model 

of temporal lobe epilepsy 

Weiss B, Tang Y, Tang F (Turkey) 

p348 Seizure prediction based on changes in 

vagus nerve activity (VENG) 

Harreby K, Sevcencu C, Struijk J (Denmark) 



p349 MAM-pilocarpine rat: double-hit animal 

model of chronic epilepsy associated 

with MCDs 

Colciaghi F, Finardi A, Frasca A, Balosso S, 

Vezzani A, Battaglia G (Italy) 

p350 Increased dopaminergic tone in 

genetic absence epilepsy rats from 

Strasbourg (GAERS): evidence from 

quinpirole-induced yawning and 

microdialysis experiments 

Deransart C, Bernard H, Bertrand A, Savasta M, 

Depaulis A (France) 

p35 Mossy cells of the hippocampal dentate 

gyrus are not selectively vulnerable in 

human temporal lobe epilepsy 

Ábrahám H, Seress L, Horváth Z, Dóczi T, 

Janszky J, Klemm J, Byrne R, Bakay R (Turkey) 

p352 Identification of differentiated Proteins in 

GAERS by proteomics approach 

Gunel A, Danis O, Demir S, Ogan A, Aker R, 

Onat F, Galaebi M (Turkey) 

p353 A basic neurophysiological study of 

amygdala kindling to developmental 

rat SNR 

Zhou H (China) 

p354 Hippocampal expression of glutamateglutamine 

cycle genes during 

epileptogenesis in the rat juvenile Li+/ 

pilocarpine model and in human MTLE 

Van Der Hel W, Bos I, Mulder S, Verlinde S, 

de Graan P (The Netherlands) 

p355 Valproate prevents diabetic 

polyneuroapthy by decreasing glucose 

level in the OLETF rats 

Koh S, Yoo H, Park H, Kim J (Korea) 

p356 RNAi inhibits Coriaria lactone-induced 

MDR b overexpression in rat brain 

microvascular endothelial cells 

Tian L, Chen L, Yang T, Zhou D (China) 

p357 Longitudinal changes in chemokine 

signalling in a juvenile model of temporal 

lobe epilepsy 

Kan A, van der Hel S, Verlinde S, 

van Nieuwenhuizen O, 

de Graan P (The Netherlands) 

p358 Spermine enhances the GABAA receptor 

endogenous phosphorylation and 

function: relationship with human epilepsy 

Sid Ahmed M, Kurcewicz I, Louvel J, Pumain R, 

Laschet J (France) 

p359 The neuroprotective effect of the A 

receptor agonist R-Pia in the pilocarpine 

model is accompanied by metabolic and 

circulatory equilibration during seizures 

Elisa Rosim F, Ribeiro Silva I, Nehlig A, Vignoli T, 

Suzete Persike D, Ferrandon A, Koning E, 

Silva Fernandes M (Brazil) 


p360 Evaluation of dopaminergic 

neurotransmission in fully kindled rats 

Alcantara-Gonzalez D, Luna-Munguia H, 

Rocha L (Mexico) 

p36 Kainic acid-induced occipital lobe 

epilepsy: impact to understand its 

mechanism of seizure propagation 

Tanaka T, Saitou M, Satou M, Hodozuka A, 

Anei R, Hayashi Y, Hiroshima S, Orimoto R (Japan) 

p362 Status epilepticus is associated 

with altered synaptic plasticity in 

dorsomedial striatum 

Kirschstein T, Avshalomov J, Köhling R (Germany) 

p363 Purinergic P2 receptors are up-regulated 

in the hippocampus of patients with 

temporal lobe epilepsy associated with 

hippocampal sclerosis 

Silva Fernandes M, Souza Speciali D, Blini J, 

Canzian M, Abrão Cavalheiro E, Ulrich H, 

Carrete Jr. H, Silva Centeno R, Yacubian E (Brazil) 

p364 Epileptic behavior with a distinguished 

preictal period in a large-scale neural 

network model 

Pyrzowski J, Signerska J, Pyrzowski M, 

Sulkowski B (Poland) 

p365 Prenatal acute stress attenuated 

epileptiform activities in neonate mice 

Saboory E, Heshmatian B, Khademansari M, 

Roshan-Milani S (Iran) 

p366 Effects on neuronal cell survival of cooling 

rat hippocampal slice epileptic model 

Han C, Lu X, Ye P, Liao J (China) 

p367 The epileptic human hippocampal CA2 

region generates spontaneous interictal 

like activity in vitro 

Wittner L, Huberfeld G, Clémenceau S, Erõss L, 

Dezamis E, Entz L, Ulbert I, Baulac M, 

Miles R (France) 

p368 Influence of L-arginine on seizures in 

homocysteine - treated adult rats 

Hrncic D, Rasic - Markovic A, Dekanska D, 

Radenovic L, Mitrovic D, Susic V, Djuric D, 

Stanojlovic O (Serbia) 

p369 Isolation of neural stem cells from adult 

patients with refractory epilepsy: 

goal for a better understanding of 

epilepsy mecanism 

Alves-Leon S, Azevedo R, Medei E, 

Marcondes De Souza J, Mendez-Otero R (Brazil) 

p370 Biologically active lignan arctigenin 

effectively reduces neuronal excitability 

Borbely S, Jocsak G, Sedlak E, Borsodi L, 

Boldizsar I, Atlason P, Molnar E, Vilagi I (Turkey) 

p37 Plasticity destruction of polar excitations 

in frog sciatic nerve using semiconductor 

pulse laser irradiation 

Hirayama Y, Ishizuka S, Grigorievich Z, 

Yamakawa T (Japan) 



p372 Hippocampal high frequency stimulation 

modifies amino acid release and seizure 

susceptibility in kindled rats 

Luna-Munguia H, Neri-Bazan L, 


p373 Antiepileptic drugs associated with high 

frequency electrical stimulation in the 

ventral hippocampus modify pilocarpineinduced 

status epilepticus in rats 

Cuellar M, Neri-Bazan L, Alcantara-Gonzalez D, 


p374 In vivo study of the impact of amygdala 

kindling on the firing pattern of thalamic 

reticular nucleus neurons in GAERS 

Carcak N, Onat F, Pinault D, French C, Gulhan R, 

O`Brien T (Turkey) 

p375 The Mu and the Third and their relationship 

Parvizi J, Stern J (USA) 

p376 Cellular, molecular and electrophysiological 

mechanisms of enhanced hippocampal 

excitability following peripheral 

inflammation 

Riazi K, Galic M, Kuzmiski J, Sharkey K, 

Pittman Q (Canada) 

p377 Group psychotherapy 

Buljan R, Santic A (Croatia) 

p378 Antiangiogenic treatment with sunitinib 

ameliorates inflammatory infiltrate and 

gliosis in the pilocarpine model of 


Li Y, Zhe X, Bai J, Wang M, Wang B, Guo C, 

Shi S (China) 

p379 Effects of activated astrocyte and 

microglia on aberrant neurogenesis in 

the hippocampus of adult rats after 


Fang Y, Jing C, Shijun Z, Qingyun Q, Zhirong L, 

Yuangui H, Wen J (China) 

p380 Kallikrein-kinin system in human temporal 

lobe epilepsy: cross-talk between glial and 

neural cells 

Rodrigues Simões P, Perosa S, Argañaraz G, 

Yacubian E, Carrete Jr. H, Centeno R, 

Sakamoto A, Varella P, Santiago J, Caboclo L, 

Canzian M, Amado D, Mortara R, Silva Jr. J A, 

Cavalheiro E, Naffah-Mazzacoratti M (Brazil) 

p38 A trafficing defective Kv7.2 mutation 

causing neonatal seizures 

Maljevic S, Naros G, Yalcin O, Caglayan H, 

Steinlein O, Lerche H (Germany) 

p382 Prognostic impact of encephalomalacia 

in central nervous system infectionrelated 

epilepsy 

Park S, Sunwoo Y, Kim H, Lee M, Kim Y (Korea) 

86 


p383 What is the biological significance of 

distinguished CA2 characteristics of 

Amazon spiny rat Proechimys? Clues from 

resistance to epilepsy 

Scorza C, Arida R, Scorza F, Cavalheiro E (Brazil) 

p384 Association between anxiety and 

susceptibilty to temporal lobe epilepsy 

in rats 

Kohek S, Blanco M, dos Santos Jr J, 

Mello L (Brazil) 

p385 Spontaneous ripples in the human 

hippocampal formation 

Toth E, Fabo D, Magloczky Z, Eross L, Solyom A, 

Czirjak S, Rasonyi G, Halasz P, Freund T, 

Karmos G, Ulbert I (Turkey) 

p386 Antiepileptic therapy modifies antioxidant 

enzyme activity and protein oxidative 

damage in epileptic patients 

Ercegovac M, Jovic N, Simic T, 

Beslac-Bumbasirevic L, Jovanovic D, 

Ercegovac D, Djukic T, Pljesa-Ercegovac M (Serbia) 

p387 Disparities in injury outcomes for people 

with epilepsy and seizure disorders 

Bowman S, Aitken M (USA) 

p388 Effect of antiepileptic drugs on 

total antioxidant, total lipid and Lp(a) 

concentrations 

Khademansari M, Saboory E (Iran) 

p389 Effects of eslicarbazepine acetate in 

the amygdala kindling model of temporal 

lobe epilepsy 

Soerensen J, Pekcec A, Soares-da-Silva P, 

Potschka H (Germany) 

p390 Cortical region and layer specific 

activation during epileptiform seizure 

Világi I, Borbély S, Körössy C, 

Somogyvári Z (Turkey) 

p39 Altered glutamate transporer expression 

and increased glutamate levels in tumours 

are specifically associated with tumour 

associated seizures 

O’Brien T, Yuen T, Morokoff A, Bjorksten A, 

D’Abaco G, Powell K, Reid C, Drummond K, 

Rosenthal M, Paradiso L, Kaye A (Australia) 

p392 3D movement quantification in epilepsy: 

new contribution for quantitative 

semiology analysis 

Cunha J, Fernandes J, Bento V, Paula L, Oliveira F, 

Bilgin C, Noachtar S (Portugal) 

p393 Towards a new model of epilepsy: the 

hamster GASH:Sal 

López D, Carballosa M, Yanowsky K, 

Sancho C, Horta-Júnr J, Castellano O, 

Muñoz-Pascua L (Spain) 



p394 The influence of vagus nerve stimulation 

on the interactal EEG 

Ardesch J, de Vos C, Van Schoonhoven J, 

de Weerd A, Van Lambalgen H, 

Van Putten M (The Netherlands) 

p395 Motor threshold in mesial temporal lobe 

epilepsy: effect of seizures 

Wright M, Hara K, Orth M, Smith S, 

Richardson M (UK) 

p396 Different role of the frontal cortex 

in initiation of absences and hypomotor 

seizures 

Karlov V (Russia) 

p397 In- and out-patient therapeutic video EEG 

monitoring for difficult to treat epilepsies 

Stefan H, Kasper B, Graf W, Rauch C, Kerling F, 

Kreiselmeyer G, Hopfengärtner R (Germany) 

p398 Quantitative analysis of movement 

patterns in mesial temporal lobe epilepsy 

Chen L, Yang X, Zeng D, Zhou D (China) 

p399 The quantification of random and genuine 

correlation patterns in absence EEG 

Baier G, Goodfellow M, Müller M, Rummel C (UK) 

p400 Epilepsy causing pupillary hippus 

Farrell F, McCauley L, Smith S, Feldman M, 

Centeno M, Harriso N, Sisodiya S (UK) 

p40 Complex network analysis of 

pharmacologically induced activity 

correctly lateralize in temporal 

lobe epilepsy patients 

Ortega G, Wix R, García de Sola R, Pastor J (Spain) 

p402 Educational problems related to 

quantitative electroencephalogram 

changes in benign childhood epilepsy 

with centrotemporal spikes 

Tedrus G, Fonseca L, Melo E, Ximenes V (Brazil) 

p403 Chronotopographic analysis of the 

generalized spike-slow wave EEG 

discharges in human epilepsy 

Sobieszek A, Swiderski B (Poland) 

p404 Predicting success of vagus nerve 

stimulation from interictal EEG 

Melching L, van Schoonhoven J, de Vos C, 

Cloostermans M, de Weerd A, van Lambalgen H, 

Ardesch J, van Putten M (The Netherlands) 

p405 A seizure detection method for long-term 

invasive EEG recordings in adults without 

requiring any prior information about the 

patient´s seizure pattern 

Hopfengärtner R, Kasper B, Rauch C, Kerling F, 

Weigel D, Buchfelder M, Stefan H (Germany) 

p406 Ictal generalized fast 

electroencephalographical activity: 

an intermediate pattern in the spectrum 

of generalized epilepsies 

Guilhoto L, Cabral F, Guaranha M, Uchida C, 



p407 Neurolopsychological evaluation in non 

lesional frontal epilepty patients 

Gudin M, Burriel L, Carrasco S, 

Vaamonde J (Spain) 

p408 Neuropathology of epilepsy 

Tristán-Agundis M, Galván-Contreras R, 

Palacios-Escalona S, Manzanarez-Colin M, 

Peralta-Rodríguez B, Castañeda-Gonzáles C, 

Rembao-Bojórquez D, 

Villeda-Hernández J (Cuba) 

p409 Long-term effects of temporal lobe 

epilepsy on local neural networks: 

a graph theoretical analysis of 

corticography recordings 

van Dellen E, Douw L, Baayen J, Heimans J, 

Ponten S, Vandertop W, Velis D, Stam C, 

Reijneveld J (The Netherlands) 

p4 0 Demyelinating lesions involving the 

brainstem may be an important factor 

in the development of epilepsy in 

multiple sclerosis patients: a large 

retrospective study 

Papathanasiou E, Papacostas S, 

Myrianthopoulou P, Kkolou E, 

Pantzaris M (Cyprus) 

p4 Monitoring the brain in the adult ICU 

Cloostermans M, de Vos C, Melching L, 

van Putten M (The Netherlands) 

p4 2 Change of EEG pattern caused by 

carbamazepine (CBZ) 

Khachidze I (Georgia) 

p4 3 Brainstem autonomic abnormality causes 

attacks that mimic clinical seizures 

Hansen S, Julu P, Witt Engerström I, 

Apartopoulos F, Delamont R, Smeets E, Curfs L, 

Pini G, Bigoni S, Halbach N (UK) 

p4 4 Coupling between the basal ganglia 

and hippocampal EEG activity during 

an epileptic seizure 

Rektor I, Kuba R, Brazdil M, Halamek J, 

Jurak P (Czech Republic) 

p4 5 Multiple band frequency analysis of 

ictal high frequency oscillations in 

patients with temporal lobe epilepsy 

Nakamura F, Terada K, Usui N, Usui K, Baba K, 

Tottori T, Matsuda K, Fujitani S, Inoue Y (Japan) 

p4 6 Activation clinic: an audit of a new 

clinical cervice 

Valente I, Amin D, Brunnhuber F (UK) 

p4 7 Laughter induced by direct electrical brain 

stimulation during SEEG investigation in 


Mahjoub D, Régis J, Chauvel P, 

Bartolomei F (France) 



p4 8 Interictal high-frequency oscillations 

recorded using standard depth 

macroelectrodes in patients with focal 


Brazdil M, Halamek J, Jurak P, Daniel P, Kuba R, 

Chrastina J, Novak Z, Rektor I (Czech Republic) 

p4 9 Arousal in early sleep and its relationship 

to interictal epileptiform activity in 

patients with partial epilepsy 

Delamont R, Richardson N, Evans B, Elwes R (UK) 

p420 Ventricular bigeminus rhythm during 

hyperventilation: physiological response 

or ominous predictor of unrecognized 

fatal genetic heart and brain disorder? 

Ravnik I, Bricelj V (Slovenia) 

p42 Sensitivity to intermittent photic 

stimulation in photosensitive patients: is 

there a circadian rhythm? 

Cantonetti L, Kasteleijn-Nolst Trenité D, 

Caporro M, Ferraldeschi M, Campana C, Tisei P, 

Reed R, Buttinelli C (Italy) 

p422 Early (within 24 hours) EEG and careful 

clinical assessment after a first seizure: can 

we predict the future? 

Maillard L, Boyez R, Vignal J, Maignan M, 

Guillemin F, Vespignani H (France) 

p423 Usefulness of electromagnetic 

tomography methods for epileptogenic 

zone localization in pharmacoresistant 

focal epilepsy 

Morales Chacon L, Trapaga Quincoses O, 

Bobes M, Iglesias J, Santos Y, Rodriguez R, 

Bender J, Estupiñan B, Garcia I, 

Sanchez Coroneaux A, 

Zaldivar Bermudes M (Cuba) 

p424 Characteristics of focal electrographic 

seizures in awake Vs. comatose patients 

Siddiqui K, Marasigan M, Alcala W, Bunyan R, 

ElMubarak M, Sinha S (Saudi Arabia) 

p425 The relationship between depth ictal EEG 

patterns and subdural ictal EEG patterns 

in mesial temporal lobe epilepsy 

Kang J, Kang B, Lee E, Lee S, Hong S, Lee J (Korea) 

p426 Clinical role of subclinical seizure patterns 

in children with focal epilepsy 

Velkey Á, Siegler Z, Fogarasi A (Turkey) 

p427 Wavelet-denoising of 

electroencephalogram and the absolute 

slope method: a tool to improve 

electroencephalographic localization and 

lateralization 

Leung H, Schindler K, Chan A, Lau A, Leung K, 

Ng E, Wong K (Hong Kong) 

p428 Analysis of risk factors associated with 

polycystic ovarian syndrome in women 

with epilepsy 

Chen L, Zhou L, Zhou J, Chen Z, Chen S, Wang Q, 

Yang L, Li X (China) 

88 


p429 A study on the correlations between EEG 

characteristics and histopathological 

changes in epilepsy patients due to focal 


Cai L, Piao Y, Liu L, Lu D, Li Y (China) 

p430 New cortical stimulator simplifies 

functional mapping 

Larsson P, Lombardi D, Quinlivan L, Nelson B, 

Stabell K, Ramm-Pettersen J (Norway) 

p43 Role of circadian chronotypes in 

modulating the occurrence of IEA in 

adult subjects with idiopathic 

generalized epilepsy 

Manni R, Zambrelli E, Repetto A, Rustioni V, 

Terzaghi M (Italy) 

p432 Proprioceptive stimuli-induced reflexseizures 

are consistent with exacerbated 

long loop reflexes 

Szucs A, Solyom A, Hollo A, Janszky J, 

Rasonyi G (Turkey) 

p433 Ictal phenomenology recorded during 

video-electroencephalographic evaluation 

in patients with absence seizures 

identified from a cohort of patients with 

drug-resistant epilepsy 

Alves-Leon S, Bento de Souza Cardoso M, 

Monteiro M, D’Andrea Meira I (Brazil) 

p434 Inter-hemispheric propagation of seizures 

in mesial temporal lobe epilepsy (MTLE): 

a study with comnined scalp and foramen 

ovale electrodes 

Erõss L, Entz L, Fabó D, Jakus R, Szûcs A, 

Rásonyi G, Kelemen A, Barcs G, Juhos V, 

Balogh A, Brasi P, Clemens Z, Halász P (Turkey) 

p435 Decrease in propagation of interictal 

epileptiform activity after introduction 

of levetiracetam visualized with electric 

source imaging 

Lantz G, Michel C, Seeck M, 

Larsson P (Switzerland) 

p436 Single pulse cortical electrical stimulation 

induced slow oscillation in different 

vigilance states in epileptic patients 

Entz L, Fabó D, Erõss L, Halász P, Wittner L, 

Karmos G, Ulbert I (Turkey) 

p437 EEG monitoring of the anaesthetic effect 

of Brevital in the presurgical Wada-test 

Larsson P, Stabell K, Heminghyts E, Nome T, 

Bjørnæs H (Norway) 

p438 Autonomic disfunction in idiopathic 


Pisano T, Brazzo D, Betteridge H, Pinci M, 

Bombardieri R, Cerminara C, Seri S (UK) 

p439 The yield of routine EEG in geriatric patients 

Nguyen Michel V, Ourabah Z, Boudali Y, Elwan S, 

Sebban C (France) 



p440 EEG activity associated with symptoms 

suspects of epilepsy in patients older than 

65 years 

Osorio Caicedo P, Mauri Llerda J, Adelantado S, 

Gonzalez P, Abad F, Martinez S (Spain) 

p44 Juvenile myoclonic epilepsy in 

Marrakech region 

Adali N, Kissani N (Morocco) 

p442 Modifications in local hemodynamic 

preceeds epileptic spike: an animal model 

combining simultaneous ECoG and near 

infrared spectroscopy analysis 

Wallois F, Osharina V, Ponchel E, Aarabi A, 

Grebe R (France) 

p443 Petit-mal Sonata: Predominant EEG 

seizure patterns in childhood absence 

epilepsy (CAE) 

Sogawa Y, Moshé S, Shinnar S, Dlugos D, 

Conry J, Cnaan A, Glauser T (USA) 

p444 Two years in the treatment of status 

epilepticus with intravenous levetiracetam 

Eue S, Grumbt M, Müller M, Schulze A (Germany) 

p445 The effect of thymoquinone on pediatric 

intractable seizures 

Akhondian J, Moayyedpour A, Raouf Ziai M, 

Khaje Dalui M, Hosseini H (Iran) 

p446 Zonisamide and topiramate: 

an obsercational comparison of 

cognitave functions 

Wagner K, Metternich B, Buschmann F, Saar J, 

Carius A, Schulze-Bonhage A (Germany) 

p447 Single dose bioequivalence between 

brivaracetam oral solution formulation 

and oral film-coated tablet in 

healthy subjects 

Otoul C, Watanabe S, Burton I, Guénolé E, 

Hulhoven R, McCabe S, Sargentini-Maier M, 

Stockis A (Belgium) 

p448 Interaction study between brivaracetam 

and a combination oral contraceptive 

Stockis A, Hulhoven R, Astruc B, Watanabe S, 

Boulton M, Daoust A, 

Sargentini-Maier M (Belgium) 

p449 Bioavailability and safety of intravenous 

brivaracetam in healthy subjects 

Valgaeren A, Hulhoven R, Scheen A, 

Watanabe S, Troenaru M, Otoul C, 

Sargentini-Maier M, von Rosenstiel P, 

Stockis A (Belgium) 

p450 Brivaracetam does not impair cognitive 

performance in normal and kindled rats 

Detrait E, Leclercq K, Kaminski R, Matagne A, 

Lamberty Y (Belgium) 

p45 Activation of focal epileptic activity during 

MEG recordings by means of etomidate 

Heers M, Stefan H, Schmitt H, Rauch C, 

Kaltenhäuser M, Rampp S (Germany) 


p452 The cost-effectiveness of adjunctive 

treatment with lacosamide in patients 

with uncontrolled partial epilepsy 

Berggren F, Bolin K, Germe M, 

Forsgren L (Sweden) 

p453 Experiences in generic substitution of 

antiepileptic drugs in Taiwan 

Hsieh L, Tsai J, Yu H, Chi J (Taiwan) 

p454 Three-year data on efficacy and 

tolerability of Levetiracetam as add-on 

therapy in patients with treatmentresistant 

epilepsy 

Kkolou E, Dietis A, Flourentzou A, Malikkidou A, 

Petsa M, Stylianidou G, Papacostas S (Cyprus) 

p455 Efficacy and safety of topiramate as 

monotherapy and an adjunctive treatment 

for epileptic patients of age above 

thirteen in five year follow up 

Lang S, Li C, Shi X, Wang X (China) 

p456 Lamotrigine monotherapy in pregnancy: 

outcome of 0 exposed pregnancies 

Rysz A (Poland) 

p457 An open-label, add-on study of pregabalin 

in patients with partial seizures: a 

multicenter trial in Greece 

Tsounis S, Kimiskidis V, Kazis D, Gkiatas K, 

Garganis K, Karageorgiou K, Giannakodimos S, 

Papathanasopoulos P, Plaitakis A, 

Papadimitriou A, Donevan S, Lyras L (Greece) 

p458 Monotherapy versus polytherapy in 

refractory epilepsy: a comparative study 

of adverse effects 

Alexandre V, De Fazio S, Fattore C, Frassine B, 

Gatti G, La Briola F, Ladogana M, Licchetta L, 

Papantonio A, Pellacani S, Rosati E, 

Striano P (Italy) 

p459 Weight change associated with 

antiepileptic drugs (AED) 

Guerreiro C (Brazil) 

p460 Antiepileptic drug inhibits hippocampal 

neurogenesis in the developing brain 

Chen J, Cai F, Cao J (China) 

p46 Levetiracetam in children, adolescents and 

adults with primary generalized seizures: 

open-label, non-comparative, multicenter, 

long-term, follow-up study 

Delanty N, Jones J, Wash M, Tonner F, 

On behalf of the N167 Levetira (Ireland) 

p462 Zonisamide as a substitute for topiramate 

in patients with refractory epilepsy: a 

single centre study 

Fallah M, Kharazmi E, Peltola J (Finland) 

p463 Evaluation of the new QMS® lamotrigine 

immunoassay on the olympus AU 640 

Berry D, Clarke L, Khan R (UK) 



p464 Lamotrigine and oxcarbazepine in 

bitherapy during pregnancy: therapeutic 

drug monitoring in two cases 

Wegner I, Edelbroek P, 

De Haan G (The Netherlands) 

p465 ‘Real Life’ cohort study on levetiracetam 

versus carbamazepine monotherapy: 

a controlled surveillance study 

Helmstaedter C (Germany) 

p466 Predictive factors of intractable epilepsy 

in malformations of cortical development 

Amel M, Hela M, Nadia B, Neila A, 

Sarra T (Tunisia) 

p467 The early effects of levetiracetam 

treatment on serum folic acid, vitamin B 2, 

lipid levels and tyroid hormones in 


Canbaz Kabay S, Ozýsýk Karaman H, 

Erdýnc O (Turkey) 

p468 The differences in efficacy and safety 

between brand and generic antiepileptic 

drugs in children with partial epilepsy 

Hernández M, Barragán E (Mexico) 

p469 Efficacy and tolerability of levetiracetam 

monotherapy in patients with primary 

brain tumors and epilepsy 

De Groot M, Toering S, Douw L, Vecht C, Klein M, 

Aronica E, Heimans J, 

Reijneveld J (The Netherlands) 

p470 Adjunctive levetiracetam in children aged 

month to


p486 Development and validation of a rapid 

and inexpensive pharmacogenetic test of 

HLA-B* 502 allele for carbamazepine 

prescription 

Cheng S, Kwan P, Ng H, Ng M (Hong Kong) 

p487 Treatment status of people with epilepsy 

in Pakistan 

Mogal Z, Aziz H, Ali S (Pakistan) 

p488 Efficacy and tolerability of zonisamide in 

childhood-onset focal epilepsies 

Neuwirth M, Pálmafy B, Siegler Z, Hegyi M, 

Paraicz É, Fogarasi A (USA) 

p489 Efficacy of pregabalin used adjunctively 

with levetiracetam (Keppra) in placebocontrolled 

pregabalin epilepsy trials 

Uthman B, Emir B, Leon T, Giordano S (Qatar) 

p490 Response to drug treatment in newlydiagnosed 

epilepsy: a pilot study of H 

NMR- and MS-based metabonomic analysis 

Sills G, Alzweiri M, Leach J, Brodie M, 

Robertson C, Watson D, Parkinson J (UK) 

p49 Pregnancy outcomes and mode of delivery 

in EURAP 

Tomson T, 

On behalf of EURAP Study Group (Sweden) 

p492 Epilepsy and Buccal Midazolam training in 

Ireland for health professionals 

Farrell A (Ireland) 

p493 An open-label extension of two controlled 

studies of carisbamate as adjunctive 

treatment of partial onset seizures 

in adults 

Halford J, Kalviainen R, Ben-Menachem E, 

Schmitt J, Wiegand F, Novak G (USA) 

p494 Current reporting of adverse events in anti 

epileptic drug trials: a quantitative and 

qualitative analysis 

Shukralla A, Marson A (UK) 

p495 Correlation between clinical efficacy, 

SCN A polymorphism and unbound 

fraction of carbamazepine 

Sterjev Z, Kiteva G, Mladenovska K, Suturkova L, 

Dimovski A (Macedonia) 

p496 Lamotrigine-intoxication due to 

interaction with codeine: three 

case reports 

Stepanek P, Krämer G, Dorn T (Switzerland) 

p497 Different therapeutic regimens in seizurefree 

patients 

De Maria G, Valente L, Guarneri B, 

Antonini L (Italy) 

p498 Gabapentin kinetics during delivery, in the 

neonatal period, and during lactation 

Öhman I, Tomson T (Sweden) 


p499 Carbonic anhydrase inhibitor-induced 

renal tubular acidosis 

Mirza N, Marson A, Pirmohamed M (UK) 

p500 Reversible visual hallucinations induced 

by topiramate: report of two cases 

Park H, Yang K, Jeong D, Oh H, Kim T (Korea) 

p50 Levetiracetam: a retrospective study on 

the relationship between serum 

concentration, dosage and adverse events 

in childhood epileptic patients 

Rasmini P, Vonella G, Vercellino F, Maurizio C, 

Dante B (Italy) 

p502 Prospective surveillance of Croatian 

pregnant women under lamotrigine 

monotherapy: aspects of pre-pregnancy 

counseling and drug monitoring 

Miskov S, Gjergja Juraski R, Fucic A, 

Bosnjak-Pasic M, Ivicevic-Bakulic T, 

Cvitanovic-Sojat L, Bosnjak J, 

Demarin V (Croatia) 

p503 The effect of Carbamazepine therapy on 

serum leptin levels 

Uludað I, Kulu U, Þener U, Zorlu Y, 

Köse Þ (Turkey) 

p504 Efficacy of Levetiracetam study at pacients 

with epilepsy 

Pendefunda L, Cucos L, Despina O (Romania) 

p505 Clinical usage of visual-analog version 

of adverse events profile questionare in 

patients with complex partial epilepsy 

Lukic S, Spasic M (Serbia and Montenegro) 

p506 Effect of antiepileptic drugs on bone 

density in ambulatory patients 

Kharbanda P, Duberkar D, Prabhakar S, 

Khandelwal N (India) 

p507 Prognostic factors for 2-month remission 

Bonnett L, Tudur-Smith C, Williamson P, 

Marson T (UK) 

p508 The safety and tolerability of lacosamide 

in randomized, double-blind, placebocontrolled 

phase II/III clinical trials 

Gil-Nagel A, Biton V, Fountain N, Rosenow F, 

Hebert D, Doty P (Spain) 

p509 Antiepileptic drug monotherapy in a 

veteral population 

Nguyen V, Tran H, Makhijani V, Nguyen C, 

Shah N, Kaunitz J, Dergalust S (USA) 

p5 0 Evaluation of lacosamide efficacy in 

subjects with partial-onset seizures 

across the dose range used in phase II/III 

clinical trials 

Ben-Menachem E, Chung S, Rudd D, Hebert D, 

Doty P (Sweden) 



p5 Seizure count while switching back 

and forth between branded and 

generic oxcarbazepine 

Hagemann G, Fuchs M, Zinke J, 

Witte O (Germany) 

p5 2 A multicenter, open-label trial to assess 

the safety and tolerability of a single 

intravenous loading dose of lacosamide 

followed by oral maintenance as 

adjunctive therapy in subjects with 

partial-onset seizures: an interim report 

Fountain N, Krauss G, Isojarvi J, Dilley D, 

Doty P (USA) 

p5 3 Evaluation of seizure freedom and 75% 

responder rates with lacosamide in 

subjects with partial-onset seizures in 

phase II/III clinical trials 

French J, Brodie M, Hebert D, Isojarvi J, 

Doty P (USA) 

p5 4 Patient - perceived drug related cognitive 

impairment of valproate and lamotrigine 

duotherapy in patients with complex 


Spasic M, Lukic S, 

Nikolic M (Serbia and Montenegro) 

p5 5 Efficacy of lacosamide in partialonset 

seizures with and without secondary 

generalization: a pooled analysis of three 

phase II /III trials 

Isojarvi J, Rosenow F, Faught R, Hebert D, 

Doty P (USA) 

p5 6 Improvement in patient-reported 

outcomes seen in patients responding to 

lacosamide: Pooled QOLIE-3 , SSS and 

PGIC data from 3 Phase II/III clinical trials 

De La Loge C, Cramer J, Borghs S, Mueller K, 

Eggert A, Doty P (Belgium) 

p5 7 Effect of eslicarbazepine acetate 

and oxcarbazepine on cognition 

and psychomotor function in 

healthy volunteers 

Almeida L, Milovan D, Nunes T, Romach M, 

Rocha J, Sellers E, Sokowloska M, 

Soares-da-Silva P (Portugal) 

p5 8 Pharmacotherapy for childhood 

non-idiopathic partial epilepsies based 

on seizure symptoms: retrospective and 

prospective studies 

Sugai K, Nakagawa E, Komaki H, Sakuma H, 

Saito Y, Sasaki M (Japan) 

p5 9 Intravenous levetiracetam vs placebo in 

canine status epilepticus 

Leppik I, Patterson E, Hardy B, Cloyd J (USA) 

p520 Case reports of pregnancies in pregabalin 

clinical studies 

Shah J, Giordano S, Karkanias G, Leon T (USA) 

92 


p52 Vulnerability of an epileptic case to 

psychosis: sodium valproate with 

lamotrigine, forced normalization, 

postictal psychosis or all? 

Bahar A, Boz M, Taskapilioglu O, Eker S, 

Bora I (Turkey) 

p522 STEP ONE: Study on the treatment of 

elderly patients with older and newer 

anti-epileptic drugs. Interim report on 

recruitment and drop-out rates 

Krämer G, Trinka E, Werhahn K (Switzerland) 

p523 Psychopathology, psychosocial 

functioning and IQ in children with 

drug-resistant epilepsy before and 

after epilepsy surgery 

Danielsson S, Viggedal G, Steffenburg S, 

Rydenhag B, Gillberg C, Olsson I (Sweden) 

p524 Surgical outcome of frontal lobe epilepsy: 

prognostic factors in a longitudinal analysis 

Chung C, Kim C (South Korea) 

p525 Outcome after centro-median thalamic 

stimulation in patients with generalized 

epilepsy previously submitted to 

extended callosal section: an insight into 

the pathophysiological mechanisms of 


Cukiert A, Burattini J, Mariani P, Agapito D, 

Cukiert C, Baise C, Forster C, Mello V, 

Argentoni-Baldochi M (Brazil) 

p526 Outcome after cortico-amygdalohippocampectomy 

according to preoperative 

magnetic resonance findings 

Argentoni-Baldochi M, Cukiert A, Burattini J, 

Mariani P, Agapito D, Cukiert C, Baise C, 

Forster C, Mello V (Brazil) 

p527 Therapeutical strategies in epilepsy 

patients with ictal asystoles 

Kerling F, Duetsch M, Kasper B, 

Stefan H (Germany) 

p528 Outcome after cortico-amygdalohippocampectomy 

in patients with severe 

bilateral mesial temporal sclerosis 

submitted to invasive recording 

Cukiert A, Burattini J, Mariani P, Agapito D, 

Cukiert C, Baise C, Forster C, Mello V, 

Argentoni-Baldochi M (Brazil) 

p529 Long-term seizure outcome in adult 

patients initially non-seizure free after 

epilepsy surgery 

Elsharkawy A, Alabbasi A, Pannek H, Urak L, 

Schulz R, Hoppe M, Oppel F, Ebner A (Germany) 

p530 Magnetoencepahlography-directed 

epilepsy surgery in children: 

can invasive intracranial electrode 

monitoring be avoided? 

Murakami H, Kameyama S, Masuda H, Saito N, 

Akasaka N, Tohyama J, Kakita A, 

Takahashi H (Japan) 



p53 Epilepsy surgery in grey matter 

heterotopias: a case series 

Gofton T, Steven D, McLachlan R, 

Burneo J (Canada) 

p532 Initial experience of the temporal lobe 


Kostiuk K, Laponogov O, Tsymbaliuk V (Ukraine) 

p533 MRI-guided stereotactic radiofrequency 

thermocoagulation for epileptogenic 

hypothalamic hamartomas 

Kameyama S, Murakami H, Masuda H (Japan) 

p534 Analysis of ictal high frequency 

oscillations using gradient magnetic-field 

topography on magnetoencephalography 

in patients with intractable epilepsy 

Iida K, Kurisu K, Hashizume A, Kagawa K, Kiura Y, 

Hanaya R, Arita K, Otsubo H (Japan) 

p535 Usefulness and the value of intracranial 

EEG monitorings in epilepsy surgery 

Lu Y, Xu X, Zhao C, Xu R (China) 

p536 Imaging and pathology characteristics of 

8 patients with Rasmussen’s encephalitis 

Luan G, Guan Y (China) 

p537 Hemispherotomy for intractable epilepsy 

in infancy and early childhood 

Otsuki T, Takahashi A, Kaido T, Kaneko Y, Sugai K, 

Nakagawa E, Sasaki M (Japan) 

p538 Clinical experience with vagus nerve 

stimulation in refractory epilepsy 

Rodriguez-Osorio X, Lopez-Gonzalez F, 

Pardo J, Prieto A, Peleteiro M, Guijarro M, 

Arcos A, Castillo J (Spain) 

p539 Age of seizure-onset in pediatric epilepsy 

surgery patients 

Wilfong A, Malphrus A, Schultz R, 

Yoshor D (USA) 

p540 Neuropsychological outcomes in adults 

with medically intractable epilepsy 

treated with responsive cortical 

stimulation by the RNS- System 

Morrell M, Loring D (USA) 

p54 Insular epilepsy surgery under 

neuronavigation guidance using 

depth electrode 

Kim D, Kim H, Lee J (Korea) 

p542 A design of low-cost minimally invasive 

surgical instruments for epileptogenic 

intracranial EEG measurement and 

brain stimulation 

Yamakawa T, Yamakawa T, Suzuki M, 

Fujii M (Japan) 

p543 Resective surgery in intractable partial 

epilepsy with normal MRI in adults 

Lee B, Heo K, Cho Y, Jang S, Chang J, Yi S (Korea) 


p544 Efficacy of levetiracetam (LEV) in 

54 postsurgical patients with 

continuing seizures 

Carius A, Brandt A, Schulze-Bonhage A (Germany) 

p545 A bidirectional relationship between 

depressive symptoms and seizure 

frequency in epilepsy surgery patients 

Metternich B, Wagner K, Buschmann F, 

Zentner J, Schulze-Bonhage A (Germany) 

p546 An epileptogenic zone and morphological 

changes in brain cortex 

Stepanenko A, Arkhipova N, 

Shishkina L (Moscow) 

p547 Successful surgical treatment for 

intractable epilepsy caused by 


Kishima H, Amami K, Satoru O, Masayuki H, 

Koichi H, Tetsu G, Takufumi Y, Okinaga T, 

Shimono K, Youichi S, Toshiki Y (Japan) 

p548 Application of focal brain cooling to the 

treatment of intractable epilepsy; 

experimental and clinical studies 

Fujii M, Fujioka H, Oku T, Tanaka N, Imoto H, 

Nomura S, Suehiro E, Fujisawa H, Kunitsugu I, 

Saito T, Grigorievich Z, Yamakawa T, 

Suzuki M (Japan) 

p549 The long-term outcome after 


de Tisi J, Duncan J, McEvoy A, Harkness W (UK) 

p550 A micro-cryoprobe for necrotizing the 

epileptogenic focus 

Yamakawa T, Ishizuka S, Grigorievich Z, Fujii M, 

Suzuki M (Japan) 

p55 Surgical treatment of patients with drugresistant 

hypermotor seizures 

Tao Y, Yongjie L (China) 

p552 Propagation patterns of ictal discharges in 

temporal epilepsy 

Guangming Z (China) 

p553 Outcome predictors for surgical 

treatment of temporal lobe epilepsy with 

mesial sclerosis 

Teotónio R, Bento C, Sales F (Portugal) 

p554 Mortality after epilepsy surgery 

McIntosh A, Averill C, Berkovic S (Australia) 

p555 Long term follow up of behavioural 

and cognitive outcome in 

hemispherectomized epilepsy patients 

Buddewig S, Gleissner U, Elger C, Schramm J, 

Helmstaedter C (Germany) 

p556 Seizure outcome of epilepsy surgery in 

focal epilepsies assocaited with temporomesial 

glioneuronal tumors: lesionectomy 

versus tailored resection 

Giulioni M, Rubboli G, Marucci G, 

Martinoni M, Volpi L, Michelucci R, Marliani A, 

Bisulli F, Tinuper P, Castana L, Sartori I, 

Calbucci F (Italy) 



p557 Localizing value of pharmacologically 

provoked ictal SPET in extratemporal 

lobe epilepsies 

Barba C, Di Giuda D, Policicchio D, Fuggetta F, 

Papacci F, Meglio M, Colicchio G (Italy) 

p558 Vagus nerve stimulation in patients with 

medically refractory epilepsy: our first 

hundred cases 

Brust Mascher E, Alonso-Vanegas M, Castillo 

Montoya C, Rocha L, Paez M, Pérez S, 

Rubio Donnadieu F (Mexico) 

p559 Functional restoration after surgical 

treatment for intractable epilepsy relating 

sensorimotor system studied by synthetic 

aperture magnetometry 

Kato A, Kishima H, Hirata M, Oshino S, 

Nakano N, Lin Y, Ninomiya H, Okinaga T, 

Shimono K, Yoshimine T (Japan) 

p560 Temporal lobectomy in children: 

predictors and outcomes 

Desai N, Harrison S, Harkness W, Khadem F, 

Cross H (UK) 

p56 Lesional intractable frontal lobe epilepsy: 

90 cases 

Senties-Madrid H, Alonso-Vanegas M, 

Brust-Mascher E, Castillo-Montoya C, Rocha L, 

Bramasco-Avilez A, Rubio-Donnadieu F (Mexico) 

p562 Reactivation of herpes simplex 

encephalitis in an adult patient: possible 

severe complication of epilepsy surgery 

Krysl D, Sramek M, Amlerova J, Krijtova H, 

Tomasek M, Mohapl M, 

Marusic P (Czech Republic) 

p563 Bedside removal of subdural strip 

electrodes 

Steven D, Burneo J (Canada) 

p564 Impact of epilepsy surgery on quality 

of life: how one asks, determines what 

one finds 

Wiebe S, Seiam A, Dhaliwal H (Canada) 

p565 Differences between patients with early vs 

late onset mesial temporal lobe epilepsy 

Arpad Ö, Benbir G, Uzan M, Yeni N, Karaagac N, 

Yalçinkaya C, Özyurt E, Ozkara C (Turkey) 

p566 Lack of association between ABCB , 

ABCG2, and ABCC2 genetic 

polymorphisms and multidrug resistance 

in epilepsy 

Kim D, Lee S, Chu K (South Korea) 

p567 Analysis of MDR and MRP2 

polymorphisms in drug-resistant epilepsy 

Yoshida S, Shoko T, Norio Y, Naoko O, Shukuko Y, 

Kojima T, Masamitu I, Kazuko N, Sunao K (Japan) 

p568 Linkage analysis in a familial case of 

idiopathic epilepsy in Malta 

Mifsud J, Cassar M (Malta) 

94 


p569 Mapping of chromosomal breakpoints 

associated with mental retardation and 

myoclonic-astatic epilepsy: isolation of 

candidate disease genes 

Klitten L, Tommerup N, Hjalgrim H, 

Møller R (Denmark) 

p570 Mutations in SCN A promoter and 

5’-untranslated regions in patients with 

severe myoclonic epilepsy in infancy 

Liao W, Long Y, Yu M, Liu X, Lin S (China) 

p57 Association of LGI4 gene polymorphisms 

with benign familial infantile convulsions 

Ishii A, Zhang B, Kaneko S, Hirose S (Japan) 

p572 Febrile seizure or Darvet Syndrome: 

a clinical and molecular study of SCN Arelated 

epilepsy in Iranian families 

Ebrahimi A, Zeinali S, Fallah S, Tonekaboni H, 

Seied Hassani S, Ataei M, Modaber G, 

Houshmand M (Iran) 

p573 Clinical and genetic survey of Chinese Han 

families with epilepsy 

Lu Y, Wang X (China) 

p574 Genetic variations of ABCC2 transporters 

associated with adverse drug reactions 

Kim W, Lee J, Cho Y, Heo K, Lee M, Lee B (Japan) 

p575 Molecular genetic study for mental 

retardation with epilepsy 

Nakagawa E, Inazawa J, Okazawa H, Kato M, 

Kubota T, Kurosawa K, Saitoh S, Nanba E, 

Matsumoto N, Toda T, Wada T, Goto Y (Japan) 

p576 Duplication of CHRNB2 in a patient with 

early-onset absence epilepsy 

Muhle H, Helbig I, Tönnies H, Steinich I, von 

Spiczak S, Franke A, Schreiber S, Siebert R, 

Stephani U, Sander T (Germany) 

p577 Polymorphisms at ABCB gene and 

correlation with drug resistance 

in epilepsy 

Pelliccia V, Pizzanelli C, Di Paolo A, Jensen S, 

Lastella M, Galli R, Danesi R, Iudice A, 

Del Tacca M, Murri L (Italy) 

p578 Familial SME patients with SCNIA 

gene mutations 

Chen L, Yu M, Shi Y, Deng W, Liu X, Mai Y, Gao M, 

Liao W (China) 

p579 Epilepsy, mental retardation and 

developmental abnormalities: cryptic 

genomic imbalances detected by whole 

genome array-CGH 

Marini C, Novara F, Dalla Bernardina B, Gana S, 

Torniero C, Parrini E, Mei D, Ferrari A, Darra F, 

Pramparo T, Zuffardi O, Guerrini R (Italy) 

p580 Mosaic mutation in family with 

epilepsy with febrile sizures caused by 

SCN A mutation 

Shi Y, Yu M, Deng W, Gao M, Chen L, Long Y, 

Liao W (China) 



p58 The clinical and genetic spectrum of 

familial lateral temporal epilepsies 

Michelucci R, Pasini E, Busolin G, 

Di Bonaventura C, Mecarelli O, Gambardella A, 

Elia M, Bisulli F, Avoni P, Binelli S, Striano P, 

Striano S, Coppola G, Tinuper P, Egeo G, 

Giallonardo A T, Boniver C, Riguzzi P, 

Nobile C (Italy) 

p582 Four-generation family with generalized 

epilepsy caused by a deletion of the 

SCN A gene 

Suls A, Velizarova R, Yordanova I, Deprez L, 

Van Dyck T, Wauters J, Guergueltcheva V, 

Claes L, Jordanova A, De Jonghe P (Belgium) 

p583 Phenotypic variability in patients with 

Glut mutations 

Weber Y, Kamm C, Suls A, Kempfle J, 

Wuttke T, Salov-Vargas A, Bellan-Koch A, 

Maljevic S, Gasser T, DeJonghe P, Auburger G, 

Lerche H (Germany) 

p584 Failure to find CHRNB2 mutations in the 

southern Chinese ADNFLE population 

Chen Z, Zhai Q (China) 

p585 Predictive genetic risk factors for 

febrile seizures and mesial temporal 

lobe epilepsy 

Leal B, Chaves J, Carvalho C, Bettencourt A, 

Barros M, Pereira C, Costa P, Rocha F, Temudo T, 

Monteiro L, Lopes Lima J, Martins Silva A, 

Martins Silva B (Portugal) 

p586 Suggestion of Linkage to FEB in a 

Colombian family with autosomal 

dominant epilepsy with 

febrile seizures plus 

Pineda-Trujillo N, Caro-Gomez M, 

Tejada-Moreno J, Cabrera D, Bedoya G, 

Ruiz-Linares A, Franco A, Gomez-Castillo C, 

Cornejo W, Carrizosa J (Colombia) 

p587 A novel CACNA A missense mutation in 

absence epilepsy and episodic ataxia 

Carmen-Ionela B, Emmanuel R, Gilles H, 

Vincent N, Claude A, Michel B, Isabelle G (France) 

p588 Bilateral perisylvian polymicrogyria shows 

a wide severity spectrum and significant 

skewing towards males 

Leventer R, Jansen A, Pilz D, Stoodley N, Marini C, 

Dubeau F, Malone J, Mitchell A, Mandelstam S, 

Scheffer I, Berkovic S, Andermann E, 

Andermann F, Guerrini R, Dobyns W (Australia) 

p589 Deletions involving both KCNQ2 and 

CHRNA4 present with a phenotype of 

benign familial neonatal convulsions 

Kurahashi H, Wang J, Ishii A, Kaneko S, 

Hirose S (Japan) 

p590 Can defective retrograde axonal transport 

cause seizures? 

Pandey J, Mesngon M, Hebbar S, Smith D (USA) 


p59 Quantification of intracerebral GABA by 

H-MRS: how reproducible are results? 

Hammen T, Bogner W, Gruber S, Stadlbauer A, 

Doelken M, Mennecke A, Doerfler A, 

Stefan H (Germany) 

p592 T2-relaxometry and apparent diffusion 

coefficient mapping of the thalamus in 


Ferreira H, Manaças R, 

Gonçalves Pereira P (Portugal) 

p593 Mesial temporal sclerosis is associated 

with febrile seizures in the absence 

of epilepsy 

Gross D, Gong G, Beaulieu C (Canada) 

p594 Video-EEG-fMRI: a proximal in-bore Video- 

EEG system within a 3T MRI scanner 

Fernandes J, Cunha J, Tafula S, Brandão S, 

Bastos Leite A, Ramos I (Portugal) 

p595 Language fMRI pre- and post-surgery: 

evidence for functional plasticity 

Bonelli S, Powell R, Yogarajah M, Focke N, 

Stretton J, Thompson P, Symms M, Koepp M, 

Duncan J (UK) 

p596 EEG-fMRI changes and generalised 

epileptic activity. What is the link? 

Hamandi K, Murphy K, Evans J, Wise R (UK) 

p597 Postsurgically preserved verbal memory 

associated with presurgically widespread 

temporo-frontal memory-fMRI activation 

in left-sided temporal lobe epilepsy 

Labudda K, Mertens M, Aengenendt J, Ebner A, 

Woermann F (Germany) 

p598 Tractography and the distributed network 

damage underlying memory impairment 

in temporal lobe epilepsy 

Yogarajah M, Focke N, Bonelli S, Parker G, 

Alexander D, Thompson P, Symms M, Koepp M, 

Duncan J (UK) 

p599 Voxel-based morphometry of gray matter 

abnormalities in MRI-negative temporal 

lobe epilepsy 

No Y, Kang J (Korea) 

p600 The value of FDG-PET for detecting 

cortical malformation in West syndrome 

Kagitani-Shimono K, Morita Y, Kitai Y, 

Araya K, Tominaga K, Okinaga T, Mohri I, 

Taniike M, Nagai T, Ozono K (Japan) 

p60 The electro-clinical-imagiological 

spectrum and outcome of reversible 

neuroimaging abnormalities induced by 

presenting seizures 

Canas N, Soares P, Calado S, Romero C, Vale J, 

Jordão C (Portugal) 

p602 Single-subject voxel-based T2 relaxometry 

in focal epilepsy of uncertain origin 

Kosior R, Sharkey R, Frayne R, 

Federico P (Canada) 



p603 Cortical reorganization and reduced 

efficiency of visual word recognition in 

right temporal lobe epilepsy: a functional 

MRI study 

Jensen E, Pexman P, Goodyear B, 

Federico P (Canada) 

p604 Preoperative 23I-iomazenil SPECT and 

8F-fluorodeoxyglucose PET in temporal 

lobe epilepsy 

Hosomi K, Kishim H, Saitoh Y, Hirata M, 

Oshino S, Goto T, Maruo T, Yanagisawa T, Ali M, 

Kato A, Yoshimine T (Japan) 

p605 Emotional attack with localized focus near 

left amygdala on MEG 

Tsuru N (Japan) 

p606 Voxel-based morphometry of temporal 

lobe epileptic patients 

Labate A, Cerasa A, Mumoli L, Aguglia U, 

Quattrone A, Gambardella A (Italy) 

p607 BOLD correlates of interictal epileptic 

activity: additional contributions from 

continuous EEG Source Imaging 

Vulliemoz S, Rodionov R, Thornton R, 

Carmichael D, Guye M, Lhatoo S, Duncan J, 

Michel C, Lemieux L (UK) 

p608 Epileptic Nystagmus: a case report 

Tseng Y (Taiwan) 

p609 Simultaneous EEG and functional MRI 

study of the ictal and interictal epileptic 

activity in patients with absence epilepsy 

Li Q, Luo C, Zhou D (China) 

p6 0 Alteration of resting-state functional 

magnetic resonance imaging in 

paroxysmal kinesigenic choreoathetosis 

Zhou B, Chen Q, Zhou D, Gong Q (China) 

p6 Study of the causes of symptomatic 

epilepsies diagnosed in an epilepsy clinic 

in Nepal 

Bajaj S, Bajaj N (Nepal) 

p6 2 Reduced serotonin transport in 

epilepsy measured by positron 

emission tomography 

Theodore W, Fingerish A, Cannon D, Lim Y, 

Dustin I, Reeves-Tyer P, Herscovitch P (USA) 

p6 3 Comparison of multimodal non-invasive 

imaging with intracranial EEG for epileptic 

focus localization 

Spinelli L, Brodbeck V, Delavelle J, Wissmeyer M, 

Michel C, Seeck M (Switzerland) 

p6 4 Morphological changes of the cortex in 

juvenile mycolonic epilepsy (JME): 

an MRI study 

Ronan L, Alhusaini S, Scanlon C, Fitzsimons M, 


96 


p6 5 Evidence of neuronal dysfunction 

measured by proton MR spectroscopy TLE 

patients differs in responders and nonresponders 

to the first AED monotherapy 

Campos B, Yasuda C, Castellano G, Bilevicius E, 

Li L, Cendes F (Brazil) 

p6 6 Non-invasive dynamic imaging of seizures 

in epileptic patients 

Tyvaert L, LeVan P, Dubeau F, 

Gotman J (Canada) 

p6 7 Focal magnetic source imaging 

in extensive malformations of cortical 

development 

Russi A, Santiuste M, Nowak R, Tarancón T, 

Oliver B, Ayats E (Spain) 

p6 8 A functional magnetic resonance study 

of language lateralization in frontal 

lobe epilepsy 

Bongiovanni L, Zoccatelli G, Cavallin M, 

Rizzuto N, Dalla Bernardina B, Beltramello A, 

Alessandrini F (Italy) 

p6 9 Time-frequency and spatial structure 

of typical and atypical discharges in 

nonconvulsive epilepsy 

Gabova A, Gnezditsky V, Dikanev T, 

Kuznetsova G, Obukhov Y (Russia) 

p620 Are reductions in D2-receptor availability 

reversible one year after epilepsy surgery 

for mesial temporal sclerosis? 

Werhahn K, Yakushev I, Landvogt C, Buchholz H, 

Glaser M, Schreckenberger M (Germany) 

p62 Functional brain mapping of seizures 

in focal epilepsy using simultaneous 

EEG/fMRI recordings 

Leal A, Secca M, Jordão C (Portugal) 

p622 Post stroke seizures and BBB(blood brain 

barrier)-DTPA SPECT studies 

Gilad R, Eilam A, Loberboim M, Lampl Y (Israel) 

p623 Comparison of the magnetometer and 

synthetic planar gradiometer MEG data 

in the detection of deep sources: 

preliminary report 

Nowak R, Buchanan S, Santiuste M, 

Graetz G (Spain) 

p624 Engagement of the medial temporal lobe 

in verbal and non-verbal memory: 

assessment with fMRI in normal subjects 

Villani F, Rosazza C, Minati L, Ghielmetti F, 

Maccagnano E, Erbetta A, Epifani F, Dylgjeri S, 

Bruzzone M (Italy) 

p625 Brain structure endophenotypes 

in mesial temporal lobe epilepsy: 

a quantitative MRI study 

Scanlon C, Ronan L, Doherty C, Cavalleri G, 

Delanty N, Fitzsimons M (Ireland) 



p626 PGP action in temporal lobe epilepsy 

explored with [ 8F] MPPF: intermediate 

results after blockade of PGP with 

cyclosporine A 

Hammers A, Bouvard S, Costes N, 

Perreira de Sousa Neto E, Lothe A, 

Keihaninejad S, Le Bars D, Didelot A, 

Mauguière F, Koepp M, Hirsch E, Ryvlin P (UK) 

p627 Comparison of language fMRI in primary 

and secondary language for non English 

native speakers 

Centeno M, Bonelli S, Rodionov R, Vollman C, 

Duncan J (UK) 

p628 Idiopathic generalized epilepsy is 

associated with atrophy in pulvinar and 

somatomotor thalamic nuclei 

Bernasconi A, Bernhardt B, Kim H, Natsume J, 

Bernasconi N (Canada) 

p629 Prospective voxel based morphometry 

analysis of benign familial mesial 

temproal lobe epilepsy 

Morita M, Betting L, Yasuda C, Conz L, 

Costa A, Kobayashi E, Lopes-Cendes I, 

Guerreiro C, Cendes F (Brazil) 

p630 School performance and language 

features in children with rolandic epilepsy 

Oliveira E, Neri M, Guimarães C, Medeiros L, 

Guerreiro M (Brazil) 

p63 Working memory in patients with 

mesial temporal lobe epilepsy with 

unilateral hippocampal sclerosis 

Tudesco I, Vaz L, Noffs M, Mantoan M, 

Belzunces E, Caboclo L, Yacubian E, Sakamoto A, 

Bueno O (Brazil) 

p632 Executive dysfunction in patients with 

nonlesional, well-controlled epilepsy: 

a long-term effect of antiepileptic drugs 

Park S, Lee D, Lee J, Suh C (South Korea) 

p633 Impact of surgical outcome, side of lesion 

and interictal epileptiform discharges 

on attention and memory in temporal 

lobe epilepsy 

Wisniewski I, Wendling A, Steinhoff B (Germany) 

p634 Neuropsychological and 

neurophysiological achievements from 

two cases of epilepsy with occipital 

calcifications: how the administration 

of a simple cognitive task in a clinical 

context highlights selective impairment 

of visual cortex 

Gubernale M, Negrin S, Durisotti C, 

Piacentino M, Garofalo P, Gobbo A, Perin S, 

Antoniazzi L, Bonanni P (Italy) 

p635 Benign childhood epilepsy with 

centro-temporal spikes: word and 

pseudoword discrimination 

Fonseca L, Tedrus G, Oliveira E, 

Ximenes V (Brazil) 


p636 Quality of life following resective surgery: 

initial outcomes 

Wan Mohamad W, Socorro Pieter M, Tharakan J, 

Sayuthi S, Kanti Pal H, Abdullah J (Malaysia) 

p637 Septal glutamatergic system promotes the 

development of epileptic focus in the 

model of temporal lobe epilepsy 

Garaeva E (Russia) 

p638 Benefits of a memory training program in 

epileptic patients: an exploratory study 

Cunha C, Sousa L, Sales F, Santana I (Portugal) 

p639 The neuropsychological profile of children 

with continuous spikes and waves during 

slow sleep 

Winczewska-Wiktor A, Zesawska A, 

Kaczmarek I, Gurda B, Starczewska M, 

Zarowski M, Kupczyk K, Steinborn B (Poland) 

p640 Cognitive function and quality of 

life effect of valproate, carbamazepine, 

and lamotrigine in patients with newly 

diagnosed epilepsy after 2-year follow-up 

Yu P, Zhu G, Xu Y, Zhao D, Wu X, Hong Z (China) 

p64 Postsurgical decline of naming 

performance in patients with left-sided 


Aengenendt J, Prochnow D, Labudda K, 

Schulz R, Hoppe M, Woermann F, 

Ebner A (Germany) 

p642 Cognitive abilities of children exposed to 

Levetiracetam in utero: preliminary findings 

Shallcross R, Bromley R, Morrow J, Baker G (UK) 

p643 Behavioural abilities of children exposed 

to carbamazepine or sodium valproate in 

utero: preliminary prospective 

evidence from the Liverpool and 

Manchester Neurodevelopment Group 

Bromley R, Shallcross R, Gummery A, Mawer G, 

Clayton-Smith J, Baker G (UK) 

p644 Memory in a group of children with 


Lopes A, Simões M, Robalo C, Fineza I, 

Gonçalves O (Portugal) 

p645 Visual and spatial agnosia associated with 

multifocal posterior epilepsy 

Sauvée M, Schaff J, Rumilly E, Beis J, Maillard L, 

Vignal J, Vespignani H (France) 

p646 Dysfunction of the social cognition 

revealed by Iowa gambling test in patients 

with mesial temporal lobe epilepsy 

Akamatsu N, Yamano M, Tsuji S, Kobayakawa H, 

Kawamura M (Japan) 

p647 Cognitive rehabilitation: a (needed) way to 

promote focal epilepsy outpatients’ 

quality of life? 

Meneses R, Pais-Ribeiro J, Martins da Silva A, 

Giovagnoli A (Portugal) 



p648 The Boston Naming Test as a predictor of 

post-surgical naming dysfunctions in 


Escorsi-Rosset S, Souza-Oliveira C, 

Miotto E, Bianchin M, Wichert-Ana L, 

Terra-Bustamante V, Alexandre V, Santos A, 

Sakamoto A (Brazil) 

p649 An exploration of cognitive function and 

cognitive endophenotypes in mesial 


Maher H, Burke T, Pender N, Doherty C, 


p650 Measuring driving performance during 

EEG events: contribution to individualized 

counseling on traffic safety in a patient 

with ring20 chromosome syndrome 

Gosar D, Ravnik I (Slovenia) 

p65 Temporal lobe epilepsy and abnormal 

forgetting of autobiographical memories: 

a diary intervention 

Reynders H, Isaac C, Howell S (UK) 

p652 Amnesic syndrome and hippocampal 

atrophy related to febrile convulsions 

Carrasco S, Burriel L, Ibañez R, Gallardo M, 

Vaamonde J, Gudin M (Spain) 

p653 The role of levetiracetam in the treatment 

of limbic seizure status in rats: 

electrophysiology and metabolism 

Sato M, Saito M, Hodozuka A, Anei R, Hayashi Y, 

Hiroshima S, Orimoto R, Tanaka T (Japan) 

p654 Automatic abnormal waves detection from 

the electroencephalograms of epilepsy 

cases to sort out the spikes, the sharps, the 

polyphase based on their statistical 

zerocrossing and 

temporal characteristics 

Noertjahjani S (Indonesia) 

p655 Neuropsychological assessment protocol 

for temporal lobe epilepsy pharmacoresistant 

adult patients candidates for 

neurosurgery procedure 

Alves-Leon S, Leite Monteiro M, 

Ottoni Brito G (Brazil) 

p656 Diffusion tensor imaging (DTI) aids in the 

presurgical ecaluation and surgical 

planning in patients with lesional 

temporal and extra temporal epilepsy 

Radhakrishnan A, Kesavadas C, Bahuleyan B, 


p657 Memory evaluation and antiepileptic 

action of intra-hippocampal injection 

of adeno-associated viral (AAV) gene 

of the neuropeptides Y (NPY) in the 

pilocarpine model in marmosets 

(CALLITHRIX JACCHUS) 

Blanco M, Kohek, S, Albertini L, Cinini S, 

Perez Mendes P, Bland R, Fitzsimons H, 

During M, Vezzani A, Mello L (Brazil) 

98 


p658 Corsi’s Blocks revisited 

Alpherts W (The Netherlands) 

p659 Voxel based morphometry and 

intellectual assessment in patients with 

congenital bilateral perisylvian syndrome 

(CBPS): correlation with epilepsy and 

cognitive performance 

Abraão Guimarães C, Guerreiro M, Lin Yasuda, C, 

C. Teixeira K, Montenegro M, Cendes F (Brazil) 

p660 Psychological effects of the refractar 

epilepsy 

Alecu T (Romania) 

p66 The natural history of cognitive 

functioning in patients with newly 

diagnosed epilepsy: the longer term 

impact of epilepsy and its treatment 

Taylor J, Baker G (UK) 

p662 Neuropsychological outcomes after 

epilepsy surgery: relationship with extents 

of hippocampal resections 

Cunha C, Pereira S, Santos G, Brito O, 

Machado E, Bento C, Sales F, Santana I (Portugal) 

p663 Frontal lobe epilepsy in children 

Lee H, Chi C (Taiwan) 

p664 The factor analytic structure of the WISC-R 

and WISC-III in children with epilepsy: a 

study across countries and cultures 

Van Iterson L, San Miguel L, 

Rios Motta M (The Netherlands) 

p665 Generalised epilepsy with febirle seizures 

plus in two sisters 

Gustavo L, Antonio P, Francisco C, Maria A, 

Pablo M, Paloma Q (Spain) 

p666 Reccurrent para-infectious seizures 

apropos of four cases 

Lorenzo G, Pedrera A, Corral F, Buenache R, 

Sáez J, Paradinas F (Spain) 

p667 Long-term outcome of difficult-to-treat 

epilepsy in childhood 

Beume L, Steinhoff B (Germany) 

p668 Lateralising signs in infantile spasms: 

differences in video and EEG analysis 

Dressler A, Klaus M, Franz B, MIchael F, Marco K, 

Gerald P, Edith R, Rainer S, Lydia U, 

Martha F (Austria) 

p669 Adrenocorticotrop hormone therapy in 

acquired childhood epileptic aphasia 

Szabó L, Nagy J, Kálmánchey R (Turkey) 

p670 Epilepsy in children with Angelman 

syndrome 

Budisteanu M, Arghir A, Chirieac S, Lungeanu A, 

Magureanu S (Romania) 

p67 Analysis of rolandic discharges in patients 

with idiopathic and symptomatic epilepsy 

Medeiros L, Yasuda C, Guerreiro M (Brazil) 



p672 Age, dose, and environmental temperature 

are risk factors for topiramate-related 

hyperthermia in children with epilepsy 

Chung S (South Korea) 

p673 Refractory epilepsy associated with 

anti-GAD antibodies in a 6-year old girl 

Korff C, Parvex P, Wilhelm-Bals A, 

Schwitzgebel V, Lalive P, Seeck M (Switzerland) 

p674 Vagus nerve stimulation in pediatric 

epileptic syndromes 

Ruiz-Falcó M, García-Peñas J, Lara Herguedas J, 

Duat-Rodríguez A, López-Marín L, 

Cantarín-Extremera V, Gutiérrez N, Gutiérrez- 

Solana L, García M, Pérez-Jimenez M, 

Villarejo F (Spain) 

p675 Electro-clinical clinical picture of 

benign epilepsy with centro-temporal 

spikes (BECTS) 

Tanaka M (Japan) 

p676 Autism spectrum disorder and epilepsy: a 

retrospective follow-up study 

García-Peñas J, Cantarín-Extremera V, 

Lara-Herguedas J, Ruiz-Falcó M, 

Duat-Rodríguez A, López-Marín L, Rodrigo M, 

Gutiérrez N, Gutiérrez-Solana L, 

Pérez-Jiménez M (Spain) 

p677 Epileptic encephalopathy with negative 

myoclonic seizures of musculus mentalis 

during non-REM slee 

Ogihara M, Miyajima T, Hoshika A, Wang C, 

Hirabayashi S (Japan) 

p678 Can we predict seizure recurrence after 

anti-epileptic medication withdrawal 

following seizure freedom in children? 

Nickels K, Wirrell E (USA) 

p679 Extensive hemispherial polymicrogyria 

as the cause of electrical status epilepticus 

during slow sleep (ESES) syndrome 

Siegler Z, Hegyi M, György I, Barsi P, Fekésházy A, 

Szakáll S, Bognár L, Novák L, Fogarasi A (Turkey) 

p680 Epileptics manifestations in children with 

Down Syndrome 

Lara-Herguedas J, García-Peñas J, Ruiz-Falcó M, 

Duat-Rodríguez A, López-Marín L, 

Cantarín-Extremera V, Rodrigo M, 

Gutiérrez-Cruz N, Gutiérrez-Solana L, 

Pérez-Jiménez M, García-Pérez J (Spain) 

p68 Electro-clinical semiology at onset of the 

Lennox-Gastaut syndrome 

Nikanorova M, Miranda M (Denmark) 

p682 Rufinamide in children with Lennox- 

Gastaut syndrome and other related 

refractory epileptic encephalopathies: 

a prospective, add-on, open-label 

treatment study 

Cantarín V, García-Peñas J, Ruiz-Falcó M, 

Lara-Herguedas J, Duat-Rodríguez A, 

López-Marín L, Gutiérrez-Solana L, 

Rodrigo M, Gutiérrez N, Pérez-Jiménez M (Spain) 


p683 Combination of epilepsy with benign 

epileptiform pattern of childhood and 

structural brain lesion 

Perunova N, Tomenko T (Russia) 

p684 Phenotypic characterisation of 36 

Colombian patients with juvenile 

myoclonic epilepsy Universidad De 

Antioquia-Hospital Universitario San 

Vicente De Paul, Medellin 997-2008 

Jaime C, William C, Silvia P, Dagoberto C, 

Nicolas P, Christhian G, Laura R (Colombia) 

p685 Factors influencing admission to ICU 

in children presenting with status 

epilepticus (SE) 

Tirupathi S, McMenamin J, Webb D (Ireland) 

p686 High dose of thiopental therapy for 

refractory status epilepticus in children 

Kwon Y, Kim D, Cho K (Korea) 

p687 Treatment of 2 patients of hypothalamic 

hamartoma with gelastic seizure by 

various modalities. Operative results and 

Neuropathological characteristics 

Hori T, Ochiai T, Akagawa H, Kubota Y, 

Miyata H (Japan) 

p688 Magnetoencephalography for atypical 

benign partial epilepsy: localization of 

Rolandic-sylvian spike sources 

Otsubo H, Chan D, Haginoya K, Nakagawa E, 

Shiraishi H (Canada) 

p689 Seizure control with dietary therapies: 

the ketogenic diet versus the low glycemic 

index and modified ketogenic diet 

Malphrus A, Schultz R, Rivera A, Riviello J, 

Wilfong A (USA) 

p690 EEG characteristics of lissencephaly 

Kim K, Cho A, Lim B, Hwang H, Chae J, 

Hwang Y (South Korea) 

p69 Abnormal development of neurons in 

focal cortical dysplasia: neuronal 

mis-maturation from an 

immunohistochemical consideration 

Hanai S, Saito T, Nakagawa E, Arai A, Otsuki T, 

Sasaki M, Goto Y, Itoh M (Japan) 

p692 Clinical effectiveness of antiepileptic 

drugs against refractory status epilepticus 

and its outcome in children 

Kwon S, Seo H, Hwang S (Korea) 

p693 Comparison of first attack of febrile 

seizure and benign convulsion with 

gastroenteritis 

You S, Kang H (South Korea) 

p694 Incidence and prognosis of frontal lobe 

epilepsy in Korean children 

Lee C, Rhyu S, Moon K, Baek K, 

Geum S (South Korea) 



p695 Mortality following antiepileptic drug use 

in children and adolescents 

Besag F, Ackers R, Hughes E, Squier W, 

Wong I (UK) 

p696 Abnormal cytoarchitecture of focal 


Arai A, Hanai S, Saito T, Nakagawa E, Ohtsuki T, 

Itoh M (Japan) 

p697 Prospective, observational, multi-center 

study to assess the effect of Topiramate on 

quality of life in childhood epilepsy 

Jung D (South Korea) 

p698 Acute symptomatic seizures and status 

epilepticus in children in Cheongju, 

South Korea 

Kim W, Sim J (South Korea) 

p699 Efficacy and safety of levetiracetam 

in children younger than 4 years of age 

with refractory epilepsy 

Sixiu L, Famgcheng C (China) 

p700 Corpus callosotomy in intractable epilepsy 

with nonlesional MRI 

Hur Y, Kim H, Kim D, Lee J (South Korea) 

p70 White matter diffusion abnormalities 

correlate with grey matter FDG-PET 

metabolism in epileptic children 

Lippe S, Archambaud F, Poupon C, Cachia A, 

Chiron C, Hertz-Pannier L (France) 

p702 The continuous spikes and waves 

during slow sleep in children. A series of 

patients 

Winczewska-Wiktor A, Starczewska M, Gurda B, Ź 

arowski M, Źesawska A, Kaczmarek I, Kupczyk K, 

Steinborn B (Poland) 

p703 Epileptic negative myoclonus as 

the presenting seizure type in benign 

childhood epilepsy with 

centro-temporal spikes 

Watemberg N, Leitner Y, Fattal-Valevski A, 

Kramer U (Israel) 

p704 Atkin’s diet in childhood refractory 

seizure: an Iranian experience 

Tonekaboni H, Mostaghimi P (Iran) 

p705 Rufinamide as add-on treatment for 

patients with Lennox-Gastaut syndrome 

Nakken O, Eriksson A, Lossius M, 

Nakken K (Norway) 

p706 MEG in pediatric epilepsy: dipole 

analysis vs. SAM 

Fasano R, Shamim S, Liew C, Wlker J, 

Theodore W, Gaillard W, Sato S (USA) 

p707 Epilepsy in children with schizencephaly 

Lee Y, Lee J, Kim S, Lee J, Kim H (South Korea) 

00 


p708 Electroencephalographic evolution in 

Panayiotopoulos syndrome and benign 

occipital epilepsies of childhood 

Martinovic Z, Cvorovic Z, Stanisic J, 

Milovanovic M (Serbia and Montenegro) 

p709 Behavioral abnormalities and psychiatric 

disorders in epileptic children 

Gniatkowska-Nowakowska A (Poland) 

p7 0 General or specific language impairment? 

Electrophysiological and 

neuropsychological study of Landau- 

Kleffner Syndrome 

Kálmánchey R, Szabó L, Honbolygó F, 

Csépe V (Turkey) 

p7 Clinical characteristics in epileptic children 

with electrical status epilepticus during 

slow sleep (ESES) 

Kollár K, Rosdy B, Móser J (Turkey) 

p7 2 Does socioeconomic status influence 

incidence of epilepsies in childhood? 

Zubcevic S, Gavranovic M, Catibusic F, 

Uzicanin S (Bosnia and Herzegovnia) 

p7 3 Study of non-convulsive status epilepticus 

(NCSE) in children and young people with 

complex epilepsy and learning disabilities 

Das K, Sadek H, Chivers F, Iga P (UK) 

p7 4 Bilateral Sturge Weber syndrome: 

to operate or not? 

Rosdy B, Kollár K, Móser J, Barsi P, Várallyay G, 

Bognár L, Siegler Z, Fogarasi A (Turkey) 

p7 5 Transient evolution to hypsarrhythmia in 

malignant migrating partial seizures in 

infancy: a case report 

Ong H, Liano A, Lim K, Wong J (Singapore) 

p7 6 Clinical and electroencephalographic 

findings in channelopathies 

Preto P, Guimarães C, Guerreiro M (Brazil) 

p7 7 A study of clinical features, EEG, 

pathophysiology and prognosis of 8 

patients with panayiotopoulos syndrome 

Liang J (China) 

p7 8 X-linked lissencephaly with abnormal 

genitalia caused by mutation of aristalessrelated 

homeobox gene exhibits abnormal 

distribution of GAB Aergic interneurons 

Itoh M, Okazaki S, Kuki I, Kawawaki H, Hai E, 

Inoue T, Goto Y, Yamano T, Tomiwa K (Japan) 

p7 9 Short-term ketogenic diet in intractable 

infantile spasms 

Lee Y, Eom S, Lee Y, Kang H, Lee J, Kim H (Korea) 

p720 EEG patterns and neurological outcome in 

neonates treated with extracorporeal 

membrane oxigenation (ECMO) 

Acevedo K, Margarit C, Mesa T, Escobar R, 

Godoy J, Santin J, Kattan J (Chile) 



p72 Study of the electroclinical features of 

cases of juvenile myoclonic epilepsy 

diagnosed in an epilepsy clinic in Nepal 

Bajaj N, Bajaj S (Nepal) 

p722 Early-onset benign childhood 

occipital epilepsy: epidemiological and 

clinical characteristics and outcome 

Mª Eugenia Y, Teodoro D, Amalia A, 

Souto S (Spain) 

p723 Levetiracetam in pediatric patients with 

devastating epilepsy syndrome 

Ko T, Yum M, Jeong M, Lee E (Korea) 

p724 Cortical mechanisms underlying late onset 

epileptic spasms associated with temporal 

lobe lesions 

Milh M, Villeneuve N, Régis J, Scavarda D, 

Chabrol B, Chauvel P, Bartolomei F (France) 

p725 Long-term outcome of growth in children 

treated with ketogenic diet 

Song J, Lee Y, Lee E, Lee Y, Kang H, Lee J, 

Kim H (South Korea) 

p726 Outcome of the management of acute 

seizures in children admitted to a district 

hospital in sub-Saharan Africa 

Ikumi M, Muchohi S, Ohuma E, Kokwaro G, 

Newton C (Kenya) 

p727 Clinical and electroencephalic effect 

of folinic acid treatment in Dutch 

rett patients 

Hagebeuk E, Koelman H, Duran R, Abeling N, 

Poll-The B (The Netherlands) 

p728 Pyridoxin dependency (PD)-pyridoxin 

withdrawal test is not enough for 

the diagnosis 

György I (Turkey) 

p729 Treatment options and outcome in 

childhood absence and myoclonic 

epilepsies 

Dimova P, Bojinova V (Bulgaria) 

p730 Abnormal background EEG activity 

and mental retardation are main 

predictors of intractable epilepsy in 

tuberous sclerosis patients 

Jahodova A, Krsek P, Petrak B, Kaluzova M, 

Kudr M, Kyncl M, Komarek V (Czech Republic) 

p73 Low effectiveness of overnight videoEEG 

monitoring in nocturnal enuresis 

Sterbová K, Komárek V (Czech Republic) 

p732 Vagus nerve stimulation improves 

sialorrhea in a patient with Lennox- 

Gastaut-Syndrome 

Hela M, Parain D, Hattab N, Mrabet A (Tunisia) 

p733 Epilepsy and neurocutaneous syndromes: 

what should we look for 

Martins C, Monteiro J, Fonseca M (Portugal) 


p734 Therapeutical approach and prognosis 

in pharmacoresistant idiopathic 

generalized epilepsies in childhood 

Bojinova V, Dimova P, Pencheva G (Bulgaria) 

p735 A retrospective analysis of treatment with 

stiripentol in 22 children of the Epilepsy 

Centre Kork 

Wiemer-Kruel A, Ernst J (Germany) 

p736 Childhood absence seizures and GLUT 

deficiency 

Webb D, Byrne S, Kearns J, 

McMenamin J (Ireland) 

p737 Epilepsy and Anderson Fabry disease in 

6 years old girl 

Saftic V, Zakanj Z (Croatia) 

p738 Focal polyspikes in adolescents with 

idiopathic generalized epilepsy 

Ahmed Z, Akhter A, Mobin M, Malik A, Khan F, 

Siddiqui K (Pakistan) 

p739 Valproate responsive pseudointractable 

epilepsy with focal epileptogenesis 

in children 

Lin K, Wang H (Taiwan) 

p740 Study of intellectual prerequisites 

dinamics in childres with absence seizures 

Zaitsev D, Lyutin D, Eletskova L (Russia) 

p74 Clinical outcome in childhood epilepsy 

with electrodecremental event: in aspect 

of response to treatment 

Nam S, Lee Y (Korea) 

p742 Standardised hyperventilation during 

EEG in children with absence epilepsy and 

attack disorders 

Coughlan A, Mc Menamin J (Ireland) 

p743 Reappraisal of ‘gmyoclonic absence’ h: 

symptoms and clinical course 

Ikeda H, Imai K, Shigematsu H, Kubota Y, 

Kubota H, Ikeda H, Takahashi Y, Fujiwara T, 

Inoue Y (Japan) 

p744 Childhood frontal lobe epilepsy due 

to cingular polymicrogyria: report of 

four cases 

Hegyi M, Barsi P, Szakáll S, Lengyel Z, Siegler Z, 

Bognár L, Neuwirth M, Fogarasi A (Turkey) 

p745 Hypohidrosis related symptoms in 

pediatric epileptic patients with topiramate 

Kim S, Kim S (Korea) 

p746 High-dose diazepam treatment in 

epileptic encephalopathy associated with 

ring chromosome 20 

Morse R, Filiano J, Holmes G, Gardner D, 

Gaelic S (USA) 



p747 Neuropsychological outcome in children 

belonging to the benign childhood 

epilepsy with centrotemporal spikes 

(BCECTS) Spectrum: a follow up study 

Gobbi G, Filippini M, Boni A (Italy) 

p748 Effect of UGTIA6 T 9G A54 G A552C 

genetic polymorphisms on the 

metabolism of Sodium Valproate in Han 

Chinese children with epilepsy 

Gao L, Wang Y, Hang N (China) 

p749 CSWS: 5 cases treated with Levetiracetam 

at low-medium dosage 

Ravagnan E, Dainese F, Paladin F (Italy) 

p750 Seizure characteristics of Dravet Syndrome 

Voronkova K, Kholin A, Lemeshko I, Il’ina E, 

Petrukhin A (Russia) 

p75 Quantitative EEG, MRI analysis and 

cognitive outcome in children with 

unilateral Sturge Weber Syndrome 

Mathieson S, Boyd S, Rankin P, Bradbury D, 

Chong K, Aylett S (UK) 

p752 Is eyelid myclonia with absences 

underdiagnosed in children? 

Prasad A, Kumar S, Elia M, Levin S (Canada) 

p753 Outcome of antiepileptic drugs withdrawal 

Pavlovic M, Jovic N, 

Knezevic Pogancev M (Serbia and Montenegro) 

p754 Is prediction of vagus nerve stimulation 

(VNS) therapy outcome possible? 

Orosz I, Hoffmann J, Panzer A, König I, 

Sperner J (Germany) 

p755 Hippocampal malrotation in children with 

febrile seizures 

Giraldes De Manreza M, Pereira de Brito 

Sampaio L, M Nagae L, S F Caboclo L, 


p756 Syndrome of continuous spike-wave of 

slow sleep: different clinical 

manifestations in children 

Uscategui A, Ortiz S, Granados L (Colombia) 

p757 Features of status epilepticus at infancy 

and early childhood 

Kholin A, Voronkova K, Aivazjan S, 

Shevchenko A, Lemeshko I, Il’ina E, 

Petrukhin A (Russia) 

p758 Angelman syndrome: two atypical cases 

Yilmaz S, Serdaroglu G, Cogulu O, Ozkinay F, 

Tekgul H, Gokben S (Turkey) 

p759 Prevalence and management of children 

with drug-resistant focal epilepsies - plus 

- benign idiopathic focal epilepsies / 

benign focal epileptiform discharges of 

childhood in addition 

Hans H, Antje B, Celina v, Tom P, Stephanie K, 

Hans E, Gerhard K (Germany) 

02 


p760 A treatable metabolic encephalopathy: 

clinical and neuroimaging findings in 

three Turkish patients with pyridoxinedependent 

epilepsy and mutations of the 

antiquitin (ALDH7A ) gene 

Topcu M, Haliloglu G, Salomons G, Oguz K, 

Struys E, Coskun T, Jakobs C (Turkey) 

p76 The use of Italian blue spectacles 

in blocking photosensitivity: 

electrophysiological and clinical 

implications 

Domañska-Pakiea D, Chmielik J, Kmieæ T, 

Bachañski M, Olszaniecka M, Krajnik-Gwód A, 

Kocoñ-adowska H, Chmielewski D, 

Kasprzyk-Obara J, Kaczorowska M (Poland) 

p762 Clinical experience with rufinamide 

(Inovelon) in therapy of Lennox-Gastaut 

syndrome 

Ryzí M, Ošlejšková H, Cahová P (Czech Republic) 

p763 0 years pediatric epilepsy surgery: 

the Vogtareuth experience 

Kessler S, Pieper T, Eitel H, Zsoter A, 

Zeches-Kansy C, Kudernatsch M, 

Kolodziejczyk D, Karlmeier A, Blümcke I, 

Holthausen H (Germany) 

p764 Epileptic syndromes in infancy 

Frassine B, Beccaria F, Cagdas S, 

Capovilla G (Italy) 

p765 The impact of Lennox-Gastaut Syndome 

(LGS) on health related quality of life: 

a conceptual model 

Wild D, Verdian L, Gallop K, Falconer S (UK) 

p766 The electro-clinical seizure pattern of 

benign epilepsy with centro-temporal 

spikes in 30 patients 

Capovilla G, Beccaria F, Bianchi A, Canevini M, 

Frassine B, Giordano L, Gobbi G, Mastrangelo M, 

Peruzzi C, Pisano T, Striano P, Veggiotti P, 

Vignoli A, Pruna D (Italy) 

p767 Autoantibodies to glutamate receptors in 

children with epilepsy and seizures 

Globa O, Sorokina E, Bazarnaya N, 

Karkashadze G, Maslova O, Pinelis V, 

Kuzenkova L (Russia) 

p768 Febrile crises and epilepsy 

Pesantez Cuesta G, Rios M, 

Dalla Bernardina B (Ecuador) 

p769 Idiopathic generalized epilepsy of early 

infancy: from GEFS+ to Dravet´s 

Syndrome-clinical and genetic 

Heterogeneity. Four cases of SCN A 

positive and six cases of SCN A 

negative children 

Holert N, Mayer T (Germany) 



p770 Features of conduct and treatment of 

resistant epileptic attacks in children of 

early age with a tuberous sclerosis 

Kyrylova L, Shevchenko A, Tkachuk L, 

Vasilenko M, Sylaeva L, Lysytsa V, 

Prikhodko V (Ukraine) 

p77 Acute seizures and chromic epilepsy: 

epileptologic aspects of childhood 

encephalitis 

Liptai Z, Mihaly I, Barsi P (Turkey) 

p772 Comparison of the effects of 

phenobarbital versus carbamazepine as 

single drug therapy in partial seizure with 

secondary generalization in children 

Bidabadi E (Iran) 

p773 ESES secondary to valproate treatment 

Sahin S, Uysal S (Turkey) 

p774 SCN A-related epileptic encephalopathies: 

long-term evolution according to early 

pharmacological treatment 

Vrielynck P, Ghariani S, 

van Rijckevorsel K (Belgium) 

p775 Neurological and psychological outcomes 

of children with cryptogenic localization 

related epilepsy 

Ayadi I, Kamoun F, Ellouze E, Hsairi I, Mzuouo M, 

Triki C (Tunisia) 

p776 Epileptic seizures in three children with 

undetermined leukodystrophies 

Ellouze E, Kamoun F, Ayadi I, Hsairi I, 

Chaabene A, Triki C (Tunisia) 

p777 High Resolution DC EEG and Nera Infrared 

Spectroscopy in focal seizure like activity 

in neonates: an hemodynamic and 

electrical analysis 

Wallois F, Patil A, Kongol G, Goujil S, 

Grebe R (France) 

p778 Focal epilepsy in children. Prognostic 

factors of recurrence 

Pozo Alonso A, Pozo Lauzán D, 

Oliva Pérez M (Cuba) 

p779 The incidence of epileptic seizures and 

electroencephalogram abnormalities in 

children with autism 

Diaconu G, Grigore I, Burlea M, Trandafir L, 

Moisa S (Romania) 

p780 Early clinical features of sulphite oxidase 

deficiency can mimic hypoxic ischemic insult 

Choong C (Singapore) 

p78 Case of GLUT (glucose transporter) 

deficiency or De Vivo disease 

Jaladyan V, Sukhudyan B (Armenia) 

p782 Auditory processing disorder in children 

with perisylvian polymicrogyria 

Boscariol M, Garcia V, Guimarães C, Hage S, 

Cendes F, Guerreiro M (Brazil) 


p783 Epilepsy and anti-epileptic drug use in 

an in-patient population with intellectual 

disability 

Barrett E, Mulryan N, Mc Laughlin M, Lane J, 

Barrett C, Kelly F, McCarthy P (Ireland) 

p784 Health service use by patients with 

dissociative (non-epileptic) seizures or 

epilepsy: a pilot study 

Goldstein L, Delamont R, Mellers J (UK) 

p785 Psychiatric familial history and left 

hemisphere epileptiform activity are 

independent risk factors for humor 

disorders in temporal lobe 


Bragatti J, Assmann J, Fontana V, Rigotti C, 

Hidalgo M, Manfro G, Segal S, Jardim L, 

Bianchin M (Brazil) 

p786 Epilepsy in children diagnosed with 

attention-deficit/hyperactivity disorder 

(ADHD): diagnostic difficulties, seizure risk 

and ADHD inattentive subtype 

Socanski D, Herigstad A (Norway) 

p787 Public attitude toward epilepsy in rural 

Mongolian residents 

Avirmed T, Guntev T, Bayarmagnai M, 

Dash K (Mongolia) 

p788 Risk of suicide and quality of life in 

patients with epilepsy 

Buttinelli C, Ferraldeschi M, Saglimbene A, 

Caporro M, Campana C, Tisei P, Pompili M (Italy) 

p789 Psychiatric comorbidities in 

pharmacological resistant focal epilepsy 

according to the epileptogenic zone: a 

study of 490 surgical patients 

Sakamoto A, Dalmagro C, Velasco T, Bianchin M, 

Martins A, Hallak J, Cescato M, Guarnieri R, 

Carlotti Jr C, Assirati Jr J (Brazil) 

p790 Hippocampal changes and dissociative 

seizures 

Williams E, Yogarajah M, Burdett J, Duncan J, 

Sisodiya S, Koepp M, Fong J (UK) 

p79 Experiences of application of mood 

stabilizer antiepileptics - for psychiatrists 

Rajna P (Turkey) 

p792 Psychiatric co-morbidities and risk factors 

in patients with psychogenic non-epileptic 

seizures 

Nezadal T, Hovorka J, Herman E, Stichova E, 

Nemcova I, Bajacek M (Czech Republic) 

p793 Psychiatric disorders in patients with 

epilepsy and psychogenic non-epileptic 

seizures 

Barbieri V, Turner K, Chiesa V, Tisi G, Piazzini A, 

Gardella E, Scarone S, Canger R, Gambini O, 

Canevini M (Italy) 



p794 Basal hypercortisolism and trauma 

in patients with psychogenic non 

epileptic seizures 

Bakvis P, Kuyk J, Spinhoven P, 

Roelofs K (The Netherlands) 

p795 Phenotypic variability of neuropsychiatric 

symptoms in EPM -Unverricht-Lundborg 

disease (ULD) 

Amrom D, Talani M, Andermann F, Lehesjoki A, 

Andermann E (Canada) 

p796 Lamotrigine dosing, renal failure and 

dialysis: case analysis with literature review 

Kaufman K, Connolly S, Kim S (USA) 

P797 Structural differences between refractory 

mesial temporal lobe epilepsy (MTLE) with 

and without depression: a voxel based 

morphometry (VBM) analysis 

Salgado P, Yasuda C, Pereira F, Cendes F (Brazil) 

p798 Child rearing practices of women 

with epilepsy: effect of structured 

instructional module 

Padinjarathu Paulose S, Sanjeev Varghese T, 

Sankara S (India) 

p799 Focus on the family of patients with 

epilepsy: a qualitative study of experience 

with the loved one’s illness 

Mueller M, Jaggi S, Spirig R, 

Mahrer-Imhof R (Switzerland) 

P800 Medical direct cost of the epilepsy in 

a hospitable population of the social 

security (EsSALUD) from Lima, Peru 

Perez Galdos P (Peru) 

p80 The difference in the quality of life 

between newly diagnosed and refractory 

epilepsy patients 

Cho Y, Lee J, Yi S, Lee M, Shin W (South Korea) 

p802 Specific predictors of QOLIE-3 

individual domains 

Braga P (Uruguay) 

p803 Quality of life assessment in adult epilepsy 

patients from Uruguay: a pilot study 

Braga P, Bogacz A, Bonilla C, Camejo C, 

Scaramelli A (Uruguay) 

p804 Social and biomedical determinents of 

stigma among people with epilepsy 

in Zambia 

Birbeck G, Mbewe E, Atadzhanov M, Chomba E, 

Haworth A (USA) 

p805 Epilepsy in The Gambia 

Spensley T (The Gambia) 

p806 Demographics and characteristics of 

patients with generalized epilptogenic 

potentials from a tertiary care setting in 

Saudi Arabia 

Baz S, Al Semari A, Al Dhalaan H, Al Thubaity I, 

Chedrawi A, Al Yamani S (Saudi Arabia) 

04 


p807 Outpatient rehabilitation groups as a 

psychosocial support method 

Sormunen P, Kälviäinen R, Nylén M, Roivainen R, 

Tervonen S (Finland) 

p808 Quality of life in adolescents with epilepsy 

in Shanghai, China 

Ding D, Wu D, Wang Y, Hong Z (China) 

p809 What are the concerns of people with 

epilepsy? A qualitative survey of patients’ 

and health caregivers’ view 

Heritier Barras A, Seeck M (Switzerland) 

p8 0 Epilepsy treatment gap in Kilifi, Kenya: 

using formative research to develop 

interventions to reduce the gap 

Kathomi C, Newton C, Carter J (Kenya) 

p8 Recurrence and epilepsy after a first 

unprovoked seizure in childhood: a 

retrospective hospital study 

Cvitanovic-Sojat L, Lerotic I, Kukuruzovic M, 

Bilonic-Covic I, Malenica M, Gjergja-Juraski R, 

Vugrinec M (Croatia) 

p8 2 Knowledge, attitudes and perceptions 

of epilepsy among secondary 

school-teachers in Nigeria: a community 

based study 

Mustapha A, Odu O, Akande O (Nigeria) 

p8 3 Parent’s perception of integration of their 

children with epilepsy in the mainstream 

school system in Bulgaria 

Markova G, Sabeva V (Bulgaria) 

p8 4 Epilepsy, healthcare cost and loss of 

productivity in Sweden: a register-based 

approach 

Berggren F, Bolin K, Lundgren A, 

Källen K (Sweden) 

p8 5 Exploring predictors of health-related 

quality of life in childhood epilepsy 

Ronen G, Lach L, Streiner D, Verhey L, Boyle M, 

Cunningham C, Rosenbaum P (Canada) 

p8 6 Illustrating the semiology of seizures 

in depictions of patron saints of epilepsy 

in the Roman Catholic, Russian Orthodox 

and Greek Orthodox church over the 

course of seven centuries 

Kudernatsch V, Pollak D, Kholin A, Muchin K, 

Ramantani G, Kluger G (Germany) 

p8 7 What can a developing country do in 

integral epilepsy care? 

Fandiño-Franky J, Diaz S, Olave M (Colombia) 

p8 8 Quality of life and sexual function in men 

with epilepsy: a survey at the Bethel 

Epilepsy Centre 

May T, Schürmann I, Pfäfflin M, 

Pohlmann-Eden B, Brandt C (Germany) 



p8 9 Domains of concern for families whose 

child has Lennox Gastaut Syndrome 

Cramer J, Gallop K, Wild D, Falconer S, 

Verdian l (USA) 

p820 Maternal characteristics and neonatal 

outcome of women with epilepsy 

Prpic I, Radic J, Bilic I, Vukelic P, 

Petrovic O (Croatia) 

p82 Breastfeeding of women with epilepsy 

Radic J, Prpic I, Mahulja-Stamenkovic V, Bilic I, 

Milardovic A (Croatia) 

p822 An investigation into the experience of 

progression and advancement through 

the Irish education system of a group of 

people with epilepsy 

Broderick H (Ireland) 

p823 Assessment of health-related behaviors 

among epileptic adult patients 

Hamdy M, Reizian A, El-Sayed N, 

Ahmed D (Egypt) 

p824 PWEs self-help organization and activities 

in China 

Wu J, Li S (China) 

p825 The effect of perceived stigma on the 

quality of life of adults with epilepsy in an 

African population 

Fawale M, Ogunniyi S (Nigeria) 

p826 Is it helpful to produce epilepsy brochures 

in patient speech? 

Porschen T (Germany) 

p827 Impact of maternal anxiety about epilepsy 

and age of child on restrictions in 

childhood activities 

Schultz R, Chapieksi L, Evankovich K, Wilfong A, 

Collins R (USA) 

p828 Sexuality in male patients after anterior 

temporal lobectomy (ATL) for mesial 

temporal lobe epilepsy-hippocampal 

sclerosis (MTLE): a case control study 

Kallakatta Nekkare R, Ashalatha R, 

Padickaparambal S, Sankara P, 



p829 What family planning really means for 

women with epilepsy 

Winterbottom J, Kierans C, Jacoby A, 

Baker G (UK) 

p830 Comprehensive Rural Epilepsy Study 

South India (CRESSI): the impact on the 

knowledge, attitude, practice of epilepsy, 

drug adherence, and treatment gap: 

a follow-up study 

Seshadri V, Murthy J, Kumar A (India) 

p83 What factors determine compliance 

amongst epilepsy patients seen at a 

tertiary care centre in New Delhi, India? 

Singh M, Aggarwal M, Singh V, 

Srivastava A (India) 

p832 Developmental cognitive plasticity 

following hemispherotomy 

Bulteau-Peyrie C , Jambaque-Aubourg I, 

Dellatolas G, Fohlen M, Dorfmüller G, Oliver M, 

Delalande O (France) 

p833 Sleep disturbances in patients with 

epilepsy and the impact on QoL 

Doneva A, Cvetkovska E, Pili-Kuzeva K, 

Donev V (Macedonia) 

p834 How to improve the management 

of epilepsy in cities and rural areas 

without neurologists in Morocco? 

Kissani N (Morocco) 

p835 Symptoms of autistic behaviour 

or epilepsy? 

Merete Kristin K, Evjen K, Klonteig K, Larsen I, 

Schøyen L, Snarset V, Tarjem Turi A (Norway) 

p836 The history of foundation of the Russian 

League Against Epilepsy 

Neznanov N, Mikhailov V, Akimenko M (Russia) 


PLATFORM SESSION ABSTRACTS 

Monday 29th June 2009 

0:30 - 2:00 

Hall 2 

Platform Session 


00 

The serbian version of the quality-of-life in 

epilepsy inventory (QUOLIE-3 ): translation and 

psychometric evaluation 

Milovanovic M, Martinovic Z, Djokic R, Jovanovic M, Buder 

N, Simonovic P 

Institute of Mental Health, Serbia and Montenegro 

Purpose: To translate Quality-of-Life in Epilepsy 

Inventory (QUOLIE-31) into Serbian and to assess the 

psychometric properties of translation. 

Method: We performed the procedure of translation 

/ backtranslation and cultural adaptation. The study 

population comprised of 202 consecutive outpatients 

with epilepsy. Internal validity was tested by factor 

analysis and by multitrait/multiitem analysis to 

assess item convergent and discriminant validity. 

Subgroup of 110 patients without changes in seizure 

frequency was retested after 2-3 weeks for assessing 

test-retest reliability. Construct validity was assessed 

by relationship between scales and external measures 

(sociodemographic characteristics, seizure frequency, 

Short form 36 health survey, SF-36, and Neurotoxicity 

scale-II). 

Results:The domains showed high internal consistency 

(Cronbach-á 0.94).Test-retest reliability measured with 

Pearson’s coefficient was 0.83 for total score (0.61 to 

0.80 for subscales), indicating temporal stability. The 

discrimiminant validity was best for Seizure worry 

and Cognitive subscales. The QUOLIE-31 was highly 

correlated with SF-36 (rho=0.898). QUOLIE- 31 Energy/ 

fatigue subscore was especially related to SF-36 

Vitality subdimension (rho=0.55). Employment status 

significantly affected: Overall quality of life (F=5.79, 

p


antiepileptic drugs, seizure type, age at onset, patients 

age and educational level was significantly related to 

the change of cognitive function. Control of seizures 

plays a definite role in cognitive prognosis. 

004 

SUDEP recorded by a responsive neurostimulator: 

one mechanism for sudden death in intractable 

epilepsy clarified 

Van Ness P, Whitworth L A 

University Of Texas Southwestern Medical Center, USA 

Sudden unexplained death in epilepsy (SUDEP) is a 

tragic but incompletely understood complication 

of intractable epilepsy. A 46 year old woman with 

cryptogenic bitemporal independent epilepsy since 

age 21 and continuous intracranial EEG monitoring 

using bitemporal hippocampal depth electrodes 

inserted from a posterior approach as part of a 

responsive neurostimulation study (NeuroPace) had 

a typical witnessed seizure at home lasting < 3.3 

minutes that was recorded by the device. After the 

seizure, the patient was pulseless and apneic and did 

not respond to appropriate measures to maintain the 

airway by caregivers. Despite eventual, but prolonged 

resuscitation from pulseless electrical activity as her 

cardiac rhythm, the patient died after 12 hours. EEG 

remained extremely low voltage after the seizure.After 

death, the EEG data saved by the NeuroPace device, 

showed a left hippocampal seizure onset and 80 

seconds of seizure activity that ended by the next EEG 

sample 3.3 minutes later Postmortem findings were 

consistent with hypoxic-ischemic brain injury and the 

seizure of < 3.3 minutes duration was the cause of death. 

Cardiac exam was normal at postmortem. This case 

suggests that even brief seizures can result in death, 

possibly by inducing a cardiac dysfunction and apnea, 

even with witnesses trained in first aid for seizures. In 

this case, asphyxiation, trauma, and prolonged seizure 

did not appear to be primarily responsible for death. 

SUDEP likely has multiple etiologies but in this case, 

the explanation was a typical seizure. 

005 

Startle disease V’s propriospinal myoclonia on 

idiopathic generalized epilepsy (IGE) 

Pepe F 1, Famà F 1, Morrone E 1, Ferrari A 1, Grancelli T 1, 

Morrone C 1, Spizzica F 1, Ferrillo F 1, Striano P 2 

1) S.Martino Hospital Genoa, Italy, 2) U.O. Malattie 

Muscolari E Neurodegenerative Osp. G. Gaslini Genova, 

Italy 

Introduction: Massive myoclonic jerks may be the 

clinical manifestation of various central nervous 

system diseases (such as Startle Disease and 

Propriospinal Myoclonia) and may create differential 

diagnosis problems. 

Method: We report a case of 64 y.o. woman who 

reached our hospital due to known Idiopathic 

Generalized Epilepsy (IGE) treated with valproic 

acid. Her pedigree suggests autosomal dominant 

hineritance of IGE. Since the age of 16, the patient 

presents sporadic tonic-clonic-generalized seizures 

and generalized massive jerks of arms and legs, and 

important photosensitivity without eyelid myoclonia. 

These jerks may be spontaneous in relax, when 

she falls asleep or secondary to sudden 


somatosensorial stimuli. 

Results: Neurological evaluation shows only massive 

hyperekplexia secondary to sudden somatosensorial 

stimuli (acustic and visual). Neurophysiologic studies 

during sleep shows jerks during relax with great sleep 

latency. EEG recordings does not show any correlation 

to these involuntary movements and during deep 

sleep only shows big amplitude generalized sharpwaves 

without clinical manifestations. 

Conclusion: By now, we can confirm the diagnosis of 

IGE, the presence of hyperekplexia on semeiologic 

evaluation of the patient on the oldest sibling of three 

and the presence of clinical manifestation typical of 

propriospinal myoclonia. These particular movements 

disorders in a patient with a diagnosis IGE, 

need a deeper electrophysiological study and 

genetical investigations. 

006 

Application of brief electrical pulses in the primary 

motor and supplementary motor cortex for the 

termination of afterdischarges 

Jobst B, Darcey T, Bujarski K, Thadani V, Roberts D 

Dartmouth-Hitchcock Medical Center,New Hampshire, 

USA 

Purpose: In epilepsy surgery functional mapping of 

intracranial electrodes using standard 50 Hz 5 second 

long pulses is common practice.This frequently causes 

afterdischarges. Some investigators suggested that 

brief electrical countershocks abort afterdischarges. 

Method: We report two patients with intracranial grid 

electrodes implanted both over the primary motor 

cortex and the supplementary motor area (SMA), who 

underwent functional mapping. If afterdischarges 

induced by 5sec stimulation occurred, termination 

with 200-300 ms long pulses at 50 Hz was attempted. 

Results: 20 total episodes of afterdischarges were 

recorded (14 in patient 1, 6 in patient 2). In all cases 

afterdischarges (mean duration 20.5 sec) terminated 

without evolving into clinical seizures.The first stimulus 

was delivered on average 2.9 sec after onset. In 7 of 

the 20 episodes (35%) termination of afterdischarges 

occurred less than one second after the stimulus was 

delivered. In the remaining 14 episodes discharges 

continued for 27.3 sec (4.7 to 48.8 sec) despite 

repeated bursts of stimulation. Four prolonged 

electrographic seizures occurred despite delivering 

early stimuli (time to stimulus delivery 2.5sec). 

Duration of the afterdischarges was independent of 

the time of stimulus application (ANOVA p= 0.87), but 

dependent on the number of electrodes involved at 

the time of the abortive stimulation (ANOVA p



0:30 - 2:00 

Hall 6 



007 

Melatonin administration after the status 

epilepticus induced by pilocarpine experimental 

model: could be a possible way to prevent or 

attenuate the post lesion epilepsy? 

Lima E 1, Cavalheiro E A 2, 

da Graça Naffah-Mazzacoratti M 2, Amado D 2 

1) Universidade De São Paulo - USP, Brazil, 

2) Universidade Federal De São Paulo - UNIFESP, Brazil 

Purpose: The aim of work was to verify the effects of 

treatment with melatonin on the epilepsy model 

induced by pilocarpine. 

Method: The animals were divided in 4 groups: 1 - 

Control animals that received saline (Saline n=13); 2 

- Animals that received pilocarpine and presented SE 

(SE n=21); 3 - Animals treated with N-acetylserotonin 

(9X2,5mg/kg) 30min, 1h, 2h, 4h, 6h, 12h, 24h, 36h and 

48h after the SE (SE+NAS n=6); 4 - Animals treated with 

melatonin (9X2,5mg/kg) 30min, 1h, 2h, 4h, 6h, 12h, 24h, 

36h and 48h after the SE (SE+MEL n=10). The animals 

received pilocarpine (350mg/kg) for epilepsy model 

induction and three behavioral phases were observed: 

SE, silent period and chronic phase. After 48h to SE, the 

animals were continuously video-recorded for 60 days 

to study behavior parameters. After this period the 

animals were killed and the brain sections were Nissl 

and neo-Timm stained. 

Results: The animals of SE+MEL group presented 

a decreased number of spontaneous seizures in 

the chronic period (p


beneficial to counteract cognitive deficits in immature 

rats subjected to SE. 

0 0 

Restraint stress accelerates amygdala kindling 

epileptogenesis in rats 

Salzberg M 1, Lee H E 1, Kumar G 1, Morris M 2, 

Rees S 1, O’Brien T 1, Jones N 1 

1) University of Melbourne, Australia, 2) University of 

New South Wales, Australia 

Purpose: We previously demonstrated that 

corticosterone supplementation, used as a model of 

chronic stress/depression, accelerates epileptogenesis 

in the amygdala kindling rat model of temporal lobe 

epilepsy (TLE). In this study we tested whether an 

actual - as opposed to simulated - stress state also 

affect the development of experimental epilepsy in 

the rat. 

Method:Female Non-Epileptic Control rats 10-13 weeks 

of age were implanted with a bipolar electrode into 

the left amygdala and, following recovery, randomly 

assigned into stressed (n=13) or non-stressed (n=13) 

groups. All rats underwent conventional amygdala 

kindling (2 electrical stimulations per day) until 5 

Class V seizures had been experienced (‘fully kindled’). 

Stressed rats were exposed to 30 minutes restraint 

immediately prior to each kindling stimulation, and 

blood samples taken at appropriate intervals to assess 

stress responsivity. Non-stressed rats received control 

handling prior to stimulation. 

Results: Restraint stress increased circulating 

corticosterone levels in stressed rats (pre-stress: 

122±17 ng/ml; post-stress: 632±33 ng/ml) with 

no habituation to repeated episodes of restraint 

was observed over the experiment. Stressed rats 

reached the fully kindled state in significantly fewer 

stimulations than non-stressed rats (20±1 vs. 30±3 

stimulations; p=0.015; ANOVA). Further, the length of 

each electrographic seizure was significantly longer 

in stressed rats (p=0.001; ANOVA). Conclusion: These 

data demonstrate that chronic stress accelerates the 

vulnerability to limbic epileptogenesis in the rat, an 

effect which may be related to elevated corticosterone 

levels. This chronic stress and depression, common 

co-morbidities of epilepsy, may act to enhance 

vulnerability to initiation and progression of TLE. 

0 

Progressive functional and structural brain changes 

on serial manganese-enhanced MRI acquisition 

following traumatic brain injury in the rat 

Bouilleret V 1, 2, Cardamone L 1, Liu Y 1, Koe A 1, 

Myers D 1, O’Brien T 1 

1) University Of Melbourne, Victoria, Australia, 

2) CHU Bicetre, Paris, France 

Aim:Traumatic brain injury (TBI) has a high incidence of 

long-term morbidity, including epilepsy. Manganeseenhanced 

MRI (MEMRI) provides high contrast 

structural and functional detail of the brain in-vivo. 

The study utilized serial MEMRI scanning in the fluid 

percussion injury (FPI) rat’s model to assess long term 

changes in the brain following TBI. 

Method: Rats underwent a left-sided craniotomy and 

a 3.5 atmosphere FPI pulse (n=23) or sham (n=22). 

MEMRI acquisition was performed at baseline, 1 day, 


1 month and 6 months after FPI/sham injury. Volumes 

changes and MnCl enhancement were measured 

blindly using region-of-interest analysis and the results 

analysed with repeated measures MANOVA. 

Results: Compared to the sham, FPI animals showed a 

progressive decrease in brain volume from 1 (Right p 

=0.02, Left p=0.008) to 6 months (Right p =0.04, Left 

p=0.006) with progression over (F=7.16, p =0.00018). 

Similar changes were found in the cortex. In the 

hippocampus, the injured side was also reduced at 1 

(p < 0.01) and 6 months (p < 0.005) with progression 

over time (F=6.3, p =0.0005). Conversely, the ventricule 

volume was increased in injured animals at 1 (p = 

0.02) and 6 months (p = 0.003), with progression over 

time (F=7.27, p = 0.0001). There were no differences 

in thalamic or amygdale volumes. Differential MnCl 

enhancement occurred only in the dentate gyrus at 1 

month on the side of trauma (p=0.04). 

Conclusion: Progressive functional and structural 

changes may play a role in long-term adverse 

neurological outcomes of head trauma such 

as epilepsy. 

0 2 

Transvascular delivery of siRNAs into the rat brain 

in an animal model of temporal lobe epilepsy 

Pascoal V 1, Marchesini R B 1, Pereira T C 1, Gilioli R 2, 

Cavalheiro E A 3, Lopes-Cendes I 1 

1)UniversityofCampinas;UNICAMP,Campinas,SP,Brazil, 

2) Multidisciplinary Center For Biological Investigation 

(CEMIB); University of Campinas; UNICAMP, Campinas, 

SP, Brazil, 3) Laboratory of Experimental Neurology, 

Department of Pathology Anatomy, Federal University 

of São Paulo; São Paulo, SP, Brazil 

Purpose:We report here for the first time the successful 

use of rabies virus glycoprotein (RVG) complex to 

deliver small interfering RNA (siRNA) molecules into 

the rat brain.We target interleukin-1â (il1-b) gene in an 

animal model of temporal lobe epilepsy (TLE) induced 

by pilocarpine.The aim of our study was to investigate 

the importance of il1-b in the pathophysiology of 

epilepsy in the pilocarpine model. 

Method: siRNAs against rat interleukin-1â (siil-1â) 

were designed using the Strand Analysis program and 

after synthesis were complexed with a short peptide 

derived from RVG, enabling the transvascular delivery 

of siRNAs into the mouse brain (Kumar et al., 2007).The 

complexes (at molar ratio of 10:1 peptide to siRNA) 

were delivered through intravenous injection in the 

caudal vein. 

Results: Transvascular injection of siil-1â promoted 

gene silencing in the rat brain 48hs post-injection 

(p.i.), with higher effects at 72hs p.i. SiRNA injections 

provided a dose-response curve, and the successful 

gene knockdown was achieved in four out of five 

brain regions analyzed. We were able to produce gene 

silencing in both conditions, controls and animals 

subjected to pilocarpine induced status epilepticus. 

Conclusion: We successfully promoted gene silencing 

in the rat brain using a non-invasive transient method 

with RNA interference. We knocked-down the il1b 

gene during the acute phase of the pilocarpine 

model. We are currently observing the knocked-down 

animals into the silent and chronic phases of the 

model in order to evaluate the direct role of il1-b in the 

pathophysiology of TLE. 




6:00 - 7:30 

Hall 2 


Drug therapy 

0 3 

Improvement in health related quality of life in 

epilepsy after withdrawal of carbamazepine in 

seizure-free patients 

Lossius M I 1, Hessen E 2, Gjerstad L 3 

1) National Centre For Epilepsy, Norway, 2) Akershus 

University Hospital, Norway, 3) Division For Clinical 

Neuroscience, Oslo University Hospital, Norway 

Purpose: We have recently reported no significant 

overall effect of double blind withdrawal of 

antiepileptic drugs (AEDs) on health related quality 

of life HRQOL in patients with epilepsy. In this study 

we have performed subgroup analyses looking at 

possible effects of AED withdrawal on HRQOL in 

patients treated with carbamazepine (CBZ). 

Method: The study was randomized and double blind. 

160 patients who had been seizure free on AEDs for 

more than two years were included and randomized 

to withdrawal or not and 150 (80 females, 53 %) 

patients went through the intervention. 91 patients 

on CBZ completed the Quality of life in epilepsy 

89 (QOLIE 89) questionnaire (Norwegian version) 

pre and post withdrawal. and was included in this 

analyses. Student’s t test and chi square test were 

used for testing group differences for continuous 

and categorical variables, respectively. Independent 

t-test was used for comparing mean differences 

of changes between the two groups before and 

after intervention. 

Results: We found in those who withdrew CBZ a 

significant mean increase in score on the QOLIE 89 

compared to those who continued medication (7 vs. 

0,6 p=0.026).We also found significant increase in score 

on the health thermometer in the withdrawal group 

compared to non-withdrawal (7 vs 0,6, p= 0.025). We 

found however no significant increase between the 

groups when using T-score. 

Conclusion: We found a slight improvement in HRQOL 

using raw-scores in the QOLIE 89 after withdrawal of 

CBZ. Indicating a possible negative effect of CBZ on 

HRQOL in some patients. 

0 4 

A meta-analytic comparison of topiramate-related 

adverse drug reactions in epilepsy and migraine 

Carpay J 1, Luykx J 1, 2, Mason M 3, Ferrari M 4 

1) Tergooiziekenhuizen, Blaricum, Netherlands, 

2) University Medical Center, Utrecht, Netherlands, 

3) University of California, Los Angeles (UCLA), CA, 

USA, 4) Leiden University Medical Center, Leiden, 

Netherlands 

To compare topiramate’s adverse drug reactions (ADRs) 

in migraine and epilepsy patients, we systematically 

reviewed all published RCTs comparing topiramate 

monotherapy in epilepsy and migraine. We included 

four epilepsy (N = 1,179 patients; versus active 

comparators) and six migraine RCTs (N = 1,723 patients; 

versus placebo). Behavioral ADRs and headache were 

found only for epilepsy; whereas cognitive complaints 

0 


and alteration of taste only for migraine.The risk ratios 

for paraesthesia in migraine vs. epilepsy trials were 2.5 

(99% CI: 1.66-3.77) for 50 mg, 2.7 (99% CI: 1.80-3.97) 

for 100 mg, and 3.0 (99% CI: 1.95- 4.56) for 200 mg. For 

ADR-related drop outs, the risk ratio was 2.5 (95% CI: 

2.03 - 2.98) for 50 mg, but no different for the other 

doses. We conclude that when treated with the same 

doses of topiramate, migraineurs show different ADRs 

than epilepsy patients, and are more likely to drop-out 

due to ADRs. 

0 5 

Protective effects of brivaracetam in phenytoinresistant 

amygdala-kindled mice: a comparison 

with levetiracetam 

Kaminski R, Matagne A, Klitgaard H 

UCB Pharma S.A., Braine-L’Alleud, Belgium 

Purpose: Brivaracetam, currently in Phase III 

development for epilepsy, is a novel high-affinity 

synaptic vesicle protein 2A (SV2A) ligand with 

inhibitory activity at neuronal voltage-dependent 

sodium channels and displays potent protection 

against amygdala-kindled seizures in rats. The present 

study compares the protective effects of brivaracetam 

to those of levetiracetam (Keppra®) in mouse amygdala 

kindling model that is resistant to phenytoin. 

Method: Male C57BL/6 mice were implanted with a 

bipolar electrode in the amygdala and kindled by once 

daily supra-threshold stimulations. Test compounds 

were injected i.p. in fully kindled mice: brivaracetam 

(6.8-210 mg/kg), levetiracetam (17-540 mg/kg) and 

phenytoin (10-70 mg/kg). 

Results: Brivaracetam produced dose-dependent 

protection against generalized seizures with an ED50 

value of 68.3 mg/kg, while levetiracetam produced 

only 60% protection at the highest dose tested and 

phenytoin was completely ineffective. It is noteworthy 

that complete protection against partial seizures 

was observed in 70% of the animals treated with 

the highest dose of brivaracetam, while none of the 

mice was fully protected after pretreatment with 

maximal doses of either levetiracetam or phenytoin. 

Brivaracetam (134 and 210 mg/kg) significantly 

decreased the afterdischarge duration, while the 

effects of levetiracetam and phenytoin on this 

parameter were less pronounced. 

Conclusion: The present results demonstrate that 

brivaracetam displays significant protection against 

both partial and generalized seizures in amygdalakindled 

mice, which were resistant to phenytoin. The 

superior activity of brivaracetam compared to both 

levetiracetam and phenytoin in this preclinical model 

highlights a promising treatment potential in drugresistant 

epilepsy. 

0 6 

Clinical research in epilepsy is dominated by the 

pharmaceutical industry 

Morrow J 1, Bergin P 2 

1) National Hospital For Neurology and Neurosurgery, 

Queen Square, London, United Kingdom, 2) Auckland 

City Hopsital, Auckland, New Zealand 

Purpose: We wanted to determine what 

proportion of epilepsy drug trials registered on 

the National Institute of Health (NIH) 



website, (http://www.clinicaltrials.gov) are 

investigator-driven, and what proportion are 

sponsored by the pharmaceutical industry. 

Method: We analysed the epilepsy trials registered 

on the NIH website: (http://www.clinicaltrials.gov). 

Results: As of 16th December 2008, 375 trials relating 

to epilepsy had been registered since the NIH website 

was set up in 2000. Pharmaceutical companies have 

sponsored 241 of these trials (64%). 282 trials are drug 

studies,with 213 assessing efficacy (control of seizures) 

as the primary outcome. 126 of these are randomisedcontrolled 

trials (96 double blind, 30 open label). 83% 

(80 of 96) of these double-blind randomised controlled 

trials are sponsored by pharmaceutical companies. 

Only 36 of 213 studies (17%) directly compare antiepileptic 

drugs, and only one examines a combination 

of drugs. Only 42 of 213 studies (20%) have enrolled 

patients with specific epilepsy syndromes. 

Conclusion: Most clinical research of drug treatment 

for epilepsy is driven by the pharmaceutical industry. 

Doctors and patients often want different questions 

addressed. We propose that the epilepsy community 

establish a multi-centre Internet-based research 

programme to facilitate investigator-driven trials. 

Multiple prospective, pragmatic, randomised research 

studies could run in parallel. 

Recruitment, randomisation and data collection 

would be simple and via the internet. Studies would 

focus on patients with specific seizure types, epilepsy 

syndromes or aetiologies. Studies could be either 

double-blind or open.Any neurologist could propose a 

trial, with a steering committee deciding on respective 

merits of different possible trials. 

0 7 

Patterns of drug utilization in patients with 

refractory epilepsy at tertiary referral centres in 

Italy. The SOPHIE study 

Malerba A 1, Canevini M P 2, Ciampa C 3, Franco V 1, 

Frassine B 4, Galimberti C A 5, Gambardella A 6, 

La Neve A 7, Pellacani S 8, Rosati E 9, Tinuper P 10, 

Perucca E 1, 5 

1) University of Pavia, Clinical Pharmacology Unit, 

Pavia, Italy, 2) Epilepsy Center, San Paolo Hospital, 

Milan, Italy, 3) Epilepsy Center, Federico II University, 

Napoli, Italy, 4) Epilepsy Center, C. Poma Hospital, 

Mantova and Department of Pediatrics, University of 

Brescia, Brescia, Italy, 5) Institute of Neurology IRCCS 

C. Mondino Foundation, Pavia, Italy, 6) Institute of 

Neurology, Magna Graecia University, Catanzaro, Italy, 

7) Epilepsy Center, University of Bari, Bari, Italy, 

8) Children’s Hospital A. Meyer, Florence, Italy, 

9) Epilepsy Center, Careggi Hospital, Florence, Italy, 

10) Institute of Neurology, University of Bologna, 

Bologna, Italy 

Purpose:To assess the utilization of antiepileptic drugs 

(AEDs) in patients with refractory epilepsy. 

Method: This work is part of a prospective multicentre 

study aimed at assessing seizure control and adverse 

effects in patients with refractory epilepsy attending 

tertiary referral centres. At enrolment, details about 

demographics and drug treatment are obtained for 

each patient. 

Results: A total of 1,124 patients (933 adults,191 

children) aged 1-86 years were enrolled. Most patients 

had localization-related epilepsy (83.8% of adults 

and 58.1% of children). Polytherapy was used in 741 



(79.4%) adults and 144 (75.4%) children. Among 

patients on polytherapy, 46.4% of adults and 54.2% of 

children received combinations of three or more AEDs. 

New generation AEDs were used in 81.3% of adults 

and 54% of children. Levetiracetam, carbamazepine, 

and lamotrigine (in decreasing order) were the most 

frequently prescribed AEDs in adults. In children, most 

common AEDs were valproic acid, benzodiazepines, 

carbamazepine and topiramate. Phenobarbital was 

prescribed in 17.5% of adults and 20.4% of children, 

usually in polytherapy. Non-AED comedications 

were taken by 31.9% of adults and 16.8% of children. 

Conclusion: Despite the fact that a superiority of 

polytherapy over monotherapy in refractory epilepsy 

has not been proven, the large majority of patients 

at participating centres received combinations 

of AEDs. The high prevalence of complex 

polytherapies involving three or more AEDs is a source 

of particular concern. 

*On behalf of the SOPHIE (Study Of Pharmacoresistance 

In Epilepsy) Study Group. This study was supported by 

a grant from the Italian Drug Agency (AIFA). 

0 8 

Neuroprotective effect of Lamotrigine on hypoxicischemic 

injury in neonatal rat brain 

Eun B L 1, Shin H K 1, Eun S 1, Chung H J 2 

1) Korea University College Of Medicine, Seoul, 

Korea, 2) National Health Insurance Corporation, Ilsan 

Hospital, Goyang-Si, Kyunggi-Do, Korea 

Objective: The antiepileptic drug lamotrigine (LTG) 

is a phenyltriazine derivative that acts by stabilizing 

voltage-sensitive sodium channels in a usagedependent 

manner, preventing glutamate and 

aspartate release and reversibly blocking excitatory 

neurotransmission. We tested whether treatment of 

LTG would be beneficial against hypoxic-ischemic (HI) 

brain injury in postnatal day 7 Sprague-Dawley rats. 

Method: The right common carotid artery of the rat 

was coagulated and the rats were exposed to 8% 

oxygen for 2 hrs. Rats in pre-treatment group (25, 50, 

100 mg/kg/dose, n=52) were received LTG by gavage 

tube immediately before and again after hypoxia, and 

then 12 h interval during 5 days, or equivalent volume 

of saline solution were received by same schedule 

(n=54). Rats in post-treatment group (50, 100 mg/kg/ 

dose, n=35) were received LTG immediately and again 

two hours after hypoxia, and then 12 h interval during 

5 days. The severity of injury was assessed 5 days later 

by visual inspection and by measurement of bilateral 

hemispheric cross sectional areas. 

Results: Pretreatment and post-HI rescue treatment 

with oral administration of LTG resulted in significant 

neuroprotective effect in all doses except 25 mg/kg. 

Quantification of hemispheric areas in rats receiving 

LTG and control littermates confirmed the results of 

initial inspection. 

Conclusion: Treatment with LTG decreases the 

incidence and severity of brain damage in the animal 

model of perinatal cerebral hypoxia-ischemia. These 

data indicate that LTG may offer an effective means 

to decrease the incidence and severity of perinatal HI 

brain injury.



6:00 - 7:30 

Hall 6 



0 9 

Pyramidal cells and interneurons interactions in 

the initiation of ictal discharges in human epileptic 

tissue in vitro 

Huberfeld G 1,2,3, Menendez de la Prida L 1,4, 

Clemenceau S 1,2, Pallud J 1,5, Cohen I 1, 

Le Van Quyen M 6, Baulac M 1,2, Miles R 1 

1) INSERM U 739 ‘Cortex & Epilepsy’, UPMC, CHU Pitie- 

Salpetriere, Paris, France, 2) Epilepsy Unit, UPMC, CHU 

Pitie-Salpetriere, Paris, France, 

3) Neurophysiology Lab, UPMC, CHU Pitie-Salpetriere, 

Paris, France, 4) Laboratorio de circuitos neurales, 

Instituto Cajal Ð CSIC, Madrid, Spain, 

5) Neurosurgery Unit, Hopital Ste Anne, Paris, France, 

6) CNRS UPR640 LENA, UPMC, CHU Pitie-Salpetriere, 

Paris, France 

Compared to tissues from normal rodents, 

postoperativehumanepileptictissueprovidesaunique 

opportunity to study nervous structures rearranged 

by epileptogenesis processes. In vitro, subiculum slices 

obtained after surgery on patients with temporal lobe 

epilepsies associated with hippocampal sclerosis 

retain interictal-like discharges. This activity is 

spontaneous, seems to be initiated by interneurons 

and is sustained by glutamatergic transmission and 

depolarizing actions of GABA. Ictal discharges can be 

generated after exposure to convulsants: combination 

of an increase in excitability with alkalinization or low 

Mg2+ media. The transition from the interictal state 

to the first seizure is characterized by the progressive 

emergence of population events distinct from interictal 

discharges: the pre-ictal discharges. We studied their 

network by extracellular and juxtacellular recordings. 

Their generation site and spread characteristics differ 

and pre-ictal discharges synchronize a larger amount 

of pyramidal cells. Their pharmacology is also specific 

since GABAA receptors blockade suppresses interictal 

but not pre-ictal events. Once established, pre-ictal 

discharges recur and complexify before seizure 

onset. Such dynamic of the initiation of a seizure has 

pharmacological correlates. While pre-ictal discharges 

are glutamatergic they trigger seizures only if GABAA 

signaling is efficient and intracellular recordings show 

a progressive depolarization of GABAergic postsynaptic 

potentials. Specific networks are involved 

in the generation of interictal, pre-ictal events and 

seizure onset. They depend on the differential role 

of pyramidal cells and interneurons and on the 

basal (epileptogenesis) and dynamic (ictogenesis) 

modifications in Cl- homeostasis. 

020 

Differential presence of HHV-6 DNA in hippocampi 

of temporal lobe epilepsy patients with 

distinct etiology 

Niehusmann P, Drexler J F, Bien C G, Grote A, Schoch S, 

Becker A J 

University Of Bonn Medical Center, Bonn, Germany 

Purpose: Temporal lobe epilepsy (TLE) is the most 

common form of focal epilepsy with mesial temporal 

2 


sclerosis (MTS) as major pathological finding. Early age 

of initial precipitating injury is an important predictor 

of hippocampal pathology. Febrile seizures in children 

are frequently associated with human herpesvirus-6 

(HHV-6) infections and more than 95% of children 

older than two years are HHV-6 seropositive.HHV-6 can 

establish lifelong latency in the CNS. A pathogenetic 

relationship of persistent HHV-6 infection and TLE 

has been suggested. Here, we analyzed viral HHV-6 

DNA presence in surgical tissue from well-defined 

subgroups of TLE-patients. 

Method: The subgroups of pharmacoresistant TLEpatientwereclassifiedbyclinicalandneuropathological 

criteria as follows: Complex febrile seizures (n=6), 

history of encephalitis (n=10), idiopathic MTS (n=8), 

lesion-associated (n=10). Temporal autopsy samples 

without a history of neurological disorders served as 

controls (n=10). DNA amplification was performed, 

using specific nested and real time PCR. 

Results: HHV-6 DNA was detected in 50% of specimens 

from patients with a history of encephalitis. In 

contrast, lesion-associated TLE and autopsy-control 

specimens were negative for HHV-6 DNA. Intriguingly, 

in non-lesional MTS (with or without history of febrile 

seizures) our molecular analysis did not detect HHV- 

6 DNA. Conclusion: Our data suggest HHV-6 DNA to 

be present in hippocampal tissue of patients with a 

history of encephalitis but not other TLE subgroups. 

Future efforts will concentrate on the activity level of 

the HHV-6 infection in the affected brain tissue. 

Acknowledgment: Supported by DFG (SFB-TR3; KForG 

‘Innate Immunity’), BMBF (NGFNplus), EU EPICURE 

and BONFOR. 

02 

Olfactory function in patients after temporal lobe 

resection compared to normosmic controls 

Hopp P 1, Henkel S 2, Gerber J 3, Reuner U 3, 

Hallmeyer-Elgner S 3, Lutz M 1, Mayer T 1, 

Schackert G 3, Hummel T 2 

1) Kleinwachau, Saxonian Epilepsy Centre, Radeberg, 

Germany, 2) Smell and Taste Clinic, Medical Faculty 

“Carl Gustav Carus”, Technical University, Dresden, 

Germany, 3) Medical Faculty, ‘Carl Gustav Carus’, 

Technical University, Dresden, Germany 

Purpose: Temporal lobe epilepsy (TLE) is the most 

common focal epilepsy. Epilepsy surgery is an effective 

treatment option for medically refractory cases 

leading to long-term seizure freedom in two thirds of 

patients. Anatomical and electrophysiological findings 

suggest that temporal lobe structures are involved 

in the processing of odour perception. Olfactory 

function of postoperative TLE patients was studied 

and compared with 

age-matched controls. Additionally, we addressed the 

influence of laterality of lesions on odour processing. 

Method: The study population included 22 surgically 

treated TLE patients (12 left and 10 right TLE) and 22 

subjective normosmic controls (age range 20 to 59 

years). Odour-evoked potentials (OEP) were recorded 

in response to lateralised presentation of phenyl 

ethyl alcohol and hydrogen sulfide using a computer 

controlled olfactometer (OM2s; BURGHART, Wedel, 

Germany). Additionally psychophysical olfactory 

testing was performed using ‘Sniffin’ Sticks’ including 

assessment of odour thresholds, odour identification, 

and odour discrimination. 



Results: In patients psychophysical olfactory tests 

demonstrated lateralised dysfunction in accordance 

to the side of lesion (F[1,20]=10.0, p=0.005). OEP 

peak P2 following stimulation with hydrogen sulfide 

were reduced ipsilesionally (F[1,17]=6.73, p=0.019). 

Performance in all psychophysical tests was better in 

controls (F[1,42]=20.0, p5.0, p


channelopathy co-expressed in heart and brain. The 

expression of KCNQ1 channel protein in brainstem 

nuclei of the vagal nerve defines a critical circuit for 

cardiac dysrhythmia within the central autonomic 

pathways. The other LQT ion channels are also 

expressed in brain, suggesting a family of candidate 

genes for SUDEP. These data validate a combined 

clinical and genetic diagnostic strategy to improve risk 

prediction of early mortality in individuals 


Tuesday 30th June 2009 

0:30 - 2:00 

Hall 5 



025 

Characterising the role of brainstem physiology as 

a cause of asystole in seizures 

Pini G 1, Julu P 2, Hansen S 3, Bigoni S 4, Smeets E 5, 

Witt Engerström I 6, Russell A 3, Delamont R 7, 

Apartopoulos F 3, Curfs L 5 

1) Versilia Hospital, Lido Di Camaiore (LU), Italy, 

2) Queen Mary’s School of Medicine University of 

London, London, UK, 3) South Glasgow University 

Hospitals Division,Glasgow,UK,4) Azienda Ospedaliera 

Universitaria Di Ferrara, Ferrara, Italy, 

5) University Hospital Maastricht, Maastricht, The 

Netherlands, 6) Rett Center Östersund Hospital, 

Östersund, Sweden, 7) King’s College Hospital NHS 

Foundation Trust, London, UK 

Purpose:To identify the physiological conditions at the 

time of cardiac asystole during seizures. 

Method: Cortico-bulbar neurophysiology was used to 

monitor physiological dysfunction in patients 1) with 

the neuro-developmental disorder, Rett Syndrome 

(RTT) or 2) with seizure-like events while undergoing 

telemetry studies. The physiological parameters 

include EEG, Heart Rate (HR), real-time Cardiac Vagal 

tone (CVT) and breathing movements. 

Results: We report two different patients with asystole. 

One patient with RTT was a Feeble Breather and 

had brainstem storm during asphyxia, indicated by 

repetitive large fluctuations in CVT. A large increase 

in CVT preceded the asystole. The asystole did not 

affect breathing rhythm. The patient later recovered 

from the asphyxia and blood gases returned to 

normal. There were no brainstem storms at normal 

blood gas levels. In contrast, a 44 year old man with 

a 28 year history of turns treated as seizures had 

three episodes of Abnormal Spontaneous Brainstem 

Activations (ASBAs), the last one caused a sustained 

gamma-rhythm in the CVT leading directly to asystole. 

The ASBAs were associated with excessive sweating 

and nausea. This reproduced his typical attacks and 

there were no epileptiform discharges. Conclusion: 

This is the first time that a brainstem storm and ASBAs 

have been demonstrated to cause asystole. Detailed 

analysis of seizures with assessment of physiological 

function is needed to characterise dysfunction of 

brainstem control seen during seizures and in neurodevelopmental 

disorders and to differentiate between 

cardiac and autonomic causes of asystole. These 

techniques will contribute to an understanding of 

Sudden Unexpected Death in Epilepsy. 

4 


026 

Brainstem autonomic influence on cortical 

epileptiform activity: evidence of music-induced 

vagal suppression of seizure pattern 

Witt Engerström I 1, Julu P 2, Hansen S 3, Delamont R 4, 

Bergström-Isacsson M 1, Smeets E 5, Apartopoulos F 3, Pini 

G 6, Bigoni S 7, Curfs L 5 

1) Rett Center Östersund Hospital, Östersund, Sweden, 

2) Queen Mary’s School of Medicine University of 

London, London, UK, 3) South Glasgow University 

Hospitals Division, Glasgow, UK, 4) King’s College 

Hospital NHS Foundation Trust, London, UK, 

5) University Hospital Maastricht, Maastricht, The 

Netherlands, 6) Versilia Hospital, Lido Di Camaiore (LU), 

Italy, 7) Azienda Ospedaliera Universitaria Di Ferrara, 

Ferrara, Italy 

Purpose:To investigate whether interictal epileptiform 

activities in Rett syndrome were influenced by central 

parasympathetic activity. 

Method: Cortico-bulbar neurophysiology was used 

to monitor both cortical and brainstem activities 

continuously and in real-time in a patient with 

Rett Syndrome (RTT). Music was used to stimulate 

parasympathetic response. The physiological 

parameters recorded included EEG, Cardiac Vagal 

Tone (CVT), Heart rate (HR), breathing movements, 

and Cardiac Sensitivity to Baroreflex (CSB). All 

the physiological parameters were recorded 

simultaneously and time-locked with EEG and 

video images. 

Results: We report a 4-year old patient with RTT who 

has a Feeble Breather cardiorespiratory phenotype. 

She had repeated sub-clinical seizure pattern in the 

EEG for >80% of the autonomic monitoring time (1 

hour). A favourite Pop music tune identified by the 

parents consistently stimulated large parasympathetic 

responses indicated by big increases in both CVT 

and CSB and decreases in HR. A piece of Horn music 

chosen by a music therapist had little effects on 

parasympathetic activity. Seizure patterns in the EEG 

were consistently suppressed during the Pop music 

when CVT levels were high, but resumed immediately 

when CVT fell to low levels after the music.The chosen 

horn music did not affect either CVT or the seizure 

pattern in the EEG. Conclusion: Brainstem autonomic 

activity affects cortical discharges in RTT. Large 

increases in CVT can suppress persistent sub-clinical 

seizure pattern in the EEG. Monitoring physiological 

functions regulated by the brainstem during seizures 

is essential to fully understand the pathophysiology of 

seizure disorders. 

027 

In-phase synchronized gamma oscillations 

precede spike-and-wave complexes in human 

absence seizures 

Kohsaka S 1, Kohsaka M 2, Shiraishi H 1, Saitoh S 1 

1) Hokkaido University School Of Medicine, Sapporo, 

Japan, 2) Sapporo Ishikane Hospital, Sapporo, 

Hokkaido, Japan 

Gamma oscillations (40-100Hz) are considered to play 

a role for binding the neuronal activities between 

remote cortical areas. 3-Hz spike-and-wave complexes 

(SWCs) in childhood absence epilepsy (CAE) are 



the prototype of synchronized seizure activities 

in humans. Here, we investigated the existence of 

gamma oscillations before and during 3-Hz SWCs in a 

case with CAE. 

Method: Five SWCs were recorded, and sampled 

(1.25kHz) in a girl with CAE (Fp1-C3, C3-T3, T3-O1, 

Fp2-C4, C4-T4, T4-O2, C3-Cz and Cz-C4). The EEG 

data were notch-filtered at 50Hz and its harmonic 

frequencies.Five segments (2048 points for a segment) 

were selected so as the last segment to cover the 

first SWCs. 

Results: Wavelet analyses at Fp1-C3 and Fp2-C4, and 

their grand average showed three gamma oscillations 

(around 105Hz, 83Hz and 58Hz) pre- and during the 

SWCs. These gamma oscillations were extracted, and 

the data were subdivided into 512 points. Hilbert 

transform was applied to the extracted gamma 

oscillations. The multiplied product of instantaneous 

amplitude between Fp1-C3 and Fp2-C4 is a measure 

for synchronized oscillations. The data exceeding 

a threshold (> 25microV^2) were selected, and its 

instantaneous phase difference was calculated. 

Synchronized gamma oscillations (around 58Hz) 

increased around 3.3 seconds before the onset 

of SWCs, and the ratio of in-phase oscillations 

also increased. 

Discussion: The preceding, in-phase synchronized, 

gamma oscillations probably bind the wide-spread 

cortical activities before the onset of seizures in 

human CAE. 

028 

Anatomo-functional organization of the 

insular cortex in epileptique humans: study by 

intracerebrale electrical stimulations 

Afif A, Minotti L, Kahane P, Hoffmann D 

INSERM U318; Grenoble University Hospital, BP 217, 

38043 Grenoble Cedex 9, France 

Purpose: Few data exist from human 

electophysiological studies performed in vivo by 

direct electrical stimulation of the insular cortex. The 

determination of clinical signs in the relationship with 

the participation of the insula permits to analysis with 

more accuracy the electro-clinical data. 

Material and Method: We undertook a retrospective 

work concerning the anatomo-functional organization 

of the insula by the intracerebral electrical stimulations 

during explorations Stereo-Electo-Encéphalo-Graphics 

using an oblique approach. 25 patients with epilepsy 

in whom at least one electrode was used to explore 

the insula were selected for this study. Targeting of 

the insular cortex was performed using a 3D cerebral 

presurgical T1- MRI scan computed with stereotactic 

software. a postoperative contrast enhanced 3D CT 

scan was fused with the preoperative 3D MRI in the 

same stereotactic referenced system. We could then 

identify its cortical location and anatomical position in 

reference to gyri. 

Results: Our results were discussed in terms of their 

anatomical and electrical significances. The data 

suggest an organization of the insular cortex in 

terms of the sulci and gyri much more than a simple 

distinction between anterior and posterior insula. We 

have been able to identify the areas in which direct 

electrical stimulation causes of language disorders, 

painful phenomena or sensory-motor responses. For 

the latter, a somatotopy has been identified. 


Conclusion: The large sampling authorized by this 

exploration using an oblique approach allows us to 

develop a first drawing of the anatomo-functional 

insular cortex organization in terms of its sulcal and 

gyral anatomy. 

029 

Apneas associated with temporal lobe seizures are 

dependent on contralateral spread of the seizure: 

results from intracranial EEG recordings 

Seyal M, Bateman L 

University Of California, Davis, USA 

Purpose: We previously showed that ictal hypoxemia 

occurs in one-third of partial onset seizures in patients 

undergoing video-EEG telemetry (VET) (Brain, 

2008,131,3239-3245). Scalp-recorded EEG indicated 

that ictal hypoxemia was more likely with temporal lobe 

seizures (odds ratio (OR)=5.2; 95%CI=(1.665,16.257)), 

contralateral seizure spread (OR=2.591; 

95%CI=(1.112,6.039)) and right-sided onset (OR=2 

.098;95%CI=(1.078,4.085)). Most ictal hypoxemias 

are associated with central apneas. Descending 

limbic pathways to brainstem respiratory centers 

are ipsilateral. Therefore, central apneas may require 

bilateral spread of seizures. To precisely evaluate 

respiratory parameter changes relative to seizure 

onset and spread, we have now studied patients 

undergoing invasive VET. 

Method: Nasal airflow and abdominal excursion data 

was available for 27 of 37 seizures (11 right temporal, 

16 left temporal) lasting 10 seconds or longer in 7 

patients with temporal lobe epilepsy undergoing 

invasive VET. Intracranial recordings included bilateral 

amygdala and hippocampal depth electrodes and/or 

bilateral subtemporal subdural electrodes. 

Results: In 2 patients, 9 seizures of left temporal onset 

remained unilateral without accompanying apneas. 

Apneas occurred in the remaining 7 left temporal 

and 11 right temporal onset seizures concurrent with 

electrographic evidence of contralateral spread. In 4 

right-sidedseizures,apneasstartedbeforecontralateral 

spread. Mean apnea duration was 41 seconds (S.D. 29). 

Oxygen desaturation


Majority of EEG-fMRI reported studies to date have 

been in focal and idiopathic generalized epilepsies, 

but not in secondary generalized epilepsy (SGE), the 

classic example of which is LGS. 

Method: Institutional Ethics Committee approved 

the study for written informed consent. Thirteen 

subjects had continuous EEG-fMRI in a 3T GE magnet. 

Functional images were acquired using multi-slice 

gradient-recalled echo-planar imaging sequences.The 

hemodynamic response to PFA and SSW was estimated 

using SPM2. Results:We recruited 13 subjects with LGS 

with EEG documented tonic or atonic and absence 

seizures. On EEG-fMRI 7 subjects had PFA and 9 had 

GSW. In 7 with PFA cortical BOLD was positive but 

with GSW the BOLD signals were biphasic or positive. 

Subcortical BOLD responses were present in thalamic 

(75%), caudate (75%) and brainstem (67%). 

Conclusion: The epileptiform discharges in LGS are 

associated with 2 robust,and distinguishable networks. 

Tonic seizures associated with paroxysmal fast activity 

predominately showed widespread positive cortical 

BOLD signals whereas generalized slow spike wave, 

associated with ‘atypical absence’, showed widespread 

cortical deactivation and activation. 


0:30 - 2:00 

Hall 6 



03 

2 -24 year follow-up mortality rates from the 

National General Practice Study of Epilepsy 

(NGPSE) 

Neligan A, Bell G, Goodridge D M, Shorvon S D, 

Sander J W 

UCL Institute Of Neurology, DCEE, UK 

The National General Practice Study of Epilepsy 

(NGPSE) was set up in 1984 and is one of the longest 

established epilepsy community-based studies in 

existence.The study has followed up 792 patients with 

definite or possible epilepsy and 220 patients with 

febrile seizures who were enrolled by their General 

Practitioners (GPs). Mortality data in the cohort were 

presented in 19941 and 2001. At seven years of followup 

150 deaths had occurred in those with definite 

or possible epilepsy and the Standardised Mortality 

Ratio(SMR) was 2.5 (95% CI 2.1 to 2.9). The SMR was 

highest in the first year after presentation (SMR 5).At 14 

years of follow-up there were 199 deaths in this cohort 

and the SMR was 2.1 (95% CI 1.8 to 2.4). Current followup, 

after 24 years, shows that 290 people have died; 

additionally, two who presented with febrile seizures 

have also died. On primary analysis, the most frequent 

causes of death included pneumonia, cancer (eg 

brain, breast, lung, and bladder), myocardial infarction 

and stroke. There were few reported epilepsyrelated 

deaths - a further one in addition to the five 

already reported. This study continues to confirm the 

increased premature mortality in people with epilepsy. 

The community basis of the study is important to put 

this risk into perspective as this is often exaggerated in 

hospital-based studies. 

6 


032 

The incidence rate of epilepsy in a rural district 

of Vietnam: a population-based study from the 

EPIBAVI project 

Nguyen Ahn Tuan T 1, Le Quang C 1, Allebeck P 2, Nguyen 

Thi Kim C 1, Persson H 2, Tomson T 2 

1) Hanoi Medical University, Hanoi, Vietnam, 

2) Karolinska Institutet, Stockholm, Sweden 

Purpose:As part of a population-based epidemiological 

project in Vietnam, EPIBAVI, we prospectively studied 

the incidence of epilepsy in people 1 year or older in a 

representative rural region of the country. 

Method: Two separate field surveys were carried out 

utilizing the same methodology three years apart 

(January to December 2005, and January to June 

2008) in the same population of the BaVi District in 

northern Vietnam. On both occasions, members of 

approximately 13 000 households were first screened 

using a WHO screening questionnaire for seizure 

disorders. A clinical examination of all screened 

positive was performed by a neurologist to verify the 

epilepsy diagnosis, and all epilepsy cases were offered 

an EEG. 

Results: On the first survey year 2005, out of 47,269 

screened, 1338 (2.8%) had a positive response to the 

questionnaire. Of these, 20 cases were found to have 

seizure onset within 1 year preceding the screening, 

yielding an epilepsy incidence rate of 42.3 per 100,000 

(95%CI 23.8-60.9). On the second survey in year 2008, 

49,780 people aged 1 year and up were screened, 872 

(1.8%) had a positive response to the questionnaire. 

Of these, 18 cases had seizure onset within 1 year 

preceding the screening. The incidence rate of 

the second screening was 36.2 per 100,000 

(95%CI 19.5-52.4). 

Conclusion: The incidence rate of active epilepsy 

in rural Vietnam in our study was similar at the two 

surveys and comparable to those of recent studies 

in China and India, but lower than in other 

developing countries. 

033 

Survival in epilepsy patients: an year follow 

up study 

Kharazmi E, Fallah M, Peltola J 

Tampere University Hospital,Tampere, Finland 

Purpose: Despite the fact that mortality in epilepsy 

patients is higher than their non-epileptic peers, a 

follow-up study to evaluate the survival in epilepsy 

patients and its determinants is lacking. 

Method: The population-based incident cohort of 

epilepsy patients diagnosed in Tampere University 

Hospital in 1995-2005 (N=549; age at diagnosis: 9- 

87) was used. The follow-up was from diagnosis date 

to their death or last visit. Kaplan-Meier and Cox 

proportional hazard analyses were performed. 

Results: The survival probability in epilepsy patients 

was 97% at one year, 91% at three years, 87% at five 

years, and 64% at eleven years after diagnosis. One 

year seizure free patients had 2.2 times lower mortality 

than patients with continuous seizure [hazard ratio 

(HR) adjusted for age, sex, age at diagnosis, and current 

use of new antiepileptic drugs (AEDs: levetiracetam, 

lamotrigine, topiramate, tiagabine, pregabaline, or 

gabapentin): 0.46, 95% CI: 0.24-0.89]. Older age at 



diagnosis was significantly associated with higher 

mortality (HR adjusted for seizure status, age, sex, and 

use of new AEDs: 1.81, 95% CI: 1.60-2.05). Our data 

did not show any significant association between 

mortality and sex or using new AEDs. In our 11 year 

follow-up study, smoothed hazard estimate curve 

showed highest mortality at 8 years after diagnosis 

(9 years in seizure free patients and 7 years in others). 

Conclusion: Our study shows that about two third 

of epilepsy patients survive in eleven years after 

diagnosis and emphasizes the significance of seizure 

freedom, as a major determinant, on prolonging the 

survival of epilepsy patients. 

034 

Summary of the U.S. National Institute of 

Neurological Disorders and Stroke (NINDS) 

Workshop on SUDEP 

L. So E 1, J. Hirsch L 2, J. Donner E 3, L. Noebels J 4, 

P. Jacobs M 5, R. Buchhalter J 6 

1) Mayo Clinic, Rochester, MN, USA, 2) Columbia 

University, New York, NY, USA, 3) Hospital For Sick 

Children, Toronto, OT, Canada, 4) Baylor University, 

Houston,TX, USA, 5) NINDS, Washington D.C. USA, 

6) Phoenix Children’s Hospital, Phoenix, AZ, USA 

Purpose: To develop directions for basic science and 

clinical research;identify possible preventive strategies 

for SUDEP; investigate when, what, & how to best 

discuss SUDEP with patients and caregivers; design 

methods by which medical and lay communities 

become aware of SUDEP. 

Method:Weinvitednationalandinternationalclinicians, 

researchers,patient advocates,ethics and legal experts 

to participate in the Workshop (November 12 - 14, 

Washington D.C.). Many had no prior work in SUDEP, 

but their expertise offers potentially novel approaches 

to the workshop objectives. Interactive discussions 

were emphasized and lectures were minimized. A 

Research Session and an Education Session were 

concurrently held but subsequently joined to achieve 

overall consensus on the issues discussed. 

Results: Key Research Session recommendations are: 

assess family history for sudden death and conduct EKG 

in all epilepsy patients; explore relevance of risk factors 

of other types of sudden death, including genetics; 

explore respiratory, autonomic and serotonin-related 

mechanisms in animal models and high-risk patients; 

establish a SUDEP registry and central tissue bank. Key 

Education Session recommendations are: determine 

the best method to educate patients, families, and 

medical professionals; develop instrument to assess 

the level of interest of the patient and family to 

learn about SUDEP; develop guidelines on when 

and how to counsel patients and families; develop 

educational materials in different formats for different 

patient populations. 

Conclusion: This unique Workshop offers directions 

for research and education on SUDEP, but much work 

remains to be done to provide the framework towards 

the goal of eliminating SUDEP. 

035 

Epilepsy care and information and communication 

technology (ICT) in Irish general practice: results of 

a national survey 

Varley J 1, Fitzsimmons M 1, Delanty N 1, Collins C 2, 

Boland M 2, Normand C 3 


1) Beaumont Hospital, PO Box 1297, Beaumont 

Rd, Dublin 9, Ireland, 2) Irish College of General 

Practitioners, 4/5 Lincoln Place, Dublin 2, Ireland, 

3) Dept of Health Policy & Management,Trinity College, 

Dublin 2, Ireland 

Epilepsy care should be long term, multidisciplinary 

and integrated across organisational boundaries 

(Hadjikoutis & Smith, 2005). Such integrated care 

frameworks generally encompass a specifically 

designed information exchange system (Smith et al, 

2008). At Beaumont Hospital, the epilepsy programme 

is developing an electronic information exchange 

system (www.epilepsyprogramme.ie). This epilepsy 

specific Electronic Patient Record (EPR) consolidates 

electronically the medical records of people with 

epilepsy (PWE). It is currently accessible to authorised 

personnel within Beaumont Hospital and will become 

available to external users e.g. General Practitioners 

(GPs). To evaluate the impact of the EPR we examined 

the current use of ICT by Irish GPs and their role in 

managing the care of PWE. A total of 247 GPs (35%) 

returned completed postal questionnaires from a 

random sample (n=700) of Irish GPs. Computerization, 

broadband availability and use of GP specific practice 

management software was widely reported (90%). 

However GP software functionality specific to 

chronic disease management appeared underused. 

54% currently link electronically to external ICT 

systems with 93% supporting the concept of linking 

electronically to the epilepsy specific EPR. While 

supporting the concept of epilepsy shared care (96%), 

Irish GPs were highly dissatisfied with current access to 

specialist neurology services. Consequently many GPs 

(75%) refer PWE inappropriately to local Emergency 

Departments. A deficit in GP knowledge regarding 

epilepsy management was acknowledged (39%). 

In conclusion, this survey indicates inadequate and 

fragmented pathways of epilepsy care in Ireland.There 

is an opportunity to exploit ICT to improve continuity 

of care across primary, secondary and tertiary services. 

036 

Interictal electrocardiographic (ECG) abnormalities 

and cardiac morbidity in an adult population 

with difficult to control epilepsy and learning 

disabilities 

Petkar S 1, Masih I 2, Mitchell P 2, Clifford A 1, Homa S 1, 

Forrester C 2, Thomas H 2, Madden P 2, Hammonds G 2, 

Cooper P 2, Fitzpatrick A 1 

1) Manchester Heart Centre, Manchester Royal 

Infirmary, Manchester, UK, 2) David Lewis Centre For 

Epilepsy, Mill Lane, Warford, Alderley Edge, Cheshire, UK 

Purpose: Cardiac arrhythmias are postulated to be a 

mechanism for SUDEP. While studies have analysed 

cardiac rhythm during seizures, little is known about 

interictal ECG findings and cardiac morbidity in 

patients with epilepsy. 

Method: Interictal 12 lead ECG’s performed in adult 

patients with difficult to control epilepsy and learning 

difficulties, resident of an epilepsy centre, between 

2005-2007. Automatic machine reports compared 

with interpretation by tertiary care cardiologists. 

Suitable patients, with abnormal ECG’s, investigated by 

echocardiography and external ECG monitoring. 

Results: n= 214, 136/214 (63.6%) males. Age: 38.1±17.6 

years (median: 33.5, range: 17-83). Duration of epilepsy: 



33.5±17.7 years (median 33, range: 2-73). Comorbid 

conditions: 3.6±3.7 (median: 3, range: 0-40). Number 

of AED’s: 5±2.8 (median: 4, range: 0-15). Satisfactory 

ECG’s obtained in majority: 211/214 (98.6%). All in 

sinus rhythm. No difference (p=ns) in automatically 

vs manually calculated mean heart rate, mean QT/ 

QTc interval. QTc (450 msecs only in 4/214 (1.9%). 

Minority (85/214, 39.7%) ECG’s normal. Most common 

abnormalities: incomplete RBB and non progression 

of R: 17/214 (7.9%) each, ST-T changes: 15/214 (7.0%), 

RVH: 13/214 (6.1%), RBBB and I° heart block: 10/214 

(4.7%) each. External ECG monitoring advised: 23/214 

(10.8%), possible: 12/23 (52.2%). Echocardiogram 

advised: 68/214 (31.8%), possible: 25/68 (36.8%). Echo 

findings: normal: 15/25 (60%), old MI: 3/25 (12.0%), 

LVH 2/25 (8%), hypertrophic cardiomyopathy, ASD, 

mitral regurgitation and constrictive pericarditis: 1/25 

(4%) each. 

Conclusion: One of the first studies to prospectively 

and systematically evaluate epilepsy patients for 

cardiac abnormalities.While majority (60.3%) interictal 

ECG’s abnormal, only a minority had cardiac morbidity 

/ structural heart disease. 


6:00 - 7:30 

Hall 4 



037 

Effects of 532 or 808 nm low-power laser irradiation 

on the paroxysmal discharge threshold in the 

rabbit hippocampus CA 

Kogure S, Saito N, Kozuka K, Tsuchiya K, Kakuno M 

Soka University,Tokyo, Japan 

Purpose: In frog sciatic nerves, Ar+ low-power laser 

irradiation (LLI) blocked the generation of anode break 

excitation, which was consistent with the result when 

applying ZD7288 (Y. Matsuda et al. Lasers Surg Med 

2006;38:608-614). Based on the similar effect between 

an Ih blocker and LLI, we examined the effects of LLI 

(532 nm or 808 nm) on the paroxysmal discharge 

threshold (PADT) in the rabbit hippocampus CA1. 

Method: Sixty-two adult male rabbits were used. A 

pair of concentric electrodes was implanted into the 

CA1 region: the right anterior electrode was used for 

stimulating and LLI. The stimulus train for PAD was 1ms 

pulses of 50 Hz for 1 s. The laser was introduced 

with an optical fiber (125 microampere). We measured 

PADT before and after LLI. 

Results: The averaged PADT was 185(}10 microampere 

(mean} SE; n=24) before LLI. After 10 min LLI (532 nm) 

of 50, 75 and 100 mW, PADT magnitude increased to 

111(}14 (n=8), 138(}19 (n=9, p


electrophysiologically by both whole-cell patch-clamp 

techniques and field recordings, while the frequency 

of STIB was unaltered. Membrane input resistance 

and action potential characteristics 

of individual NpHR expressing cells remained 

unaltered. Reversal potential for IPSCs in the 

transfected cells was also similar to that of the control 

non-transfected cells. 

Discussion: Transgene NpHR light activation 

significantly decreases after-discharge duration in 

both CA1 and CA3 areas of the hippocampus. These 

data suggest that optogenetic cell control has a 

potential for suppressing seizure activity in epilepsy. 

040 

Effectiveness and tolerability of rufinamide in 

children and adults with refractory epilepsy: first 

experience as orphan drug 

Kluger G 1, Kurleman G 2, Haberlandt E 3, Ernst J P 4, 

Runge U 5, Schneider F 5, Makowski C 6, Boor R 7, Bast T 8 

1) BHZ Vogtareuth, Vogtareuth, Germany, 2) UKM, 

Munster, Germany, 3) Medical University Innsbruck, 

Innsbruck, Austria, 4) Epilepsy Centre Kork, Kehl-Kork, 

Germany, 5) Ernst-Moritz-Arndt-University, Greifswald, 

Germany, 6) Ev. Krankenhaus Ko Nigin Elisabeth 

Herzberge, Berlin, Germany, 7) North German Epilepsy 

Centre Raisdorf/Kiel, Schwentinental, Germany, 

8) University Hospital, Heidelberg, Germany 

Purpose: To assess the effectiveness and tolerability 

of rufinamide in a heterogeneous group of patients 

with refractory epilepsies, after rufinamide achieved 

orphan drug status for the adjunctive treatment of 

Lennox-Gastaut syndrome (LGS). 

Method: An open-label, retrospective, noninterventional, 

multicentre study performed in 

Germany and Austria. The clinical course of patients 

treated with rufinamide was documented over an 

observation period of =16 weeks. Effectiveness was 

evaluated by comparing seizure frequency at baseline 

with the last 4-week period of observation. 

Results: The study included 45 children and 15 adults 

(mean age 14.5 ±11.6 years, range 1-50 years) with 

severe, inadequately controlled epilepsy syndromes: 

LGS (n=31), idiopathic generalised epilepsy syndromes 

(n=5), cryptogenic unclassified generalised epilepsy 

(n=7) and partial epilepsy (n=17).Preliminary data after 

16 weeks’ observation showed that 46.7% patients 

(28/60) experienced =50% reduction in seizure 

frequency. Overall, 25.0% patients (15/60) experienced 

=75% reduction; of these, 5 patients (4 with LGS) 

became seizure-free. 21.7% patients (13/60) had a 

seizure reduction of 50-75%.The highest response rate 

was observed in patients with LGS (17/31; 54.8%), the 

lowest in patients with partial epilepsy (4/17, 23.5%). 

Response rate in patients with unclassified generalised 

epilepsy was 42.9% (3/7). In total, 67 adverse events 

(AEs) were reported in 58.3% patients (35/60). The 

most frequently occurring AEs were fatigue (18.3%), 

vomiting (13.3%) and loss of appetite (10.0%). No 

serious AEs were observed. 

Conclusion: Rufinamide may be effective and well 

tolerated in the treatment of children and adults with 

various refractory epilepsy syndromes. 


04 

Vascular endothelial growth factor suppresses 

epileptic activity in mice 

Nikitidou L, Kanter-Schlifke I, Kokaia M 

ExperimentalEpilepsyGroup,WallenbergNeuroscience 

Center, BMC A-11, Lund University Hospital, Sweden 

Purpose: Vascular endothelial growth factor (VEGF) 

is expressed in the brain by neurons and glia and 

it’s proven to have neuroprotective effects in the 

central nervous system. The expression of VEGF is 

increased after seizures to protect cell degeneration. 

This mechanism is thought to be mediated by VEGF 

receptor 2. In this study, we evaluated the effect of the 

overexpression of VEGFR-2 on epileptogenesis and 

seizures. 

Method: Mice with overexpression of VEGFR-2 (n=5) 

and wild-type controls (wt,n=12),were used.Electrodes 

were implanted in the ventral hippocampus, and 

animals were stimulated using a conventional kindling 

protocol. First, we evaluated the threshold at which the 

animals exhibited an EEG afterdischarge with at least 

five seconds duration. Then, the mice were stimulated 

once a day at their threshold until three stage five 

seizures were observed. 

Results: Our results show that animals with 

overexpression of VEGFR-2 had a significantly higher 

initial threshold for seizure induction than the wt 

group (VEGFR-2 60±7.1 µA, wt 30±3.5 µA; p


of SSSE from a dose of 10 mg/kg, with a reduction 

from 998 min in vehicle-treated controls to 50 min 

with BRV 100 mg/kg. When combined with sub-active 

dose of diazepam (1 mg/kg), as little as 0.3 mg/kg 

BRV significantly reduced duration of SSSE. Six weeks 

after SSSE, the number of SRS was dose-dependently 

reduced by BRV and by the BRV-diazepam combination 

(1 mg/kg diazepam, 10 mg/kg BRV). After one year, 

survivors treated with BRV-diazepam combination 

showed >90% reduction of SRS compared to vehicletreated 

controls. 

Conclusion: These data suggest that BRV has 

anticonvulsant and disease-modifying effects 

against refractory SSSE in rats, and that BRV is 

effective at lower doses when combined with 

low-dose diazepam. 


6:00 - 7:30 

Hall 5 



043 

Anterior temporal lobe resection without 

hippocampectomy due to epileptogenic lesion 

in amygdala 

Gyimesi C 1, Pannek H 2, Woermann F 2, Schulz R 2, 

Hoppe M 2, Elsharkawy A 2, Tomka-Hoffmeister M 2, 

Horstmann S 2, Aengenendt J 2, Janszky J 1, Ebner A 2 

1) University of Pécs, Pécs, Hungary, 2) Bethel Epilepsy 

Center, Mara GGmbH, Bielefeld, Germany 

Purpose:To evaluate the clinical data and the results of 

epilepsy surgery in patients who underwent anterior 

temporal lobe resection without hippocampectomy 

due to epileptogenic lesions in amygdala not affecting 

the hippocampus. 

Method: Anterior temporal lobe resection without 

hippocampectomywasperformedinforty-fivepatients 

(mean age at surgery: 30.9±11.6) with epileptogenic 

lesion in amygdala. Presurgical evaluation including 

video-EEG monitoring and high-resolution brain MRI 

was carried out in all patients. 

Results: The 6-month seizure outcome was assessed 

in all patients. All patients had an improvement 

postoperatively: 91.1% of them became seizure-free 

(Engel 1), 6.7% of them became almost seizure-free 

(Engel 2) and 2.2% were non-seizure free but had 

significantly improved seizure outcome (Engel 3). The 

2-year seizure outcome was assessed in 34 patients. 

70.6% of them became seizure-free (Engel 1), 11.8% 

of them became almost seizure-free (Engel 2) and 

14.7% were non-seizure free but had significantly 

improved seizure outcome (Engel 3). Altogether 97.1% 

of all patients had improvement postoperatively. 

Histopathology showed tumors in 19 cases, 

malformations of cortical development in 10 cases and 

cavernomas in 4 cases. 

Conclusion: More than 70% of patients became 

seizure-free postoperatively, which is comparable 

to standard surgical procedures in temporal lobe 

epilepsy. Anterior temporal lobe resection without 

hippocampectomy is an effective surgical therapy in 

patients with epileptogenic lesions in amygdala not 

affecting the hippocampus. 

20 


044 

Predicting outcome following epilepsy surgery 

Baxendale S, Heaney D, Duncan J, McEvoy A 

National Society For Epilepsy, Buckinghamshire, UK 

Background: Since epilepsy surgery is an elective 

procedure, patients need to weigh the risks of the 

procedure against the likely outcome if they are to 

make an informed decision to proceed.The aim of this 

study was to compare the accuracy of multidisciplinary 

team expert review and a logistic regression model, in 

the prediction of postoperative outcome in epilepsy 

surgery candidates. 

Method: An experienced multidisciplinary team 

provided preoperative predictions of postoperative 

outcome in 100 epilepsy patients who subsequently 

proceeded to surgery and were followed up one year 

later. Logistic regression was also used to examine the 

predictive value of demographic and clinical variables 

in predicting postoperative seizure control. 

Results: Team predictions of postoperative outcome 

were accurate for patients judged to have a 30%, 40% 

50% or 60% chance of becoming seizure free. Team 

estimates of odds tended to regress towards the 

mean and were less accurate for patients judged to 

have a very good (>70%) or very poor chance (80%) 

or very poor (


Results: 52 patients were seizure-free or without 

medication two years after surgery. In 36 patients 

the medication was discontinued. 27 patients were 

seizure-free for these years (outcome 1a). Nine 

patients had seizures one year after surgery (6 patients 

were seizure-free after 2 years, 3 patients still have 

seizures). 10 patients stopped AEDs without medical 

advice. 6 patients stopped AEDs within the first 

year and had outcome 1a (follow up 5 to 11 years). 

26 patients being seizure-free 2 years after surgery 

refused to discontinue AEDs. Seizure recurrence 

was unaffected by the duration of postoperative 

AED treatment, the date of discontinuation and the 

pre/postoperative data. 

Conclusion: Discontinuation of AEDs after surgery for 

epilepsy seems to be save. These results are useful 

in counselling patients about discontinuing AED 

treatment after epilepsy surgery. 

046 

High frequency oscillations as markers 

of epileptogenicity - correlation with the 

postsurgical outcome 

Jacobs J, Zijlmans M, Zelmann R, Chatillon C E, 

Hall J, Olivier A, Dubeau F, Gotman J 

Montreal Neurological Institute, Canada 

Purpose: High Frequency Oscillations (HFOs), 

particularly fast ripples (FR,250-500Hz),but also ripples 

(80-250Hz), have been linked to the seizure onset zone 

and are believed to be markers of epileptogenicity. 

We investigated whether HFOs can delineate 

epileptogenic areas even outside the seizure onset 

zone by correlating the resection of HFO-generating 

areas with postsurgical outcome. 

Method: Twenty patients were studied with 

intracerebral EEG (500Hz filter and 2000Hz sampling 

rate),had at least 12-month postsurgical follow-up and 

postsurgical MRI. HFOs were identified visually during 

10 min of slow wave sleep, using high-pass filters at 

80Hz for ripples and 250Hz for FRs. Rates of HFOs in 

resected vs. non-resected areas were compared 

with postsurgical outcome (Engel classification). 

Results: Seven patients had good (Engel 1+2) and 13 

bad (Engel 3+4) outcomes. Mean duration of followup 

was 19 months. Patients with good outcome all 

showed removal of areas with the highest rates of 

FR. In two patients some areas with ripples remained, 

but more than 50% were removed. In the majority 

of patients with bad outcome, large areas with HFO 

remained. In four patients the channels with the 

highest rates were removed, but in all bad-outcome 

patients channels with HFOs remained. 

Conclusion: This study suggests that the removal of 

areas with HFOs is correlated with good postsurgical 

outcome. The predictive value of HFOs cannot be 

estimated by this retrospective study and especially 

for ripples further investigations are needed. 

Nevertheless, HFOs may be an important measure 

of epileptogenicity and allow a better prediction of 

surgical outcome. 

047 

AED outcomes after resective epilepsy surgery: a 

systematic review 

Tellez-Zenteno J 1, Hamiwka L 2, Jette N 2 


1) University Of Saskatchewan, Canada, 2) University of 

Calgary, Canada 

Purpose: To perform a systematic review on postsurgery 

AED outcomes in those with temporal and 

extra-temporal epilepsy 

Method: Inclusion criteria: 20 patients undergoing 

resective epilepsy surgery; quantitative AED outcomes 

reported after surgery; surgery type and number of 

patients per intervention reported. Exclusion criteria: 

duplicate publications, case reports, papers on nonresective 

surgery. Two reviewers independently 

abstracted all data, resolving disagreements 

through discussion. 

Results: Of the 45 articles (including 11 review 

articles) discussing AED outcomes in the original 

RAND literature search, 26 met the final inclusion/ 

exclusion criteria.These 26 articles were fully reviewed 

and included both adults and pediatric subjects. 

After temporal resection, 42% of patients were on 

monotherapy (n=1016), 32% were on polytherapy 

(n=916) while 27% were both seizure and AED free 

(n=2352). In patients after temporal or extratemporal 

epilepsy surgery, the weighted average of patients on 

monotherapy was 36% (n=1080) and on polytherapy 

was 40% (n=1225) at last follow-up. Twenty-seven 

percent of patients were seizure free and completely 

off AEDs (n=3202) at last follow-up. The majority of 

the studies did not outline criteria for weaning or 

discontinuing AEDs. 

Conclusion: Criteria for and methods of weaning or 

discontinuing AEDs are not specified or clearly defined 

in the majority of articles. Overall, 27% of patients are 

AED and seizure free after temporal +/- extratemporal 

surgery. However, similar to what is demonstrated 

in surgical outcomes after epilepsy surgery, early 

AED and seizure free outcome rates tend to decline 

over time. 

048 

Seizure outcome after resective epilepsy surgery: 


Burneo J 1, Tellez-Zenteno J 2, Jette N 3 

1) Epilepsy Programme, University Of Western Ontario, 

Canada, 2) Royal University Hospital, Canada, 

3) University of Calgary, Canada 

Purpose: To perform a systematic review on outcome 

following resective epilepsy surgery. 

Method: Inclusion criteria: 20 patients undergoing 

resective epilepsy surgery; quantitative seizure 

outcome reported after surgery; surgery type and 

number of patients per intervention. Exclusion 

criteria: duplicate publications, case reports, papers 

on non-resective surgical procedures. Two reviewers 

independently abstracted all data, resolving 

disagreements through discussion. 

Results: Three meta-analyses were identified: Engel et 

al: 65% of patients were seizure-free after anteromesial 

temporal resections, with similar seizure freedom 

(63%, 95% CI=60%¨C66%) after 2-5 years of follow-up 

(f/u). McIntosh et al. found variable seizure-free rates 

(33%¨C93%) after TLE resection. Tellez-Zenteno et al. 

found better long term ((5 years) seizure outcome in 

patients operated after 1980 and young patients. We 

identified 76 additional articles (2004-2008) published 

after the latest meta-analysis (n=7784 patients). 18 

focused on TLE surgery (n=1577, f/u 0.5-29.9 years). 



Seizure freedom rates: 69-95.5% at last f/u. One study 

focused on long term f/u (29.9 +/- 4.9 years) with 50% 

of patients seizure free. 22 studies focused on mesial 

TLE surgery (n= 2351 patients, f/u 12-103 months). 

Seizure freedom rate: 41.2-89.6%. Nine studies focused 

on extra-TLE surgery (n=569, f/u=2-16.3 years). Seizure 

freedom rate: 40.7-76%. 27 studies combined TLE and 

extra-TLE surgery (n=3387, f/u 1-10 years). Seizure-free 

rates: 35-83.3%. 

Conclusion: Short term studies report that 60-65% 

of patients are seizure free after temporal resections, 

compared to only 40% after extra-TLE surgery. Longterm 

surgical results were consistently similar to those 

of short-term studies, supporting durability of surgical 

benefits for epilepsy. 

Wednesday st July 2009 

0:30 - 2:00 

Hall 3 


Neuroimaging 

049 

Prediction of postoperative verbal and non-verbal 

memory decline using preoperative memory fMRI 

Duncan J, Bonelli S, Powell R, Yogarajah M, Samson R, 

Focke N, Thompson P, Symms M, Koepp M 

UCL Institute Of Neurology, London, UK 

Purpose: Anterior temporal lobe resections (ATLR) 

for intractable temporal lobe epilepsy (TLE) may be 

complicated by material specific memory impairment, 

typically of verbal memory following left ATLR and 

non-verbal memory following right ATLR. The aim of 

this study was to investigate whether preoperative 

functional MRI (fMRI) may predict memory changes 

following ATLR. 

Method:We scanned 38 patients with unilateral mesial 

TLE (22 left) on a 3T GE-MRI scanner, before ATLR. 

All subjects performed an fMRI memory encoding 

paradigm for words, pictures and faces, testing verbal 

and non-verbal memory in a single scanning session. 

Results: Event-related analysis revealed that in left 

TLE patients, greater left anterior hippocampal 

fMRI activation for encoding words correlated with 

greater postoperative verbal memory decline. In 

right TLE patients, greater right anterior hippocampal 

fMRI activation for encoding faces was predictive 

for greater non-verbal memory decline after ATLR. 

Relatively greater ipsilateral than contralateral 

posterior hippocampal activation predicted better 

verbal memory outcome in left TLE and better nonverbal 

memory outcome in right TLE, following ATLR. 

Conclusion: Preoperative memory fMRI may be a 

useful non-invasive predictor of postoperative verbal 

and non-verbal memory outcome following ATLR. 

Our findings provide evidence for reorganisation 

of hippocampal function within the ipsilateral 

temporal lobe, suggesting that it is the capacity of 

the damaged, ipsilateral hippocampus rather than the 

functional reserve of the contralateral hippocampus 

that determines whether and to which extent a 

decline in verbal or non-verbal memory function will 

be observed. 

22 


050 

EEG-Triggered fMRI and EEG source analyses to 

evaluate anatomical and functional networks in 

Landau Kleffner Syndrome 

Brazzo D 1,2, Pisano T 1, Bill P 3, Thaj J 1, Seri S 1,3 

1) Aston University, Birmingham, UK, 2) IRCCS ‘C. 

Mondino- Pavia, Italy, 3) The Birmingham Children’s 

Hospital NHS Trust, Birmingham, UK 

Purpose: Aim of this study was to determine the brain 

regions showing BOLD signal changes associated with 

inter-ictal EEG epileptic spikes and the relationship 

with the 3D source distribution of the focal EEG 

discharges in three patients with Landau Kleffner 

Syndrome (LKS). 

Method:Three patients with LKS aged 8, 9 and 15 years 

were studied using simultaneous EEG-fMRI acquisition 

at rest and during the presentation of an auditory 

paradigm consisting of a tonal stimulus modulated in 

amplitude and frequency. EEG source analysis on the 

interictal EEG transients recorded from the 21 scalp 

locations of the international 10-20 system during the 

EEG-fMRI session was performed using the distributed 

linear local autoregressive average (LAURA) solution. 

Functional MRI data was analysed using SPM5. 

Results: In the three cases there was a good 

correspondence between hemodynamic changes 

and source localization. We have found a primary 

involvement of the superior temporal gyrus (STG) 

corresponding to primary auditory cortex. An increase 

in BOLD signal during interictal spikes was also 

seen in the lateral frontal cortex and the 

parieto-temporal junction. 

Conclusion: Our findings suggest the anatomical and 

functional background of this epileptic syndrome 

could be related to a more widespread dysfunction 

than that previously hypothesized by MEG and EEG 

studies, involving more complex cortical networks 

and cortical areas. Source analyses from data acquired 

during the simultaneous EEG-fMRI seems to be 

applicable in spite of the limited spatial sample and 

could contribute to the comprehension of the complex 

relationships between bioelectric and hemodynamic 

changes related to interictal spikes. 

05 

Functional connectivity changes in frontalhippocampus 

circuity after withdrawal of 

topiramate in epilepsy patients 

Chen Q 1, Wu X 1, Zhou B 1, Lui S 2, Tang H H 2, 

Gong Q Y 2,3, Shang H 1, Yan B 1, Zhou D 1 

1) West China Hospital Of Sichuan University, China, 

2) Huaxi MR Research Center (HMRRC), Department of 

Radiology, West China Hospital of Sichuan University, 

China, 3) University of Liverpool, UK 

Purpose: Topiramate (TPM) associated language 

dysfunction was reported in about 7.2% patients with 

epilepsy and can be reversible with the dose reduction 

and discontinuation. However, the underlying 

mechanism remains unclear. Our aim was to 

investigate the alteration of brain function in patients 

with epilepsy during a TPM withdrawal procedure by 

using functional MRI (fMRI). 

Method: Six epilepsy patients, who were using TPM as 

add-on treatment and complained about language 

dysfunction, were recruited and placed on a TPM 



withdrawal therapy. A brief neurophsychological 

test battery and functional MRI (a standard verb 

generation task and resting state) on a 3.0T MR scanner 

were assessed before and after TPM withdrawal. Data 

analysis was performed on Matlab 7.0 and SPM2. 

Results: Repeated fMRI with verb generation task 

demonstrated a significant reduced activation in 

the left hippocampus after TPM withdrawal, while 

the scores of verb fluency and digital span were 

significantly improved. The reduced activation in 

left hippocampus was positively correlated with 

the improvement of verb fluency and digital span. 

Functional connectivity involving the left inferior 

frontal gyrus, and left superior temporal gyrus and 

hippocapus networks was attenuated after TPM 

withdrawal therapy. 

Conclusion: Our study firstly provides neuroimaging 

evidence that the alteration of frontal-hippocampus 

circuity was associated with the reversible TPMassociated 

language dysfunction in patients with 

epilepsy. Functional MRI could be a sensitive method 

in monitoring the clinical outcome of anti-epileptic 

drug therapy and can help further investigation of the 

underlying mechanism. 

052 

SPECT perfusion patterns in temporal lobe epilepsy 

- correlation with surgical outcome 

Lakkunta P, Sita Jayalakshmi S, Panigrahi M, 

Prabhakar Rao VV S, Sundaram C, Kaul S 

Nizam’s Instittue Of Medical Sciences, Hyderabad, 

India 

Purpose: To identify ictal and interictal SPECT 

perfusion patterns in patients with refractory mesial 

temporal lobe epilepsy (MTLE) and to correlate with 

surgical outcome. 

Method: A retrospective analysis of ictal and interictal 

SPECT, ictal EEG, MRI and surgical outcome was 

performed in 80 cases of MTLE. The mean tracer 

injection time was 20 seconds.Perfusion patterns were 

classified as typical (anteromedial, anterolateral and 

inferior) and atypical (extended and extra temporal) 

patterns. Surgical outcome was assessed according to 

Engel’s classification. 

Results: Ictal and interictal SPECT was done in 59, 

interictal alone in 21. Pathology revealed hippocampal 

sclerosis in 68, mild neuronal loss in 3, dual pathology 

in 6 and Gliosis in 3 patients.The sensitivity of Ictal and 

interictal SPECT was 92% and 75% respectively. The 

commonest Ictal hyperperfusion pattern was of typical 

(78.75%) with predominant anteromedial and lateral 

hyperperfusion. Interictal SPECT showed predominant 

anteromedial and inferior hypoperfusion. Ictal SPECT 

was diagnostic in 88% with normal MRI. Engel’s class 

1 outcome was noted in 59 (73.75%).Typical perfusion 

pattern was seen in 88% of patients with Engel’s 

class 1 outcome compared to 47% with Engel’s class 

2 and 3 outcome, the difference between the groups 

being significant (Odds ratio 9.717, (CI 2.919 – 32.342), 

p =0.002). 

Conclusion: Ictal SPECT is an important diagnostic tool 

in the presurgical evaluation of medically refractory 

TLE with a sensitivity of 92%.Typical perfusion pattern 

was commonest correlating well with good surgical 

outcome. Ictal SPECT has high sensitivity in TLE 

patients with normal MRI. 


053 

Presurgical evaluation using combined fMRI/EEG 

in temporal lobe epilepsy 

Hauf M, Schindler K, Jann K, Koenig T, Wiest R 

University of Bern, Switzerland 

Purpose: We have applied the Independent 

Component Analysis (ICA)-based EEG/fMRI approach 

to identify regions with altered hemodynamics 

related to interictal epileptic discharges (IEDs) and 

tested the localizing value of ICA based EEG /fMRI in 

the presurgical workup of refractory temporal lobe 

epilepsy (TLE). Method: Eight patients with refractory 

TLE, seven with unilateral mesial temporal sclerosis 

(MTS) and one with focal cortical dysplasia (FCD) were 

examined with EEG/fMRI @ 3 T MR. ICA-based factors 

coding for epileptic activity were convolved with a 

HRF to predict the BOLD signal. The ICA-derived BOLD 

correlates were spatially compared with the seizure 

onset zone as defined by video-EEG, semiinvasive EEG, 

structural MR and FDG-PET. 

Results: In 6 patients BOLD correlates of the EEG/fMRI 

matched the seizure onset zone. One patient without 

structural lesion on MRI,localisation of BOLD correlates 

guided the implantation of depth electrodes. 

Histological workup disclosed a FCD in the area of the 

identified seizure onset zone. In two patients no IED’s 

were present at the recordings thus no further analysis 

was feasible. 

Conclusion: ICA-based EEG/fMRI recordings are a 

non-invasive tool to localize the irritative zone in 

TLE patients. In our current series a concordance of 

the BOLD correlates with the seizure onset zone was 

observed in 75%. The unambiguous localisations are 

promising, especially in regard to non-lesional TLE. 

054 

Abnormal functional hippocampal interconnectivity 

in patients with unilateral mesial TLE 

is worse in left-sided hippocampal seizure focus 

Pereira F 1, Alessio A 1,2, Rondina J 1,2, Pedro T 1, 

Sercheli M 2, Ozelo H 2, Bilevicius E 1, Zibetti M 3, 

Castellano G 2, Covolan R 2, Damasceno B 1, Cendes F 1 

1) University of Campinas - UNICAMP, Cidade 

Universitária, Campinas, SP, Brazil, 2) Neurophysics 

Group, Gleb Wataghin Institute of Physics, University of 

Campinas - UNICAMP, Campinas, SP, Brazil, 

3) Institute of Mathematics, Statistics and Scientific 

Computation, University of Campinas, Cidade 

Universitária, Campinas, SP, Brazil 

Purpose: We investigated functional connectivity 

(fcMRI) of left and right hippocampi in patients with 

unilateral medial temporal lobe epilepsy (MTLE). 

Method: Resting state fMRI-EPI scans were obtained 

in 27 subjects: controls (n=9), patients with right 

MTLE (n=9) and left MTLE (n=9), all with unilateral 

hippocampal atrophy ipsilateral to EEG. All were 

right-handed. Data were reconstructed using Matlab 

routines, SPM5 and temporal bandpass filtered (0.01 < 

f < 0.08 Hz) in AFNI. Hippocampi were masked by AAL 

atlas in order to make left and right seeds for correlation 

across whole-brain time-series. Pearson scores were 

converted to z-values and used for one-sample t-tests. 

Functional maps were used to determine differences 

across groups using two-sample t-tests. Contrasts 

were thresholded at p


Results: Intra-group comparison demonstrated: 

(a) strong connectivity between hippocampi of 

controls but not in patients groups; (b) stronger 

connectivity within hippocampus ipsilateral to the 

seed, being smaller on right hemisphere of controls 

and ipsilateral to EEG focus for patients groups. Intergroup 

comparisons presented two main differences. 

(a) controls had stronger connectivity than patients 

groups for seeds on both hippocampi; (b) patients 

with right MTLE presented stronger connectivity than 

patients with left MTLE for seeds in both hippocampi. 

Conclusion: These findings indicate a disruption 

of functional connectivity between left and right 

hippocampus in patients with MTLE which is 

more affected in patients left MTLE. The abnormal 

epileptogenic plasticity in MTLE appears to differ 

according to hemisphere dominance for language 

and may be related to different cognitive outcomes in 

patients with MTLE. 


0:30 - 2:00 

Hall 4 


Genotype and phenotype 

055 

Clinical spectrum of Ohtahara syndrome caused by 

STXBP mutation 

Kato M 1, Saitsu H 2, Mizuguchi T 2, Osaka H 3, Tohyama J 

4, Uruno K 5, Kumada S 6, Hamada K 7, Nishimura A 2, 

Hirai S 8, Kumada T 9, Fukuda A 9, Ogata K 7, 

Hayasaka K 1, Matsumoto N 2 

1) Yamagata University School Of Medicine, Japan, 

2) Graduate School of Medicine, Yokohama City 

University, Japan, 3) Clinical Research Institute, 

Kanagawa Children’s Medical Center, Japan, 4) Epilepsy 

Center, Nishi-Niigata Chuo National Hospital, Japan, 

5) Epilepsy Center,Yamagata National Hospital, Japan, 

6) Tokyo Metropolitan Neurological Hospital, Japan, 

7) Yokohama City University, Japan, 8) Yokohama City 

University, Japan, 9) Hamamatsu University School of 

Medicine, Japan 

Ohtahara syndrome (OS) is one of the most severe 

and earliest forms of epileptic encephalopathy with 

a characteristic suppression-burst pattern on EEG. 

OS has been believed to be associated with brain 

malformations, while ARX has been found as the first 

responsible gene for OS. STXBP1 (syntaxin-binding 

protein 1), which functions in synaptic vesicle fusion 

and neurotransmitter release,is the second responsible 

gene for OS.We found a microdeletion and 4 missense 

mutations of the STXBP1 gene in 5 patients with OS 

but no brain malformation. All patients with STXBP1 

mutation showed tonic spasms with suppressionburst 

pattern on EEG. No patients had myoclonic 

seizures. The onset of their initial symptoms was from 

4 days to 2 months. Three patients showed subtle 

symptoms like blinking or oral automatism before 

tonic spasms. Suppression-burst on EEG was noted 

from 1 to 3 months. Transition to West syndrome 

started from 3 to 9 months in four patients and TRH 

injection was temporarily effective in 2 patients. Brain 

MRI demonstrated normal in 1, delayed myelination 

in 3, and mild cortical atrophy in 4 patients. All 

patients had profound mental retardation and motor 

disturbance except for 1 patient who could walk by 

24 


himself. One patient had choreo-ballistic movement. 

Patients had variable symptoms, and there were no 

specific findings for OS with STXBP1 mutation. The 

frequency of STXBP1 mutation is high in patients with 

OS, and synaptic dysfunction would constitute the 

pathological mechanism of OS. 

056 

A novel three base-pair, in-frame, LGI deletion 

leading to loss of function in a family with 

autosomal dominant lateral temporal epilepsy and 

migraine-like episodes 

Lesca G 1, de Bellescize J 2, Boutry N 1, Chabrol E 3, 

André-Obadia N 4, Arzimanoglou A 2, Leguern E 3, 

Baulac S 3, Calender A 1, Ryvlin P 2 

1) Service De Génétique Moléculaire Et Clinique, 

Hôpital Edouard Herriot Et CTRS-IDEE, Lyon, France, 2) 

Service Epilepsie,Sommeil,Explorations Fonctionnelles 

Neurolopédiatriques Et CTRS-IDEE, Hôpital Femme- 

Mère-Enfant, Hospices Civils De Lyon, Lyon, France, 3) 

Inserm UMR 679, Groupe Hospitalier Pitié-Salpétrière, 

Paris, France, 4) Service D’Explorations Fonctionnelles 

Neurologiques, Centre Hospitalier Lyon Sud, Lyon, 

France 

Several mutations in the leucine-rich, gliomainactivated 

1 (LGI1) gene that encodes epitempin,have 

been reported in families with autosomal dominant 

lateral temporal epilepsy (ADLTE). In this study, we 

report on a family of five individuals with simple 

partial seizures with auditory and/or visual symptoms. 

Three of the patients also experienced migraine-like 

episodes that occurred upon awakening, long after 

the nocturnal generalized seizures. LGI1 mutation 

screening revealed a novel three base-pair in-frame 

deletion in exon 4, c.377_379delACA. This mutation 

was not found in 192 control chromosomes and results 

in the deletion of an asparagine residue (p.Asn126del) 

in the second leucine-rich repeat. Functional studies 

showed that the mutated protein was not secreted 

when transfected in COS cells, consistent with a 

causative role in the disease. 

057 

Does a SCN A gene mutation confer earlier age 

of onset of febrile seizures in GEFS+? 

Sijben A 1, 2, Sithinamsuwan P 1, Radhakrishnan A 1, 

Badawy R 1, Dibbens L 3, Mazarib A 4, Lev D 5, 

Lerman-Sagie T 5, Straussberg R 6, Berkovic S 1, 

Scheffer I 1, 7 

1) Epilepsy Research Centre, The University of 

Melbourne, Austin Health, Australia, 2) Medisch 

Spectrum Twente, Enschede,The Netherlands, 

3) Women’s and Children’s Hospital, North Adelaide, 

South Australia, Australia, 4) Tel Aviv Sourasky Medical 

Centre,Tel Aviv,Israel,5) Metabolic Neurogenetic Clinic, 

Wolfson Medical Center, Holon, Israel; Department of 

Child Neurology, Israel, 

6) Schneider Children’s Medical Centre of Israel, Petach 

Tikvah, Israel, 7) The University of Melbourne, Royal 

Children’s Hospital, Melbourne, Australia 

Purpose: SCN1A is the most clinically relevant epilepsy 

gene and is associated with GEFS+ and Dravet 

syndrome. We postulated that earlier onset of febrile 

seizures in the Febrile Seizure and Febrile Seizures Plus 

phenotypes may occur in the presence of a SCN1A 



mutation. This was because of the age-related onset 

of Dravet syndrome which typically begins in the first 

year of life. 

Method: Patients with a pure phenotype of FS or FS+ 

and a known mutation of major effect who presented 

initially with a febrile seizure were included from both 

our families and literature review. We searched for the 

median age of onset of each mutation and compared 

with the population median. 

Results: A total of 92 patients were identified with 

SCN1A, SCN1B or GABRG2 mutations (62 and 30 

affected individuals from our series and literature 

review respectively). We found that patients with FS 

and FS+ with SCN1A mutations had earlier median 

onset of febrile seizures compared to the population 

median. Patients with GABRG2 mutations had a 

similar early onset in contrast to patients with SCN1B 

mutations where onset was later. 

Conclusion:This study is the first to demonstrate that a 

specific genetic abnormality directly influences the FS 

and FS+ phenotype in terms of age of onset. 

058 

Mesial temporal lobe epilepsy has differential 

gene expression pattern in familial and 

sporadic forms 

Maurer-Morelli C, Rocha C, Domingues R, Tedeschi H, 

De Oliveira E, Cendes F, Lopes-Cendes I 

Faculty of Medical Sciences, University of Campinas, 

Campinas, SP, Brazil 

Purpose: The aim of this study was to investigate gene 

expression profile in hippocampal tissue from patients 

with pharmacoresistant mesial temporal lobe epilepsy 

(MTLE) in familial and sporadic forms. 

Method: Eight surgical specimens were obtained 

from patients with MTLE (n=4 familial MTLE and 

n=4 sporadic MTLE), as well as control tissue (n=3) 

from autopsy. This study was performed using the 

Human Genome U133 Plus 2.0 array (Affymetrix). 

We used 5 µg of total RNA in the One-Cycle Target 

Labeling protocol (Affymetrix). Data was acquired by 

GeneChip Scanner 3000 (Affymetrix) and analyzed 

using DNA-Chip Analyzer (dChip). Statistical analysis 

was performed by t-test with p(0.01 for a significant 

difference between groups. 

Results: We found 101 genes which were differentially 

expressed (up and down regulated) in samples from 

all patients with MTLE (familial+sporadic forms) as 

compared to controls; 35 genes were differentially 

expressed when we compared controls and patients 

with familial MTLE and 64 genes were different 

between controls and patients with sporadic MTLE. In 

addition, we identified a significant difference in gene 

expression profile (191 genes up and down regulated) 

in samples from patients with familial and sporadic 

MTLE such as GRINA, NKTR, SCN2B, RIMS3, GABRB3 

and KCTD16. 

Conclusion: This is the first study using microarray 

in MTLE with HS to explore the differential gene 

expression between familial and sporadic forms of 

MTLE. Our results clearly show that, although similar 

in the clinical, imaging and neuropathologic features, 

familial and sporadic forms of MTLE have distinct 

molecular signatures. 

Supported by FAPESP and CNPq 


059 

STXBP mutation screening in a cohort of patients 

with early onset epileptic encephalopathies 

Weckhuysen S 1, 2, 3, 4, Deprez L 2, 3, 4, Holmgren P 2, 3, 4, 

Verhaert K 6, 8, An J 5, Lagae L 7, 8, Van Paesschen W 7, 

Jordanova A 2, 3, 4, Ceulemans B 6, 8, De Jonghe P 2, 3, 4, 6 

1) Epilepsy Centre Kempenhaeghe, Oosterhout, The 

Netherlands, 2) Department of Molecular Genetics, VIB, 

Antwerpen,Belgium,3) University of Antwerp,Antwerpen, 

Belgium, 4) Institute Born-Bunge, Antwerpen, Belgium, 

5) University Hospital of Brussels, Brussel, Belgium, 6) 

University Hospital of Antwerp, Antwerpen, Belgium, 7) 

University Hospital Gasthuisberg, Katholieke Universiteit 

Leuven, Leuven, Belgium, 8) Revalidatiecentrum 

Pulderbos, Pulderbos, Belgium 

Purpose: Recently STXBP1 mutations have been 

identified in Ohtahara-syndrome. This devastating 

disease is characterized by neonatal onset, intractable 

seizures and a burst-suppression pattern on EEG. 

We aimed to delineate the spectrum of clinical 

syndromes associated with STXBP1 mutations by 

analyzing a cohort of patients with early-onset 

epileptic encephalopathies. 

Method: Twelve patients with Ohtahara syndrome, 

18 with West syndrome, 27 with Lennox Gastaut 

syndrome, 1 with Early Myoclonic Encephalopathy, 

and 18 with an undefined neonatal epileptic 

encephalopathy were screened for mutations by 

performing sequence analysis of exons and intronexon 

boundaries in STXBP1. 

Results: Three novel mutations were found: the 

frameshift mutation c.893-894delAG, the nonsense 

mutation c.1434G>A, and the splice site mutation 

c.1029+1G>T. The c.1434G>A and c.1029+1G>T 

mutations are proven de novo mutations. No parental 

DNA was available for the frameshift mutation. All 

three mutations were predicted to cause loss of 

function. The three patients had seizure onset in 

the first weeks of life. Two patients presented with 

myoclonic seizures, one with spasms. None of them 

had a burst-suppression pattern on EEG. In one patient 

myoclonic seizures were easily controlled with antiepileptic 

drugs. At last follow-up he is seizure-free but 

mentally retarded and ataxic. The two other patients 

evolved into West syndrome. At last follow-up both are 

mentally retarded and wheelchair bound. One of them 

has daily intractable seizures, the other is seizure free. 

Conclusion:In this study we demonstrated that STXBP1 

mutations are not only found in Ohtahara syndrome 

but are present in a broad spectrum of early-onset 

epileptic encephalopathies. 

060 

Partial epilepsy with auditory features: clinical and 

genetic features of 20 sporadic cases 

Bisulli F 1, Stipa C 1, Pittau F 1, Capanelli D 1, 

Licchetta L 1, Naldi I 1, Striano P 2, Striano S 2, 

Michelucci R 3, Nobile C 4, Tinuper P 1 

1) University of Bologna, Bologna, Italy, 2) University 

Federico II, Naples, Italy, 3) Bellaria Hospital, Bologna, 

Italy, 4) University of Padua, Italy 

Purpose: In 2004 we described 53 cases of partial 

epilepsy with auditory features (PEAF) and a good 

clinical outcome.The syndrome was named Idiopathic 

Partial Epilepsy with Auditory Features (IPEAF). Since 



2004 we have observed 67 additional cases and the 

present study summarizes the clinical features of this 

group of 120 patients (60 females and 60 males). 

Method: Patients were selected according to the 

following criteria: partial epilepsy with auditory 

symptoms, negative family history for epilepsy and 

absence of cerebral lesions. All patients underwent a 

full clinical, neuroradiological and neurophysiological 

examination. Forty-three patients were screened 

for LGI1 mutations observed in more than half of 

the familial cases with autosomal dominant partial 

epilepsy with auditory features (ADPEAF). 

Results: Age at onset ranged from 3 to 57 years (mean 

20.5 years). Secondarily generalized seizures were 

the most common type of seizures at onset (70%). 

Auditory auras occurred either in isolation (34%) or 

associated with visual, psychic or aphasic symptoms 

(66%). Low seizure frequency at onset and good drug 

response were common, with 47% of patients seizurefree. 

Seizures tended to recur after drug withdrawal. 

We observed a de novo mutation in LGI1 gene in only 

one patient of the 43 tested. 

Conclusion: Our data confirm the existence of a 

peculiar form of non-lesional temporal lobe epilepsy, 

closely related to ADPEAF, in which auditory aura 

could represent a clinical marker of benign outcome 

in the majority of patients. Although LGI1 mutations 

have been found in only 2.3%, another gene could 

be involved. 


6:00 - 7:30 

Hall 2 



06 

Isprognosisofepilepsypredictableinmalformations 

of cortical development? 

Jovic N 

Clinic for neurology and psychiatry for children and 

youth, Serbia and Montenegro 

Malformations of cortical development (MCD) are 

often recognized as underlying etiology for intractable 

seizures in children. Early prediction of unfavorable 

clinical course are challenge in their management. 

A Group of 244 children and adolescents aged 0.5 

to 17 years with MCD was prospectively studied 

(3.5-10 years) for clinical course, prognosis and 

seizure control. Various MCD were disclosed by MRI 

techniques and classified (Barkovich, Brain Dev 

2002;24:2-12; Palmini et al. Neurology 2004;62:S2-8). 

Seizures occurred in 182(74.6%) MCD patients with 

mean seizure onset of 4.1 years. Mental retardation 

was found in 62.3% of children. Generalized epileptic 

syndromes were diagnosed in 69, partial epilepsies 

in 113 patients. Epileptic status occurred in 18.4% 

epileptics. Pharmacoresistent seizures occurred in 

44.5% patients (Group A). Complete long-term seizure 

control was achieved in 17.6%, till >50% seizure 

reduction was noted in 37.5% (Group B). MCD with 

multilobar/diffuse involvement, were more often 

associated with intractable epilepsy in comparison 

with unilobar affection. Seizure onset was significantly 

earlier in Group A (mean 2.1 yrs) when compared with 

Group B (6.9 yrs). Infantile spasms occurred in 13.7% 

of children with later pharmacorestance vs. 4.4% of 

26 


children from Group B. Favourable initial therapeutic 

response was significantly higher in a Group B (61/101) 

vs. Group A (23/81). Pharmacoresistant seizures were 

often associated with mental retardation, sensory 

impairment and multifocal/bilateral EEG abnormalities 

camparing with well-controlled patients. Early seizures 

onset, history of infantile spasms, poor response 

to initial treatment, multilobar/bilateral MCD and 

early development of severe clinical condition were 

identified as main predictors of seizure intractability. 

062 

Prevalence of epilepsy in children with emphasis 

on etiology: a population based study in a Brazilian 

area of high deprivation 

Pereira De Brito Sampaio L 1, Caboclo L O 1, 

Kuramoto K 1, Reche A 1, Yacubian E 2, 

Giraldes de Manreza M L 3 

1) Hospital Israelita Albert Einstein, Sao Paulo, Brazil, 2) 

UNIFESP, Sao Paulo, Brazil, 3) Hospital Das Clinicas Da 

FMUSP, Sao Paulo, Brazil 

Purpose: The aim of this study was to assess the 

prevalence rate of epilepsy and its causes in children 

and adolescents under the age of 16 years in a area 

of high deprivation in São Paulo city, São Paulo state, 

Southeast of Brazil. 

Method: Between July 2005 and June 2006, 4947 

families from a total population of 22013 inhabitants, 

of which 10405 were children and adolescents 

between the ages of 0 and 16 years living in 

Paraisópolis Community were interviewed. In the first 

phase a validated questionnaire was applied in order 

to identify the occurrence of seizures in children. 

In the second phase, clinical history, neurological 

examination, electroencephalogram and structural 

neuroimaging were performed for confirmation of 

epilepsy. The diagnosis of epilepsy, including etiology, 

seizure and epileptic syndrome classification was 

established according to criteria proposed by the 

International League Against Epilepsy (ILAE)(1993, 

1981, 1989). 

Results: The screening phase identified 353 

presumptive cases. In the second phase, 101 (33.8%) 

subjects received the diagnosis of epilepsy (51.5% 

female). Crude prevalence of epilepsy was 9.7/1000 

and prevalence of active epilepsy was 8.7/1000. Partial 

seizures were the most frequent seizure type (61.4%). 

Conclusion: Symptomatic focal epilepsy was the most 

common form, and hypoxic-ischemic encephalopathy 

the most common etiology, reflecting the socioeconomic 

conditions of this specific population. 

This result indicates that adequate public policies 

regarding perinatal assistance could help reducing the 

prevalence rate of epilepsy. 

063 

MEG identification of epileptic focus in children 

with generalized EEG abnormalities but focal 

imaging abnormalities 

Shukla G, Gupta A, Jin K, Mosher J, Jones S, Burgess R 

Cleveland Clinic, Cleveland, Ohio, USA 

Purpose: Children with generalized seizures are 

generally not good surgical candidates. This 

prospective study was conducted to a) refine the 

location of the ‘irritative zone’ using MEG in children 



with single lesions on MRI but with generalized 

ictal EEG findings, b) assess MEG’s convenience in 

young children. 

Method: Patients admitted with refractory epilepsy, 

imaging studies showing focal or hemispheric 

abnormalities, and EEG showing generalized or multiregional 

abnormalities were included. Patients were 

encouraged into natural sleep and simultaneous 

whole-head MEG/EEG was recorded. Sourcelocalization 

of epileptic spikes on MEG was carried out 

while blinded to other results.Acceptable dipoles were 

classified into focal, hemispheric clusters, single focal 

cluster with additional widespread dipoles. 

Results: Seven patients (3 female, 4 males; ages 

10 months to15 years) were included. Two had 

focal features on clinical semiology, while all had 

generalized or multi-regional interictal and ictal EEG. 

Etiologies included TS (2), post-encephalitic sequelae 

(1), FCD (1), unknown (2). Five patients had clear focal 

lesions on brain MRI while the other 2 had focal PET 

abnormalities. An average of 38 spikes were accepted 

(avg gof = 85.3%). A single tight cluster of dipoles 

was identified in 5 patients, one had dipoles with 

propagation from left occipital to right temporal. One 

patient had 2 distinct dipole clusters. 

Conclusion: This study demonstrates the convenience 

of MEG recording in pediatric patients without 

sedation. It also suggests that neurophysiologic 

evidence of focal abnormalities in patients with focal 

brain lesions and generalized EEG findings can be 

strengthened using MEG. 

064 

Risk of subsequent non-febrile seizure in Korean 

children who experienced first provoked seizure 

with fever over 6 years of age: preliminary report 

H Kim S 1, J Seol I 2 

Ajou University Medical Center, Korea, 2) Hanyang 

University Medical Center, Korea 

Purpose: To evaluate the risk of subsequent nonfebrile 

seizure (SNFS) and risk factors in children who 

experienced a first provoked seizure with fever over 6 

years of age. 

Method: From January 2002, 31 children who 

experienced seizure with fever over 6 years of age 

were enrolled, and followed prospectively to October 

2008. Children who had a first seizure with fever due 

to clinical evidence of CNS infection were excluded 

from this study. According to the presence of personal 

history (PHx) of febrile seizure (FS), study population 

was classified into two group (Group I: patients with 

a first provoked seizure with fever and without PHx 

of FS, n=15, Group II: patients with provoked seizure 

with fever and with PHx of FS, n=16). Risk of SNFS 

was analyzed by Kaplan-Meier analysis and potential 

risk factors were analyzed by Cox proportional 

hazard model. 

Results: 7 (22.6%) children experience SNFS within 

mean period, 13 months after their first provoked 

seizure. The cumulative probability of SNFS was 6.5%, 

12.9%,16.1%, 19.4%, and 22.6% at 6, 12, 18, 24, and 36 

months, respectively.There is no statistically significant 

difference of the risk of SNFS between group I and 

group II (Odd Ratio:2.955, 95% CI:0.476~18.342, 

p=0.629). There is no other statistically significant risk 

factors to predict SNFS. 

Conclusion: Risk of SNFS in children who had a first 


provoked seizure with fever over 6 years of age and 

without a personal history of FS is not different from 

those who had a personal history of FS. 

065 

Efficacy of a three day treatment protocol with oral 

Pyridoxine in children with West syndrome 

Haas-Lude K 1, Kratzer W 2, Krägeloh-Mann I 1, 

Wolff M 1 

1) University Children’s Hospital D-72076 Tübingen, 

Germany, 2) Hospital Konstanz, Germany 

Purpose: Pyridoxine-HCL (vitamin B6) has been 

proposed as an alternative treatment option in 

children with West syndrome (WS). In several studies 

using different treatment protocols, response rates 

between 0 and 30% were reported. Because of these 

inconsistent results, current guidelines actually do not 

recommend this treatment option. During the last 

years, we identified 2 children with West syndrome 

who showed a partial response to a single dose B6 

iv. Pyridoxine dependent seizures could be excluded. 

Both children get seizure free when B6 doses were 

increased. Therefore, we established a standardized 

treatment protocol using B6 in children with WS. 

Method: 25 children of our department diagnosed 

with WS were treated with 3 x 300mg/day pyridoxine- 

HCl (vitamin B6) for at least three days. If at least a 

partial response occurred, treatment was prolonged. 

Results: In five children with WS (symptomatic origin 

N=2, cryptogenic N=3) seizures improved markedly 

within three days and disappeared some days later 

as well as Hypsarrhythmia in the EEG. No serious side 

effects were noted. Pyridoxine dependent seizures 

were excluded in all cases. 

Conclusion:B6 was effective in 20% of the children with 

WS.Considering the short time lag to response and the 

excellent tolerability this treatment protocol can be 

recommended as first line therapy.The application of a 

single dose B6 iv is not useful, 

since neither Pyridoxine dependent seizures nor a 

possible pharmacological effect can be excluded by 

this procedure. 

066 

Head or heart: a diagnostic dilemma 

Agrawal S, Philip S 

Birmingham Children’s Hospital, UK 

Purpose: We report an unusual case of recurrent 

cardiac asystole secondary to a complete heart block 

manifesting with a semiology akin to epileptic seizures 

and an abnormal electroencephalogram (EEG), who 

after failing several antiepileptic drugs responded 

to a cardiac pacemaker when the diagnosis was 

established. 

Method: Case note and literature review. 

Description: A previously healthy girl presented at the 

age of three years with a history of frequent unusual 

episodes. During the attacks she would stare for 15- 

20 seconds and be unresponsive to vocal or tactile 

stimuli though partially conscious. She also had 

episodes where she would scream, head would lean 

leftwards with chewing movements accompanied 

by stiffening of arms and legs resulting in a fall to the 

ground. The neurological examination was normal. 

Sleep EEG revealed a single burst of sharp activity 



over the right temporal region followed by slowing. 

Subsequent ambulatory EEG revealed several clinical 

episodes accompanied by EEG changes as above with 

generalised slowing. She was tried on carbamazepine, 

lamotrigine, valproic acid and clobazam with no effect. 

Repeat ambulatory EEG revealed similar picture as 

above but all the attacks were noted to have associated 

bradycardia. A prolonged EEG with electrocardiogram 

(ECG) and video monitoring revealed several episodes 

of cardiac asystole associated with the events. An 

urgent trans-venous pacemaker completely abolished 

the attacks. A literature review and the video will 

be presented. 

Conclusion: This case reiterates the importance of 

diagnosis of epilepsy before treatment. A correct 

diagnosis in the beginning would avoid unnecessary 

treatment and consequent adverse effects. 


6:00 - 7:30 

Hall 5 



067 

Evidence for idiosyncratic and dose-dependent 

effects of Topiramate on verbal fluency 

Witt J A, Elger C E, Helmstaedter C 

University Hospital Of Bonn, Germany 

Purpose: To evaluate the impact of dosage and drug 

load of topiramate (TPM) mono- and polytherapy on 

verbal fluency. 

Method: This retrospective study assessed phonemic 

word fluency in TPM-treated patients as being 

representative for executive functions. To disentangle 

TPM-induced effects from impacts of epilepsy and 

overall drug load, written verbal fluency under TPM 

(N=422) was compared to the performance of random 

sample of patients with other antiepileptic drugs 

(AED) (N=501),untreated patients (N=108),and normal 

controls (N=389). 

Results: Impaired performance (1.5 standard 

deviations below the average performance of the 

healthy controls) was indicated in 86% of the patients 

taking TPM versus 58% of the patients with another 

antiepileptic medication than TPM, or 29% of the 

untreated patients. Correlations between daily dosage 

of TPM and verbal fluency performance were obtained 

with an intake of TPM as monotherapy (r=-0.51) or 

when combined with one additional AED (r=-0.32), but 

not in polytherapies comprising more than two AED. 

Conclusions: The data of the evaluated cohorts 

indicate a negative effect of the epilepsy and of the 

anticonvulsive treatment on verbal fluency. TPM 

significantly adds to this when given in monotherapy 

and further impairment becomes evident with 

each additional anticonvulsive agent within the 

AED regimen. Compared to other AED the relative 

risk of an impaired verbal fluency performance under 

TPM was 1.5 (odds ratio: 4.3). The results thus indicate 

idiosyncratic and dose dependent effects of the 

treatment with TPM on executive functions which may 

demand strict monitoring in the individual patient. 

28 


068 

Neuropsychological outcome in adults with 

intractable epilepsy after hemispherectomy 

Le N M 1, Busch R 1, Jehi L 1, Alexopoulos A 1, 

Kalman C 1, Loddenkemper T 2 

1) Cleveland Clinic, USA, 2) Children’s Hospital Boston, 

USA 

Intro: Hemispherectomy is rarely performed in adult 

patients with intractable epilepsy. Its cognitive 

outcomes remain unexamined. 

Method: We retrospectively reviewed adult patients 

who underwent hemispherectomy at Cleveland 

Clinic from 1995-2007. Variables included pre 

and postoperative clinical data and select 

neuropsychological test scores. Reliable change 

indices and standardized regression based norms (90% 

confidence interval) were used to define meaningful 

changes in intelligence and memory indices 

following surgery. 

Results: Of 810 adults undergoing epilepsy surgery, 

five patients underwent functional hemispherectomy 

and had complete pre and postoperative 

neuropsychological data. All were seizure-free at last 

follow-up (mean 28.6 months). Average postoperative 

testing time was 9.8 months (range 6-18 months). 

Consistent with left-sided resection, one patient 

declined on measures of verbal comprehension, 

auditory immediate memory, and naming, but also 

on measures of visual memory. Another patient (right) 

had expected declines on measures of perceptual 

organization and visual memory and posted 

improvements in naming.Two other patients (one left, 

one right) did not demonstrate significant changes on 

the cognitive measures examined, and the remaining 

patient (right) improved on measures of verbal 

comprehension and verbal immediate memory. The 

two patients with score declines had intact (average or 

better) cognitive functioning at baseline. Patients did 

not differ on demographic or seizure variables. 

Conclusion: Despite small numbers due to infrequency 

of hemispherectomies performed (0.6% of adult 

epilepsy surgeries), this is the first study describing 

neuropsychological outcome on adults undergoing 

hemispherectomy. Results are mixed, but suggest 

that patients with intact cognitive functioning are at 

greatest risk for decline following hemispherectomy. 

069 

Executive functions of patients treated with stable 

dose of topiramate measured by Wisconsin Card 

Sorting Test 

Sokic D 1, Ristic A 1, Salak-Djokic B 1, Milosevic N 2, 

Trajkovic G 3, Bascarevic V 4, Vojvodic N 1, 

Jankovic S 1, Zovic L 1 

1) Institute Of Neurology CCS, Belgrade, Serbia, 

2) Medical School In Kosovska Mitrovica, Serbia, 

3) Institute of Statistics and Informatics, Medical 

School, Belgrade, Serbia, 4) Institute of Neurosurgery 

CCS, Belgrade, Serbia 

Objective: To investigate cognitive side effects 

(CSE) of topiramate (TPM) treatment with 

emphasize on executive functions measured by 

Wisconsin Card Sorting Test (WCST) in patients with 

pharmacoresistant epilepsy. 

Method: In 46 prospectively recruited, TPM naive 



patients with cryptogenic or symptomatic focal 

epilepsy, neuropsychological investigation included 

memory, attention, concentration, executive functions, 

visuo-constructional abilities, and language were 

performed. After 6 months of therapy (77% in 

polytherapy) with 200 mg of TPM all applied tests were 

repeated except brain MRI. 

Results: In 40 patients (female 24; mean age 41±14.1) 

available on retest significant worsening of scores on 

WCST (perseverative responses) (p=0.009), as well as 

tests for fluency,attention,concentration,memory,and 

visio-constructional abilities were registered. Lesional 

brain MRI (47%) did not change scores for executive 

functions on retests. 

Conclusion: Our findings recommend screening of 

the executive functions by WCST with emphasis on 

perseverative answers, attention and working memory 

in order to detect even subtle but clinically significant 

CSE of TPM. 

070 

Language and executive functions in medial 


Borbély C 

National Institute Of Neurosurgery, Budapest, Hungary 

Purpose: The current study aimed to clarify the role of 

medial temporal lobe (MTL) pathology in language 

and executive functions, and to examine the impact 

of lesion side and seizure characteristics (age at onset 

and duration) on these functions. 

Method: We studied 59, right handed patients with 

unilateral MTLE (38 left, 21 right) with no significant 

differences in demographics between the left 

and right groups. Neuropsychological evaluation 

included: Boston Naming Test (BNT), Controlled Oral 

Word Association Test (COWAT), Verbal Fluency Test, 

category: animals (VFT), Stroop CWTest (SCWT), Corsi 

Blocks Test, Visual Pattern Test and Digit Span. 

Results: Multivariate analysis of variance and multiple 

regression analyses were performed to model the 

relationshipbetweenthescoresonneuropsychological 

tests and the following predictors:duration of temporal 

lobe epilepsy seizures, age of onset education, and 

diagnostic group. There were significant main effects 

for age at onset and duration on Digit backward and 

Stroop Color-word task performances and for group on 

Semantic word fluency. Significant group differences 

we obtained in BNT (F=6,26, p


myoclonus severity scores.Cognitive performance was 

significantly worse across measures of intelligence and 

visuomotor speed in patients with severe disability 

compared to patients with mild or moderate disability. 

On the other hand, in the delayed verbal memory 

measures the groups did not differ. 

Conclusion: Impaired intellectual performance 

correlates with the extent of general disability in 

EPM1. Visuomotor performance is most often affected 

but verbal memory performance is usually preserved. 

Acknowledgements:The study has been funded by the 

Academy of Finland, the NEURO Research Programme 

and UCB Pharma. 

Thursday 2nd July 2009 

0:30 - 2:00 

Hall 4 



073 

How common is ictal hypoxemia in children with 

partial complex and generalized convulsive seizures? 

Wirrell E, Nickels K 

Mayo Clinic, Rochester, USA 

Objective: (1) To determine the prevalence and risk 

factors for ictal hypoxemia (defined as a measured 

oxygen saturation of


figures were 32-21% and 38-18%, respectively. There 

were no differences for the respiratory parameters.The 

total score on the Bruni list was abnormal in 35% of 

the patients and in 17% of controls with similar data 

for the MOS. 

Conclusion: In children with epilepsy about twice as 

much sleep disturbances were encountered when 

compared to controls, in particular regarding initiating 

and maintaining sleep, parasomnia and sleepiness 

during the day. 

076 

Benign focal epilepsy in childhood: evidence for 

interference of interictal spikes with selective 

cognitive deficits 

Wolff M, Serra E, Pastoors C, Krägeloh-Mann I 

University Childrens Hospital, Germany 

Purpose: Children with Benign Focal Epilepsy (BFE) 

often exhibit neuropsychological deficits. Recently, 

by using MEG, we showed a correlation between 

left perisylvian and occipital location of spikes and 

deficits in sequential and simultaneous information 

processing tasks, respectively, in a cohort of children 

with BFE (Epilepsia, 2005). However, it remains unclear 

whether there is a predisposition for both focal spikes 

and selective cognitive deficits in these children or 

whether the spikes interfere directly with cognitive 

functions. Therefore, we performed a longitudinal 

study in order to evaluate the effect of focal EEG 

improvement on selective cognitive deficits in children 

with BFE. 

Method: Twenty-nine children diagnosed with BFE 

were enrolled in the study. All were examined by 

repeated EEG and neuropsychological assessment 

(Kaufman - ABC battery) over a period of one to three 

years. EEG improvement was defined as a > 25% 

reduction of spikes. All children with spike location 

in the left perisylvian or in the occipital regions and a 

stable location of the spike focus over the time were 

included in the correlation analysis (N=16). 

Results: Focal spikes were located in the perisylvian 

region in eight and in the occipital region in eight 

children. EEG improved in 7/8 children with left 

perisylvian spikes and in none with occipital spikes 

(p=0.01).EEG improvement was significantly correlated 

with an improvement of sequential information tasks 

(p=0.001). Simultaneous information processing tasks 

remained stable. 

Conclusion: Our results indicate a direct interference 

of left perisylvian spikes with complex cognitive 

functions. Therapeutic consequences must 

be considered. 

077 

Language lateralization in childhood-onset focal 

epilepsy: evidence from fMRI 

Pahs G 1, 2, Rankin P 1, Cross J 2, Northam G 1, 

Vargha-Khadem F 1, Baldeweg T 1 

1) Developmental Cognitive Neurosciene Unit, UCL 

Institute of Child Health, UK, 2) Neurosciences Unit, 

UCL Institute of Child Health, UK 

Purpose: We investigated language lateralization 

using functional MRI (fMRI) in children suffering from 

left-sided, medically refractory, childhood-onset focal 

epilepsy and determined factors associated with 


atypical lateralization. 

Method: Twenty-four children suffering from drugresistant, 

left-sided, early-onset epilepsy underwent 

fMRI-scanning using a covert verb-generation task. 

Twenty-nine healthy volunteers, matched for age and 

gender,served as controls.Images were analyzed using 

SPM5 and lateralization indices (LI) were calculated 

within regions of interest (Broca’s area, temporal 

lobe, cerebellum) using the LI-toolbox (Wilke et al., J 

Neurosci Methods, 2007;163:128-36). Typical language 

lateralization (left-sided) was defined as LI>0.2 and 

atypical language (right-sided or bilateral) as LI ¡Ü 0.2. 

Factors contributing to atypical language distribution 

were investigated including: age at seizure-onset, 

seizure frequency, handedness, lesion location, lesion 

size, size and asymmetry of the planum temporale. 

Results: There was no statistically significant 

correlation between age at seizure-onset, seizure 

frequency, handedness, lesion location or lesion size 

and atypical language lateralization (p>0.05).However, 

the correlation between PT-asymmetry and the fMRI 

language lateralization index was highly significant 

(r=0.823,p


epilepsies in Latinamerican not only depend on the 

type of epilepsy or the pharmacological treatment, 

but its very important social-cultural influence for the 

different treatment recommendations. 

Thursday 2nd July 2009 

0:30 - 2:00 

Hall 6 



079 

Designing research in epilepsy to ensure policy 

change: Sydney epilepsy incidence study to 

measure illness consequences (SEISMIC) 

Martiniuk A 1, Anderson C 1, Somervile E 2, Hackett M 1, 

Glozier N 3, Bleasel A 4, Lawson J 5, Jan S 1, 

Mohamed A 6, Hassan B 1 

1) The George Institute For International Health, 

Sydney,Australia,2) Prince of Wales Hospital,Randwick, 

Australia, 3) University of Sydney, Sydney, Australia, 

4) Westmead Hospital, Westmead, Australia, 5) Sydney 

Children’s Hospital, Randwick, Australia, 6) Royal Prince 

Alfred Hospital, Camperdown, Australia 

Background: Little is known about the process of care, 

psychosocial and household economic impact of 

epilepsy; and certainly less known from population 

based data.This reflects logistical barriers encountered 

in engaging with service providers and policy makers. 

Purpose: To document the process of designing a 

collaborative,policy-focused research study in epilepsy 

that involves government, the local health service, civil 

society organisations and academia. 

Such a study aims to inform changes in health 

systems to improve efficiency and quality of care, 

underpin development of clinical guidelines, 

community-based support programs, education and 

workplace legislation. 

Method: A case study in how a research organization 

can work with key policy players in designing a 

rigorous 4-year, population-based, prospective cohort 

of all people newly diagnosed with epilepsy. 

Results: To date a research protocol and pilot study 

have been completed. Buy-in is secured from relevant 

hospitals, private practitioners and GPs within the 

defined study region; funding has been secured from 

project partners with a grant proposal submitted for 

matching funding from conventional peer review 

agencies; and screening and patient recruitment 

has commenced. This study was designed to directly 

influence epilepsy policy and thus required the active 

participation of partners Epilepsy Society of Australia, 

Epilepsy Action Australia and the State Department 

of Health. 

Conclusion: Designing the study through an iterative 

process of consultation with government, epilepsy 

professional and community organisations has 

established a research study with a high degree of 

policy relevance and feasibility which may potentially 

serve as a template for future studies. 

080 

Cost of hospitalisations of 772 patients with 

epilepsy within a one-year (2006) observation. 

Preliminary report 

Majkowska-Zwoliñska B, Majkowski J 

32 


Foundation Of Epileptology, Poland 

Objective: To determine the frequency, duration and 

costs of, and causes for, hospitalisation of patients 


Method: A prospective questionnaire survey was 

conducted in 18 antiepileptic/neurological centres 

in Poland, including 969 consecutive patients with 

epilepsy (mean age -27,8 yrs.). Ultimately, 772 patients 

underwent 12-month observation (5 questionnaires). 

Frequency and duration of hospitalisation in each of 

the four seasons were analysed. Cost of hospitalization 

were estimated taking the Polish National Health 

Service perspective. The generalised Poisson 

regression model was used to analyse hospitalisation 

IR. Relations between IR and season were expressed in 

IR ratios (IRR) with a 95% CI. 

Results: 150 (19.4%) patients were hospitalised; 56% of 

the admissions were epilepsy-related (ER) and 44 not 

ER. Among ER admissions 19% were directly related 

to acute seizures and 81% other epilepsy problems. 

Average duration of hospitalisation was 11 days. Total 

hospitalization cost in one year was 136118( and on 

average 907( per person. Cost of hospital admissions 

due to seizures and other ER problems constituted 

64% of all costs and due to not ER problems -36%. 

The number of hospitalisations was largest in autumn: 

7.82% (95%C.I.[5.85; 9.79%] and smallest in spring: 

5.77% (95%C.I)[4.08%; 7.1%]; in autumn the number 

was double as in spring and summer: IRR=1.43; 

p=0.026. Conclusion: Nearly 2/3 of all hospitalization 

costs were epilepsy-related and 1/3 constituted other 

medical problems. Season of the year has a significant 

effect on the number of hospitalisation and therefore 

on costs. 

08 

The experience of epilepsy in Australia 

Chapman D, Cole R, Cummins J, Elphinstone K, 

Pollard R, Roberts K, Sharp D, Whitehead H 

Joint Epilepsy Council Of Australia, Australia 

Aim: To understand experience of having epilepsy in 

Australia, particularly in relationship to work, transport, 

discrimination, and mental health. 

Method: In 2006, 467 individuals with epilepsy 

and 495 carers completed either a paper-based 

or online survey. They were recruited through the 

state based community epilepsy organizations. This 

recruitment method is likely to have biased the sample 

towards people whose epilepsy is not currently 

well-managed by medication (52% had a seizure in the 

previous month). 

Results: Only 12% of respondents with epilepsy work 

in full time employment, with many in part-time or 

full-time education. The average household income 

for respondents with epilepsy was $40,889 (well 

below the national average of $58,656) and 12% lived 

alone. 43% of respondents with epilepsy owned their 

own car and of these 53% had their driver’s licence 

suspended at some time. Respondents with epilepsy 

had family and friends who drove them (44%), 

used public transport (39%) and taxis (18%). 52% 

have experienced discrimination, and 51% of these 

experienced discrimination in the last 12 months, 

most commonly in work or education contexts. Twothirds 

were uncomfortable telling new friends and 

around half were uncomfortable telling employers or 



colleagues. Emotional problems were very common: 

anxiety (49%), depression (36%), behavioural disorders 

(35%) and mood disorders (34%). 

Conclusion: The survey showed that the experience of 

epilepsy has a profoundly negative effect on the lives 

of those with epilepsy, particularly in relationship to 

work, transport, discrimination,and mental health. 

082 

Psychosocial impact of diagnosis and treatment of 

epilepsy in young people 

Mesa T 1, 2, Peralta M 1, Fuentes D 1, González L 1 

1) Liga Chilena Contra La Epilepsia, Santiago, Chile, 

2) Pontificia Universidad Católica De Chile, Santiago, 

Chile 

Purpose: Epilepsy influences the quality of life, 

especially in psychological and social areas of people 

with this syndrome who also become stigmatized.The 

aim of this work is to measure the psychosocial impact 

on two groups of young people with epilepsy and 

compare it on year 2004 and 2008. 

Method:Young people whose epilepsy is controlled by 

LICHE and who are studying in High Education were 

evaluated by the Epilepsy Psycho-Social Effects Scale 

(EPSES). 42 parameters were considered, 14 of which 

evaluates psychosocial areas. One group was polled 

in 2004 and another one in 2008. The results were 

analyzed and cross-matched. 

Results: Group 2004: 52 patients; average age: 23 years; 

52% women and 73% on monotherapy; average of the 

crisis beginning: 19 years old and 21% on comorbidity 

treatment. Group 2008: 45 patients; average age: 

24 years; 38% women and 67% on monotherapy; 

average of the crisis beginning: 14 years old, and 8.8% 

on comorbidity treatment. The crisis control and the 

responce to the treatment were good: 69% on year 

2004 and 84.4% on year 2008.The impact is significant 

for both groups, highlighting the fear of having a crisis 

in public and of suffering labor discrimination. 

Conclusion: On both groups the epilepsy has a 

significant impact in the psychosocial aspects and 

especially in social and labor areas. Those who 

are more psychosocial affected have one or more 

characteristics: politherapy, lower crisis control, a 

recent diagnosis or comorbidity.The group of 2008 has 

less fear of suffering labor discrimination. 

083 

Are social class and level of education important 

factors regarding different formulation of 

antiepileptic drugs? 

Santos C, Alexandre Jr. V, Martins H, Silva A, 

Mesquita S, Castro A, Faveret E, Lin K, Masuko A, 

Guilhoto L, Yacubian E 

Brazilian Association of Epilepsy, Brazil 

Purpose: Controversy persists whether generic 

AEDs are interchangeable with brand name/similar 

drugs regarding efficacy and adverse events. This is 

important in underdeveloped countries with limited 

health expenditures. 

Method: After Ethical Committee approval ABE 

applied questionnaire for people with epilepsy (PWE) 

with multiple-choice questions: sociodemography 

(4) and formulations knowledge (reference/generic/ 

similar drugs) and clinical change evidence during 


formulation switch (14)(Fisher test, level 5%). 

Results: 605 PWE from 6 Public System hospitals 

participated being 89% from middle/low income 

classes, 27% functionally illiterate, 27% completed 

elementary school, 37% high school, 8% university; 

63% received more than one AED (28% CBZ, 14% VPA); 

70% obtained AEDs from public resources and 20% 

only in private pharmacies; 64% did not know different 

formulations (more educated PWE,high income classes 

responded more correctly, p

SPEAKER LIST 

34 


Name Session Date Time Room Abs # 

Abbott D (Australia) Platform Session 5 Tues 30 10:30 Hall 5 030 

Acevedo C (Chile) Special Session Sun 28 17:00 Hall 1 

Aengenendt J (Germany) Platform Session 8 Tues 30 16:00 Hall 5 043 

Afif A (France) Platform Session 5 Tues 30 10:30 Hall 5 028 

Agrawal S (UK) Platform Session 11 Wed 01 16:00 Hall 2 066 

Äikiä M (Finland) Platform Session 12 Wed 01 16:00 Hall 5 072 

Al Yamani S (Saudi Arabia) Parallel Session Mon 29 10:30 Hall 5 

Al Yamani S (Saudi Arabia) Main Session Wed 01 9:00 Hall 1 

Al Yamani S (Saudi Arabia) Post Main Session Wed 01 10:30 Hall 1 

Al Yamani S (Saudi Arabia) Special Session Thurs 02 12:00 Hall 2 

Alessio A (Brazil) Platform Session 9 Wed 01 10:30 Hall 3 054 

Alexandre Jr.V (Brazil) Platform Session 14 Thurs 02 10:30 Hall 6 083 

Alexopoulos A (USA) Platform Session 12 Wed 01 16:00 Hall 5 068 

Allebeck P (Sweden) Platform Session 6 Tues 30 10:30 Hall 6 032 

Amado D (Brazil) Platform Session 2 Mon 29 10:30 Hall 6 007 

An J (Belgium) Platform Session 10 Wed 01 10:30 Hall 4 059 

Anand B ( India) Platform Session 1 Mon 29 10:30 Hall 2 002 

Andermann F (Canada) Special Session Sun 28 17:00 Hall 1 

Anderson C (Australia) Platform Session 14 Thurs 02 10:30 Hall 6 079 

André-Obadia N (France) Platform Session 10 Wed 01 10:30 Hall 4 056 

Apartopoulos F (UK) Platform Session 5 Tues 30 10:30 Hall 5 025 

Apartopoulos F (UK) Platform Session 5 Tues 30 10:30 Hall 5 026 

Archer J (Australia) Platform Session 5 Tues 30 10:30 Hall 5 030 

Arzimanoglou A (France) Satellite Symposium Tues 30 13:00 Hall 1 

Arzimanoglou A (France) Platform Session 10 Wed 01 10:30 Hall 4 056 

Arzimanoglou A (France) Platform Chair Wed 01 16:00 Hall 2 

Avanzini G (Italy) Special Session Sun 28 17:00 Hall 1 

Avanzini G (Italy) Platform Chair Tues 30 10:30 Hall 5 

Avanzini G (Italy) Parallel Session Wed 01 16:00 Hall 4 

Aziz H (Pakistan) Post Main Session Tues 30 10:30 Hall 1 

Badawy R (Australia) Platform Session 10 Wed 01 10:30 Hall 4 057 

Baldeweg T (UK) Platform Session 13 Thurs 02 10:30 Hall 4 077 

Baldwin R (USA) Platform Session 7 Tues 30 16:00 Hall 4 042 

Baram T Z (USA) Main Session Tues 30 14:30 Hall 1 

Baram T Z (USA) Parallel Session Wed 01 10:30 Hall 2 

Barragán E (Mexico) Platform Session 13 Thurs 02 10:30 Hall 4 078 

Barsi P (Hungary) Platform Chair Wed 01 10:30 Hall 3 

Bascarevic V (Serbia) Platform Session 12 Wed 01 16:00 Hall 5 069 

Bast T (Germany) Platform Session 7 Tues 30 16:00 Hall 4 040 

Bateman L (USA) Platform Session 5 Tues 30 10:30 Hall 5 029 

Baulac M (France) Platform Session 4 Mon 29 16:00 Hall 6 019 

Baulac M (France) Platform Chair Tues 30 10:30 Hall 5 

Baulac S (France) Platform Session 10 Wed 01 10:30 Hall 4 056 

Baumgartner C (Austria) Post Main Session Mon 29 10:30 Hall 1 

Baumgartner C (Austria) Parallel Session Tues 30 10:30 Hall 2 

Baxendale S (UK) Platform Session 8 Tues 30 16:00 Hall 5 044 

Becker A J (Germany) Platform Session 4 Mon 29 16:00 Hall 6 020 

Becker A J (Germany) Parallel Session Mon 29 16:00 Hall 4 

Beghi E (Italy) Parallel Session Mon 29 10:30 Hall 3 

Begley C (USA) Parallel Session Wed 01 16:00 Hall 4 

Bekes J (Hungary) Post Main Session Mon 29 16:00 Hall 1 



SPEAKER LIST 


Bekes J (Hungary) Platform Chair Thurs 02 10:30 Hall 6 

Bell G (UK) Platform Session 6 Tues 30 10:30 Hall 6 031 

Belmeguenai A (France) Platform Session 2 Mon 29 10:30 Hall 6 009 

Ben-Menachem E (Sweden) Satellite Symposium Tues 30 13:00 Hall 1 

Berg A (USA) Parallel Session Thurs 02 10:30 Hall 5 

Berg A (USA) Parallel Session Tues 30 10:30 Hall 3 

Bergin P (New Zealand) Platform Session 3 Mon 29 16:00 Hall 2 016 

Bergström-Isacsson M (Sweden) Platform Session 5 Tues 30 10:30 Hall 5 026 

Berkovic S F (Australia) Satellite Symposium Mon 29 13:00 Hall 1 

Berkovic S F (Australia) Parallel Session Tues 30 10:30 Hall 3 

Berkovic S F (Australia) Platform Session 10 Wed 01 10:30 Hall 4 057 

Berkovic S F (Australia) Platform Chair Wed 01 10:30 Hall 4 

Bernard C (France) Parallel Session Wed 01 7:30 Hall 3 

Bernasconi A (Canada) Post Main Session Thurs 02 10:30 Hall 2 

Besag F (UK) Teaching Session Tues 30 7:30 Hall 5 

Bezin L (France) Platform Session 2 Mon 29 10:30 Hall 6 009 

Bezin L (France) Parallel Session Thurs 02 7:30 Hall 5 

Bialer M (Israel) Platform Chair Mon 29 16:00 Hall 2 

Bien C G (Germany) Platform Session 4 Mon 29 16:00 Hall 6 020 

Bigoni S (Italy) Platform Session 5 Tues 30 10:30 Hall 5 025 

Bigoni S (Italy) Platform Session 5 Tues 30 10:30 Hall 5 026 

Bilevicius E (Brazil) Platform Session 9 Wed 01 10:30 Hall 3 054 

Bill P (UK) Platform Session 9 Wed 01 10:30 Hall 3 050 

Birbeck G (USA) Parallel Session Mon 29 10:30 Hall 5 

Bisulli F (Italy) Platform Session 10 Wed 01 10:30 Hall 4 060 

Bleasel A (Australia) Platform Session 14 Thurs 02 10:30 Hall 6 079 

Blumenfeld H (USA) Post Main Session Tues 30 16:00 Hall 1 

Bodennec J (France) Platform Session 2 Mon 29 10:30 Hall 6 009 

Boison D (USA) Parallel Session Thurs 02 7:30 Hall 5 

Boland M (Ireland) Platform Session 6 Tues 30 10:30 Hall 6 035 

Bonelli S (UK) Platform Session 9 Wed 01 10:30 Hall 3 049 

Bonnet C (France) Platform Session 2 Mon 29 10:30 Hall 6 009 

Boor R (Germany) Platform Session 7 Tues 30 16:00 Hall 4 040 

Borbély C (Hungary) Platform Session 12 Wed 01 16:00 Hall 5 070 

Borbély C (Hungary) Platform Chair Wed 01 16:00 Hall 5 

Bouilleret V (Australia) Platform Session 2 Mon 29 10:30 Hall 6 011 

Boutry N (France) Platform Session 10 Wed 01 10:30 Hall 4 056 

Bragin A (USA) Workshop Mon 29 7:30 Hall 4 

Bragin A (USA) Parallel Session Thurs 02 10:30 Hall 3 

Brazzo D (UK) Platform Session 9 Wed 01 10:30 Hall 3 050 

Brodie M J (UK) Parallel Session Wed 01 10:30 Hall 5 

Brodie M J (UK) Satellite Symposium Wed 01 13:00 Hall 1 

Brodie M J (UK) Parallel Session Thurs 02 10:30 Hall 5 

Buchhalter J (USA) Platform Session 6 Tues 30 10:30 Hall 6 034 

Buder N (Serbia and Montenegro) Platform Session 1 Mon 29 10:30 Hall 2 001 

Bujarski K (USA) Platform Session 1 Mon 29 10:30 Hall 2 006 

Burgess R (USA) Platform Session 11 Wed 01 16:00 Hall 2 063 

Burneo J (Canada) Platform Session 9 Tues 30 16:00 Hall 5 048 

Burneo J (Canada) Parallel Session Tues 30 16:00 Hall 6 

Busch R (USA) Platform Session 12 Wed 01 16:00 Hall 5 068 

Buzsaki G (USA) Parallel Session Thurs 02 10:30 Hall 3 


SPEAKER LIST 

36 



Caboclo L O (Brazil) Platform Session 11 Wed 01 16:00 Hall 2 062 

Calender A (France) Platform Session 10 Wed 01 10:30 Hall 4 056 

Campos M (Chile) Post Main Session Mon 29 16:00 Hall 1 

Canevini M P (Italy) Platform Session 3 Mon 29 16:00 Hall 2 017 

Capanelli D (Italy) Platform Session 10 Wed 01 10:30 Hall 4 060 

Cardamone L (Australia) Platform Session 2 Mon 29 10:30 Hall 6 011 

Carpay J (The Netherlands) Platform Session 3 Mon 29 16:00 Hall 2 014 

Carr D (USA) Parallel Session Tues 30 16:00 Hall 6 

Castellano G (Brazil) Platform Session 9 Wed 01 10:30 Hall 3 054 

Castro A (Brazil) Platform Session 14 Thurs 02 10:30 Hall 6 083 

Catani M (UK) Parallel Session Tues 30 16:00 Hall 3 

Cavalheiro E A (Brazil) Platform Session 2 Mon 29 10:30 Hall 6 007 

Cavalheiro E A (Brazil) Platform Session 2 Mon 29 10:30 Hall 6 012 

Cendes F (Brazil) Platform Session 9 Wed 01 10:30 Hall 3 054 

Cendes F (Brazil) Platform Session 10 Wed 01 10:30 Hall 4 058 

Ceulemans B (Belgium) Platform Session 10 Wed 01 10:30 Hall 4 059 

Chabrol E (France) Platform Session 10 Wed 01 10:30 Hall 4 056 

Chapman D (Australia) Platform Session 14 Thurs 02 10:30 Hall 6 081 

Chatillon C E (Canada) Platform Session 9 Tues 30 16:00 Hall 5 046 

Chen Q (China) Platform Session 9 Wed 01 10:30 Hall 3 051 

Chen T (USA) Platform Session 4 Mon 29 16:00 Hall 6 024 

Chiron C (France) EUREPA Teaching Session Wed 01 7:30 Hall 6 

Chung H J (Korea) Platform Session 3 Mon 29 16:00 Hall 2 018 

Ciampa C (Italy) Platform Session 3 Mon 29 16:00 Hall 2 017 

Clemenceau S (France) Platform Session 4 Mon 29 16:00 Hall 6 019 

Clifford A (UK) Platform Session 6 Tues 30 10:30 Hall 6 036 

Cohen I (France) Platform Session 4 Mon 29 16:00 Hall 6 019 

Cole R (Australia) Platform Session 14 Thurs 02 10:30 Hall 6 081 

Collins C (Ireland) Platform Session 6 Tues 30 10:30 Hall 6 035 

Cook M (Australia) Parallel Session Mon 29 10:30 Hall 3 

Cook M (Australia) Parallel Session Tues 30 16:00 Hall 2 

Cook M (Australia) Platform Chair Wed 01 10:30 Hall 3 

Cooper P (UK) Platform Session 6 Tues 30 10:30 Hall 6 036 

Covanis T (Greece) Teaching Session Mon 29 7:30 Hall 2 

Covanis T (Greece) EUREPA Teaching Session Tues 30 7:30 Hall 3 

Covolan R (Brazil) Platform Session 9 Wed 01 10:30 Hall 3 054 

Cross H (UK) Teaching Session Mon 29 7:30 Hall 3 

Cross H (UK) Parallel Session Mon 29 10:30 Hall 4 

Cross H (UK) EUREPA Teaching Session Tues 30 7:30 Hall 3 

Cross J (UK) Platform Session 13 Thurs 02 10:30 Hall 4 077 

Cummins J (Australia) Platform Session 14 Thurs 02 10:30 Hall 6 081 

Curfs L (The Netherlands) Platform Session 5 Tues 30 10:30 Hall 5 025 

Curfs L (The Netherlands) Platform Session 5 Tues 30 10:30 Hall 5 026 

Czech T (Austria) Platform Session 8 Tues 30 16:00 Hall 5 045 

Czirjak S (Hungary) Platform Session 4 Mon 29 16:00 Hall 6 023 

da Graça Naffah-Mazzacoratti M (Brazil) Platform Session 2 Mon 29 10:30 Hall 6 007 

Damasceno B (Brazil) Platform Session 9 Wed 01 10:30 Hall 3 054 

Damtie Z G (Ethiopia) Post Main Session Wed 01 10:30 Hall 1 

Darcey T (USA) Platform Session 1 Mon 29 10:30 Hall 2 006 

de Bellescize J (France) Platform Session 10 Wed 01 10:30 Hall 4 056 

De Boer H (The Netherlands) Main Session Tues 30 9:00 Hall 1 



SPEAKER LIST 


De Curtis M (Italy) Workshop Mon 29 7:30 Hall 4 

De Jonghe P (Belgium) Platform Session 10 Wed 01 10:30 Hall 4 059 

De La Prida L M (Spain) Parallel Session Thurs 02 10:30 Hall 3 

De Oliveira E (Brazil) Platform Session 10 Wed 01 10:30 Hall 4 058 

De Toffol B (France) Parallel Session Wed 01 10:30 Hall 6 

De Weerd A (The Netherlands) Platform Session 13 Thurs 02 10:30 Hall 4 075 

Deisseroth K (USA) Platform Session 7 Tues 30 16:00 Hall 4 039 

Delamont R (UK) Platform Session 5 Tues 30 10:30 Hall 5 025 

Delamont R (UK) Platform Session 5 Tues 30 10:30 Hall 5 026 

Delanty N (Ireland) Platform Session 6 Tues 30 10:30 Hall 6 035 

Deprez L (Belgium) Platform Session 10 Wed 01 10:30 Hall 4 059 

Dibbens L (Australia) Platform Session 10 Wed 01 10:30 Hall 4 057 

Dingledine R (USA) Parallel Session Mon 29 16:00 Hall 4 

Djokic R (Serbia and Montenegro) Platform Session 1 Mon 29 10:30 Hall 2 001 

Domingues R (Brazil) Platform Session 10 Wed 01 10:30 Hall 4 058 

Donner E (Canada) Platform Session 6 Tues 30 10:30 Hall 6 034 

Dressler A (Austria) Platform Session 8 Tues 30 16:00 Hall 5 045 

Drexler J F (Germany) Platform Session 4 Mon 29 16:00 Hall 6 020 

Dua T (Switzerland) Main Session Tues 30 9:00 Hall 1 

Dubeau F (Canada) Platform Session 9 Tues 30 16:00 Hall 5 046 

Dudek F E (USA) Main Session Wed 01 14:30 Hall 1 

Dudek F E (USA) Post Main Session Wed 01 16:00 Hall 1 

Dudek F E (USA) Special Session Thurs 02 12:00 Hall 2 

Duncan J (UK) Platform Session 8 Tues 30 16:00 Hall 5 044 

Duncan J (UK) Platform Session 9 Wed 01 10:30 Hall 3 049 

Duron R (Honduras) Platform Session 13 Thurs 02 10:30 Hall 4 078 

Ebner A (Germany) Platform Session 8 Tues 30 16:00 Hall 5 043 

Elger C E (Germany) Platform Session 12 Wed 01 16:00 Hall 5 067 

Elia M (Italy) Workshop Thurs 02 7:30 Hall 6 

Elphinstone K (Australia) Platform Session 14 Thurs 02 10:30 Hall 6 081 

Elsharkawy A (Germany) Platform Session 8 Tues 30 16:00 Hall 5 043 

Engel J (USA) Platform Chair Tues 30 10:30 Hall 6 

Engel J (USA) Parallel Session Thurs 02 10:30 Hall 3 

Ernst J P (Germany) Platform Session 7 Tues 30 16:00 Hall 4 040 

Eross L (Hungary) Platform Session 4 Mon 29 16:00 Hall 6 023 

Espinosa E (Colombia) Platform Session 13 Thurs 02 10:30 Hall 4 078 

Eun B L (Korea) Platform Session 3 Mon 29 16:00 Hall 2 018 

Eun S (Korea) Platform Session 3 Mon 29 16:00 Hall 2 018 

Fabo D (Hungary) Workshop Mon 29 7:30 Hall 4 

Fabo D (Hungary) Platform Session 4 Mon 29 16:00 Hall 6 023 

Fallah M (Finland) Platform Session 6 Tues 30 10:30 Hall 6 033 

Famà F (Italy) Platform Session 1 Mon 29 10:30 Hall 2 005 

Fares R P (France) Platform Session 2 Mon 29 10:30 Hall 6 009 

Faveret E (Brazil) Platform Session 14 Thurs 02 10:30 Hall 6 083 

Fejerman N (Argentina) Post Main Session Mon 29 10:30 Hall 1 

Ferrari A (Italy) Platform Session 1 Mon 29 10:30 Hall 2 005 

Ferrari M (The Netherlands) Platform Session 3 Mon 29 16:00 Hall 2 014 

Ferrillo F (Italy) Platform Session 1 Mon 29 10:30 Hall 2 005 

Feucht M (Austria) Platform Session 8 Tues 30 16:00 Hall 5 045 

Fitzpatrick A (UK) Platform Session 6 Tues 30 10:30 Hall 6 036 

Fitzsimons M (Ireland) Platform Session 6 Tues 30 10:30 Hall 6 035 


SPEAKER LIST 

38 



Flanagan D (Australia) Platform Session 5 Tues 30 10:30 Hall 5 030 

Focke N (UK) Platform Session 9 Wed 01 10:30 Hall 3 049 

Fogarasi A (Hungary) Main Session Mon 29 9:00 Hall 1 

Fogarasi A (Hungary) Post Main Session Mon 29 10:30 Hall 1 

Fogarasi A (Hungary) Parallel Session Tues 30 10:30 Hall 2 

Fogarasi A (Hungary) Platform Chair Wed 01 16:00 Hall 2 

Fogarasi A (Hungary) Special Session Thurs 02 12:00 Hall 2 

Forrester C (UK) Platform Session 6 Tues 30 10:30 Hall 6 036 

Franco V (Italy) Platform Session 3 Mon 29 16:00 Hall 2 017 

Frassine B (Italy) Platform Session 3 Mon 29 16:00 Hall 2 017 

Freilinger M (Austria) Platform Session 8 Tues 30 16:00 Hall 5 045 

French J (USA) EUREPA Teaching Session Mon 29 7:30 Hall 5 

French J (USA) Platform Chair Tues 30 16:00 Hall 4 

French J (USA) Parallel Session Thurs 02 10:30 Hall 5 

Freund T F (Hungary) Platform Chair Mon 29 10:30 Hall 6 

Freund T F (Hungary) Platform Session 4 Mon 29 16:00 Hall 6 023 

Friedman A (Israel) Parallel Session Mon 29 16:00 Hall 4 

Friedman A (Israel) Parallel Session Tues 30 10:30 Hall 4 

Fuentes D (Chile) Platform Session 14 Thurs 02 10:30 Hall 6 082 

Fukuda A (Japan) Platform Session 10 Wed 01 10:30 Hall 4 055 

Gaddamanugu P ( India) Platform Session 1 Mon 29 10:30 Hall 2 002 

Gaillard W (USA) Parallel Session Tues 30 16:00 Hall 3 

Gaillard W (USA) EUREPA Teaching Session Wed 01 7:30 Hall 6 

Galimberti C A (Italy) Platform Session 3 Mon 29 16:00 Hall 2 017 

Gambardella A (Italy) Platform Session 3 Mon 29 16:00 Hall 2 017 

Garcia H H (Peru) Parallel Session Mon 29 10:30 Hall 5 

Geerts Y (The Netherlands) Platform Session 13 Thurs 02 10:30 Hall 4 075 

Gerber J (Germany) Platform Session 4 Mon 29 16:00 Hall 6 021 

Gil Nagel A (Spain) Satellite Symposium Wed 01 13:00 Hall 1 

Gilioli R (Brazil) Platform Session 2 Mon 29 10:30 Hall 6 012 

Gilliam F (USA) Parallel Session Mon 29 16:00 Hall 3 

Giraldes de Manreza M L (Brazil) Platform Session 11 Wed 01 16:00 Hall 2 062 

Gjerstad L (Norway) Platform Session 3 Mon 29 16:00 Hall 2 013 

Glasscock E (USA) Platform Session 4 Mon 29 16:00 Hall 6 024 

Glauser T (USA) Parallel Session Tues 30 10:30 Hall 3 

Glauser T (USA) Satellite Symposium Tues 30 13:00 Hall 1 

Glozier N (Australia) Platform Session 14 Thurs 02 10:30 Hall 6 079 

Goldman A (USA) Platform Session 4 Mon 29 16:00 Hall 6 024 

Gong Q Y (China) Platform Session 9 Wed 01 10:30 Hall 3 051 

González L (Chile) Platform Session 14 Thurs 02 10:30 Hall 6 082 

Goodridge D M (UK) Platform Session 6 Tues 30 10:30 Hall 6 031 

Gorter J (The Netherlands) Parallel Session Thurs 02 7:30 Hall 5 

Gotman J (Canada) Platform Session 9 Tues 30 16:00 Hall 5 046 

Grancelli T (Italy) Platform Session 1 Mon 29 10:30 Hall 2 005 

Greenberg D A (USA) Parallel Session Wed 01 10:30 Hall 5 

Gröppel G (Austria) Platform Session 8 Tues 30 16:00 Hall 5 045 

Grote A (Germany) Platform Session 4 Mon 29 16:00 Hall 6 020 

Guekht A (Russia) EUREPA Teaching Session Mon 29 7:30 Hall 6 

Guerreiro M (Brazil) Platform Session 13 Thurs 02 10:30 Hall 4 078 

Guerrini R (Italy) Parallel Session Mon 29 10:30 Hall 4 

Guilhoto L (Brazil) Platform Session 14 Thurs 02 10:30 Hall 6 083 



SPEAKER LIST 


Guinovart J J (Spain) Parallel Session Tues 30 10:30 Hall 4 

Gumnit R J (USA) Main Session Wed 01 9:00 Hall 1 

Gupta A (USA) Platform Session 11 Wed 01 16:00 Hall 2 063 

Gyimesi C (Hungary) Platform Session 8 Tues 30 16:00 Hall 5 043 

Haas-Lude K (Germany) Platform Session 11 Wed 01 16:00 Hall 2 065 

Haberlandt E (Austria) Platform Session 7 Tues 30 16:00 Hall 4 040 

Hackett M (Australia) Platform Session 14 Thurs 02 10:30 Hall 6 079 

Hainfellner J (Austria) Platform Session 8 Tues 30 16:00 Hall 5 045 

Halasz P (Hungary) Workshop Mon 29 7:30 Hall 4 

Halasz P (Hungary) Main Session Mon 29 9:00 Hall 1 

Halasz P (Hungary) Platform Session 4 Mon 29 16:00 Hall 6 023 

Halasz P (Hungary) Parallel Session Tues 30 10:30 Hall 2 

Halasz P (Hungary) Special Session Thurs 02 12:00 Hall 2 

Hall J (Canada) Platform Session 9 Tues 30 16:00 Hall 5 046 

Hallmeyer-Elgner S (Germany) Platform Session 4 Mon 29 16:00 Hall 6 021 

Hamada K (Japan) Platform Session 10 Wed 01 10:30 Hall 4 055 

Hamiwka L (Canada) Platform Session 9 Tues 30 16:00 Hall 5 047 

Hammonds G (UK) Platform Session 6 Tues 30 10:30 Hall 6 036 

Hansen S (UK) Platform Session 5 Tues 30 10:30 Hall 5 025 

Hansen S (UK) Platform Session 5 Tues 30 10:30 Hall 5 026 

Hargis E (USA) Post Main Session Tues 30 10:30 Hall 1 

Hargis E (USA) Parallel Session Tues 30 16:00 Hall 6 

Harvey S (Australia) Parallel Session Mon 29 10:30 Hall 4 

Hassan B (Australia) Platform Session 14 Thurs 02 10:30 Hall 6 079 

Hauf M (Switzerland) Platform Session 9 Wed 01 10:30 Hall 3 053 

Hayasaka K (Japan) Platform Session 10 Wed 01 10:30 Hall 4 055 

Heaney D (UK) Platform Session 8 Tues 30 16:00 Hall 5 044 

Heinemann U (Germany) Parallel Session Wed 01 7:30 Hall 3 

Helmstaedter C (Germany) Platform Session 12 Wed 01 16:00 Hall 5 067 

Henkel S (Germany) Platform Session 4 Mon 29 16:00 Hall 6 021 

Herfurt K (Germany) Platform Session 12 Wed 01 16:00 Hall 5 071 

Hermann B (USA) Parallel Session Mon 29 10:30 Hall 3 

Hernández M (Mexico) Platform Session 13 Thurs 02 10:30 Hall 4 078 

Hessen E (Norway) Platform Session 3 Mon 29 16:00 Hall 2 013 

Hirai S (Japan) Platform Session 10 Wed 01 10:30 Hall 4 055 

Hirata M (Japan) Parallel Session Tues 30 16:00 Hall 3 

Hirsch L (USA) Platform Session 6 Tues 30 10:30 Hall 6 034 

Hoffmann D (France) Platform Session 5 Tues 30 10:30 Hall 5 028 

Holmes G L (USA) Main Session Wed 01 14:30 Hall 1 

Holmgren P (Belgium) Platform Session 10 Wed 01 10:30 Hall 4 059 

Homa S (UK) Platform Session 6 Tues 30 10:30 Hall 6 036 

Hong Z (China) Platform Session 1 Mon 29 10:30 Hall 2 003 

Hopp P (Germany) Platform Session 4 Mon 29 16:00 Hall 6 021 

Hoppe M (Germany) Platform Session 8 Tues 30 16:00 Hall 5 043 

Horstmann S (Germany) Platform Session 8 Tues 30 16:00 Hall 5 043 

Huberfeld G (France) Platform Session 4 Mon 29 16:00 Hall 6 019 

Hummel T (Germany) Platform Session 4 Mon 29 16:00 Hall 6 021 

Ikonomidou, H (USA) Special Session Mon 29 16:00 Hall 5 

Inoue Y (Japan) Post Main Session Wed 01 10:30 Hall 1 

Jackson G (Australia) Platform Session 5 Tues 30 10:30 Hall 5 030 

Jackson G (Australia) Post Main Session Thurs 02 10:30 Hall 2 


SPEAKER LIST 

40 



Jacobs J (Canada) Special Session Mon 29 16:00 Hall 5 

Jacobs J (Canada) Platform Session 9 Tues 30 16:00 Hall 5 046 

Jacobs M (USA) Platform Session 6 Tues 30 10:30 Hall 6 034 

Jain S (India) Teaching Session Wed 01 16:00 Hall 5 

Jan S (Australia) Platform Session 14 Thurs 02 10:30 Hall 6 079 

Jankovic S (Serbia) Platform Session 12 Wed 01 16:00 Hall 5 069 

Jann K (Switzerland) Platform Session 9 Wed 01 10:30 Hall 3 053 

Janszky J (Hungary) Post Main Session Mon 29 10:30 Hall 1 

Janszky J (Hungary) Parallel Session Tues 30 10:30 Hall 2 

Janszky J (Hungary) Platform Session 8 Tues 30 16:00 Hall 5 043 

Janszky J (Hungary) Platform Chair Tues 30 16:00 Hall 5 

Jayalakshmi S ( India) Platform Session 1 Mon 29 10:30 Hall 2 002 

Jehi L (USA) Platform Session 12 Wed 01 16:00 Hall 5 068 

Jerney J (Hungary) Platform Chair Thurs 02 10:30 Hall 4 

Jette N (Canada) Platform Session 9 Tues 30 16:00 Hall 5 047 

Jette N (Canada) Platform Session 9 Tues 30 16:00 Hall 5 048 

Jette N (Canada) Platform Session 14 Thurs 02 10:30 Hall 6 084 

Jin K (USA) Platform Session 11 Wed 01 16:00 Hall 2 063 

Jobst B (USA) Platform Session 1 Mon 29 10:30 Hall 2 006 

Johannessen-Landmark C (Norway) EUREPA Teaching Session Mon 29 7:30 Hall 6 

Johannessen S I (Norway) EUREPA Teaching Session Mon 29 7:30 Hall 6 

Jones N (Australia) Platform Session 2 Mon 29 10:30 Hall 6 010 

Jones S (USA) Platform Session 11 Wed 01 16:00 Hall 2 063 

Jordanova A (Belgium) Platform Session 10 Wed 01 10:30 Hall 4 059 

Jovanovic M (Serbia and Montenegro) Platform Session 1 Mon 29 10:30 Hall 2 001 

Jovic N (Serbia) Platform Session 11 Wed 01 16:00 Hall 2 061 

Jovic N (Serbia) Workshop Thurs 02 7:30 Hall 6 

Juhasz C (USA) Post Main Session Thurs 02 10:30 Hall 2 

Juhos V (Hungary) Platform Chair Mon 29 10:30 Hall 2 

Julu P (UK) Platform Session 5 Tues 30 10:30 Hall 5 025 

Julu P (UK) Platform Session 5 Tues 30 10:30 Hall 5 026 

Kahane P (France) Platform Session 5 Tues 30 10:30 Hall 5 028 

Kahane P (France) EUREPA Teaching Session Thurs 02 7:30 Hall 4 

Kahane P (France) Main Session Thurs 02 9:00 Hall 2 

Kakooza A (Uganda) Workshop Thurs 02 7:30 Hall 6 

Kakuno M (Japan) Platform Session 7 Tues 30 16:00 Hall 4 037 

Kalman C (USA) Platform Session 12 Wed 01 16:00 Hall 5 068 

Kälviäinen R (Finland) Satellite Symposium Mon 29 18:00 Hall 1 

Kälviäinen R (Finland) Platform Session 12 Wed 01 16:00 Hall 5 072 

Kaminski R (Belgium) Platform Session 3 Mon 29 16:00 Hall 2 015 

Kanemoto K (Japan) Workshop Wed 01 7:30 Hall 4 

Kanner A M (USA) Main Session Mon 29 14:30 Hall 1 

Kanner A M (USA) Parallel Session Wed 01 10:30 Hall 6 

Kanter-Schlifke I (Sweden) Platform Session 7 Tues 30 16:00 Hall 4 041 

Kapur J (USA) Satellite Symposium Mon 29 18:00 Hall 1 

Karmos G (Hungary) Platform Session 4 Mon 29 16:00 Hall 6 023 

Kasteleijn-Nolst Trenité D (The Netherlands) Parallel Session Wed 01 10:30 Hall 5 

Kato M (Japan) Platform Session 10 Wed 01 10:30 Hall 4 055 

Kaul S (India) Platform Session 9 Wed 01 10:30 Hall 3 052 

Kelemen A (Hungary) EUREPA Teaching Session Wed 01 7:30 Hall 5 

Kelemen A (Hungary) Platform Chair Wed 01 10:30 Hall 4 



SPEAKER LIST 


Kerr M (UK) Teaching Session Tues 30 7:30 Hall 5 

Khan S (Saudi Arabia) Main Session Wed 01 9:00 Hall 1 

Kharazmi E (Finland) Platform Session 6 Tues 30 10:30 Hall 6 033 

Khazipov R (France) Parallel Session Wed 01 10:30 Hall 2 

Khyuppenen J (Finland) Platform Session 12 Wed 01 16:00 Hall 5 072 

Kim H S (Korea) Platform Session 11 Wed 01 16:00 Hall 2 064 

Kimiskidis V (Greece) Parallel Session Thurs 02 10:30 Hall 7 

Kipiani T (Georgia) Platform Session 13 Thurs 02 10:30 Hall 4 074 

Klassen T (USA) Platform Session 4 Mon 29 16:00 Hall 6 024 

Klitgaard H (Belgium) Platform Session 3 Mon 29 16:00 Hall 2 015 

Klitgaard H (Belgium) Platform Session 7 Tues 30 16:00 Hall 4 042 

Kluger G (Germany) Platform Session 7 Tues 30 16:00 Hall 4 040 

Koe A (Australia) Platform Session 2 Mon 29 10:30 Hall 6 011 

Koenig T (Switzerland) Platform Session 9 Wed 01 10:30 Hall 3 053 

Koepp M J (UK) Platform Session 9 Wed 01 10:30 Hall 3 049 

Koepp M J (UK) Main Session Thurs 02 9:00 Hall 2 

Kogure S (Japan) Platform Session 7 Tues 30 16:00 Hall 4 037 

Kohsaka M (Japan) Platform Session 5 Tues 30 10:30 Hall 5 027 

Kohsaka S (Japan) Platform Session 5 Tues 30 10:30 Hall 5 027 

Kokaia M (Sweden) Platform Session 2 Mon 29 10:30 Hall 6 008 

Kokaia M (Sweden) Platform Session 7 Tues 30 16:00 Hall 4 038 



Komarek V (Czech Republic) Teaching Session Mon 29 7:30 Hall 3 

Koutroumanidis M (UK) Teaching Session Mon 29 7:30 Hall 2 

Kozuka K (Japan) Platform Session 7 Tues 30 16:00 Hall 4 037 

Krägeloh-Mann I (Germany) Platform Session 11 Wed 01 16:00 Hall 2 065 

Krägeloh-Mann I (Germany) Platform Session 13 Thurs 02 10:30 Hall 4 076 

Kratzer W (Germany) Platform Session 11 Wed 01 16:00 Hall 2 065 

Krishnamoorthy E S (India) Workshop Wed 01 7:30 Hall 4 

Krishnamoorthy E S (India) Parallel Session Wed 01 10:30 Hall 6 

Krsek P (Czech Republic) Teaching Session Mon 29 7:30 Hall 3 

Kumada S (Japan) Platform Session 10 Wed 01 10:30 Hall 4 055 

Kumada T (Japan) Platform Session 10 Wed 01 10:30 Hall 4 055 

Kumar G (Australia) Platform Session 2 Mon 29 10:30 Hall 6 010 

Kuramoto K (Brazil) Platform Session 11 Wed 01 16:00 Hall 2 062 

Kurleman G (Germany) Platform Session 7 Tues 30 16:00 Hall 4 040 

Kwan P (Hong Kong) Parallel Session Thurs 02 10:30 Hall 5 

Kwon C S (Canada) Platform Session 14 Thurs 02 10:30 Hall 6 084 

Noebels J (USA) Platform Session 6 Tues 30 10:30 Hall 6 034 

La Neve A (Italy) Platform Session 3 Mon 29 16:00 Hall 2 017 

Lagae L (Belgium) Platform Session 10 Wed 01 10:30 Hall 4 059 

Lai S L (Taiwan) Post Main Session Mon 29 16:00 Hall 1 

Lakkunta P (India) Platform Session 9 Wed 01 10:30 Hall 3 052 

Lawson J (Australia) Platform Session 14 Thurs 02 10:30 Hall 6 079 

Le Cavorsin M (France) Platform Session 2 Mon 29 10:30 Hall 6 009 

Le N M (USA) Platform Session 12 Wed 01 16:00 Hall 5 068 

Le Quang C (Vietnam) Platform Session 6 Tues 30 10:30 Hall 6 032 

Le Van Quyen M (France) Platform Session 4 Mon 29 16:00 Hall 6 019 

Le Van Quyen M (France) Parallel Session Thurs 02 10:30 Hall 3 

Lee H E (Australia) Platform Session 2 Mon 29 10:30 Hall 6 010 


SPEAKER LIST 

42 



Lee P (UK) Special Session Sun 28 17:00 Hall 1 

Lee P (UK) Parallel Session Wed 01 16:00 Hall 4 

Leguern E (France) Platform Session 10 Wed 01 10:30 Hall 4 056 

Lehesjoki A E (Finland) Platform Session 12 Wed 01 16:00 Hall 5 072 

Lerche H (Germany) EUREPA Teaching Session Tues 30 7:30 Hall 4 

Lerche H (Germany) Satellite Symposium Wed 01 13:00 Hall 1 

Lerman-Sagie T (Israel) Platform Session 10 Wed 01 10:30 Hall 4 057 

Lesca G (France) Platform Session 10 Wed 01 10:30 Hall 4 056 

Lev D (Israel) Platform Session 10 Wed 01 10:30 Hall 4 057 

Li S (China) Main Session Tues 30 9:00 Hall 1 

Li S (China) Post Main Session Tues 30 10:30 Hall 1 

Li S (China) Special Session Thurs 02 12:00 Hall 2 

Licchetta L (Italy) Platform Session 10 Wed 01 10:30 Hall 4 060 

Lima E (Brazil) Platform Session 2 Mon 29 10:30 Hall 6 007 

Lin K (Brazil) Platform Session 14 Thurs 02 10:30 Hall 6 083 

Liu M (Canada) Platform Session 14 Thurs 02 10:30 Hall 6 084 

Liu Y (Australia) Platform Session 2 Mon 29 10:30 Hall 6 011 

Loddenkemper T (USA) Platform Session 12 Wed 01 16:00 Hall 5 068 

Loescher W (Germany) Post Main Session Wed 01 16:00 Hall 1 

Lopes-Cendes I (Brazil) Platform Session 2 Mon 29 10:30 Hall 6 012 

Lopes-Cendes I (Brazil) Platform Session 10 Wed 01 10:30 Hall 4 058 

Lopes-Cendes I (Brazil) Teaching Session Wed 01 16:00 Hall 5 

Loring D W (USA) Parallel Session Tues 30 16:00 Hall 3 

Lossius M I (Norway) Platform Session 3 Mon 29 16:00 Hall 2 013 

Lui S (China) Platform Session 9 Wed 01 10:30 Hall 3 051 

Lund S (Sweden) Special Session Sun 28 17:00 Hall 1 

Lund S (Sweden) Special Session Thurs 02 12:00 Hall 2 

Lundberg C (Sweden) Platform Session 2 Mon 29 10:30 Hall 6 008 

Lundberg C (Sweden) Platform Session 7 Tues 30 16:00 Hall 4 039 

Lutz M (Germany) Platform Session 4 Mon 29 16:00 Hall 6 021 

Luykx J (The Netherlands) Platform Session 3 Mon 29 16:00 Hall 2 014 

Madden P (UK) Platform Session 6 Tues 30 10:30 Hall 6 036 

Magloczky Z (Hungary) Parallel Session Wed 01 7:30 Hall 3 

Majkowska-Zwoliñska B (Poland) Platform Session 14 Thurs 02 10:30 Hall 6 080 

Majkowski J (Poland) Platform Session 14 Thurs 02 10:30 Hall 6 080 

Makowski C (Germany) Platform Session 7 Tues 30 16:00 Hall 4 040 

Malerba A (Italy) Platform Session 3 Mon 29 16:00 Hall 2 017 

Marchesini R B (Brazil) Platform Session 2 Mon 29 10:30 Hall 6 012 

Martiniuk A (Australia) Parallel Session Tues 30 16:00 Hall 6 

Martiniuk A (Australia) Platform Session 14 Thurs 02 10:30 Hall 6 079 

Martinovic Z (Serbia and Montenegro) Platform Session 1 Mon 29 10:30 Hall 2 001 

Martins H (Brazil) Platform Session 14 Thurs 02 10:30 Hall 6 083 

Masih I (UK) Platform Session 6 Tues 30 10:30 Hall 6 036 

Mason M (USA) Platform Session 3 Mon 29 16:00 Hall 2 014 

Masuko A (Brazil) Platform Session 14 Thurs 02 10:30 Hall 6 083 

Matagne A (Belgium) Platform Session 3 Mon 29 16:00 Hall 2 015 

Matagne A (Belgium) Platform Session 7 Tues 30 16:00 Hall 4 042 

Mathern G W (USA) Parallel Session Mon 29 10:30 Hall 4 

Matsumoto N (Japan) Platform Session 10 Wed 01 10:30 Hall 4 055 

Maurer-Morelli C (Brazil) Platform Session 10 Wed 01 10:30 Hall 4 058 

Mayer H (Austria) Platform Session 8 Tues 30 16:00 Hall 5 045 



SPEAKER LIST 


Mayer T (Germany) Platform Session 4 Mon 29 16:00 Hall 6 021 

Mazarib A (Israel) Platform Session 10 Wed 01 10:30 Hall 4 057 

McEvoy A (UK) Platform Session 8 Tues 30 16:00 Hall 5 044 

Medina M T (Honduras) Parallel Session Wed 01 16:00 Hall 4 

Meeren H (The Netherlands) Platform Session 4 Mon 29 16:00 Hall 6 022 

Menendez de la Prida L (France) Platform Session 4 Mon 29 16:00 Hall 6 019 

Mesa T (Chile) Platform Session 14 Thurs 02 10:30 Hall 6 082 

Mesquita S (Brazil) Platform Session 14 Thurs 02 10:30 Hall 6 083 

Mia Bohn N (Norway) Parallel Session Tues 30 16:00 Hall 6 

Michelucci R (Italy) Platform Session 10 Wed 01 10:30 Hall 4 060 

Miles R (France) Platform Session 4 Mon 29 16:00 Hall 6 019 

Mills K R (UK) Parallel Session Thurs 02 10:30 Hall 7 

Milosevic N (Serbia) Platform Session 12 Wed 01 16:00 Hall 5 069 

Milovanovic M (Serbia and Montenegro) Platform Session 1 Mon 29 10:30 Hall 2 001 

Minotti L (France) Platform Session 5 Tues 30 10:30 Hall 5 028 

Mitchell P (UK) Platform Session 6 Tues 30 10:30 Hall 6 036 

Mizrahi E M (USA) Workshop Thurs 02 7:30 Hall 6 

Mizuguchi T (Japan) Platform Session 10 Wed 01 10:30 Hall 4 055 

Mohamed A (Australia) Platform Session 14 Thurs 02 10:30 Hall 6 079 

Morales A (France) Platform Session 2 Mon 29 10:30 Hall 6 009 

Morris M (Australia) Platform Session 2 Mon 29 10:30 Hall 6 010 

Morrone C (Italy) Platform Session 1 Mon 29 10:30 Hall 2 005 

Morrone E (Italy) Platform Session 1 Mon 29 10:30 Hall 2 005 

Morrow J (UK) Platform Session 3 Mon 29 16:00 Hall 2 016 

Moshe S L (USA) Special Session Mon 29 16:00 Hall 5 

Mosher J (USA) Platform Session 11 Wed 01 16:00 Hall 2 063 

Mula M (Italy) Workshop Tues 30 7:30 Hall 6 

Mula M (Italy) Parallel Session Wed 01 10:30 Hall 6 

Myers D (Australia) Platform Session 2 Mon 29 10:30 Hall 6 011 

Naldi I (Italy) Platform Session 10 Wed 01 10:30 Hall 4 060 

Najm I (USA) EUREPA Teaching Session Thurs 02 7:30 Hall 4 

Nehlig A (France) Post Main Session Wed 01 16:00 Hall 1 

Neligan A (UK) Platform Session 6 Tues 30 10:30 Hall 6 031 

Nguyen Ahn Tuan T (Vietnam) Platform Session 6 Tues 30 10:30 Hall 6 032 

Nguyen Thi Kim C (Vietnam) Platform Session 6 Tues 30 10:30 Hall 6 032 

Nickels K (USA) Platform Session 13 Thurs 02 10:30 Hall 4 073 

Niehusmann P (Germany) Platform Session 4 Mon 29 16:00 Hall 6 020 

Nikitidou L (Sweden) Platform Session 7 Tues 30 16:00 Hall 4 041 

Niquet J (USA) Platform Session 7 Tues 30 16:00 Hall 4 042 

Nishimura A (Japan) Platform Session 10 Wed 01 10:30 Hall 4 055 

Nobile C (Italy) Platform Session 10 Wed 01 10:30 Hall 4 060 

Noebels J (USA) Platform Session 4 Mon 29 16:00 Hall 6 024 

Normand C (Ireland) Platform Session 6 Tues 30 10:30 Hall 6 035 

Northam G (UK) Platform Session 13 Thurs 02 10:30 Hall 4 077 

Nunes M L (Brazil) Workshop Thurs 02 7:30 Hall 6 

Nunez Orosco L (Mexico) Main Session Mon 29 14:30 Hall 1 

Nunez Orosco L (Mexico) Post Main Session Mon 29 16:00 Hall 1 

Nunez Orosco L (Mexico) Special Session Thurs 02 12:00 Hall 2 

O’Brien T (Australia) Platform Session 2 Mon 29 10:30 Hall 6 010 

O’Brien T (Australia) Platform Session 2 Mon 29 10:30 Hall 6 011 

O’Brien T (Australia) Parallel Session Mon 29 16:00 Hall 4 


SPEAKER LIST 

44 



O’Brien T (Australia) Main Session Tues 30 14:30 Hall 1 

O’Brien T (Australia) Post Main Session Tues 30 16:00 Hall 1 

O’Brien T (Australia) Special Session Thurs 02 12:00 Hall 2 

Ogata K (Japan) Platform Session 10 Wed 01 10:30 Hall 4 055 

Olivier A (Canada) Platform Session 9 Tues 30 16:00 Hall 5 046 

Osaka H (Japan) Platform Session 10 Wed 01 10:30 Hall 4 055 

Ottman R (USA) Teaching Session Wed 01 16:00 Hall 5 

Ozelo H (Brazil) Platform Session 9 Wed 01 10:30 Hall 3 054 

Ozkara C (Turkey) EUREPA Teaching Session Wed 01 7:30 Hall 5 

Ozkara C (Turkey) EUREPA Teaching Session Thurs 02 7:30 Hall 4 

Pahs G (UK) Platform Session 13 Thurs 02 10:30 Hall 4 077 

Pahs G (Austria) Platform Session 8 Tues 30 16:00 Hall 5 045 

Pallud J (France) Platform Session 4 Mon 29 16:00 Hall 6 019 

Panigrahi M (India) Platform Session 9 Wed 01 10:30 Hall 3 052 

Pannek H (Germany) Platform Session 8 Tues 30 16:00 Hall 5 043 

Pascoal V (Brazil) Platform Session 2 Mon 29 10:30 Hall 6 012 

Pastoors C (Germany) Platform Session 13 Thurs 02 10:30 Hall 4 076 

Patsalos P (UK) Satellite Symposium Mon 29 13:00 Hall 1 

Pauli E (Germany) Platform Session 12 Wed 01 16:00 Hall 5 071 

Pedro T (Brazil) Platform Session 9 Wed 01 10:30 Hall 3 054 

Pellacani S (Italy) Platform Session 3 Mon 29 16:00 Hall 2 017 

Peltola J (Finland) Platform Session 6 Tues 30 10:30 Hall 6 033 

Pepe F (Italy) Platform Session 1 Mon 29 10:30 Hall 2 005 

Peralta M (Chile) Platform Session 14 Thurs 02 10:30 Hall 6 082 

Pereira De Brito Sampaio L (Brazil) Platform Session 11 Wed 01 16:00 Hall 2 062 

Pereira F (Brazil) Platform Session 9 Wed 01 10:30 Hall 3 054 

Pereira T C (Brazil) Platform Session 2 Mon 29 10:30 Hall 6 012 

Persson H (Sweden) Platform Session 6 Tues 30 10:30 Hall 6 032 

Perucca E (Italy) EUREPA Teaching Session Mon 29 7:30 Hall 5 

Perucca E (Italy) Platform Session 3 Mon 29 16:00 Hall 2 017 

Perucca E (Italy) Parallel Session Tues 30 16:00 Hall 2 

Petkar S (UK) Platform Session 6 Tues 30 10:30 Hall 6 036 

Pfaefflin M (Germany) Post Main Session Wed 01 10:30 Hall 1 

Philip S (UK) Platform Session 11 Wed 01 16:00 Hall 2 066 

Pillay N (Canada) Platform Session 5 Tues 30 10:30 Hall 5 030 

Pini G (Italy) Platform Session 5 Tues 30 10:30 Hall 5 025 

Pini G (Italy) Platform Session 5 Tues 30 10:30 Hall 5 026 

Pisano T (UK) Platform Session 9 Wed 01 10:30 Hall 3 050 

Pitkanen A (Finland) Platform Chair Mon 29 10:30 Hall 6 

Pitkanen A (Finland) Main Session Tues 30 14:30 Hall 1 

Pittau F (Italy) Platform Session 10 Wed 01 10:30 Hall 4 060 

Plattner B (Austria) Platform Session 8 Tues 30 16:00 Hall 5 045 

Plouin P (France) EUREPA Teaching Session Tues 30 7:30 Hall 3 

Plouin P (France) Parallel Session Wed 01 10:30 Hall 2 

Plouin P (France) EUREPA Teaching Session Thurs 02 7:30 Hall 7 

Pollard R (Australia) Platform Session 14 Thurs 02 10:30 Hall 6 081 

Porsche B (Austria) Platform Session 8 Tues 30 16:00 Hall 5 045 

Potschka H (Germany) Parallel Session Thurs 02 7:30 Hall 5 

Powell R (UK) Platform Session 9 Wed 01 10:30 Hall 3 049 

Prabhakar Rao V V S (India) Platform Session 9 Wed 01 10:30 Hall 3 052 

Pratt J (Scotland) Special Session Tues 30 10:30 Hall 7 



SPEAKER LIST 


Prayer D (Austria) Platform Session 8 Tues 30 16:00 Hall 5 045 

Quan H (Canada) Platform Session 14 Thurs 02 10:30 Hall 6 084 

Quigg M (USA) Main Session Mon 29 9:00 Hall 1 

Radhakrishnan A (Australia) Platform Session 10 Wed 01 10:30 Hall 4 057 

Rajna P (Hungary) Platform Chair Mon 29 16:00 Hall 2 

Rajna P (Hungary) Special Session Tues 30 10:30 Hall 7 

Rankin P (UK) Platform Session 13 Thurs 02 10:30 Hall 4 077 

Rasonyi G (Hungary) Platform Session 4 Mon 29 16:00 Hall 6 023 

Rasonyi G (Hungary) Platform Chair Tues 30 10:30 Hall 6 

Ravizza T (Italy) Platform Chair Mon 29 16:00 Hall 6 

Ravizza T (Italy) Parallel Session Tues 30 10:30 Hall 4 

Reche A (Brazil) Platform Session 11 Wed 01 16:00 Hall 2 062 

Rees S (Australia) Platform Session 2 Mon 29 10:30 Hall 6 010 

Reiter E (Austria) Platform Session 8 Tues 30 16:00 Hall 5 045 

Reuner U (Germany) Platform Session 4 Mon 29 16:00 Hall 6 021 

Reynolds EH (UK) Special Session Sun 28 17:00 Hall 1 

Ristic A (Serbia) Platform Session 12 Wed 01 16:00 Hall 5 069 

Roberts D (USA) Platform Session 1 Mon 29 10:30 Hall 2 006 

Roberts K (Australia) Platform Session 14 Thurs 02 10:30 Hall 6 081 

Rocha C (Brazil) Platform Session 10 Wed 01 10:30 Hall 4 058 

Rogelius N (Sweden) Platform Session 2 Mon 29 10:30 Hall 6 008 

Rondina J (Brazil) Platform Session 9 Wed 01 10:30 Hall 3 054 

Rosati E (Italy) Platform Session 3 Mon 29 16:00 Hall 2 017 

Runge U (Germany) Platform Session 7 Tues 30 16:00 Hall 4 040 

Russell A (UK) Platform Session 5 Tues 30 10:30 Hall 5 025 

Ryvlin P (France) Platform Session 2 Mon 29 10:30 Hall 6 009 

Ryvlin P (France) Platform Chair Mon 29 10:30 Hall 2 

Ryvlin P (France) Parallel Session Mon 29 16:00 Hall 3 

Ryvlin P (France) Platform Session 10 Wed 01 10:30 Hall 4 056 

Ryvlin P (France) Satellite Symposium Wed 01 13:00 Hall 1 

Saito N (Japan) Platform Session 7 Tues 30 16:00 Hall 4 037 

Saitoh S (Japan) Platform Session 5 Tues 30 10:30 Hall 5 027 

Saitsu H (Japan) Platform Session 10 Wed 01 10:30 Hall 4 055 

Salak-Djokic B (Serbia) Platform Session 12 Wed 01 16:00 Hall 5 069 

Salzberg M (Australia) Platform Session 2 Mon 29 10:30 Hall 6 010 

Samson R (UK) Platform Session 9 Wed 01 10:30 Hall 3 049 

Sanchez P E (France) Platform Session 2 Mon 29 10:30 Hall 6 009 

Sander J W (UK) Platform Session 6 Tues 30 10:30 Hall 6 031 

Sander L (UK) Satellite Symposium Mon 29 13:00 Hall 1 

Santos C (Brazil) Platform Session 14 Thurs 02 10:30 Hall 6 083 

Schackert G (Germany) Platform Session 4 Mon 29 16:00 Hall 6 021 

Scharfman H E (USA) Parallel Session Tues 30 10:30 Hall 4 

Scheffer I (Australia) Parallel Session Tues 30 10:30 Hall 3 

Scheffer I (Australia) Post Main Session Tues 30 16:00 Hall 1 

Scheffer I (Australia) Platform Session 10 Wed 01 10:30 Hall 4 057 

Scheffer I (Australia) Teaching Session Wed 01 16:00 Hall 5 

Schindler K (Switzerland) Platform Session 9 Wed 01 10:30 Hall 3 053 

Schmitz B (Germany) EUREPA Teaching Session Mon 29 7:30 Hall 6 

Schmitz B (Germany) Workshop Tues 30 7:30 Hall 6 

Schneider F (Germany) Platform Session 7 Tues 30 16:00 Hall 4 040 

Schoch S (Germany) Platform Session 4 Mon 29 16:00 Hall 6 020 


SPEAKER LIST 

46 



Schulz R (Germany) Platform Session 8 Tues 30 16:00 Hall 5 043 

Schwarz M (Germany) Platform Session 12 Wed 01 16:00 Hall 5 071 

Secco M (Canada) Parallel Session Tues 30 16:00 Hall 6 

Seol I (Korea) Platform Session 11 Wed 01 16:00 Hall 2 064 

Sercheli M (Brazil) Platform Session 9 Wed 01 10:30 Hall 3 054 

Seress L (Hungary) Platform Chair Mon 29 16:00 Hall 6 

Seri S (UK) Platform Session 9 Wed 01 10:30 Hall 3 050 

Serra E (Germany) Platform Session 13 Thurs 02 10:30 Hall 4 076 

Seyal M (USA) Platform Session 5 Tues 30 10:30 Hall 5 029 

Shang H (China) Platform Session 9 Wed 01 10:30 Hall 3 051 

Sharp D (Australia) Platform Session 14 Thurs 02 10:30 Hall 6 081 

Shin H K (Korea) Platform Session 3 Mon 29 16:00 Hall 2 018 

Shiraishi H (Japan) Platform Session 5 Tues 30 10:30 Hall 5 027 

Shorvon S (UK) Parallel Session Mon 29 10:30 Hall 3 

Shorvon S (UK) Satellite Symposium Mon 29 18:00 Hall 1 

Shorvon S (UK) Parallel Session Tues 30 16:00 Hall 2 

Shorvon S (UK) Platform Session 6 Tues 30 10:30 Hall 6 031 

Shukla G (USA) Platform Session 11 Wed 01 16:00 Hall 2 063 

Sijben A (Australia) Platform Session 10 Wed 01 10:30 Hall 4 057 

Silva A (Brazil) Platform Session 14 Thurs 02 10:30 Hall 6 083 

Simonovic P (Serbia and Montenegro) Platform Session 1 Mon 29 10:30 Hall 2 001 

Singh G (India) Parallel Session Mon 29 10:30 Hall 5 

Sita Jayalakshmi S (India) Platform Session 9 Wed 01 10:30 Hall 3 052 

Sithinamsuwan P (Australia) Platform Session 10 Wed 01 10:30 Hall 4 057 

Sitnikova E (Russia) Platform Session 4 Mon 29 16:00 Hall 6 022 

Smeets E (The Netherlands) Platform Session 5 Tues 30 10:30 Hall 5 025 

Smeets E (The Netherlands) Platform Session 5 Tues 30 10:30 Hall 5 026 

So E (USA) Platform Session 6 Tues 30 10:30 Hall 6 034 

Sokic D (Serbia) Platform Session 12 Wed 01 16:00 Hall 5 069 

Soltesz I (USA) Special Session Mon 29 16:00 Hall 5 

Solyom A (Hungary) Platform Session 4 Mon 29 16:00 Hall 6 023 

Somervile E (Australia) Platform Session 14 Thurs 02 10:30 Hall 6 079 

Sorensen A T (Sweden) Platform Session 2 Mon 29 10:30 Hall 6 008 

Sperk G (Austria) Parallel Session Wed 01 7:30 Hall 3 

Sperling M R (USA) Parallel Session Mon 29 10:30 Hall 3 

Spizzica F (Italy) Platform Session 1 Mon 29 10:30 Hall 2 005 

Staley K J (USA) Parallel Session Wed 01 10:30 Hall 2 

Stefan H (Germany) Platform Session 12 Wed 01 16:00 Hall 5 071 

Steinhoff B (Germany) Satellite Symposium Mon 29 13:00 Hall 1 

Steinhoff B (Germany) Parallel Session Wed 01 10:30 Hall 5 

Stipa C (Italy) Platform Session 10 Wed 01 10:30 Hall 4 060 

Straussberg R (Israel) Platform Session 10 Wed 01 10:30 Hall 4 057 

Striano P (Italy) Platform Session 1 Mon 29 10:30 Hall 2 005 

Striano S (Italy) Platform Session 10 Wed 01 10:30 Hall 4 060 

Suchomelova L (USA) Platform Session 7 Tues 30 16:00 Hall 4 042 

Sundaram C (India) Platform Session 9 Wed 01 10:30 Hall 3 052 

Sutula T (USA) Satellite Symposium Mon 29 18:00 Hall 1 

Symms M (UK) Platform Session 9 Wed 01 10:30 Hall 3 049 

Szente M (Hungary) Platform Chair Tues 30 16:00 Hall 4 

Tang H H (China) Platform Session 9 Wed 01 10:30 Hall 3 051 

Tatishvili N (Georgia) Platform Session 13 Thurs 02 10:30 Hall 4 074 



SPEAKER LIST 


Tatishvili S (Georgia) Platform Session 13 Thurs 02 10:30 Hall 4 074 

Tebartz Van Elst L (Germany) Workshop Tues 30 7:30 Hall 6 

Tebartz Van Elst L (Germany) Workshop Wed 01 7:30 Hall 4 

Tedeschi H (Brazil) Platform Session 10 Wed 01 10:30 Hall 4 058 

Tellez-Zenteno J (Canada) Platform Session 9 Tues 30 16:00 Hall 5 047 

Tellez-Zenteno J (Canada) Platform Session 9 Tues 30 16:00 Hall 5 048 

Thadani V (USA) Platform Session 1 Mon 29 10:30 Hall 2 006 

Thaj J (UK) Platform Session 9 Wed 01 10:30 Hall 3 050 

Theodore W (USA) Parallel Session Mon 29 16:00 Hall 3 

Thomas H (UK) Platform Session 6 Tues 30 10:30 Hall 6 036 

Thompson P (UK) Platform Session 9 Wed 01 10:30 Hall 3 049 

Tinuper P (Italy) Platform Session 3 Mon 29 16:00 Hall 2 017 

Tinuper P (Italy) Platform Session 10 Wed 01 10:30 Hall 4 060 

Toft Sørensen A (Sweden) Platform Session 7 Tues 30 16:00 Hall 4 039 

Tohyama J (Japan) Platform Session 10 Wed 01 10:30 Hall 4 055 

Tomka-Hoffmeister M (Germany) Platform Session 8 Tues 30 16:00 Hall 5 043 

Tomson T (Sweden) Post Main Session Mon 29 10:30 Hall 1 

Tomson T (Sweden) Platform Session 6 Tues 30 10:30 Hall 6 032 

Tomson T (Sweden) Parallel Session Tues 30 16:00 Hall 2 

Tønnesen J (Sweden) Platform Session 7 Tues 30 16:00 Hall 4 039 

Toth E (Hungary) Platform Session 4 Mon 29 16:00 Hall 6 023 

Trajkovic G (Serbia ) Platform Session 12 Wed 01 16:00 Hall 5 069 

Trinka E (Austria) Teaching Session Mon 29 7:30 Hall 2 

Tsuchiya K (Japan) Platform Session 7 Tues 30 16:00 Hall 4 037 

Ulbert I (Hungary) Workshop Mon 29 7:30 Hall 4 

Ulbert I (Hungary) Platform Session 4 Mon 29 16:00 Hall 6 023 

Underhill C (UK) Parallel Session Wed 01 16:00 Hall 4 

Urak L (Austria) Platform Session 8 Tues 30 16:00 Hall 5 045 

Uruno K (Japan) Platform Session 10 Wed 01 10:30 Hall 4 055 

Valentin A (UK) Workshop Mon 29 7:30 Hall 4 

Van Emde Boas W (The Netherlands) EUREPA Teaching Session Wed 01 7:30 Hall 5 

Van Emde Boas W (The Netherlands) EUREPA Teaching Session Thurs 02 7:30 Hall 7 

Van Luijtelaar G (The Netherlands) Platform Session 4 Mon 29 16:00 Hall 6 022 

Van Ness P (USA) Platform Session 1 Mon 29 10:30 Hall 2 004 

Van Paesschen W (Belgium) Platform Session 10 Wed 01 10:30 Hall 4 059 

Vargha-Khadem F (UK) Platform Session 13 Thurs 02 10:30 Hall 4 077 

Varley J (Ireland) Platform Session 6 Tues 30 10:30 Hall 6 035 

Velis D (The Netherlands) EUREPA Teaching Session Thurs 02 7:30 Hall 4 

Verhaert K (Belgium) Platform Session 10 Wed 01 10:30 Hall 4 059 

Vezzani A (Italy) Parallel Session Tues 30 10:30 Hall 4 

Vezzani A (Italy) Post Main Session Tues 30 16:00 Hall 1 

Vinayan K P (India) Workshop Thurs 02 7:30 Hall 6 

Vojvodic N (Serbia) Platform Session 12 Wed 01 16:00 Hall 5 069 

Wasterlain C G (USA) Platform Session 7 Tues 30 16:00 Hall 4 042 

Weckhuysen S (Belgium) Platform Session 10 Wed 01 10:30 Hall 4 059 

White H S (USA) Post Main Session Wed 01 16:00 Hall 1 

Whitehead H (Australia) Platform Session 14 Thurs 02 10:30 Hall 6 081 

Whitworth L A (USA) Platform Session 1 Mon 29 10:30 Hall 2 004 

Wiebe S (Canada) Platform Chair Tues 30 16:00 Hall 5 

Wiebe S (Canada) Parallel Session Wed 01 16:00 Hall 4 

Wiebe S (Canada) Parallel Session Thurs 02 10:30 Hall 5 


SPEAKER LIST 

48 



Wiest R (Switzerland) Platform Session 9 Wed 01 10:30 Hall 3 053 

Wirrell E (USA) Platform Session 13 Thurs 02 10:30 Hall 4 073 

Witt Engerström I (Sweden) Platform Session 5 Tues 30 10:30 Hall 5 025 

Witt Engerström I (Sweden) Platform Session 5 Tues 30 10:30 Hall 5 026 

Witt J A (Germany) Platform Session 12 Wed 01 16:00 Hall 5 067 

Woermann F (Germany) Teaching Session Mon 29 7:30 Hall 3 

Woermann F (Germany) Platform Session 8 Tues 30 16:00 Hall 5 043 

Woermann F (Germany) Main Session Thurs 02 9:00 Hall 2 

Woermann F (Germany) Post Main Session Thurs 02 10:30 Hall 2 

Woermann F (Germany) Special Session Thurs 02 12:00 Hall 2 

Wolf P (Denmark) Special Session Sun 28 17:00 Hall 1 

Wolf P (Denmark) Special Session Tues 30 10:30 Hall 7 

Wolff M (Germany) Platform Session 11 Wed 01 16:00 Hall 2 065 

Wolff M (Germany) Platform Session 13 Thurs 02 10:30 Hall 4 076 

Wu J (China) Post Main Session Tues 30 10:30 Hall 1 

Wu X (China) Platform Session 1 Mon 29 10:30 Hall 2 003 

Wu X (China) Platform Session 9 Wed 01 10:30 Hall 3 051 

Xu Y (China) Platform Session 1 Mon 29 10:30 Hall 2 003 

Yacubian E M T (Brazil) Platform Session 11 Wed 01 16:00 Hall 2 062 

Yacubian E M T (Brazil) Main Session Mon 29 14:30 Hall 1 

Yamamoto H (Japan) Workshop Thurs 02 7:30 Hall 6 

Yan B (China) Platform Session 9 Wed 01 10:30 Hall 3 051 

Ycubian E (Brazil) Platform Session 14 Thurs 02 10:30 Hall 6 083 

Yogarajah M (UK) Platform Session 9 Wed 01 10:30 Hall 3 049 

Yoo J (USA) Platform Session 4 Mon 29 16:00 Hall 6 024 

Yu P (China) Platform Session 1 Mon 29 10:30 Hall 2 003 

Zara F (Italy) EUREPA Teaching Session Tues 30 7:30 Hall 4 

Zelmann R (Canada) Platform Session 9 Tues 30 16:00 Hall 5 046 

Zhao D (China) Platform Session 1 Mon 29 10:30 Hall 2 003 

Zhou B (China) Platform Session 9 Wed 01 10:30 Hall 3 051 

Zhou D (China) Platform Session 9 Wed 01 10:30 Hall 3 051 

Zhu G (China) Platform Session 1 Mon 29 10:30 Hall 2 003 

Zibetti M (Brazil) Platform Session 9 Wed 01 10:30 Hall 3 054 

Ziemann U (Germany) Parallel Session Thurs 02 10:30 Hall 7 

Zijlmans M (Canada) Platform Session 9 Tues 30 16:00 Hall 5 046 

Zovic L (Serbia) Platform Session 12 Wed 01 16:00 Hall 5 069 

Zsofia M (Hungary) Platform Session 4 Mon 29 16:00 Hall 6 023 




LIST OF EXHIBITORS AND EXHIBITION PLAN 

EXHIBITION OPENING HOURS 

50 


Monday 29 th June 2009 09:00 - 17:00 

Tuesday 30 th June 2009 09:00 - 17:00 

Wednesday 1 st July 2009 09:00 - 17:00 

Thursday 2 nd July 2009 09:00 - 12:00 

Exhibitor Stand no. 

Ad-Tech Medical 204/D 

Cyberonics 103/A 

EB Neuro SpA 203/B 

Eisai Europe Ltd. 203/A 

Electrical Geodesics, Inc. 106/A 

Elekta Neuromag 101/B&C&D 

EUCARE 103/B 

EURAP 206/D 

EUREPA / Epilepsy Academy 106/B 

EFNS 206/C 

Global Campaign 103/D 

ILAE Centenary Exhibition 205/A 

International Bureau for Epilepsy 103/C 

International League Against Epilepsy 105 

Janssen-Cilag 104 

John Libbey Eurotext 205/D 

Lifelines Ltd. 206/A 

Micromed 204/B 

The National Centre for Young People with Epilepsy 

Neurosoft Ltd. 202/C 

NeuroTech International 205/B&C 

Nihon Kohden 203/D 

Pinnacle Technology Inc. 202/B 

PMT Corporation 206/F 

Sanofi Aventis 104/A 

Special Products Ltd. 203/C 

Stellate Systems 202/E 

The Anita Kaufmann Foundation 

The Ring Chromosome 20 Foundation 204/C 

UCB Pharma 102 

Wiley-Blackwell 202/D 

Wisepress Online Bookshop 205/E 



LIST OF EXHIBITORS AND EXHIBITION PLAN 


NOTES 

52 




NOTES 


NOTES 

54 




NOTES 


Name of the medicinal product: VIMPAT® (lacosamide). Pharmaceutical form: Filmcoated 

tablets containing 50mg, 100mg, 150 mg, or 200mg lacosamide, syrup containing 15 

mg/ml lacosamide, and solution for infusion containing 10 mg/ml lacosamide. Therapeutic 

indications: VIMPAT® is indicated as adjunctive therapy in the treatment of partial-onset 

seizures with or without secondary generalisation in patients with epilepsy aged 16 years and 

older. VIMPAT® solution for infusion is an alternative for patients when oral administration is 

temporarily not feasible. Posology and method of administration: VIMPAT® must be taken 

twice a day. The recommended starting dose is 50 mg twice a day which should be increased 

to an initial therapeutic dose of 100 mg twice a day after one week. Depending on response 

and tolerability, the maintenance dose can be further increased by 50 mg twice a day every 

week, to a maximum recommended daily dose of 400 mg (200 mg twice a day). VIMPAT® 

may be taken with or without food. A maximum dose of 250 mg/day is recommended for 

patients with severe renal impairment and in patients with endstage renal disease. For patients 

requiring haemodialysis a supplement of up to 50% of the divided daily dose directly after 

the end of haemodialysis is recommended. Contraindications: Hypersensitivity to the active 

substance or any of the excipients; known second- or third-degree atrioventricular (AV) block; 

VIMPAT® film-coated tablets only: Hypersensitivity to peanuts or soya. Special warnings 

and precautions for use: Treatment with VIMPAT® has been associated with dizziness 

which could increase the occurrence of accidental injury or falls. Therefore, patients should 

be advised to exercise caution until they are familiar with the potential effects of the medicine. 

VIMPAT® may have minor to moderate influence on the ability to drive and use machines. 

VIMPAT® treatment has been associated with dizziness or blurred vision. Accordingly, 

patients should be advised not to drive a car or to operate other potentially hazardous 

machinery until they are familiar with the effects of VIMPAT® on their ability to perform 

such activities. Prolongations in PR interval with VIMPAT® have been observed in clinical 

studies. VIMPAT® should be used with caution in patients with known conduction problems 

or severe cardiac disease such as a history of myocardial infarction or heart failure. Caution 

should especially be exerted when treating elderly patients as they may be at an increased 

risk of cardiac disorders or when VIMPAT® is used in combination with products known to 

be associated with PR prolongation. Suicidal ideation and behaviour have been reported in 

patients treated with anti-epileptic agents in several indications. A meta-analysis of randomised 

placebo controlled trials of anti-epileptic drugs has also shown a small increased risk of suicidal 

ideation and behaviour. The mechanism of this risk is not known and the available data do 

not exclude the possibility of an increased risk for VIMPAT®. Therefore patients should be 

monitored for signs of suicidal ideation and behaviours and appropriate treatment should be 

considered. Patients (and caregivers of patients) should be advised to seek medical advice 

should signs of suicidal ideation or behaviour emerge. VIMPAT® syrup contains sodium 

propylhydroxybenzoate (E217) and sodium methylhydroxybenzoate (E219), which may 

cause allergic reactions (possibly delayed). Patients with rare hereditary problems of fructose 

intolerance should not take this medicine. The syrup contains aspartame (E951), a source of 

phenylalanine, which may be harmful for people with phenylketonuria. VIMPAT® syrup and 

solution for infusion contain sodium. To be taken into consideration for patients on a controlled 

sodium diet. Interaction with other medicinal products and other forms of interaction: 

VIMPAT® should be used with caution in patients treated with medicinal products known 

to be associated with PR prolongation (e.g. carbamazepine, lamotrigine, pregabalin) and in 

patients treated with class I antiarrhythmic drugs. However, subgroup analysis did not identify 

an increased magnitude of PR prolongation in patients with concomitant administration of 

carbamazepine or lamotrigine in clinical trials. The use of VIMPAT® is associated with doserelated 

increase in the PR interval. Adverse reactions associated with PR interval prolongation 

(e.g. atrioventricular block, syncope, bradycardia) may occur. Strong enzyme inducers such 

as rifampicin or St John´s wort (Hypericum perforatum) may moderately reduce the systemic 

exposure of VIMPAT®. Therefore, starting or ending treatment with these enzyme inducers 

should be done with caution. Pregnancy: There are no adequate data from the use of VIMPAT® 

in pregnant women. The potential risk for humans is unknown. VIMPAT® should not be used 

during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the 

potential risk to the foetus). If women decide to become pregnant, the use of this product 

should be carefully re-evaluated. Lactation: It is unknown whether VIMPAT® is excreted in 

human breast milk. For precautionary measures, breast-feeding should be discontinued during 

treatment with VIMPAT®. Undesirable effects: The most common adverse reactions (>10%) 

are dizziness, headache, diplopia, and nausea. Other common adverse reactions (1-10%) are 

depression, balance disorder, coordination abnormal, memory impairment, cognitive disorder, 

somnolence, tremor, nystagmus, vision blurred, vertigo, vomiting, constipation, flatulence, 

pruritus, gait disturbance, asthenia, fatigue, fall, and skin laceration. Refer to the Summary of 

Product Characteristics for other adverse reactions. Date of revision: February 2009. Refer to 

the full prescribing information in your country before prescribing. Marketing authorisation 

holder: UCB Pharma, S.A. Allée de la Recherche 60 B-1070 Bruxelles Belgium. Marketing 

authorisation number(s): EU/1/08/470/001-016. Date of first authorisation: 29 August 

2008.GPSRC CNS 027 S 0309 LCM.

See you 

in Rome 

for the 


in 20 1 1 

Fototeca ENIT as the source of the photos. 

BUDAPE 

HUNG 

28 th International Epilepsy Co 

28 th June – 2 nd 

www.epilepsybudap

BUDAPEST HUNGARY 28th International Epilepsy Congress

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?